
<html lang="en"     class="pb-page"  data-request-id="51cb2bf3-72b0-41ff-8127-d106edc93270"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.1c00890"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer" /></meta><meta name="dc.Creator" content="Zhuming  Zhang" /></meta><meta name="dc.Creator" content="Avijit  Ghosh" /></meta><meta name="dc.Creator" content="Peter J.  Connolly" /></meta><meta name="dc.Creator" content="Peter  King" /></meta><meta name="dc.Creator" content="Thomas  Wilde" /></meta><meta name="dc.Creator" content="Jianyao  Wang" /></meta><meta name="dc.Creator" content="Yawei  Dong" /></meta><meta name="dc.Creator" content="Xueliang  Li" /></meta><meta name="dc.Creator" content="Daohong  Liao" /></meta><meta name="dc.Creator" content="Hao  Chen" /></meta><meta name="dc.Creator" content="Gaochao  Tian" /></meta><meta name="dc.Creator" content="Javier  Suarez" /></meta><meta name="dc.Creator" content="William G.  Bonnette" /></meta><meta name="dc.Creator" content="Vineet  Pande" /></meta><meta name="dc.Creator" content="Karen A.  Diloreto" /></meta><meta name="dc.Creator" content="Yifan  Shi" /></meta><meta name="dc.Creator" content="Shefali  Patel" /></meta><meta name="dc.Creator" content="Beth  Pietrak" /></meta><meta name="dc.Creator" content="Lawrence  Szewczuk" /></meta><meta name="dc.Creator" content="Carlo  Sensenhauser" /></meta><meta name="dc.Creator" content="Shannon  Dallas" /></meta><meta name="dc.Creator" content="James P.  Edwards" /></meta><meta name="dc.Creator" content="Kurtis E.  Bachman" /></meta><meta name="dc.Creator" content="David C.  Evans" /></meta><meta name="dc.Description" content="Selective cyclooxygenase (COX)-2 inhibitors have been extensively studied for colorectal cancer (CRC) chemoprevention. Celecoxib has been reported to reduce the incidence of colorectal adenomas and..." /></meta><meta name="Description" content="Selective cyclooxygenase (COX)-2 inhibitors have been extensively studied for colorectal cancer (CRC) chemoprevention. Celecoxib has been reported to reduce the incidence of colorectal adenomas and..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 19, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00890" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00890" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00890" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00890" /></link>
        
    
    

<title>Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00890" /></meta><meta property="og:title" content="Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0021.jpeg" /></meta><meta property="og:description" content="Selective cyclooxygenase (COX)-2 inhibitors have been extensively studied for colorectal cancer (CRC) chemoprevention. Celecoxib has been reported to reduce the incidence of colorectal adenomas and CRC but is also associated with an increased risk of cardiovascular events. Here, we report a series of gut-restricted, selective COX-2 inhibitors characterized by high colonic exposure and minimized systemic exposure. By establishing acute ex vivo 18F-FDG uptake attenuation as an efficacy proxy, we identified a subset of analogues that demonstrated statistically significant in vivo dose-dependent inhibition of adenoma progression and survival extension in an APCmin/+ mouse model. However, in vitro–in vivo correlation analysis showed their chemoprotective effects were driven by residual systemic COX-2 inhibition, rationalizing their less than expected efficacies and highlighting the challenges associated with COX-2-mediated CRC disease chemoprevention." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00890"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00890">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00890&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00890&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00890&amp;href=/doi/10.1021/acs.jmedchem.1c00890" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00881" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00958" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Zhuming Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhuming Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#710b0b0b19101f162e42414141310810191e1e5f121e1c"><span class="__cf_email__" data-cfemail="fa808080929b949da5c9cacacaba839b929595d4999597">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhuming++Zhang">Zhuming Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-5638-5320" title="Orcid link">https://orcid.org/0000-0002-5638-5320</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Avijit Ghosh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Avijit Ghosh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Avijit++Ghosh">Avijit Ghosh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter J. Connolly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter J. Connolly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+J.++Connolly">Peter J. Connolly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter King</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter King</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++King">Peter King</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas Wilde</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Wilde</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Wilde">Thomas Wilde</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianyao Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianyao Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianyao++Wang">Jianyao Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-2559-8849" title="Orcid link">https://orcid.org/0000-0003-2559-8849</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yawei Dong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yawei Dong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry, Pharmaron Beijing, Co. Ltd., No. 6, TaiHe Road, BDA Beijing 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yawei++Dong">Yawei Dong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xueliang Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xueliang Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry, Pharmaron Beijing, Co. Ltd., No. 6, TaiHe Road, BDA Beijing 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xueliang++Li">Xueliang Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daohong Liao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daohong Liao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry, Pharmaron Beijing, Co. Ltd., No. 6, TaiHe Road, BDA Beijing 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daohong++Liao">Daohong Liao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry, Pharmaron Beijing, Co. Ltd., No. 6, TaiHe Road, BDA Beijing 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Chen">Hao Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gaochao Tian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gaochao Tian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Technology and Molecular Pharmacology, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gaochao++Tian">Gaochao Tian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Javier Suarez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Javier Suarez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Technology and Molecular Pharmacology, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Javier++Suarez">Javier Suarez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William G. Bonnette</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William G. Bonnette</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Technology and Molecular Pharmacology, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William+G.++Bonnette">William G. Bonnette</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vineet Pande</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vineet Pande</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Janssen Research and Development, Turnhoutseweg 30, B-2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vineet++Pande">Vineet Pande</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karen A. Diloreto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen A. Diloreto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen+A.++Diloreto">Karen A. Diloreto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yifan Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yifan Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yifan++Shi">Yifan Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shefali Patel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shefali Patel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shefali++Patel">Shefali Patel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Beth Pietrak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Beth Pietrak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Technology and Molecular Pharmacology, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beth++Pietrak">Beth Pietrak</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lawrence Szewczuk</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lawrence Szewczuk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Technology and Molecular Pharmacology, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence++Szewczuk">Lawrence Szewczuk</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carlo Sensenhauser</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carlo Sensenhauser</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carlo++Sensenhauser">Carlo Sensenhauser</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shannon Dallas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shannon Dallas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shannon++Dallas">Shannon Dallas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James P. Edwards</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James P. Edwards</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+P.++Edwards">James P. Edwards</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kurtis E. Bachman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kurtis E. Bachman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Discovery, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kurtis+E.++Bachman">Kurtis E. Bachman</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">David C. Evans</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David C. Evans</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#f3b7b0b685929d80b39a8780dd999d99dd909c9e"><span class="__cf_email__" data-cfemail="8ecacdcbf8efe0fdcee7fafda0e4e0e4a0ede1e3">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+C.++Evans">David C. Evans</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00890&amp;href=/doi/10.1021%2Facs.jmedchem.1c00890" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 19, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 May 2021</li><li><span class="item_label"><b>Published</b> online</span>19 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00890" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00890</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DZhuming%2BZhang%252C%2BAvijit%2BGhosh%252C%2BPeter%2BJ.%2BConnolly%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00890%26title%3DGut-Restricted%2BSelective%2BCyclooxygenase-2%2B%2528COX-2%2529%2BInhibitors%2Bfor%2BChemoprevention%2Bof%2BColorectal%2BCancer%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D27%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00890"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">292</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00890" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Zhuming&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Avijit&quot;,&quot;last_name&quot;:&quot;Ghosh&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;J. Connolly&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;King&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Wilde&quot;},{&quot;first_name&quot;:&quot;Jianyao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yawei&quot;,&quot;last_name&quot;:&quot;Dong&quot;},{&quot;first_name&quot;:&quot;Xueliang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Daohong&quot;,&quot;last_name&quot;:&quot;Liao&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Gaochao&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Javier&quot;,&quot;last_name&quot;:&quot;Suarez&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;G. Bonnette&quot;},{&quot;first_name&quot;:&quot;Vineet&quot;,&quot;last_name&quot;:&quot;Pande&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;A. Diloreto&quot;},{&quot;first_name&quot;:&quot;Yifan&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Shefali&quot;,&quot;last_name&quot;:&quot;Patel&quot;},{&quot;first_name&quot;:&quot;Beth&quot;,&quot;last_name&quot;:&quot;Pietrak&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;Szewczuk&quot;},{&quot;first_name&quot;:&quot;Carlo&quot;,&quot;last_name&quot;:&quot;Sensenhauser&quot;},{&quot;first_name&quot;:&quot;Shannon&quot;,&quot;last_name&quot;:&quot;Dallas&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;P. Edwards&quot;},{&quot;first_name&quot;:&quot;Kurtis&quot;,&quot;last_name&quot;:&quot;E. Bachman&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;C. Evans&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00890&quot;},&quot;abstract&quot;:&quot;Selective cyclooxygenase (COX)-2 inhibitors have been extensively studied for colorectal cancer (CRC) chemoprevention. Celecoxib has been reported to reduce the incidence of colorectal adenomas and CRC but is also associated with an increased risk of cardiovascular events. Here, we report a series of gut-restricted, selective COX-2 inhibitors characterized by high colonic exposure and minimized systemic exposure. By establishing acute ex vivo 18F-FDG uptake attenuation as an efficacy proxy, we identified a subset of analogues that demonstrated statistically significant in vivo dose-dependent inhibition of adenoma progression and survival extension in an APCmin/+ mouse model. However, in vitro–in vivo correlation analysis showed their chemoprotective effects were driven by residual systemic COX-2 inhibition, rationalizing their less than expected efficacies and highlighting the challenges associated with COX-2-mediated CRC disease chemoprevention.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00890&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00890" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00890&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00890" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00890&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00890" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00890&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00890&amp;href=/doi/10.1021/acs.jmedchem.1c00890" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00890" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00890" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00890%26sid%3Dliteratum%253Aachs%26pmid%3D34279934%26genre%3Darticle%26aulast%3DZhang%26date%3D2021%26atitle%3DGut-Restricted%2BSelective%2BCyclooxygenase-2%2B%2528COX-2%2529%2BInhibitors%2Bfor%2BChemoprevention%2Bof%2BColorectal%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Selective cyclooxygenase (COX)-2 inhibitors have been extensively studied for colorectal cancer (CRC) chemoprevention. Celecoxib has been reported to reduce the incidence of colorectal adenomas and CRC but is also associated with an increased risk of cardiovascular events. Here, we report a series of gut-restricted, selective COX-2 inhibitors characterized by high colonic exposure and minimized systemic exposure. By establishing acute ex vivo <sup>18</sup>F-FDG uptake attenuation as an efficacy proxy, we identified a subset of analogues that demonstrated statistically significant in vivo dose-dependent inhibition of adenoma progression and survival extension in an APC<sup>min/+</sup> mouse model. However, in vitro–in vivo correlation analysis showed their chemoprotective effects were driven by residual systemic COX-2 inhibition, rationalizing their less than expected efficacies and highlighting the challenges associated with COX-2-mediated CRC disease chemoprevention.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Colorectal cancer (CRC) is the third leading cause of cancer-related death in both men and women in the United States and also one of the most preventable malignancies.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> It is well accepted that most CRCs occur via a metachronous adenoma–carcinoma sequence characterized by well-staged genetic alterations and oncogenic transformation over many years.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> A long-term use of a single or combination of chemoprotective agents has been shown to impede, arrest, or even reverse the development of adenomas in the colon, and interfere with their progression from premalignant adenomas to carcinomas.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> In this regard, nonsteroidal anti-inflammatory drugs (NSAIDs), particularly selective cyclooxygenase COX-2 inhibitors, have been one of the most studied class of drugs in CRC chemoprevention.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> Recently, extensive epidemiological and randomized clinical studies have unequivocally established the chemopreventive effects of NSAIDs.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15 ref16">(11−16)</a> Celecoxib (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), a modestly selective COX-2 inhibitor, was approved by the FDA for adenoma prevention in patients with familial adenomatous polyposis (FAP), an inherited genetic predisposition to CRC.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of celecoxib (<b>1</b>) and etoricoxib (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">NSAIDs act by inhibiting the synthesis of prostanoids, a family of biologically active mediators generated by the activity of COXs.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> On the basis of pharmacodynamic (PD) features at therapeutic doses, NSAIDs are classified as either nonselective COX-1/COX-2 inhibitors or selective COX-2 inhibitors. The precise molecular mechanism of colorectal tumorigenesis inhibition by NSAIDs has not been fully delineated, and likely involves a combination of COX-dependent and COX-independent pathways.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> A prolonged use of nonselective NSAIDs is associated with side effects such as gastrointestinal bleeding and ulceration that is partially attributed to COX-1 inhibition in the cases of SC-560 and indomethacin.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a></div><div class="NLM_p">COX-2 and COX-1 are two isoenzymes that catalyze the initial step of the conversion of arachidonic acid to bioactive prostaglandins (PGs).<a onclick="showRef(event, 'ref18 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref18 ref25 ref26">(18,25,26)</a> Constitutive COX-1 is ubiquitously expressed in almost all tissues for housekeeping PG synthesis, whereas inducible COX-2 is upregulated via stimulation of inflammatory cytokines or growth factors.<a onclick="showRef(event, 'ref18 ref27'); return false;" href="javascript:void(0);" class="ref ref18 ref27">(18,27)</a> Increased expression of COX-2 occurs during all stages of the multistep progression of CRC,<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> and overexpression of COX-2 correlates with the colon tumor size, invasiveness, and increased PG levels.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> It is now understood that proinflammatory and immune-suppressive PGE<sub>2</sub> plays a central role in colorectal tumor growth by promoting proliferation, survival, motility, angiogenesis, and DNA methylation and potentiating Wnt signaling.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35 ref36">(32−36)</a> In preclinical studies, inhibition of COX-2 reduced the size and number of polyps in multiple adenoma and inflammation mouse models.<a onclick="showRef(event, 'ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40">(37−40)</a> In a randomized clinical study conducted in FAP patients, a significant dose-dependent reduction in polyp burden was observed in patients who received celecoxib (<b>1</b>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Rofecoxib (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was also found to significantly reduce the risk of recurrent adenomas in another clinical trial focusing on maintaining a polyp-free colon in FAP patients.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In the Prevention of Sporadic Adenomatous Polyps (PreSAP) clinical trial, the use of celecoxib was correlated with a reduced relative risk (RR of 0.64) for adenomas detected during a 3 year period.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> However, these studies also showed that cardiovascular (CV) adverse events increased with the administration of selective COX-2 inhibitors.<a onclick="showRef(event, 'ref16 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref16 ref41 ref42">(16,41,42)</a> The elevated CV hazard was associated with COX-2 dependent pathways, putatively attributed to blocked prostacyclin (PGI<sub>2</sub>) production.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> This serious CV risk has rendered celecoxib (<b>1</b>) and rofecoxib (<b>2</b>) unsuitable for a long-term use in a wider population of patients.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16 ref41 ref42">(12−16,41,42)</a></div><div class="NLM_p">To minimize the risk of CV adverse effects, but maintain the beneficial property of attenuating colon polyp progression, colon-specific prodrugs of celecoxib have been investigated.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> Other approaches to overcome systemic adverse events, including the use of formulations to deliver active drugs to different regions of the gastrointestinal tract, have also been reported.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> Instead, we pursued an alternative strategy to modulate the physicochemical properties of potent and selective COX-2 inhibitor candidate drugs in order to restrict them to the intestinal tract. In so doing, local on-target concentrations in the gastrointestinal tract are maximized while systemic exposure is minimized.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Our objective, therefore, was to identify a colon-targeted, orally administered, COX-2-selective inhibitor that would suppress local PGE<sub>2</sub> production in the target tissue (lamina propria), reduce adenoma progression for CRC chemoprevention, and be devoid of systemically mediated CV adverse effects.</div><div class="NLM_p">We chose etoricoxib (<b>3</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) as the starting point based on two key factors.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> First, we recently described the use of reoptimized MS-based COX enzymatic assays to investigate previously unpublished time-dependent inhibition kinetics of COX-2 inhibitors from several chemical series.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Our studies confirmed high specificity of COX-2 inhibition associated with etoricoxib (<b>3</b>) and close analogues (<b>4</b>–<b>12</b>) sharing a common pyridyl core ring (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In contrast, celecoxib (<b>1</b>) displayed only moderate selectivity for COX-2 over COX-1 inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Moreover, celecoxib (<b>1</b>) exhibited high overall thermodynamic potency indicated by the intrinsic inhibition constant (<i>K</i>i*), but also associated with a short dissociation half-life (<i>t</i><sub>1/2(dissociation)</sub>). By contrast, etoricoxib (<b>3</b>) and its analogues <b>10</b> and <b>11</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), while less potent than <b>1</b>, showed a longer kinetic residence time (<i>t</i><sub>1/2(dissociation)</sub>) for target occupancy.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> We envisaged that long residence time kinetics would be important for robust target engagement in local colon tissues by minimizing systemic drug recirculation resulting from gut-restricted distribution.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Potency in Human COX-2/COX-1 Enzymes, and COX-2/COX-1-Driven PGE<sub>2</sub> Synthesis in HEK293 Cells of <b>1</b>, <b>3–12</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd</th><th class="colsep0 rowsep0" align="center">hCOX-2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">hCOX-1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">PGE<sub>2</sub> COX-2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">PGE<sub>2</sub> COX-1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">0.028 ± 0.027</td><td class="colsep0 rowsep0" align="left">9.2 ± 0.81</td><td class="colsep0 rowsep0" align="left">0.057 ± 0.021</td><td class="colsep0 rowsep0" align="left">0.41 ± 0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">0.43 ± 0.03</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">0.56 ± 0.19</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">0.39 ± 0.04</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">1.50 ± 0.23</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">6.36<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">1.89 ± 0.49</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">3.24<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">0.95 ± 0.16</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">17.1 ± 1.8</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">4.10 ± 0.14</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">0.84 ± 0.06</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">0.60 ± 0.43</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">0.226 ± 0.042</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">0.047 ± 0.036</td><td class="colsep0 rowsep0" align="left">14.1 ± 4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">18.2<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">2.95<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>50</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Peroxidase fluorescent kinetic activities were measured (IC<sub>50</sub> ± S.D.) using 10-acetyl-3,7-dihydroxyphenoxazine (ADHP) as an electron donor after preincubation with inhibitors for 60 min.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Production of PGE<sub>2</sub> was measured over time (IC<sub>50</sub> ± S.D.) by tandem MS/MS analysis after pretreatment with inhibitors for 60 min in 10% FBS.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Tested only once. The number of replicates for other tested compounds was at least twice.</p></div></div></div><div class="NLM_p last">Second, compared to celecoxib (<b>1</b>, clog <i>P</i> 4.57), etoricoxib (<b>3</b>, clog <i>P</i> 2.35) was a more hydrophilic starting point for our exploration. Previously, the physicochemical property-based approach proved to be quite effective in identifying gut-restricted JAK inhibitors with low intrinsic permeability, which translated into high colonic retention and low systemic exposure after oral dosing.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Our initial plan was centered on lowering clog <i>P</i> to reduce permeability while balancing potency of COX-2 inhibition, a similar strategy utilized for enteric JAK inhibitors.<a onclick="showRef(event, 'ref47 ref52'); return false;" href="javascript:void(0);" class="ref ref47 ref52">(47,52)</a> However, an inverse correlation of potency and clog <i>P</i> counteracted our efforts for further lowering the permeability of these inhibitors. The high clearance of these analogues was recognized as a key attribute to minimize systemic exposure for the small fraction of drug that was absorbed. Herein, we describe our coordinated multidimensional optimization efforts for a series of potent, selective COX-2 inhibitors highlighting their gut-restricted pharmacological characterization in vitro and in vivo.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Analysis of cocrystal structures of celecoxib (<b>1</b>), close analogues, and rofecoxib (<b>2</b>) bound to COX-2 enzymes (PDB IDs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LN1">3LN1</a>; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIR">5KIR</a>) indicated the phenylsulfonamide or methylsulfonylphenyl groups were optimal and critical in occupying the COX-2-binding pocket surrounded by key residues, especially Arg499 and Val509.<a onclick="showRef(event, 'ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55">(53−55)</a> As etoricoxib (<b>3</b>) was also shown to share a similar binding orientation to COX-2 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S11, Figure S5</a>), these structures served as the basis for our exploration (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). We recently reoptimized COX enzymatic assays to evaluate COX-2 inhibitors.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Because COX enzymes are intracellular targets localized in subcellular compartments such as endoplasmic reticulum (ER) and the nuclear envelope, we also established MS-based orthogonal assays to confirm cellular penetration and uptake as well as COX-1/COX-2 selectivity of these inhibitors by measuring production of PGE<sub>2</sub> from arachidonic acid in stably transfected human embryonic kidney (HEK) 293 TRex cells overexpressing COX-1 or COX-2 controlled by an inducible tetracycline promoter.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking model of compound <b>11</b> (balls and sticks) in complex with COX-2 (side chains as sticks and binding pocket depicted as an electrostatic surface map—blue: positive and red: negative potential). Celecoxib (<b>1</b>, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LN1">3LN1</a>) is superimposed as purple sticks for reference.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The 5-CF<sub>3</sub> analogue <b>4</b> (clog <i>P</i> 2.06; hCOX-2 IC<sub>50</sub> 0.39 μM), with a less planar, gem-dimethyl-substituted glycol replacing its peripheral pyridinyl ring, was identified to have lower clog <i>P</i> but still retain similar enzymatic potency and selectivity to etoricoxib (<b>3</b>, clog <i>P</i> 2.35; hCOX-2 IC<sub>50</sub> 0.43 μM) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The 5-CF<sub>3</sub> moiety of <b>4</b> was anticipated to occupy a similar region in the COX-2 active site to 3-CF<sub>3</sub> of celecoxib (<b>1</b>). The nonfluorinated analogues <b>5</b> (5-Me; clog <i>P</i> 1.60; hCOX-2 IC<sub>50</sub> 6.36 μM) and <b>6</b> (5-Et; clog <i>P</i> 2.13; hCOX-2 IC<sub>50</sub> 3.24 μM) lost enzymatic potency but still maintained cellular COX-2 potency in the low micromolar range (IC<sub>50</sub> 1–2 μM). However, by reducing clog <i>P</i> below 1, analogue <b>7</b> (5-CH<sub>2</sub>OH; clog <i>P</i> 0.51; hCOX-2 IC<sub>50</sub> > 50 μM) became inactive in both enzymatic and cellular assays (PGE<sub>2</sub> COX-2 > 50 μM). Introducing an additional 6-methoxy (R<sup>1</sup> = Me) or 6-isopropoxy (R<sup>1</sup> = <i>i</i>-Pr) in <b>7</b> led to an improvement in enzymatic activity in <b>8</b> (clog <i>P</i> 0.89; hCOX-2 IC<sub>50</sub> 17.1 μM) and <b>9</b> (clog <i>P</i> 1.73; hCOX-2 IC<sub>50</sub> 4.10 μM) but did not confer cellular activity (PGE<sub>2</sub> COX-2 IC<sub>50</sub> > 50 μM). Fortunately, continued SAR development with 6-propoxy (R<sup>1</sup> = <i>n</i>-Pr) and 6-butoxy (R<sup>1</sup> = <i>n</i>-Bu) improved both enzymatic and cellular potencies as shown in analogues <b>10</b> (clog <i>P</i> 1.95; hCOX-2 IC<sub>50</sub> 0.84 μM; PGE<sub>2</sub> COX-2 IC<sub>50</sub> 0.6 μM) and <b>11</b> (clog <i>P</i> 2.48; hCOX-2 IC<sub>50</sub> 0.226 μM; PGE<sub>2</sub> COX-2 IC<sub>50</sub> 0.047 μM). In particular, <b>11</b> displayed comparable potency to etoricoxib (<b>3</b>, PGE<sub>2</sub> COX-2 IC<sub>50</sub> 0.56 μM) and celecoxib (<b>1</b>, PGE<sub>2</sub> COX-2 IC<sub>50</sub> 0.057 μM). Like etoricoxib (<b>3</b>, PGE<sub>2</sub> COX-1 IC<sub>50</sub>/COX-2 IC<sub>50</sub> ratio >80), compounds <b>10</b> (PGE<sub>2</sub> COX-1 IC<sub>50</sub> > 50 μM) and <b>11</b> (PGE<sub>2</sub> COX-1 IC<sub>50</sub> = 14.1 μM) remained more selective than celecoxib (<b>1</b>, PGE<sub>2</sub> COX-1 IC<sub>50</sub>/COX-2 IC<sub>50</sub> ratio ∼ 7). However, by lowering clog <i>P</i> below 1, compound <b>12</b> (R<sup>1</sup> = (CH<sub>2</sub>)<sub>2</sub>OMe; clog <i>P</i> 0.78) lost significant potency (hCOX-2 IC<sub>50</sub> 18.2 μM; PGE<sub>2</sub> COX-2 IC<sub>50</sub> 2.95 μM) compared to corresponding compound <b>11</b> (R<sup>1</sup> = <i>n</i>-Bu; clog <i>P</i> 2.48).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Evolution of etoricoxib (<b>3</b>) and analogues <b>4–12</b> for local enteric delivery.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>1</b>, <b>3</b>, <b>4</b>, <b>6</b>, <b>10</b>, and <b>11</b> were screened in cassette PO dosing PK studies for their systemic (plasma) and colonic exposures at 2 and 4 h time points following oral dosing of 10 mg/kg in C57BL mice (<i>T</i><sub>max</sub> ranging from 0.25 to 3 h). In vivo clearance (CL), volume of distribution (<i>V</i><sub>dss</sub>), and half-life (<i>T</i><sub>1/2</sub>) of these compounds were also determined in cassette IV dosing PK studies in mice to correlate with in vitro human or mouse liver microsomal and hepatocyte stability (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compound <b>4</b> was highly stable in human and mouse liver microsomes and hepatocytes in vitro, which was consistent with its low clearance (CL 0.54 mL/min/kg) and long half-life (<i>T</i><sub>1/2</sub> 38.5 h) in a cassette 2 mg/kg IV PK study. Compound <b>4</b> also had good exposure and equal distribution in colon (8400 ng/g) and plasma (9803 ng/mL) at 4 h (<i>T</i><sub>max</sub> 3 h) following a cassette 10 mg/kg oral dosing in vivo. Celecoxib (<b>1</b>) showed modest metabolic stability in vitro but moderate clearance (CL 10.5 mL/min/kg) and half-life (<i>T</i><sub>1/2</sub> 1.27 h) in mice in vivo, which was consistent with a high exposure in colon (9460 ng/g) and a relatively lower exposure in plasma (2553 ng/mL). Etoricoxib (<b>3</b>) was metabolically stable in human liver microsomes and hepatocytes but unstable in mouse and showed higher clearance (CL 41.3 mL/min/kg) and a short half-life (<i>T</i><sub>1/2</sub> 0.78 h), leading to a low exposure in colon (55.7 ng/g) and plasma (36.4 ng/mL) in mice. Similarly, compound <b>6</b> was metabolically unstable in mouse in vitro and unsurprisingly showed a low exposure in colon (51.6 ng/g) and plasma (21.8 ng/mL) consistent with its higher clearance (CL 65.6 mL/min/kg) and a shorter half-life (<i>T</i><sub>1/2</sub> 0.32 h) in vivo. There were no signs of gut restriction for compounds <b>1</b>, <b>3</b>, <b>4</b>, and <b>6</b> despite a wide range of physicochemical and ADME properties such as clog <i>P</i>, metabolic stability, and clearance. Their volume of distribution (<i>V</i><sub>dss</sub>) was in a narrow range of 1–2 L/kg. Unexpectedly, compounds <b>10</b> and <b>11</b> displayed high colonic exposures (>4300 ng/g) and a low systemic exposure (<6 ng/mL) with a distribution ratio of C/P > 1200 at 4 h (<i>T</i><sub>max</sub> ∼ 0.25 h) following cassette 10 mg/kg oral dosing. Both compounds exhibited high clearance (>90 mL/min/kg) with a volume of distribution (<i>V</i><sub>dss</sub>) above others (>2 L/kg) after 2 mg/kg IV cassette dosing (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The gut-restricted characteristics of compounds <b>10</b> and <b>11</b> were confirmed by single-dose time-course PK studies following colon exposures as well as systemic plasma concentration in expanded time points after an oral dosing (10 mg/kg) in C57BL Mice (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, also <a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S4, Figures S1 and S2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Human/Mouse Liver Microsomal, Hepatic Clearance, and Mean Cassette Dosing PK Parameters of Compounds <b>1</b>, <b>3</b>, <b>4</b>, <b>6</b>, <b>10</b>, and <b>11</b> in C57BL Mice by PO (10 mg/kg) and IV Dosing (2 mg/kg)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Compound</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left"><b>11</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLM <i>T</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">67.2</td><td class="colsep0 rowsep0" align="left">>184</td><td class="colsep0 rowsep0" align="left">>184</td><td class="colsep0 rowsep0" align="left">68.7</td><td class="colsep0 rowsep0" align="left">>184</td><td class="colsep0 rowsep0" align="left">27.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MLM <i>T</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">59.3</td><td class="colsep0 rowsep0" align="left">53.8</td><td class="colsep0 rowsep0" align="left">>184</td><td class="colsep0 rowsep0" align="left">13.2</td><td class="colsep0 rowsep0" align="left">19.6</td><td class="colsep0 rowsep0" align="left">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human Hep <i>T</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">57.4</td><td class="colsep0 rowsep0" align="left">>371</td><td class="colsep0 rowsep0" align="left">>371</td><td class="colsep0 rowsep0" align="left">84.2</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse Hep <i>T</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">33.1</td><td class="colsep0 rowsep0" align="left">29.2</td><td class="colsep0 rowsep0" align="left">>371</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">10.5</td><td class="colsep0 rowsep0" align="left">41.3</td><td class="colsep0 rowsep0" align="left">0.54</td><td class="colsep0 rowsep0" align="left">65.6</td><td class="colsep0 rowsep0" align="left">92.7</td><td class="colsep0 rowsep0" align="left">101.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>dss</sub> (L/kg)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.94</td><td class="colsep0 rowsep0" align="left">1.27</td><td class="colsep0 rowsep0" align="left">1.55</td><td class="colsep0 rowsep0" align="left">1.35</td><td class="colsep0 rowsep0" align="left">3.05</td><td class="colsep0 rowsep0" align="left">4.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.27</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">38.5</td><td class="colsep0 rowsep0" align="left">0.32</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colon (ng/g), 4 h<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">9460</td><td class="colsep0 rowsep0" align="left">55.7</td><td class="colsep0 rowsep0" align="left">8400</td><td class="colsep0 rowsep0" align="left">51.6</td><td class="colsep0 rowsep0" align="left">5336</td><td class="colsep0 rowsep0" align="left">4352</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma (ng/mL), 4 h<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">2553</td><td class="colsep0 rowsep0" align="left">36.4</td><td class="colsep0 rowsep0" align="left">9803</td><td class="colsep0 rowsep0" align="left">21.8</td><td class="colsep0 rowsep0" align="left">5.7</td><td class="colsep0 rowsep0" align="left">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ratio colon/plasma, 4 h<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">1276</td><td class="colsep0 rowsep0" align="left">1616</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">For HLM/MLM T<sub>1/2</sub>: high stability > 184 min; 33 min < medium stability <184 min; and low stability < 33 min.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">For hepatocytes <i>T</i><sub>1/2</sub>: high stability > 371 min; 60 min < medium stability < 371 min; and low stability < 60 min.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">IV cassette dosing of <b>2–4</b> compounds in each group, solution in 70% PEG/H<sub>2</sub>O.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Oral cassette dosing, solution in 70% PEG/H<sub>2</sub>O, values shown are the average concentration for individual animals at time point of 4 h.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">The ratios were calculated as averages of ratios from individual animals.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last"><i>T</i><sub>1/2</sub> was not obtained due to <i>R</i>-squared (<i>R</i><sub>sq</sub>) < 0.75.</p></div></div></div><div class="NLM_p">The PK results suggested that unique metabolism of compounds <b>10</b> and <b>11</b> played a critical role in the observed high colon/plasma (C/P) ratio distinct from that of compound <b>6</b>. To study its metabolic fate, compound <b>11</b> was incubated with human and mouse hepatocytes, and metabolites were identified by liquid chromatography interfaced with tandem mass spectrometric (LC–MS/MS) analysis and their relative percentages were quantitatively assessed based on peak areas in the mass spectral response (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>11</b> was found to undergo extensive metabolism with a turnover of ∼100 and 79.6% in human and mouse hepatocytes, respectively. Glucuronidation was the major metabolic pathway in both species with a single O-glucuronide M6 identified as the major metabolite in human (92.5%) and mouse (24.7%). The hydroxyl group in 5-CH<sub>2</sub>OH was the putative site for the formation of O-glucuronide M6. However, efforts to confirm the structure of M6 were unsuccessful due to the inability to isolate the putative M6 or synthesize an authentic sample for authentication. A subsequent in vitro UDP-glucuronosyltransferase (UGT) phenotyping screening identified UGT1A9 as the primary isoform responsible for driving clearance via glucuronidation (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S6</a>). Consistent with these findings, the single-dose oral and IV PK studies confirmed a minimal systemic plasma exposure and low oral bioavailability in mouse (4.25%), rat (1.5%), and monkey (4.87%) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S5, Table S4</a>). Dog was the exception, showing high oral bioavailability (74%, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Table S4</a>), possibly resulting from different UGT1A9 expression levels or substrate affinity, as reported with other human UGT1A9 substrates (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S7</a>).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Metabolite Profiling and Identification from Incubations of Compound <b>11</b> with Human and Mouse Hepatocytes<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0019.gif" alt="" id="GRAPHIC-d7e1840-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">% peak area</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">metabolite</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th><th class="colsep0 rowsep0" align="center">biotransformation</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M1</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.51</td><td class="colsep0 rowsep0" align="left">O-dealkylation and glucuronidation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M2</td><td class="colsep0 rowsep0" align="char" char=".">3.08</td><td class="colsep0 rowsep0" align="char" char=".">7.97</td><td class="colsep0 rowsep0" align="left">O-dealkylation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M3</td><td class="colsep0 rowsep0" align="char" char=".">1.15</td><td class="colsep0 rowsep0" align="char" char=".">1.56</td><td class="colsep0 rowsep0" align="left">hydroxylation and glucuronidation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M4</td><td class="colsep0 rowsep0" align="char" char=".">2.63</td><td class="colsep0 rowsep0" align="char" char="."><b>38.44</b></td><td class="colsep0 rowsep0" align="left">hydroxylation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M5</td><td class="colsep0 rowsep0" align="char" char=".">0.53</td><td class="colsep0 rowsep0" align="char" char=".">2.23</td><td class="colsep0 rowsep0" align="left">hydroxylation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M6</td><td class="colsep0 rowsep0" align="char" char="."><b>92.51</b></td><td class="colsep0 rowsep0" align="char" char="."><b>24.76</b></td><td class="colsep0 rowsep0" align="left">O-glucuronidation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">4.14</td><td class="colsep0 rowsep0" align="left">alcohol oxidation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>11</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."><b>20.40</b></td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Final compound <b>11</b> concentration of 10 μM and a cell concentration of 1 × 10<sup>6</sup> cells/mL (1000 μL final incubation volume). Cells were incubated for 0 and 2 h. The percent compositions of parent drug and its metabolites were based on peak areas from 5 ppm accurate mass measurements and with assumptions of equal positive ESIs.</p></div></div></div><div class="NLM_p">The in vitro metabolism study also identified oxidative hydroxylation of the 6-butoxy chain as the other major metabolic clearance pathway in mouse. However, this path was less significant in human hepatocytes indicated by the formation of a variable amount of hydroxylated metabolites M4 and M5 (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Minor metabolites such as o-dealkylated M2 (loss of <i>n</i>-butyl) and carboxylic acid M7 from oxidation of 5-CH<sub>2</sub>OH were also observed in human and/or mouse hepatocytes. These putative metabolites M2, M4, M5, and M7 were synthesized and found to be inactive in the COX-2 enzymatic (COX-2 IC<sub>50</sub> > 50 μM) assay and would not contribute to in vivo pharmacology (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S3, Table S2</a>). The metabolite study confirmed that compound <b>10</b> was metabolized similar to compound <b>11</b> with glucuronidation representing the dominant metabolic pathway in both human and mouse species in vitro. Hydroxylation of the 6-propoxy moiety and oxidation of 5-CH<sub>2</sub>OH to the carboxylic acid were major pathways in mouse but less significant in human hepatocytes (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S2</a>). Like compound <b>11</b>, single-dose oral and IV PK studies of compound <b>10</b> also generally demonstrated gut-restricted characteristics across species with low oral bioavailability in mouse (4.25%), rat (2.3%), and monkey (20.0%); dog was an exception (79.5%) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S4, Table S3</a>).</div><div class="NLM_p">To better understand the critical role of the primary hydroxyl group (5-CH<sub>2</sub>OH) in compound <b>10</b> or <b>11</b> leading to high in vivo clearance and high colon/plasma (C/P) ratios, compounds <b>13–20</b> were prepared for characterization (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Introducing a methyl group (R<sup>2</sup> = −CH<sub>2</sub>(OH)Me) led to compound <b>13</b> with lower clearance (CL 48.2 mL/min/kg) and a reduced colon/plasma ratio (C/P: 134.3). Adding two geminal methyl groups (R<sup>2</sup> = −CH(OH)Me<sub>2</sub>) resulted in compound <b>14</b> with a diminished colon concentration (85.8 ng/g) and a colon/plasma ratio (C/P: 2.5). Extending compound <b>11</b> (R<sup>2</sup> = −CH<sub>2</sub>OH) with a hydroxyethyl group provided compound <b>15</b> (R<sup>2</sup> = −CH<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>OH) with an attenuated colon/plasma ratio (C/P: 16.5), presumably attributed to the alteration of metabolism for hepatic clearance or less dependence on the glucuronidation pathway. These results provided direct evidence in support of the primary benzylic hydroxyl moiety (R<sup>2</sup> = −CH<sub>2</sub>OH) as the major metabolic site for glucuronidation driving clearance and resultant high colon/plasma exposure ratios.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Analogues <b>13–20</b> with modifications at R<sup>2</sup> or R<sup>3</sup> on the pyridine ring sites of compound <b>11</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibitory Potency in COX-2/COX-1-Driven PGE<sub>2</sub> Synthesis in HEK293 Cells, and Mean Cassette Dosing PK Parameters of Compounds <b>13-20</b> in C57BL Mice by IV Dosing (2 mg/kg) and PO (10 mg/kg)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">PGE<sub>2</sub>, COX-2, IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">PGE<sub>2</sub>, COX-1, IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">colon (ng/g), 4 h<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">plasma (ng/mL), 4 h<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">ratio of colon/plasma<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">0.047 ± 0.036</td><td class="colsep0 rowsep0" align="left">14.1 ± 4.2</td><td class="colsep0 rowsep0" align="char" char=".">101.2</td><td class="colsep0 rowsep0" align="char" char=".">4352</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">1616</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">2.34<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">7.69<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">48.2</td><td class="colsep0 rowsep0" align="char" char=".">2810</td><td class="colsep0 rowsep0" align="char" char=".">22.8</td><td class="colsep0 rowsep0" align="char" char=".">134.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">1.21 ± 0.30</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="char" char=".">58.8</td><td class="colsep0 rowsep0" align="char" char=".">85.8</td><td class="colsep0 rowsep0" align="char" char=".">35.8</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">0.54 ± 0.46</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="char" char=".">55.4</td><td class="colsep0 rowsep0" align="char" char=".">478.2</td><td class="colsep0 rowsep0" align="char" char=".">28.7</td><td class="colsep0 rowsep0" align="char" char=".">16.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">0.049</td><td class="colsep0 rowsep0" align="left">0.511</td><td class="colsep0 rowsep0" align="char" char=".">32.2</td><td class="colsep0 rowsep0" align="char" char=".">1942</td><td class="colsep0 rowsep0" align="char" char=".">75.9</td><td class="colsep0 rowsep0" align="char" char=".">24.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">0.036 ± 0.009</td><td class="colsep0 rowsep0" align="left">2.46 ± 0.99</td><td class="colsep0 rowsep0" align="char" char=".">101.5</td><td class="colsep0 rowsep0" align="char" char=".">1872</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td><td class="colsep0 rowsep0" align="char" char=".">402.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">1.32 ± 0.33</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="char" char=".">68.6</td><td class="colsep0 rowsep0" align="char" char=".">11920</td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">1596</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">0.21<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">>50<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">89.3</td><td class="colsep0 rowsep0" align="char" char=".">1854</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1040</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">0.037 ± 0.027</td><td class="colsep0 rowsep0" align="left">7.23 ± 2.31</td><td class="colsep0 rowsep0" align="char" char=".">100.4</td><td class="colsep0 rowsep0" align="char" char=".">5394</td><td class="colsep0 rowsep0" align="char" char=".">9.9</td><td class="colsep0 rowsep0" align="char" char=".">545.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Peroxidase fluorescent kinetic activities were measured (IC<sub>50</sub> ± S.D.) using ADHP as an electron donor after preincubation with inhibitors for 60 min.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">The production of PGE<sub>2</sub> and PGD<sub>2</sub> was measured over time (IC<sub>50</sub> ± S.D.) by tandem MS/MS analysis after pretreatment with inhibitors for 60 min in 10% FBS.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">IV cassette dosing, solution in 70% PEG/H<sub>2</sub>O.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Oral cassette dosing, solution in 70% PEG/H<sub>2</sub>O, values shown are the average concentration for individual animals at a time point of 4 h.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">The ratios were calculated as averages of ratios from individual animals.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">Tested only once. The number of replicates for other tested compounds was at least twice.</p></div></div></div><div class="NLM_p">Turning our attention to the aliphatic gem-dimethyl-substituted glycol in compound <b>11</b>, we found that replacing this group with an aromatic 4-fluorophenyl led to a lower clearance (CL 32.2 mL/min/kg) and a lower colon/plasma exposure ratio (C/P: 24.9) as shown in compound <b>16</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Also, compound <b>16</b> showed narrow selectivity in the cellular COX-1/COX-2 assays (PGE2 COX-1 IC<sub>50</sub>/COX-2 IC<sub>50</sub> ratio ∼ 10, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), highlighting that aromatic substitution at R<sup>3</sup> was unfavorable. Compounds <b>17</b>, <b>18</b>, and <b>19</b>, sharing a terminal oxetanyl group with or without an attached tertiary hydroxyl moiety, all maintained high colon/plasma ratios (C/P: >400). This finding indicated the tertiary hydroxyl group might be additive but not essential for driving the clearance and high colon/plasma ratio. It should be pointed out that modification of gem-dimethyl groups to an oxetane ring altered COX-2 potency or selectivity and colonic exposure. For example, compared to compound <b>11</b> (PGE2 COX-1 IC<sub>50</sub>/COX-2 IC<sub>50</sub> ratio ∼ 300; colon concentration 6506 ng/g at 2 h) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), analogue <b>17</b> was potent in COX-2 inhibition but 4-fold less selective (PGE2 COX-2 IC<sub>50</sub> 0.047 μM; PGE2 COX-1 IC<sub>50</sub>/COX-2 IC<sub>50</sub> ratio ∼ 70). Compound <b>18</b> was relatively less potent in cellular COX-2 activity (PGE2 COX-2 IC<sub>50</sub> 1.32 μM). The colonic exposure of compound <b>19</b> was noticeably lower (1854 ng/g). By contrast, cyclizing the terminal gem-dimethyl to a cyclobutyl group led to compound <b>20</b> with overall in vitro and in vivo properties comparable with compound <b>11</b> (<named-content content-type="anchor" rid="fig4" type="simple"></named-content><a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Tables <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Summary of Inhibitory Potency in Human COX-2/COX-1 Enzymes, Calculated Intrinsic Inhibition Constant (<i>K</i>i*), Dissociation Half-Life (<i>t</i><sub>1/2(dissociation)</sub>), COX-2-Driven PGE<sub>2</sub> Synthesis in HEK293 Cells, Human Whole Blood COX-2/COX-1 Assays, ADME, and Mean Cassette or Single-Dosing PK Exposure Parameters in C57BL Mice by PO (10 mg/kg), <sup>18</sup>F-FDG Uptake, Polyp Area Tumor Growth Inhibition, and Survival Extension in Apc<sup>Min/+</sup> Mice of Compounds <b>1</b>, <b>3</b>, <b>10</b>, <b>11</b>, and <b>20–23</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0020.gif" alt="" id="GRAPHIC-d7e2502-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound</td><td class="colsep0 rowsep0" align="left"><b>1</b> (celecoxib)</td><td class="colsep0 rowsep0" align="left"><b>3</b> (etoricoxib)</td><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left"><b>23</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hCOX-2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.028 ± 0.027</td><td class="colsep0 rowsep0" align="left">0.43 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.84 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.226 ± 0.042</td><td class="colsep0 rowsep0" align="left">0.12 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.50 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.10</td><td class="colsep0 rowsep0" align="left">0.45 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hCOX-2 <i>K</i>i* (nM)</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.08</td><td class="colsep0 rowsep0" align="left">69 ± 4</td><td class="colsep0 rowsep0" align="left">114 ± 9</td><td class="colsep0 rowsep0" align="left">12 ± 1</td><td class="colsep0 rowsep0" align="left">3.0 ± 0.2</td><td class="colsep0 rowsep0" align="left">32 ± 3</td><td class="colsep0 rowsep0" align="left">12 ± 2</td><td class="colsep0 rowsep0" align="left">19 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hCOX-2 <i>t</i><sub>1/2(dissociation)</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.71 ± 0.03</td><td class="colsep0 rowsep0" align="left">6.1 ± 0.3</td><td class="colsep0 rowsep0" align="left">8.9 ± 0.7</td><td class="colsep0 rowsep0" align="left">18 ± 1</td><td class="colsep0 rowsep0" align="left">39 ± 2</td><td class="colsep0 rowsep0" align="left">22 ± 2</td><td class="colsep0 rowsep0" align="left">27 ± 3</td><td class="colsep0 rowsep0" align="left">23 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hCOX-1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.2 ± 0.81</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PGE<sub>2</sub> COX-2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.057 ± 0.021</td><td class="colsep0 rowsep0" align="left">0.56 ± 0.19</td><td class="colsep0 rowsep0" align="left">0.60 ± 0.43</td><td class="colsep0 rowsep0" align="left">0.047 ± 0.036</td><td class="colsep0 rowsep0" align="left">0.037 ± 0.027</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.078 ± 0.049</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PGE<sub>2</sub> COX-1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.41 ± 0.20</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">14.1 ± 4.2</td><td class="colsep0 rowsep0" align="left">7.23 ± 2.31</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">21.8 ± 16.4</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HWB COX-2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">0.44 ± 0.37</td><td class="colsep0 rowsep0" align="left">0.611 ± 0.055</td><td class="colsep0 rowsep0" align="left">2.341 ± 0.002</td><td class="colsep0 rowsep0" align="left">0.346<a class="ref internalNav" href="#t5fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">0.146<a class="ref internalNav" href="#t5fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">0.877 ± 0.378</td><td class="colsep0 rowsep0" align="left">0.345 ± 0.126</td><td class="colsep0 rowsep0" align="left">7.232<a class="ref internalNav" href="#t5fn10" aria-label="j">j</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HWB COX-1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">14.8 ± 10.7</td><td class="colsep0 rowsep0" align="left">93.8 ± 54.0</td><td class="colsep0 rowsep0" align="left">193 ± 43</td><td class="colsep0 rowsep0" align="left">>180<a class="ref internalNav" href="#t5fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">>60<a class="ref internalNav" href="#t5fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">181 ± 20</td><td class="colsep0 rowsep0" align="left">>180</td><td class="colsep0 rowsep0" align="left">>60<a class="ref internalNav" href="#t5fn10" aria-label="j">j</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human PPB (fu %)</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">11.4</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human colon (fu %)</td><td class="colsep0 rowsep0" align="left">0.31</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">6.6</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left">22.4</td><td class="colsep0 rowsep0" align="left">20.4</td><td class="colsep0 rowsep0" align="left">7.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clog <i>P</i> (log <i>D</i>)</td><td class="colsep0 rowsep0" align="left">4.57 (3.55)</td><td class="colsep0 rowsep0" align="left">2.35</td><td class="colsep0 rowsep0" align="left">1.95 (2.68)</td><td class="colsep0 rowsep0" align="left">2.48 (3.15)</td><td class="colsep0 rowsep0" align="left">2.67 (3.41)</td><td class="colsep0 rowsep0" align="left">2.30 (2.53)</td><td class="colsep0 rowsep0" align="left">2.03 (2.97)</td><td class="colsep0 rowsep0" align="left">1.94 (2.56)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>P</i>app <sub>A>B</sub> (+inh.) (cm/s ×10<sup>–6</sup>)<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">22.4</td><td class="colsep0 rowsep0" align="left">35.9</td><td class="colsep0 rowsep0" align="left">++</td><td class="colsep0 rowsep0" align="left">19.88</td><td class="colsep0 rowsep0" align="left">16.19</td><td class="colsep0 rowsep0" align="left">21.5</td><td class="colsep0 rowsep0" align="left">20.19</td><td class="colsep0 rowsep0" align="left">8.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility FaSSIF (μM)<a class="ref internalNav" href="#t5fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">133.5</td><td class="colsep0 rowsep0" align="left">357.8</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">66.5</td><td class="colsep0 rowsep0" align="left">56.1</td><td class="colsep0 rowsep0" align="left">44.4</td><td class="colsep0 rowsep0" align="left">110.6</td><td class="colsep0 rowsep0" align="left">63.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colon (ng/g), 4 h<a class="ref internalNav" href="#t5fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">9460 ± 2423</td><td class="colsep0 rowsep0" align="left">55.7 ± 3.9</td><td class="colsep0 rowsep0" align="left">2910 ± 1324*</td><td class="colsep0 rowsep0" align="left">802.6 ± 679.4*</td><td class="colsep0 rowsep0" align="left">5290 ± 2745*</td><td class="colsep0 rowsep0" align="left">15520 ± 2417</td><td class="colsep0 rowsep0" align="left">15980 ± 2739</td><td class="colsep0 rowsep0" align="left">12040 ± 3242*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma (ng/mL), 4 h<a class="ref internalNav" href="#t5fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">2553 ± 422</td><td class="colsep0 rowsep0" align="left">36.4 ± 2.5</td><td class="colsep0 rowsep0" align="left">25 ± 31*</td><td class="colsep0 rowsep0" align="left">16.2 ± 15.1*</td><td class="colsep0 rowsep0" align="left">3 ± 1*</td><td class="colsep0 rowsep0" align="left">3.4 ± 1.7</td><td class="colsep0 rowsep0" align="left">3.8 ± 1.2</td><td class="colsep0 rowsep0" align="left">5.5 ± 0.9*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PV plasma (ng/mL), 4 h<a class="ref internalNav" href="#t5fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">2150 ± 544</td><td class="colsep0 rowsep0" align="left">48.6 ± 8.9</td><td class="colsep0 rowsep0" align="left">98.6 ± 45.1*</td><td class="colsep0 rowsep0" align="left">24.8 ± 5.1*</td><td class="colsep0 rowsep0" align="left">82.4 ± 52.6*</td><td class="colsep0 rowsep0" align="left">178.7 ± 90.2</td><td class="colsep0 rowsep0" align="left">230.3 ± 112.3</td><td class="colsep0 rowsep0" align="left">7.1 ± 0.5*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ratio colon/plasma, 4 h<a class="ref internalNav" href="#t5fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">3.8 ± 1.2</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.2</td><td class="colsep0 rowsep0" align="left">492 ± 612*</td><td class="colsep0 rowsep0" align="left">91.5 ± 79.3*</td><td class="colsep0 rowsep0" align="left">1718 ± 392*</td><td class="colsep0 rowsep0" align="left">5264 ± 2245</td><td class="colsep0 rowsep0" align="left">4473 ± 1204</td><td class="colsep0 rowsep0" align="left">2179 ± 245*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ratio colon/PV plasma, 4 h<a class="ref internalNav" href="#t5fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">4.6 ± 1.6</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.3</td><td class="colsep0 rowsep0" align="left">38 ± 29*</td><td class="colsep0 rowsep0" align="left">29.7 ± 19.5*</td><td class="colsep0 rowsep0" align="left">69.9 ± 21.4*</td><td class="colsep0 rowsep0" align="left">101 ± 44</td><td class="colsep0 rowsep0" align="left">77 ± 25</td><td class="colsep0 rowsep0" align="left">1692 ± 336*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ex vivo <sup>18</sup>F-FDG uptake (%)<a class="ref internalNav" href="#t5fn11" aria-label="k">k</a></td><td class="colsep0 rowsep0" align="left">31.4 (<i>P</i> < 0.001)</td><td class="colsep0 rowsep0" align="left">43.5 (<i>P</i> < 0.01)</td><td class="colsep0 rowsep0" align="left">35.6 (<i>P</i> < 0.01)</td><td class="colsep0 rowsep0" align="left">48.9 (<i>P</i> < 0.01)</td><td class="colsep0 rowsep0" align="left">61.2 (<i>P</i> < 0.001)</td><td class="colsep0 rowsep0" align="left">48.6 (<i>P</i> < 0.05)</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t5fn13" aria-label="m">m</a></td><td class="colsep0 rowsep0" align="left">54.8 (<i>P</i> < 0.001)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ex vivo <sup>18</sup>F-FDG IC50 (μM) (95% CI, μM)<a class="ref internalNav" href="#t5fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">4.4 (2.4–47)</td><td class="colsep0 rowsep0" align="left">13 (7.5–53)</td><td class="colsep0 rowsep0" align="left">5.5 (2.7–98)</td><td class="colsep0 rowsep0" align="left">4.2 (1.6–376)</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t5fn13" aria-label="m">m</a></td><td class="colsep0 rowsep0" align="left">14 (7.5–42)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vivo polyp area TGI %<a class="ref internalNav" href="#t5fn14" aria-label="n">n</a></td><td class="colsep0 rowsep0" align="left">65.9</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">41.9</td><td class="colsep0 rowsep0" align="left">35.1</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">48.7</td><td class="colsep0 rowsep0" align="left">39.8</td><td class="colsep0 rowsep0" align="left">25.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vivo survival (days)<a class="ref internalNav" href="#t5fn15" aria-label="o">o</a></td><td class="colsep0 rowsep0" align="left">>82</td><td class="colsep0 rowsep0" align="left">>82</td><td class="colsep0 rowsep0" align="left">>82<a class="ref internalNav" href="#t5fn16" aria-label="p">p</a></td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">74</td><td class="colsep0 rowsep0" align="left">62.5</td><td class="colsep0 rowsep0" align="left">NT</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Single-dose PK at 2 h following oral dosing of 10 mg/kg by solution formulation in 70% PEG/H<sub>2</sub>O.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Peroxidase fluorescent kinetic activities were measured (IC<sub>50</sub> ± S.D.) using ADHP as an electron donor after preincubation with inhibitors for 60 min.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Calculated intrinsic inhibition constant.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Production of PGE<sub>2</sub> was measured over time (IC<sub>50</sub> ± S.D.) by tandem MS/MS analysis after pretreatment with inhibitors for 60 min in 10% FBS.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">HWB = human whole blood.</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Passive permeability (cm/s ×10<sup>–6</sup>) was measured from the apical (A) to the basolateral side (B) of MDCK-MDR1 cells in the presence of a P-gp inhibitor with mass balance >60%.</p></div><div class="footnote" id="t5fn7"><sup><sup>g</sup></sup><p class="last">Equilibrium solubility assay, simulated intestinal fluid under fasted physiological conditions (FaSSIF pH 6.5).</p></div><div class="footnote" id="t5fn8"><sup><sup>h</sup></sup><p class="last">Oral cassette dosing of 10 mg/mg, solution in 70% PEG/H<sub>2</sub>O, the average concentration of individual animals at a time point of 4 h, PV = portal vein.</p></div><div class="footnote" id="t5fn9"><sup><sup>i</sup></sup><p class="last">Ratios were calculated as averages of ratios from individual animals.</p></div><div class="footnote" id="t5fn10"><sup><sup>j</sup></sup><p class="last">Tested only in one donor (<i>N</i> = 1).</p></div><div class="footnote" id="t5fn11"><sup><sup>k</sup></sup><p class="last">Ileum ex vivo percentage change was the mean difference between a dose of 0 <i>vs</i> 300 mg/kg oral daily dosing either incorporated into a chow diet or suspension by gavage for 2 weeks in curative setting (mice starting age of 16 week old).</p></div><div class="footnote" id="t5fn12"><sup><sup>l</sup></sup><p class="last">FDG uptake was plotted against the total compound concentration in ileum at >12 h. IC<sub>50</sub> was fitted for each compound in GraphPad Prism using the parameters assuming: (1) vehicle FDG uptake = no inhibition; (2) celecoxib FDG uptake = complete inhibition; (3) Hill coefficient = 1; (4) weighting = 1/<i>y</i><sup>2</sup>; and (5) 95% confidence interval (CI).</p></div><div class="footnote" id="t5fn13"><sup><sup>m</sup></sup><p class="last">Not conclusive due to animal death.</p></div><div class="footnote" id="t5fn14"><sup><sup>n</sup></sup><p class="last">Tumor growth inhibition (TGI) values from total ileum polyp area (sum of all polyp areas with diameter > 1 mm) following a daily oral dosing of 300 mg/kg as a suspension for 10–12 weeks, %TGI = 1 – (<i>T</i><sub><i>t</i></sub>/<i>C</i><sub><i>t</i></sub>), <i>T</i><sub><i>t</i></sub> = median tumor volume of treated at time <i>t</i>, and <i>C</i><sub><i>t</i></sub> = median tumor volume of control at time <i>t</i>.</p></div><div class="footnote" id="t5fn15"><sup><sup>o</sup></sup><p class="last">Kaplan–Meier survival days were recorded until 50% mortality reached in each group in curative setting (mice starting at age of 16 weeks, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S8</a>) with a daily oral dosing of 100 mg/kg as a suspension unless specified otherwise. Study was terminated at day 82.</p></div><div class="footnote" id="t5fn16"><sup><sup>p</sup></sup><p class="last">Oral daily dosing of 30 mg/kg as a suspension.</p></div></div></div><div class="NLM_p">To support the selection of compounds for in vivo PD studies, additional analogues were synthesized. Modifications to the 6-butoxy (R<sup>4</sup>) site on compounds <b>10</b> and <b>11</b> were made by varying alkoxy length and hydrophobicity, resulting in identification of the fluorinated analogues <b>21</b> (clog <i>P</i> 2.30) and <b>22</b> (clog <i>P</i> 2.03) for further studies (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). By correlating COX-2 cellular and enzymatic potency with physicochemical or ADME properties in this subset of COX-2 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), we observed a direct relationship between clog <i>P</i> (log <i>D</i>) and COX-2 activities. Compounds with low clog <i>P</i> (<1) were unlikely to have acceptable cellular COX-2 potency (PGE2 COX-2 pIC<sub>50</sub> > 6 or IC<sub>50</sub> < 1 μM). This observation was not totally unexpected given the intracellular localization of the COX-2 enzyme and the subcellular microenvironment of the COX-2-binding site, which is surrounded by hydrophobic residues. Low clog <i>P</i> (<1) would not only attenuate permeability for cellular uptake but also affect lipophilicity required for biochemical affinity. The correlation was in line with the weaker potency associated with compounds <b>8</b> (clog <i>P</i> 0.89; <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), <b>12</b> (clog <i>P</i> 0.78; <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), and putative (inactive) metabolites M2, M4, and M5 (clog <i>P</i> < 1; <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, also <a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Table S2</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Correlation between cellular PGE<sub>2</sub> COX-2 potency (pIC<sub>50</sub>) and clog <i>P</i> with human COX-2 enzymatic potency (pIC<sub>50</sub>, color coding) [pIC<sub>50</sub> = −log<sub>10</sub> (IC<sub>50</sub> μM)].</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Conversely, an empirically inverse correlation seemed to exist between a lower clog <i>P</i> (<2) and a higher colon/portal vein (PV) plasma ratio (>150) at 4 h following oral dosing (10 mg/kg) cassette PK in C57BL mice, presumably resulting from limited absorption through reduced permeability (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Careful analysis of single-dose PK studies of compounds <b>10</b> (PV plasma 98.6 ng/mL; systemic plasma 25 ng/mL), <b>20</b> (PV plasma 82.4 ng/mL; systemic plasma 3 ng/mL), <b>21</b> (PV plasma 178.4 ng/mL; systemic plasma 3.4 ng/mL), and <b>22</b> (PV plasma 230.3 ng/mL; systemic plasma 3.8 ng/mL) revealed the PV plasma concentrations were consistently higher than systemic plasma exposures, indicating that some drug was being absorbed across the gut epithelium but subsequently cleared first pass to result in apparent gut restriction (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). To minimize this effect, we incorporated bioisosteric replacements in the phenyl region (R<sup>5</sup>) aimed at attenuating clog <i>P</i> (log <i>D</i>) and permeability (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). A pyridinyl sulfonamide analogue <b>23</b> (clog <i>P</i> 1.94; PGE<sub>2</sub> COX-2 0.23 μM) was identified having acceptable, though decreased, cellular potency. Compound <b>23</b> showed the lowest MDCK based passive permeability (<i>P</i><sub>app A>B</sub> 8.15 cm/s ×10<sup>–6</sup>) and the narrowest gap between PV and systemic plasma exposures (7.1 ng/mL vs 5.5 ng/mL); its similar colon/PV plasma and colon/plasma ratios (2179 vs 1692) were indicative of limited absorption via restricted permeability (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison of the mouse exposure colon/plasma ratio to the colon/PV plasma ratio (both measured at 4 h) in cassette PK following an oral dosing of 10 mg/kg in C57BL mice. All points were color coded in relation to clog <i>P</i>. Logarithmic scale was used on all axes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Analogues <b>21–23</b> as selected representatives with modifications at various sites of compounds <b>11</b> (or <b>10</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To confirm COX-1/COX-2 selectivity in a more physiologically relevant system, compounds <b>10</b>, <b>11</b>, and <b>20–23</b> were evaluated in human whole blood (HWB) for COX-2 inhibition by measuring PGE<sub>2</sub> production stimulated by LPS, and COX-1 inhibition by measuring TXB<sub>2</sub> synthesis stimulated by a calcium ionophore.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a> All analogues displayed concentration-dependent inhibition of PGE<sub>2</sub> and achieved ∼100% inhibition at the highest tested concentration, with COX-2 IC<sub>50</sub> values ranging from 0.15 to 7.5 μM (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). By contrast, none of these compounds significantly inhibited COX-1 (IC<sub>50</sub> > 60 μM), consistent with their COX-1/COX-2 selectivities in stably transfected HEK293 cells. Except for compounds <b>10</b> (HWB COX-2 IC<sub>50</sub> 2.3 μM) and <b>23</b> (HWB COX-2 IC<sub>50</sub> 7.2 μM), compounds <b>11</b> and <b>20–22</b> showed similar potencies to celecoxib (<b>1</b>, HWB COX-2 IC<sub>50</sub> 0.44 μM) and etoricoxib (<b>3</b>, HWB COX-2 IC<sub>50</sub> 0.611 μM). Compounds <b>11</b> and <b>20–22</b> showed higher selectivity (HWB COX-1 IC<sub>50</sub>/COX-2 IC<sub>50</sub> > 200) than etoricoxib (<b>3</b>, HWB COX-1 IC<sub>50</sub>/COX-2 IC<sub>50</sub> ∼ 150). The selectivity of compound <b>10</b> (HWB COX-1 IC<sub>50</sub>/COX-2 IC<sub>50</sub> ∼ 80) was still higher than that of celecoxib (<b>1</b>, HWB COX-1 IC<sub>50</sub>/COX-2 IC<sub>50</sub> ∼ 37). The potency of compound <b>23</b> (HWB COX-2 IC<sub>50</sub> 7.2 μM) was weaker than anticipated, presumably attributable in part to high human plasma/serum protein binding as evidenced by very low unbound fractions (human PPB fu % = 0.2%) compared to others in this group (human PPB fu % in a range of 0.5–1.6%). Interestingly, the unbound fraction of compound <b>23</b> was significantly higher in colon tissue (human colon fu % = 7.5%). In contrast to compounds <b>10</b> and <b>11</b> (human colon fu % = 6.6, 2.5% respectively), fluorinated analogues <b>21</b> and <b>22</b> displayed much higher unbound fractions (human colon fu % = 22.4, 20.4% respectively) though their human plasma protein-binding values (human PPB fu %: 0.9–1.6%) were similar. All analogues showed a narrow range of solubility (FaSSIF, 25–110 μM). It was notable that compound <b>20</b> was the most potent COX-2 inhibitor (hCOX-2 IC<sub>50</sub> 0.12 μM; PGE<sub>2</sub> COX-2 IC<sub>50</sub> 0.037 μM; and HWB COX-2 IC<sub>50</sub> 0.146 μM) with low nanomolar COX-2 enzyme kinetic potency (<i>K</i>i* 2.9 nM) and a long residence time (<i>T</i><sub>1/2(dissociation)</sub> 39 h) for target occupancy.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div class="NLM_p">To evaluate the in vivo chemoprotective effects of these gut-restricted COX-2 inhibitors, we first measured attenuation of ex vivo local ileum acute glucose (as <sup>18</sup>F-FDG) uptake from short-term treatment (2 weeks) as an indirect PD surrogate and predictor of long-term efficacy (12 weeks) in a multiple intestinal neoplasia (MIN) mouse model by utilizing molecular tomographic imaging.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> This Apc mutant (Apc<sup>Min/+</sup>) mouse model, widely used in colorectal carcinogenesis and chemoprevention research, simulates human adenoma progression, in which loss of function (LOF) of tumor suppressor adenomatous polyposis coli (APC) gene by deletion/mutation leads to the initiation of adenomatous polyp formation and growth, recapitulating clinically relevant CRC tumorigenesis observed in FAP patients.<a onclick="showRef(event, 'ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref61 ref62 ref63">(61−63)</a> Celecoxib (1) has been shown to be effective in suppressing adenoma formation and growth in this Apc<sup>Min/+</sup> mouse model over a study period of 1–2 months.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> To shorten the turnaround time, we hypothesized that <sup>18</sup>F-FDG uptake attenuation could represent a sensitive biomarker for predicting efficacy as it is a common assumption that metabolic changes precede morphologic responses in the polyp size and/or number.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> By using compound <b>10</b>, we first established that there was a direct correlation between <sup>18</sup>F-FDG signals from the abdominal region in vivo and ileum ex vivo in APC mice (data not shown). We then confirmed a positive correlation between short-term dose-dependent reduction in ex vivo ileum <sup>18</sup>F-FDG PET signal from treatment with compound <b>10</b> in curative setting (dosing in chow diet, mice received doses of 30, 100, and 300 mg/kg for 2 weeks starting from the age of 16 weeks with established adenomas) and long-term does-dependent polyp area inhibition in Apc<sup>Min/+</sup> mice in a prophylactic setting (dosing of compounds in chow diet, mice received doses of 30, 100, or 300 mg/kg for 12 weeks from the age of 5–6 weeks) using celecoxib (<b>1</b>, chow diet, 300 mg/kg daily) and vehicle as positive and negative controls (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The correlation established acute <sup>18</sup>F-FDG PET signal attenuation as a prognostic biomarker to predict efficacy and quickly eliminate ineffective compounds that failed to reduce glucose uptake within 2 weeks.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Side-by-side comparison of the [<sup>18</sup>F]-FDG PET signal (expressed as average injected dose per gram (% ID/g, 20% threshold) in 2-week curative setting) and polyp area attenuation in APC<sup>Min/+</sup> mice in prophylactic setting (12 weeks) for compound <b>10</b>. Vehicle and celecoxib groups (300 mg/kg/daily in chow diet) served as negative and positive controls, respectively. Analyses were performed in R, version 3.3.2. ANOVA, adjusted for multiple comparisons in a linear regression model. *<i>P</i> < 0.05; **<i>P</i> < 0.01; ***<i>P</i> < 0.001; and ****<i>P</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>10</b> showed short-term, dose-dependent reduction of <sup>18</sup>F-FDG uptake (35.6%, <i>P</i> < 0.01; IC<sub>50</sub>, 4.4 μM) at 300 mg/kg oral daily dosing in a curative setting (2 week), which translated into a statistically significant polyp area tumor growth inhibition (TGI 41.9%) for total ileum polyp area (sum all of all polyp areas with diameter > 1 mm) in a prophylactic setting (300 mg/kg daily, 12 weeks) over celecoxib (<sup>18</sup>F-FDG, 31.4% <i>P</i> < 0.001; TGI 65.9%) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Etoricoxib (<b>3</b>, <sup>18</sup>F-FDG, 43.5%, <i>P</i> < 0.01), compounds <b>11</b> (<sup>18</sup>F-FDG, 48.9%, <i>P</i> < 0.01; IC<sub>50</sub>, 13 μM), <b>20</b> (<sup>18</sup>F-FDG, 61.2%, <i>P</i> < 0.001; IC<sub>50</sub>, 5.5 μM), and <b>23</b> (<sup>18</sup>F-FDG, 54.8%, <i>P</i> < 0.01; IC<sub>50</sub>, 14 μM) all showed short-term dose-dependent <sup>18</sup>F-FDG uptake decreases (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), but the magnitude and ranges of the decrease for compounds <b>11</b>, <b>20</b>, and <b>23</b> were smaller compared to compound <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Compound <b>23</b> showed much weaker polyp area tumor growth inhibition (TGI 25.0%, <i>p</i> > 0.05) in a long-term prophylactic setting (300 mg/kg daily, 12 weeks). Surprisingly, compound <b>11</b> was also weaker with respect to polyp area tumor growth inhibition (TGI 35.1%) despite a significant reduction of <sup>18</sup>F-FDG uptake (48.9%, <i>P</i> < 0.01; IC<sub>50</sub>, 13 μM). Based on the results, compound <b>20</b> was not considered for long-term studies. Compounds <b>21</b> (TGI 48.7%, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) and <b>22</b> (TGI 39.8%) showed comparable and statistically significant tumor growth inhibition in a prophylactic setting (300 mg/kg daily as a suspension by gavage, 10 weeks). It should be pointed out that compounds <b>10</b>, <b>21</b>, and <b>22</b> showed a statistically significant reduction of the polyp area and polyp number at all doses (30, 100, and 300 mg/kg) driven primarily by reduction in polyps of size ranging from >2 to <3 mm, as exemplified by compound <b>21</b> in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>. Compounds <b>10</b> (>82 days, 80% survival, 30 mg/kg), <b>21</b> (74 days, 50% survival, 100 mg/kg), and <b>22</b> (62.5 days, 50% survival, 100 mg/kg) all extended survival of Apc<sup>min/+</sup> mice (dosing by gavage P.O., daily starting at age of 4–6 weeks) compared to positive controls celecoxib (<b>1</b>) (>82 days, 100% survival, 100 mg/kg) and etoricoxib (<b>3</b>) (>82 days, 80% survival, 100 mg/kg) and negative control (vehicle treatment, 20 days, 50% survival) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, also <a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S8</a>). Nevertheless, compounds <b>10</b>, <b>21</b>, or <b>22</b> failed to demonstrate superior in vivo chemopreventive effects over celecoxib at the highest doses tested.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compounds <b>11</b>, <b>20</b>, and <b>23</b> for [<sup>18</sup>F]-FDG PET in curative setting (dosing in chow diet, mice received daily doses of 3, 10, 30, 100, and 300 mg/kg for 2 weeks from the age of >16 weeks) compared to compound <b>10</b>. <sup>18</sup>F-FDG PET signal expressed as average injected dose per gram (% ID/g, 20% threshold). The percentage injected dose per gram (% ID/g) was calculated as follows: % ID/g = ROI activity divided by injected dose multiplied by 100%. Vehicle and celecoxib (300 mg/kg/daily) served as negative and positive controls, respectively. Analyses were performed in R, version 3.3.2. ANOVA, adjusted for multiple comparisons in a linear regression model. *<i>P</i> < 0.05; **<i>P</i> < 0.01; ***<i>P</i> < 0.001; and ****<i>P</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Oral in vivo efficacy of compound <b>21</b> in prophylactic setting (dosing as a suspension by gavage, mice received doses of 30, 100, and 300 mg/kg for 10 weeks from the age of 5–6 weeks). Celecoxib (300 mg/kg/daily in a suspension by gavage) served as a positive control. Polyp area/number in treatment: One-way ANOVA with Dunnett’s multiple comparison test; polyp number vs polyp size: Two-way ANOVA with Dunnett’s multiple comparison test. GraphPad Prism 7.0.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To test the hypothesis that GI tissue exposure and COX-2 inhibition drive efficacy rather than systemic exposure/inhibition, separate IC<sub>50</sub>s for celecoxib (<b>1</b>) and compounds <b>10</b>, <b>21</b>, and <b>22</b> were derived using the in vivo tumor (polyp) area and either systemic or ileum concentrations. These values are shown for four compounds in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> (plots shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S9</a>), along with in vitro IC<sub>50</sub> values for HWB COX-1 and COX-2 inhibition, adjusted for unbound drug concentrations. Comparison of in vitro with in vivo potencies provides insights into factors driving efficacy. For example, by looking at the clinical comparator celecoxib, the systemic and gut in vivo IC<sub>50</sub>s are similar to the adjusted in vitro COX-2 IC<sub>50</sub>, consistent with the hypothesis that systemic or gut inhibition of COX-2 drives efficacy. The observation that celecoxib’s in vivo IC<sub>50</sub> is 14-fold lower than its adjusted in vitro COX-1 IC<sub>50</sub> suggests a minimal contribution of COX-1 inhibition driving in vivo efficacy.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Comparison of In Vitro and In Vivo IC<sub>50</sub> Values (nM, Unbound)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" char="." /></col><col align="left" char="." /></col><col align="left" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">in vivo potency<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">in vitro potency<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">systemic (IC<sub>50</sub> nM)</th><th class="colsep0 rowsep0" align="center" char=".">gut (IC<sub>50</sub> nM)</th><th class="colsep0 rowsep0" align="center" char=".">HWB COX-2 (fu % × IC<sub>50</sub> nM)</th><th class="colsep0 rowsep0" align="center">HWB COX-1 (fu % × IC<sub>50</sub> nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1 (celecoxib)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left" char=".">3.2</td><td class="colsep0 rowsep0" align="left" char=".">3.2</td><td class="colsep0 rowsep0" align="left" char=".">1.32</td><td class="colsep0 rowsep0" align="left">44.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left" char=".">35</td><td class="colsep0 rowsep0" align="left" char=".">2384</td><td class="colsep0 rowsep0" align="left" char=".">37.5</td><td class="colsep0 rowsep0" align="left">3088</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left" char=".">1.3</td><td class="colsep0 rowsep0" align="left" char=".">741.8</td><td class="colsep0 rowsep0" align="left" char=".">8.77</td><td class="colsep0 rowsep0" align="left">1810</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left" char=".">1.9</td><td class="colsep0 rowsep0" align="left" char=".">160</td><td class="colsep0 rowsep0" align="left" char=".">3.8</td><td class="colsep0 rowsep0" align="left">>1980</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Calculated based on in vivo polyp area TGI (%, 300 mg/kg oral daily dosing) and relevant plasma and ileum exposures 4 h after the last dose in a 12 week prophylactic setting in APC<sup>min/+</sup> mice.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Calculation (IC<sub>50</sub> × fu %) based on measured in vitro human whole blood COX-2/COX-1 potency (IC<sub>50</sub>) and human plasma protein-binding free faction (fu %) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Based on 9 week PK exposure in prophylactic setting (300 mg/kg oral daily dosing), assuming equal exposure in plasma and ileum, fit using Mathematica 11.</p></div></div></div><div class="NLM_p">In contrast, in vivo gut IC<sub>50</sub> values for the gut-restricted compounds <b>10</b>, <b>21</b>, and <b>22</b> are 40- to 85-fold higher than the adjusted in vitro COX-2 potency (IC<sub>50</sub>). This extreme “right-shift” of in vivo IC<sub>50</sub> and lack of in vitro–in vivo correlation (IVIVC) suggest that gut COX-2 inhibition is not driving efficacy. Assuming gut COX-2 inhibition is not driving efficacy, three other possibilities should be considered: (1) systemic COX-2 inhibition, (2) systemic COX-1 inhibition, and (3) gut COX-1 inhibition. Our results suggest systemic COX-2 is the most likely driver of efficacy both because of good IVIVC (in vitro and adjusted in vivo potency (IC<sub>50</sub>s) are within 1.0- to 6.7-fold of each other) for the gut-restricted compounds and because celecoxib, with its high systemic exposure, is effective at reducing the polyp area. Systemic COX-1 inhibition can be ruled out due to the large disconnect between in vitro and adjusted in vivo potency (88- to 1,400-fold difference in IC<sub>50</sub>s for gut-restricted compounds). Interestingly, gut COX-1 inhibition has reasonable IVIVC (1.3- to 12.4-fold difference between in vitro and adjusted in vivo potency IC<sub>50</sub>s for gut-restricted compounds), and therefore cannot be ruled out as a driver of efficacy. However, because celecoxib works systemically with minimal COX-1 inhibition, systemic COX-2 inhibition is the more likely driver of tumor growth inhibition in this mouse model.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Chemistry</h3><div class="NLM_p">Preparation of compound <b>4</b> has been reported.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The synthesis of compounds <b>5–7</b> is outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and described in detail in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">Section S1</a>. Commercially available <b>24a–c</b> were reacted with 2-methylpropane-1,2-diol in the presence of potassium <i>tert</i>-butoxide in DMF to afford the corresponding ethers <b>25a–c</b>, which were coupled with commercially available 4-(methanesulfonyl)phenylboronic acid under palladium-mediated Suzuki reaction conditions to give compound <b>5</b> and intermediates <b>26</b> (R<sup>2</sup> = COOEt) and <b>27</b> (R<sup>2</sup> = H). Intermediate <b>26</b> was reduced with sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al) in THF to provide compound <b>7</b>. Selective bromination of <b>27</b> with <i>N</i>-bromosuccinimide (NBS) in DMF led to bromide <b>28</b>. Subsequent Suzuki–Miyaura coupling of potassium trifluoro(vinyl)borate with <b>28</b> installed a vinyl group in <b>29</b>, which was reduced by palladium catalyst-mediated hydrogenation to generate compound <b>6</b>.</div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Compounds <b>5</b>, <b>6</b>, and <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) <i>tert</i>-BuOK, DMF, rt; (b) Pd(dppf)Cl<sub>2</sub> (cat) or Pd(dppf)Cl<sub>2</sub>·DCM (cat), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; (c) Red-Al, THF, rt; (d) NBS, DMF, 70 °C; (e) Pd(dppf)Cl<sub>2</sub> (cat), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; and (f) Pd–C (10%), H<sub>2</sub>, EtOH, rt.</p></p></figure><div class="NLM_p">Several flexible synthetic routes were used to access compounds <b>8–23</b>. The initial route outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> was developed for preparation of compounds <b>8</b> and <b>12</b>. Commercially available 2,6-dichloronicotinic acid <b>30</b> was converted into Weinreb amide <b>31</b> by reacting with thionyl chloride followed by coupling with dimethylhydroxylamine hydrochloride under basic conditions. Treatment of <b>31</b> with 2-methylpropane-1,2-diol in the presence of potassium <i>tert</i>-butoxide generated <b>32</b> as the major product. Selective bromination of <b>32</b> with bromine in acetic acid provided bromide <b>33</b>. The reduction of Weinreb amide <b>33</b> was achieved by using sodium borohydride to provide <b>34</b>. The coupling reaction of <b>34</b> with 4-(methanesulfonyl)phenylboronic acid under palladium-mediated Suzuki reaction conditions gave compound <b>35</b>. Finally, treatment of <b>35</b> with methanol or 2-methoxyethanol in the presence of sodium hydride-furnished compounds <b>8</b> or <b>12</b>, respectively.</div><figure id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Compounds <b>8</b> and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) SOCl<sub>2</sub>, DMF, CHCl<sub>3</sub>, 80 °C; (b) CH<sub>3</sub>NHOCH<sub>3</sub>·HCl, TEA, DCM, rt; (c) <i>tert</i>-BuOK, DMF, 60 °C; (d) Br<sub>2</sub>, NaOAc, AcOH, 80 °C; (e) NaBH<sub>4</sub>, MeOH, rt; (f) Pd(dppf)Cl<sub>2</sub> (cat), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 60 °C; and (g) NaH, DMF, rt.</p></p></figure><div class="NLM_p">Analogues <b>9</b>, <b>10</b>, <b>11</b>, <b>21</b>, and <b>22</b> were synthesized by the route outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. In this route, ortho-regioselective alkoxylation of 2,6-dichloronicotinic acid <b>30</b> was achieved using various alcohols (R<sup>1</sup>-OH) in the presence of sodium hydride under controlled conditions to afford intermediates <b>36a–e</b>.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Treatment of <b>36a–e</b> with 2-methylpropane-1,2-diol under palladium catalyzed reaction conditions to provide corresponding 2,6-di-alkoxylated acids <b>37a–e</b>. Our efforts to produce <b>37a–e</b> directly from <b>30</b> by combining steps a and b without purification of <b>36a–e</b> were unsuccessful due to difficult separation at the end. Selective bromination of <b>37a–e</b> with NBS in acetonitrile led to bromides <b>38a–e</b> in good yields, followed by coupling with 4-(methanesulfonyl)phenylboronic acid under Suzuki reaction conditions to give <b>39a–e</b> as the major products. The carboxylic acids <b>39a–e</b> were reduced by the borane–tetrahydrofuran complex to afford corresponding analogues <b>9</b>, <b>10</b>, <b>11</b>, <b>21</b>, and <b>22</b>.</div><figure id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route for Preparation of Compounds <b>9</b>, <b>10</b>, <b>11</b>, <b>21</b>, and <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) NaH, DMF or THF; (b) Xphos Pd G3 (cat), Cs<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C; (c) NBS, MeCN, rt; (d) Pd(PPh<sub>3</sub>)<sub>4</sub> (cat), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; and (e) BH<sub>3</sub>·THF, THF.</p></p></figure><div class="NLM_p">Compounds <b>13</b>, <b>14</b>, and <b>15</b> were prepared according to <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Oxidation of compound <b>11</b> using Dess–Martin periodinane gave aldehyde <b>40</b> in >90% yield. Subsequent nucleophilic addition of methylmagnesium chloride led to the formation of analogue <b>13</b>. Similarly, gem-dimethyl analogue <b>14</b> was obtained through nucleophilic addition of methylmagnesium chloride to methyl ester <b>41</b>, which was prepared by esterification of acid <b>39c</b> with TMSCHN<sub>2</sub>, described previously in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Selective alkylation of compound <b>11</b> was accomplished using ethyl bromoacetate and sodium hydride to afford ester <b>42</b>, which was readily reduced to alcohol <b>15</b> using lithium aluminum hydride under controlled anhydrous conditions.</div><figure id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of Compounds <b>13</b>, <b>14</b>, and <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) BH<sub>3</sub>·THF, THF; (b) Dess–Martin periodinane, DCM, rt; (c) MeMgCl, THF, rt; (d) TMSCHN<sub>2</sub>, MeOH, toluene, rt; (e) MeMgCl, THF, rt; (f) NaH, THF, rt; and (g) LiAlH<sub>4</sub>, THF, 0 °C.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> shows the preparation of compound <b>16</b>. Intermediate carboxylic acid <b>36c</b>, described previously in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, was coupled with 4-fluorophenylboronic acid under palladium-mediated Suzuki conditions to generate intermediate <b>43</b> in modest yield (40%). Subsequent transformations (selective bromination, palladium-mediated Suzuki coupling, and reduction of the acid moiety) led to the formation of analogue <b>16</b>.</div><figure id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub> (cat), K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; (b) NBS, TFA, MeCN, rt; (c) Pd(PPh<sub>3</sub>)<sub>4</sub> (cat), K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; and (d) BH<sub>3</sub>·THF, THF.</p></p></figure><div class="NLM_p">In a similar manner to the synthetic route as described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, compounds <b>17</b> and <b>18</b> were prepared as illustrated in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. The previously described ortho-alkylated intermediate <b>36c</b> was coupled with commercially available oxetanyl or cyclobutyl reagents <b>46a–d</b> (X = O or CH<sub>2</sub>; Y = H, Me, or OH) to provide corresponding dialkoxylated <b>47a–d</b> under palladium-mediated reaction conditions. Treatment of <b>47a–d</b> with NBS generated bromides <b>48a–d</b>. Subsequent Suzuki coupling of 4-(methanesulfonyl)phenylboronic acid with <b>48a–d</b> installed a 4-(methanesulfonyl)phenyl group in <b>49a–d</b>. The carboxylic acids <b>49a–c</b> were reduced by first reacting with isobutyl chloroformate in the presence of triethylamine to generate mixed anhydrides in situ, followed by treatment with sodium borohydride, to give analogues <b>17</b>, <b>18</b>, and <b>19</b>. Alternatively, a reduction of acid <b>49d</b> with borane tetrahydrofuran complex directly afforded analogue <b>20</b>.</div><figure id="sch6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Route for Preparation of Compounds <b>17</b>, <b>18</b>, <b>19</b>, and <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) Xphos Pd G3 (cat), Cs<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C; (b) NBS, AcOH, MeCN, rt; (c) Pd(PPh<sub>3</sub>)<sub>4</sub> (cat), K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; and (d) (i) TEA, ClC(═O)O–iBu, THF; then NaBH<sub>4</sub>; or (ii) BH<sub>3</sub>·THF, THF.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a> was used to prepare compound <b>23</b>. The previously described acid <b>38c</b> was first reduced to alcohol <b>50</b>, and then converted into boronic pinacol ester <b>51</b> by reacting with bis(pinacolato)diboron (Pin<sub>2</sub>B<sub>2</sub>)-mediated by Pd(dppf)<sub>2</sub>Cl<sub>2</sub> and potassium acetate under anhydrous and heated conditions. Suzuki coupling of <b>51</b> with commercially available 2-chloro-5-(methylsulfonyl)pyridine under palladium-mediated reaction conditions furnished analogue <b>23</b>.</div><figure id="sch7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compound <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BH<sub>3</sub>·THF, THF; (b) Pd(dppf)Cl<sub>2</sub> (cat), KOAc, 1,4-dioxane, 100 °C; and (c) Pd(dppf)Cl<sub>2</sub> (cat), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 65 °C.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41021" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41021" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we described a series of gut-restricted, selective COX-2 inhibitors with a central pyridine core as a common structural feature. These compounds were characterized by high colonic exposure and minimized systemic exposure mediated by attenuated permeability and clearance through a glucuronidation pathway via UGT1A9. By establishing short-term ex vivo <sup>18</sup>F-FDG uptake attenuation in an acute setting as an indirect, surrogate readout to predict efficacy, we evaluated a subset of analogues in long-term in vivo chemopreventive studies in APC<sup>min/+</sup> mouse models. Compounds <b>10</b>, <b>21</b>, and <b>22</b> showed dose-dependent suppression of adenoma formation and growth as well as extension of survival. Unexpectedly, in vitro potent analogues such as compounds <b>11</b> and <b>23</b> showed much weaker in vivo efficacy in terms of the polyp area and multiplicity inhibition. An IVIVC demonstrated that in vivo efficacy was not driven by local gut COX-2 inhibition. Rather, efficacy was consistent with residual systemic COX-2-driven inhibition, which may explain why none of these locally targeted inhibitors demonstrated superior in vivo effects for inhibiting adenoma progression relative to celecoxib in APC<sup>min/+</sup> mice. Our results could not rule out that gut COX-1- or COX-independent mechanisms alternatively play a significant role in driving adenoma growth inhibition, which warrants further investigation.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51688" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51688" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry</h3><div class="NLM_p last">All commercial reagents and anhydrous solvents were purchased and used without further purification, unless otherwise specified. Mass spectra (MS) were obtained on a SHIMADZU LCMS-2020 MSD or an Agilent 1200\G6110A MSD instrument using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd) mass corresponds to the exact mass. Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker model AVIII 300 MHz or 400 MHz spectrometer. Definitions for multiplicity are as follows: s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, ddd = doublet of doublet of doublets, td = triplet of doublets, dq = doublet of quartet, dt = doublet of triplets, spt = septet, quin = quintet, m = multiplet, and br = broad. <sup>1</sup>H NMR chemical shifts are expressed in parts per million (δ) downfield from tetramethylsilane as a standard. Normal-phase silica gel chromatography (FCC) was performed on silica gel (SiO<sub>2</sub>) using prepacked cartridges. All compounds sent for biological tests were confirmed with purity >95% in quantitative HPLC analysis [method: Gilson GX-281-RP-HPLC with Phenomenex Gemini C18 (10 μm, 150 × 25 mm), or Waters XBridge C18 column (5 μm, 150 × 30 mm), the mobile phase of 5–99% MeCN in water (10 mM NH<sub>4</sub>HCO<sub>3</sub>) over 10 min, and then held at 100% MeCN for 2 min, at a flow rate of 25 mL/min] or elemental analysis in addition to LCMS and <sup>1</sup>H NMR. Celecoxib (<b>1</b>), etoricoxib (<b>3</b>), and compound <b>4</b> were purchased from Combi-Blocks, Inc (San Diego), Carbosynth Ltd (UK), and Aurora Fine Chemicals LLC (San Diego), respectively.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Preparation of 2,6-Dichloro-<i>N</i>-methoxy-<i>N</i>-methylnicotinamide (<b>31</b>)</h3><div class="NLM_p">To a mixture of 2,6-dichloronicotinic acid (30 g, 156 mmol) and DMF (1 mL) in CHCl<sub>3</sub> (300 mL) under nitrogen at 0 °C was added SOCl<sub>2</sub> (55.8 g, 469 mmol). The reaction mixture was then heated and stirred at 60 °C for 1 h. The mixture was cooled to room temperature and concentrated to give crude 2,6-dichloronicotinoyl chloride as a gum (35 g), which was used directly in the next step.</div><div class="NLM_p last">To the solution of crude 2,6-dichloronicotinoyl chloride (35 g) in DCM (300 mL) at 0 °C were added triethylamine (50.9 g, 499 mmol) and <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (19.5 g, 200 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction was quenched by the addition of water (300 mL). The mixture was extracted with DCM (2 × 100 mL). The combined organic extract was washed with brine (300 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product (44 g) was recrystallized in ethyl acetate and petroleum ether (1:5) to give the title compound as a white solid (35 g, 95% yield). LCMS (ESI): mass calcd for C<sub>8</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>, 234.0; <i>m</i>/<i>z</i> found, 235.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Preparation of 2-Chloro-6-(2-hydroxy-2-methylpropoxy)-<i>N</i>-methoxy-<i>N</i>-methylnicotinamide (<b>32</b>)</h3><div class="NLM_p last">To a solution of 2-methylpropane-1,2-diol (12.7 g, 140 mmol) in anhydrous DMF (200 mL) at 0 °C was added potassium <i>tert</i>-butoxide (17.2 g, 153 mmol) under nitrogen. The mixture was stirred for 0.5 h, and then 2,6-dichloro-<i>N</i>-methoxy-<i>N</i>-methylnicotinamide (30 g, 128 mmol) was added. The reaction mixture was heated and stirred at 60 °C overnight. The mixture was cooled to room temperature, quenched with water (200 mL), and then extracted with ethyl acetate (2 × 200 mL). The combined organic extract was washed with brine (200 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash chromatography (50% ethyl acetate in petroleum ether as the eluent) to give the title compound as a white solid (24.5 g, 67% yield). LCMS (ESI): mass calcd for C<sub>12</sub>H<sub>16</sub>BrClN<sub>2</sub>O<sub>4</sub>, 288.1; <i>m</i>/<i>z</i> found, 289.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Preparation of 5-Bromo-2-chloro-6-(2-hydroxy-2-methylpropoxy)-<i>N</i>-methoxy-<i>N</i>-methylnicotinamide (<b>33</b>)</h3><div class="NLM_p last">To a solution of 2-chloro-6-(2-hydroxy-2-methylpropoxy)-<i>N</i>-methoxy-<i>N</i>-methylnicotinamide (12 g, 41.6 mmol) in glacial acetic acid (120 mL) was added sodium acetate (6.98 g, 83.1 mmol), followed by the dropwise addition of bromine (6.66 mL, 129 mmol). The reaction mixture was heated and stirred at 80 °C overnight. The mixture was cooled to room temperature, quenched with water (400 mL), and then extracted with ethyl acetate (2 × 400 mL). The combined organic extract was washed with brine (2 × 400 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (50% ethyl acetate in petroleum ether as the eluent) to give the title compound as a white solid (7.5 g, 49% yield). LCMS (ESI): mass calcd for C<sub>12</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>4</sub>, 366.0; <i>m</i>/<i>z</i> found, 367.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Preparation of 1-((3-Bromo-6-chloro-5-(hydroxymethyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>34</b>)</h3><div class="NLM_p last">To a solution of 5-bromo-2-chloro-6-(2-hydroxy-2-methylpropoxy)-<i>N</i>-methoxy-<i>N</i>-methylnicotinamide (27 g, 70.7 mmol) in MeOH (200 mL) at 0 °C was added NaBH<sub>4</sub> (16.1 g, 424 mmol). The resulting reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure, and water was added. The resulting mixture was extracted with ethyl acetate (2 × 200 mL). The combined organic extract was washed with brine (100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product as a gum (22 g, 100% yield), which was used directly into the next step. LCMS (ESI): mass calcd for C<sub>10</sub>H<sub>13</sub>BrClNO<sub>3</sub>, 309.0; <i>m</i>/<i>z</i> found, 310.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Preparation of 1-((6-Chloro-5-(hydroxymethyl)-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>35</b>)</h3><div class="NLM_p last">To a mixture of crude 1-(3-bromo-6-chloro-5-(hydroxymethyl)pyridin-2-yloxy)-2-methylpropan-2-ol (<b>34</b>, 5 g, 16.1 mmol), 4-(methylsulfonyl)phenylboronic acid (3.86 g, 19.3 mmol), and aqueous Na<sub>2</sub>CO<sub>3</sub> (2.0 M, 16.1 mL, 32 mmol) in 1,4-dioxane (40 mL) was added Pd(dppf)Cl<sub>2</sub> (1.18 g, 1.61 mmol) under nitrogen. The reaction mixture was heated with stirring at 60 °C for 3 h. The mixture was cooled to room temperature, quenched with water (40 mL), and extracted with ethyl acetate (2 × 80 mL). The combined organic extract was washed with brine (40 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (50% ethyl acetate in petroleum ether as the eluent) to give the title compound as a yellow solid (5 g, 80% yield). LCMS (ESI): mass calcd for C<sub>17</sub>H<sub>20</sub>ClNO<sub>5</sub>S, 385.1; <i>m</i>/<i>z</i> found, 386.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.01 (d, <i>J</i> = 8.7 Hz, 2H), 7.98 (s, 1H), 7.92 (d, <i>J</i> = 8.7 Hz, 2H), 4.54 (s, 2H), 4.10 (s, 2H), 3.84 (br s, 2H), 3.25 (s, 3H), 1.15 (s, 6H) ppm.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Preparation of 1-((5-(Hydroxymethyl)-6-methoxy-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>8</b>)</h3><div class="NLM_p last">To a solution of anhydrous methanol (1.25 g, 38.9 mmol) in DMF (30 mL) at 0 °C was added NaH (60%, 1.56 g, 38.9 mmol). The mixture was stirred for 0.5 h, and then 1-((6-chloro-5-(hydroxymethyl)-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (1.5 g, 3.89 mmol) was added. The reaction mixture was stirred at room temperature overnight. The mixture was quenched with water (40 mL), and then extracted with ethyl acetate (2 × 50 mL). The combined organic extract was washed with brine (2 × 60 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash chromatography (60% ethyl acetate in petroleum ether as the eluent), and the crude product was further purified by prep-HPLC (10–90% MeCN in water) to give the title compound as a white solid (280 mg, 19% yield). LCMS (ESI): mass calcd. for C<sub>18</sub>H<sub>23</sub>NO<sub>6</sub>S, 381.1; <i>m</i>/<i>z</i> found, 382.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.95 (d, <i>J</i> = 8.7 Hz, 2H), 7.89 (d, <i>J</i> = 8.7 Hz, 2H), 7.83 (s, 1H), 5.09 (t, <i>J</i> = 5.7 Hz, 1H), 4.63 (s, 1H), 4.45 (d, <i>J</i> = 5.7 Hz, 2H), 4.16 (s, 2H), 3.94 (s, 3H), 3.25 (s, 3H), 1.17 (s, 6H) ppm.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Preparation of 1-((5-(Hydroxymethyl)-6-(2-methoxyethoxy)-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>12</b>)</h3><div class="NLM_p last">To a solution of anhydrous 2-methoxyethanol (2.96 g, 38.9 mmol) in DMF (30 mL) at 0 °C was added NaH (60%, 1.56 g, 38.9 mmol). The mixture was stirred for 0.5 h, and then 1-((6-<b>c</b>hloro-5-(hydroxymethyl)-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>35</b>, 1.5 g, 3.89 mmol) was added. The reaction mixture was stirred at room temperature overnight. The mixture was quenched with water (40 mL), and then extracted with ethyl acetate (2 × 50 mL). The combined organic extract was washed with brine (2 × 60 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash chromatography (60% ethyl acetate in petroleum ether as the eluent), and the crude product was further purified by prep-HPLC (10–90% MeCN in water) to give the title compound as a white solid (100 mg, 19% yield). LCMS (ESI): mass calcd for C<sub>20</sub>H<sub>27</sub>NO<sub>7</sub>S, 425.2; <i>m</i>/<i>z</i> found, 426.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 (s, 1H), 5.11 (t, <i>J</i> = 5.7 Hz, 1H), 4.64 (s, 1H), 4.44–4.49 (m, 4H), 4.13 (s, 2H), 3.69–3.72 (m, 2H), 3.33 (s, 3H), 3.26 (s, 3H, s), 1.16 (s, 6H) ppm.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Preparation of 6-Chloro-2-isopropoxynicotinic Acid (<b>36a</b>)</h3><div class="NLM_p last">To a solution of 2-propanol (2.35 g, 39.1 mmol) in anhydrous THF (150 mL) was added NaH (60%, 2.29 g, 57.3 mmol). The mixture was stirred at 50 °C for 0.5 h, and then 2,6-dichloropyridine-3-carboxylic acid (5 g, 26.0 mmol) was added. The reaction mixture was heated and stirred at 70 °C for 3 h. The mixture was cooled to room temperature, quenched with water (2 L), and concentrated to a small volume. The mixture was acidified to “pH” 1 using aqueous HCl (1 M) and extracted with ethyl acetate (3 × 100 mL). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a yellow solid (5 g, 89% yield). LCMS (ESI): mass calcd for C<sub>9</sub>H<sub>10</sub>ClNO<sub>3</sub>, 215.0; <i>m</i>/<i>z</i> found, 216.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_10a" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Preparation of 6-chloro-2-propoxynicotinic acid (<b>36b</b>)</h3><div class="NLM_p last">To a solution of 1-propanol (46.4 g, 772 mmol) in anhydrous DMF (2.6 L) at 0 °C was added NaH (60%, 56.6 g, 1415 mmol). The mixture was stirred at 0 °C for 1 h, and then 2,6-dichloropyridine-3-carboxylic acid (130 g, 643 mmol) was added in several portions. The reaction mixture was stirred at room temperature for 30 h. The mixture was quenched with iced water (7.8 L). The mixture was acidified to “pH” 1 using aqueous HCl (1 M). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, The precipitate was collected and dried to give the title compound as a white solid (91 g, 66% yield). LCMS (ESI): mass calcd. for C<sub>9</sub>H<sub>10</sub>ClNO<sub>3</sub>, 215.0; <i>m</i>/<i>z</i> found, 216.1 [M+H]<sup>+</sup>.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Preparation of 2-Butoxy-6-chloronicotinic Acid (<b>36c</b>)</h3><div class="NLM_p last">To a solution of 1-butanol (63.7 g, 859 mmol) in anhydrous DMF (200 mL) at 0 °C was added NaH (60%, 65.6 g, 1.64 mol). The mixture was stirred at 0 °C for 1 h, and then 2,6-dichloropyridine-3-carboxylic acid (10 g, 52 mmol) was added in several batches. The reaction mixture was stirred at room temperature overnight. The mixture was quenched with ice water (2 L). The mixture was acidified to “pH” 5 using aqueous HCl (1 M) and extracted with ethyl acetate (3 × 2 L). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a white solid (165 g, 89% yield). LCMS (ESI): mass calcd for C<sub>10</sub>H<sub>12</sub>ClNO<sub>3</sub>, 229.1; <i>m</i>/<i>z</i> found, 228.0 [M-H]<sup>+</sup>.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Preparation of 6-Chloro-2-(3,3,3-trifluoropropoxy)nicotinic Acid (<b>36d</b>)</h3><div class="NLM_p last">To a solution of 3,3,3-trifluoropropan-1-ol (267 g, 2.34 mol) in anhydrous THF (9 L) was added NaH (60%, 137.5 g, 3.44 mol). The mixture was stirred at room temperature for 1 h, and then 2,6-dichloropyridine-3-carboxylic acid (300 g, 1.56 mmol) was added. The reaction mixture was stirred at room temperature for 48 h. The mixture was quenched with water (5 L), acidified to “pH” 1 using aqueous HCl (1 M), and then extracted with ethyl acetate (3 × 3.5 L). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by Flash-Prep-HPLC (Column, C-18, mobile phase, water (a)/MeCN (b), <i>b</i> %: 30%–55%, 30 min; detector, UV 210 nm) to give the title compound as a white solid (170 g, 40% yield). LCMS (ESI): mass calcd for C<sub>9</sub>H<sub>7</sub>ClF<sub>3</sub>NO<sub>3</sub>, 269.0; <i>m</i>/<i>z</i> found, 270.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Preparation of 6-Chloro-2-(4,4,4-trifluorobutoxy)nicotinic Acid (<b>36e</b>)</h3><div class="NLM_p last">To a solution of 4,4,4-trifluorobutan-1-ol (150 g, 1.17 mol) in anhydrous THF (4.5 L) was added NaH (60%, 68.7 g, 1.72 mol). The mixture was stirred at 50 °C for 0.5 h, and then 2,6-dichloropyridine-3-carboxylic acid (150 g, 0.781 mol) was added. The reaction mixture was heated and stirred at 70 °C for 3 h. The mixture was cooled to room temperature, quenched with water (2 L), acidified to “pH” 1 with aqueous HCl (1 M), and then extracted with ethyl acetate (3 × 2 L). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a white solid (156 g, 70% yield). LCMS (ESI): mass calcd for C<sub>10</sub>H<sub>9</sub>ClF<sub>3</sub>NO<sub>3</sub>, 283.0; <i>m</i>/<i>z</i> found, 284.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Preparation of 6-(2-Hydroxy-2-methylpropoxy)-2-isopropoxynicotinic Acid (<b>37a</b>)</h3><div class="NLM_p last">To a mixture of 6-chloro-2-(propan-2-yloxy)pyridine-3-carboxylic acid (<b>36a</b>, 5 g, 23.2 mmol), Cs<sub>2</sub>CO<sub>3</sub> (18.9 g, 57.8 mmol), and 2-methylpropane-1,2-diol (4.18 g, 46.4 mmol) in toluene (150 mL) under nitrogen was added XPhos Pd G3 (196 mg, 0.23 mmol). The reaction mixture was heated and stirred at 90 °C overnight. The mixture was cooled to room temperature and then quenched with water (200 mL). The organic layer was separated, and the “pH” of the aqueous layer was adjusted to 1 with aqueous HCl (1 M). The aqueous solution was extracted with ethyl acetate (3 × 150 mL). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a white solid (5.5 g, 88% yield). LCMS (ESI): mass calcd for C<sub>13</sub>H<sub>19</sub>NO<sub>5</sub>, 269.1; <i>m</i>/<i>z</i> found, 270.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Preparation of 6-(2-Hydroxy-2-methylpropoxy)-2-propoxynicotinic Acid (<b>37b</b>)</h3><div class="NLM_p last">To a mixture of 6-chloro-2-propoxynicotinic acid (<b>36b</b>, 91 g, 422 mmol), Cs<sub>2</sub>CO<sub>3</sub> (344 g, 1055 mmol), and 2-methylpropane-1,2-diol (57.0 g, 633 mmol) in toluene (270 mL) under nitrogen was added XPhos Pd G3 (7.1 g, 8.74 mmol). The reaction mixture was heated and stirred at 90 °C overnight. The mixture was cooled to room temperature and then quenched with water. The organic layer was separated, and the “pH” of the aqueous layer was adjusted to 1 with aqueous HCl (1 M). The aqueous solution was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a brown oil (100 g, 88% yield). LCMS (ESI): mass calcd for C<sub>13</sub>H<sub>19</sub>NO<sub>5</sub>, 269.1; <i>m</i>/<i>z</i> found, 270.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Preparation of 2-Butoxy-6-(2-hydroxy-2-methylpropoxy)nicotinic Acid (<b>37c</b>)</h3><div class="NLM_p last">To a mixture of 2-butoxy-6-chloronicotinic acid (<b>36c</b>, 5 g, 21.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (27.9 g, 85.4 mmol), and 2-methylpropane-1,2-diol (4.8 g, 53.4 mmol) in toluene (150 mL) under nitrogen were added dicyclohexyl(2′,6′-dimethoxybiphenyl-2-yl)phosphine (876 mg, 2.1 mmol) and Pd(OAc)<sub>2</sub> (1.03 g, 4.3 mmol). The reaction mixture was heated and stirred at 90 °C overnight. The mixture was cooled to room temperature and then quenched with water (500 mL). The mixture was filtered through a short celite pad, and the filtrate was extracted with ethyl acetate (200 mL). The “pH” of the aqueous layer was adjusted to 1 using aqueous HCl (1 M), and then extracted with ethyl acetate (2 × 200 mL). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a light yellow oil (5 g, 60% yield). LCMS (ESI): mass calcd for C<sub>14</sub>H<sub>21</sub>NO<sub>5</sub>, 283.1; <i>m</i>/<i>z</i> found, 282.2 [M – H]<sup>+</sup>.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Preparation of 6-(2-Hydroxy-2-methylpropoxy)-2-(3,3,3-trifluoropropoxy)nicotinic Acid (<b>37d</b>)</h3><div class="NLM_p last">To a mixture of 6-chloro-2-(3,3,3-trifluoropropoxy)nicotinic acid (<b>36d</b>, 130 g, 482 mmol), Cs<sub>2</sub>CO<sub>3</sub> (393 g, 1210 mmol), and 2-methylpropane-1,2-diol (86.9 g, 964 mmol) in toluene (3.9 L) under nitrogen was added XPhos Pd G3 (4.08 g, 4.82 mmol). The reaction mixture was heated and stirred at 90 °C overnight. The mixture was cooled to room temperature and then quenched with water (3 L). The mixture was extracted with ethyl ether (1 L). The organic layer was separated, and the “pH” of the aqueous layer was adjusted to 1 with aqueous HCl (1 M). The aqueous solution was extracted with ethyl acetate (2 × 2 L). The organic layers were combined, washed with brine (2 L), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a brown oil (130 g, 83% yield). LCMS (ESI): mass calcd for C<sub>13</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>5</sub>, 323.1; <i>m</i>/<i>z</i> found, 324.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Preparation of 6-(2-Hydroxy-2-methylpropoxy)-2-(4,4,4-trifluorobutoxy)nicotinic Acid (<b>37e</b>)</h3><div class="NLM_p last">To a mixture of 6-chloro-2-(4,4,4-trifluorobutoxy)nicotinic acid (<b>36e</b>, 156 g, 550 mmol), Cs<sub>2</sub>CO<sub>3</sub> (448 g, 1375 mmol), and 2-methylpropane-1,2-diol (99 g, 1100 mmol) in toluene (4.68 L) under nitrogen was added XPhos Pd G3 (4.6 g, 5.5 mmol). The reaction mixture was heated and stirred at 90 °C overnight. The mixture was cooled to room temperature and then quenched with water (3 L). The organic layer was separated, and the “pH” of the aqueous layer was adjusted to 1 with aqueous HCl (1 M). The aqueous solution was extracted with ethyl acetate (3 × 1 L). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a yellow solid (130 g, 83% yield). LCMS (ESI): mass calcd for C<sub>14</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>5</sub>, 337.1; <i>m</i>/<i>z</i> found, 338.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Preparation of 5-Bromo-6-(2-hydroxy-2-methylpropoxy)-2-isopropoxynicotinic Acid (<b>38a</b>)</h3><div class="NLM_p last">To a solution of 6-(2-hydroxy-2-methylpropoxy)-2-isopropoxynicotinic acid (<b>37a</b>, 5.5 g, 20.4 mmol) and acetic acid (6.13 g, 102 mmol) in acetonitrile (55 mL) was added NBS (4.36 g, 74.1 mmol). The reaction mixture was stirred at room temperature for 2 h, quenched by the addition of water (50 mL), and then extracted with ethyl acetate (3 × 100 mL). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was recrystallized in acetonitrile to give the title compound as a white solid (3.3 g, 46% yield). LCMS (ESI): mass calcd for C<sub>13</sub>H<sub>18</sub>BrNO<sub>5</sub>, 347.0; <i>m</i>/<i>z</i> found, 348.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Preparation of 5-Bromo-6-(2-hydroxy-2-methylpropoxy)-2-propoxynicotinic Acid (<b>38b</b>)</h3><div class="NLM_p last">To a solution of 5-bromo-6-(2-hydroxy-2-methylpropoxy)-2-propoxynicotinic acid (<b>37b</b>, 109 g, 340 mmol) in acetonitrile (2.7 L) was added NBS (72.9 g, 410 mmol). The reaction mixture was stirred at room temperature for 3 h. The mixture was concentrated and the residue was purified by flash chromatography (5% MeOH in DCM) to give the title compound as a white solid (119 g, 92% yield). LCMS (ESI): mass calcd for C<sub>13</sub>H<sub>18</sub>BrNO<sub>5</sub>, 347.0; <i>m</i>/<i>z</i> found, 348.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Preparation of 5-Bromo-2-butoxy-6-(2-hydroxy-2-methylpropoxy)nicotinic Acid (<b>38c</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-(2-hydroxy-2-methylpropoxy)nicotinic acid (<b>37c</b>, 5.1 g, 14.1 mmol) in acetonitrile (130 mL) was added NBS (2.8 g, 15.5 mmol). The reaction mixture was stirred at room temperature for 2 h. Water was added (500 mL). The precipitate was collected by filtration and dried in vacuo to give the title compound as a white solid (4.5 g, 72% yield). LCMS (ESI): mass calcd for C<sub>14</sub>H<sub>20</sub>BrNO<sub>5</sub>, 361.1; <i>m</i>/<i>z</i> found, 362.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Preparation of 5-Bromo-6-(2-hydroxy-2-methylpropoxy)-2-(3,3,3-trifluoropropoxy)nicotinic Acid (<b>38d</b>)</h3><div class="NLM_p last">To a solution of 6-(2-hydroxy-2-methylpropoxy)-2-(3,3,3-trifluoropropoxy)nicotinic acid (<b>37d</b>, 130 g, 402 mmol) and acetic acid (120.7 g, 2.01 mol) in acetonitrile (1.3 L) was added NBS (78.7 g, 442 mmol). The reaction mixture was stirred at room temperature for 2 h. The precipitate was collected by filtration, washed with cold acetonitrile (200 mL) and water (1 L), and then dried in vacuo to give the title compound as a white solid (116 g, 72% yield). LCMS (ESI): mass calcd for C<sub>13</sub>H<sub>15</sub>BrF<sub>3</sub>NO<sub>5</sub>, 401.0; <i>m</i>/<i>z</i> found, 402.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Preparation of 5-Bromo-6-(2-hydroxy-2-methylpropoxy)-2-(4,4,4-trifluorobutoxy)nicotinic Acid (<b>38e</b>)</h3><div class="NLM_p last">To a solution of 6-(2-hydroxy-2-methylpropoxy)-2-(4,4,4-trifluoro-butoxy)nicotinic acid (<b>37e</b>, 180 g, 533 mmol) and acetic acid (160 g, 2.67 mol) in acetonitrile (1.8 L) was added NBS (114 g, 640 mmol). The reaction mixture was stirred at room temperature for 2 h, and then quenched with water (1.5 L). The mixture was concentrated to half of its volume under reduced pressure. The precipitate was collected by filtration and recrystallized in acetonitrile to give the title compound as a yellow solid (140 g, 63% yield). LCMS (ESI): mass calcd for C<sub>14</sub>H<sub>17</sub>BrF<sub>3</sub>NO<sub>5</sub>, 415.0; <i>m</i>/<i>z</i> found, 416.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Preparation of 6-(2-Hydroxy-2-methylpropoxy)-2-isopropoxy-5-(4-(methylsulfonyl)phenyl)nicotinic Acid (<b>39a</b>)</h3><div class="NLM_p last">To a mixture of 5-bromo-6-(2-hydroxy-2-methylpropoxy)-2-isopropoxynicotinic acid (<b>38a</b>, 1 g, 2.87 mmol), 4-(methylsulfonyl)phenylboronic acid (689 mg, 3.44 mmol), and aqueous Na<sub>2</sub>CO<sub>3</sub> (2.0 M, 5.7 mL, 11.4 mmol) in 1,4-dioxane (8 mL) was added Pd(dppf)Cl<sub>2</sub> (210 mg, 0.29 mmol) under nitrogen. The reaction mixture was heated with stirring at 80 °C for 3 h. The mixture was cooled to room temperature and quenched with water (20 mL). The mixture was acidified to “pH” 1 with aqueous HCl solution (1 M) and then extracted with ethyl acetate (2 × 50 mL). The combined organic extract was washed with brine (40 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by reverse-phase Combi-Flash chromatography (column, C18; eluent, 25–55% MeCN in water; time, 30 min) to give the title compound as a yellow solid (0.8 g, 66% yield). LCMS (ESI): mass calcd for C<sub>20</sub>H<sub>25</sub>NO<sub>7</sub>S, 423.1; <i>m</i>/<i>z</i> found, 424.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Preparation of 6-(2-Hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)-2-propoxynicotinic Acid (<b>39b</b>)</h3><div class="NLM_p last">To a mixture of 5-bromo-2-butoxy-6-((1-hydroxycyclobutyl)methoxy)nicotinic acid (<b>38b</b>, 115 g, 342 mmol), 4-(methylsulfonyl)phenylboronic acid (82 g, 410 mmol), and aqueous Na<sub>2</sub>CO<sub>3</sub> (2.0 M, 513 mL, 1.03 mol) in 1,4-dioxane (1.2 L) was added Pd(dppf)Cl<sub>2</sub> (25 g, 34.2 mmol) under nitrogen. The reaction mixture was heated with stirring at 100 °C for 2 h. The mixture was cooled to room temperature and quenched with water. The mixture was acidified to “pH” 1 with aqueous HCl solution (1 M) and then extracted with a mixture of ethyl acetate and THF (1:1). The combined organic extract was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (4% MeOH in DCM as the eluent) to give the title compound as a light yellow solid (70 g, 48% yield). LCMS (ESI): mass calcd for C<sub>20</sub>H<sub>25</sub>NO<sub>7</sub>S, 423.1; <i>m</i>/<i>z</i> found, 424.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.48 (s, 1H), 8.02 (d, <i>J</i> = 8.4 Hz, 2H), 7.78 (d, <i>J</i> = 8.4 Hz, 2H), 4.61 (d, <i>J</i> = 6.6 Hz, 2H), 4.30 (s, 2H), 3.13 (s, 3H), 1.91–2.01 (m, 2H), 1.33 (s, 6H), 1.13 (t, <i>J</i> = 7.5 Hz, 6H) ppm.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Preparation of 2-Butoxy-6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)nicotinic Acid (<b>39c</b>)</h3><div class="NLM_p last">To a mixture of 5-bromo-2-butoxy-6-(2-hydroxy-2-methylpropoxy)nicotinic acid (<b>38c</b>, 2 g, 4.5 mmol), 4-(methylsulfonyl)phenylboronic acid (1.2 g, 5.9 mmol), and K<sub>2</sub>CO<sub>3</sub> (2.8 g, 20.4 mmol) in 1,4-dioxane (40 mL) and water (4 mL) was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (524 mg, 0.45 mmol) under nitrogen. The reaction mixture was heated with stirring at 80 °C overnight. The mixture was cooled to room temperature and quenched with water. The mixture was acidified to “pH” 1 using aqueous HCl solution (1 M) and then extracted with ethyl acetate (3 × 90 mL). The combined organic extract was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (3–10% MeOH in DCM as the eluent) to give the title compound as a white solid (1.2 g, 52% yield). LCMS (ESI): mass calcd for C<sub>21</sub>H<sub>27</sub>NO<sub>7</sub>S, 437.2; <i>m</i>/<i>z</i> found, 438.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.48 (s, 1H), 8.02 (d, <i>J</i> = 8.4 Hz, 2H), 7.78 (d, <i>J</i> = 8.4 Hz, 2H), 4.65 (d, <i>J</i> = 6.6 Hz, 2H), 4.30 (s, 2H), 3.13 (s, 3H), 1.88–2.02 (m, 2H), 1.49–1.60 (m, 2H), 1.33 (s, 6H), 1.05 (t, <i>J</i> = 7.5 Hz, 6H) ppm.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Preparation of 6-(2-Hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)-2-(3,3,3-trifluoropropoxy)nicotinic Acid (<b>39d</b>)</h3><div class="NLM_p last">To a mixture of 5-bromo-6-(2-hydroxy-2-methylpropoxy)-2-(3,3,3-trifluoropropoxy) nicotinic acid (<b>38d</b>, 116 g, 288 mmol), 4-(methylsulfonyl)phenylboronic acid (86.5 g, 433 mmol), and Na<sub>2</sub>CO<sub>3</sub> (91.7 g, 865 mmol) in 1,4-dioxane (928 mL) and water (232 mL) was added Pd(dppf)Cl<sub>2</sub> (21.1 g, 28.8 mmol) under nitrogen. The reaction mixture was heated with stirring at 100 °C for 5 h. The mixture was cooled to room temperature and quenched with water. The mixture was acidified to “pH” 1 using aqueous HCl solution (1 M) and then extracted with ethyl acetate (2 × 1 L). The combined organic extract was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by reverse-phase prep-HPLC (column, C18; eluent, 25–55% MeCN in water; time, 30 min; detector, UV 210 nm) to give the title compound as a white solid (100 g, 73% yield). LCMS (ESI): mass calcd for C<sub>20</sub>H<sub>22</sub>F<sub>3</sub>NO<sub>7</sub>S, 477.1; <i>m</i>/<i>z</i> found, 478.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Preparation of 6-(2-Hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)-2-(4,4,4-trifluorobutoxy)nicotinic Acid (<b>39e</b>)</h3><div class="NLM_p last">To a mixture of 5-bromo-6-(2-hydroxy-2-methylpropoxy)-2-(4,4,4-trifluorobutoxy)nicotinic acid (<b>38e</b>, 140 g, 336 mmol), 4-(methylsulfonyl)phenylboronic acid (80.7 g, 404 mmol), and aqueous Na<sub>2</sub>CO<sub>3</sub> (2 M, 504 mL, 1.0 mol) in 1,4-dioxane (1.4 L) was added Pd(dppf)Cl<sub>2</sub> (24.6 g, 33.6 mmol) under nitrogen. The reaction mixture was heated with stirring at 100 °C for 1 h. The mixture was cooled to room temperature and quenched with water. The mixture was acidified to “pH” 1 using aqueous HCl solution (1 M) and then extracted with ethyl acetate (3 × 1 L). The combined organic extract was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by reverse-phase Combi-Flash (column, C18; eluent, 25–55% MeCN in water) to give the title compound as a white solid (90 g, 54% yield). LCMS (ESI): mass calcd for C<sub>21</sub>H<sub>24</sub>F<sub>3</sub>NO<sub>7</sub>S, 491.1; <i>m</i>/<i>z</i> found, 492.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Preparation of 1-((5-(Hydroxymethyl)-6-isopropoxy-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>9</b>)</h3><div class="NLM_p last">To a solution of 6-(2-hydroxy-2-methylpropoxy)-2-isopropoxy-5-(4-(methylsulfonyl)phenyl)nicotinic acid (<b>39a</b>, 0.8 g, 1.89 mmol) in anhydrous THF (24 mL) at 0 °C was added a THF solution (1 M) of BH<sub>3</sub>·THF (5.7 mL, 5.7 mmol). The reaction mixture was stirred at room temperature for 1 h. The mixture was quenched with MeOH (5 mL) and brine (10 mL), and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 × 30 mL). The combined organic extract was washed with brine (2 × 30 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by reverse-phase Combi-Flash (column, C18; eluent, 25–60% MeCN in water) to give the title compound as a white solid (435 mg, 56% yield). LCMS (ESI): mass calcd for C<sub>20</sub>H<sub>27</sub>NO<sub>6</sub>S, 409.2; <i>m</i>/<i>z</i> found, 410.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.95 (d, <i>J</i> = 8.7 Hz, 2H), 7.88 (d, <i>J</i> = 8.7 Hz, 2H), 7.82 (s, 1H), 5.27 (sept, <i>J</i> = 6.3 Hz, 1H), 5.05 (t, <i>J</i> = 5.7 Hz, 1H), 4.63 (s, 1H), 4.42 (d, <i>J</i> = 5.7 Hz, 2H), 4.11 (s, 2H), 3.25 (s, 3H), 1.34 (d, <i>J</i> = 6.3 Hz, 6H), 1.17 (s, 6H) ppm.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Preparation of 1-((5-(Hydroxymethyl)-3-(4-(methylsulfonyl)phenyl)-6-propoxypyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>10</b>)</h3><div class="NLM_p last">To a solution of 6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)-2-propoxynicotinic acid (<b>39b</b>, 72.8 g, 163 mmol) in anhydrous THF (1.4 L) at 0 °C was added a THF solution (1 M) of BH<sub>3</sub>·THF (653 mL, 653 mmol). The reaction mixture was stirred at room temperature for 3 h. MeOH (1 L) and SiliaMrtS DMT (7 g) were added. The mixture was stirred at room temperature for 12 h, filtered, and concentrated. The residue was purified by reverse-phase Combi-Flash (column, C18; eluent, 25–55% MeCN in water; time, 40 min), followed by recrystallization in acetonitrile to give the title compound as a white solid (45.1 g, 67% yield). LCMS (ESI): mass calcd for C<sub>20</sub>H<sub>27</sub>NO<sub>6</sub>S, 409.2; <i>m</i>/<i>z</i> found, 410.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.95 (d, <i>J</i> = 8.8 Hz, 2H), 7.88 (d, <i>J</i> = 8.8 Hz, 2H), 7.83 (s, 1H), 5.07 (t, <i>J</i> = 5.6 Hz, 1H), 4.62 (s, 1H), 4.46 (d, <i>J</i> = 5.6 Hz, 2H), 4.31 (t, <i>J</i> = 6.6 Hz, 2H), 4.13 (s, 2H), 3.25 (s, 3H), 1.79–1.74 (m, 2H), 1.17 (s, 6H), 0.99 (t, <i>J</i> = 7.6 Hz, 3H) ppm; Anal. Calcd for C<sub>20</sub>H<sub>27</sub>NO<sub>6</sub>S: C, 58.66; H, 6.65; N, 3.42. Found: C, 58.63; H, 6.68; N, 3.37; Pd level < 1 ppm.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Preparation of 1-((5-(Hydroxymethyl)-3-(4-(methylsulfonyl)phenyl)-6-propoxypyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>11</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)nicotinic acid (<b>39c</b>, 1.2 g, 2.74 mmol) in anhydrous THF (24 mL) at 0 °C was added a THF solution (1 M) of BH<sub>3</sub>·THF (7.05 mL, 7.05 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was quenched with MeOH (10 mL) and water (60 mL), and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 × 30 mL). The combined organic extract was washed with saturated aqueous NaHCO<sub>3</sub> (30 mL), brine (30 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was recrystallized in acetonitrile to give the title compound as a white solid (860 mg, 74% yield). LCMS (ESI): mass calcd for C<sub>21</sub>H<sub>29</sub>NO<sub>6</sub>S, 423.2; <i>m</i>/<i>z</i> found, 424.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.95 (d, <i>J</i> = 8.7 Hz, 2H), 7.88 (d, <i>J</i> = 8.7 Hz, 2H), 7.82 (s, 1H), 5.08 (t, <i>J</i> = 5.7 Hz, 1H), 4.63 (s, 1H), 4.45 (d, <i>J</i> = 5.4 Hz, 2H), 4.36 (t, <i>J</i> = 6.6 Hz, 2H), 4.13 (s, 2H), 3.25 (s, 3H), 1.68–1.78 (m, 2H), 1.40–1.50 (m, 2H), 1.16 (s, 6H), 0.99 (t, <i>J</i> = 7.5 Hz, 3H) ppm; Anal. Calcd for C<sub>21</sub>H<sub>29</sub>NO<sub>6</sub>S: C, 59.56; H, 6.90; N, 3.31. Found: C, 59.54; H, 7.04; N, 3.32; Pd level 1 ppm.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Preparation of 1-((5-(Hydroxymethyl)-3-(4-(methylsulfonyl)phenyl)-6-(3,3,3-trifluoropropoxy)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>21</b>)</h3><div class="NLM_p last">To a solution of 6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)-2-(3,3,3-trifluoro-propoxy)nicotinic acid (<b>39d</b>, 100 g, 209 mmol) in anhydrous THF (3 L) at 0 °C was added a THF solution (1 M) of BH<sub>3</sub>·THF (628 mL, 628 mmol). The reaction mixture was stirred at room temperature for 3 h. The mixture was quenched with MeOH (100 mL) and concentrated. The residue was triturated in acetonitrile (500 mL) and water (1 L). The precipitate was collected by filtration, washed with water, and then recrystallized in acetonitrile (200 mL) to give the title compound as a white solid (71.3 g, 73% yield). LCMS (ESI): mass calcd for C<sub>20</sub>H<sub>24</sub>F<sub>3</sub>NO<sub>6</sub>S, 463.1; <i>m</i>/<i>z</i> found, 464.4 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.96 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 (s, 1H), 5.10 (br s, 1H), 4.61 (s, 1H), 4.60 (t, <i>J</i> = 6.0 Hz, 2H), 4.45 (s, 2H), 4.14 (s, 2H), 3.25 (s, 3H), 2.78–2.90 (m, 2H), 1.17 (s, 6H) ppm; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −63.05 ppm; Anal. Calcd for C<sub>20</sub>H<sub>24</sub>F<sub>3</sub>NO<sub>6</sub>S: C, 51.83; H, 5.22; N, 3.02. Found: C, 51.82; H, 5.24; N, 2.96; Pd level < 5.4 ppm.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Preparation of 1-((5-(Hydroxymethyl)-3-(4-(methylsulfonyl)phenyl)-6-(4,4,4-trifluorobutoxy)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>22</b>)</h3><div class="NLM_p last">To a solution of 6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)-2-(4,4,4-trifluorobutoxy)nicotinic acid (<b>39e</b>, 90 g, 183 mmol) in anhydrous THF (2.5 L) at 0 °C was added a THF solution (1 M) of BH<sub>3</sub>·THF (550 mL, 550 mmol). The reaction mixture was stirred at room temperature for 3 h. The mixture was slowly quenched with MeOH (500 mL) dropwise and concentrated. The residue was diluted with water (3 L). The precipitate was collected by filtration, washed with water, and then recrystallized in acetonitrile (150 mL) and ethanol (150 mL) to give the title compound as a white solid (62.1 g, 70% yield). LCMS (ESI): mass calcd for C<sub>21</sub>H<sub>26</sub>F<sub>3</sub>NO<sub>6</sub>S, 477.1; <i>m</i>/<i>z</i> found, 478.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 (s, 1H), 5.06 (t, <i>J</i> = 5.6 Hz, 1H), 4.60 (s, 1H), 4.46 (d, <i>J</i> = 5.6 Hz, 2H), 4.31 (t, <i>J</i> = 6.4 Hz, 2H), 4.13 (s, 2H), 3.25 (s, 3H), 2.41–2.46 (m, 2H), 1.95–2.02 (m, 2H), 1.16 (s, 6H) ppm; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −64.70 ppm; Anal. Calcd for C<sub>21</sub>H<sub>26</sub>F<sub>3</sub>NO<sub>6</sub>S: C, 52.82; H, 5.49; N, 2.93. Found: C, 52.76; H, 5.50; N, 2.89; Pd level < 4.1 ppm.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Preparation of 2-Butoxy-6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)nicotinaldehyde (<b>40</b>)</h3><div class="NLM_p last">To a solution of 1-[[6-butoxy-5-(hydroxymethyl)-3-(4-methanesulfonylphenyl)pyridin-2-yl]oxy]-2-methylpropan-2-ol (<b>11</b>, 860 mg, 2.03 mmol) in dichloromethane (20 mL) at 0 °C was added Dess–Martin periodinane (2.34 g, 5.52 mmol) in several batches. The resulting reaction mixture was stirred at room temperature overnight. The reaction was then quenched by aqueous KHCO<sub>3</sub> solution (60 mL). The resulting solution was extracted with ethyl acetate (3 × 30 mL). The combined organic extract was washed with brine (30 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by chromatography (33% ethyl acetate in petroleum ether as the eluent) to give the title compound as a white solid (810 mg, 95% yield). LCMS (ESI): mass calcd for C<sub>21</sub>H<sub>27</sub>NO<sub>6</sub>S, 421.2; <i>m</i>/<i>z</i> found, 422.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Preparation of 1-((6-Butoxy-5-(1-hydroxyethyl)-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>13</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)nicotinaldehyde (<b>40</b>, 810 mg, 1.83 mmol) in anhydrous THF (20 mL) at 0 °C was added a THF solution (3 M) of methylmagnesium chloride (1.8 mL, 5.4 mmol). The reaction mixture was stirred at 0 °C for 2 h. The reaction was then quenched by aqueous saturated NH<sub>4</sub>Cl solution (40 mL). The resulting solution was extracted with ethyl acetate (3 × 20 mL). The combined organic extract was washed with brine (40 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by reverse-phase prep-HPLC [Column, XBridge Prep C18 OBD 19 × 150 mm 5 μm C-0013; mobile phase, phase A: water(0.1% NH<sub>4</sub>HCO<sub>3</sub>+0.1%NH<sub>3</sub>.H<sub>2</sub>O), phase B: MeCN from 43 to 54; detector, 254 nm] to give the title compound as a white solid (423 mg, 53% yield). LCMS (ESI): mass calcd for C<sub>22</sub>H<sub>31</sub>NO<sub>6</sub>S, 437.2; <i>m</i>/<i>z</i> found, 438.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.96 (d, <i>J</i> = 8.4 Hz, 2H), 7.87 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 (s, 1H), 5.12 (d, <i>J</i> = 4.2 Hz, 1H), 4.84–4.90 (m, 1H), 4.62 (s, 1H), 4.36 (dq, <i>J</i> = 4.2, 6.6 Hz, 2H), 4.13 (s, 2H), 3.25 (s, 3H), 1.70–1.79 (m, 2H), 1.39–1.46 (m, 2H), 1.32 (d, <i>J</i> = 6.3 Hz, 3H), 1.17 (s, 6H), 0.93 (t, <i>J</i> = 6.6 Hz, 3H) ppm.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Preparation of Methyl 2-Butoxy-6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)nicotinate (<b>41</b>)</h3><div class="NLM_p last">To a stirring solution of 2-butoxy-6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)nicotinic acid (<b>39c</b>, 1.2 g, 2.4 mmol) in MeOH (12 mL) and toluene (12 mL) at 0 °C was added a hexane solution (1 M) of (trimethylsilyl)diazomethane (3.5 mL, 3.5 mmol) dropwise. The resulting reaction mixture was stirred at 0 °C for 0.5 h. The reaction was then quenched by water (60 mL). The resulting solution was extracted with ethyl acetate (3 × 30 mL). The combined organic extract was washed with brine (30 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (25% ethyl acetate in petroleum ether as the eluent) to give the title compound as a white solid (1.1 g, 71%). LCMS (ESI): mass calcd for C<sub>22</sub>H<sub>29</sub>NO<sub>7</sub>S, 451.2; <i>m</i>/<i>z</i> found, 452.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Preparation of 1-((6-Butoxy-5-(2-hydroxypropan-2-yl)-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>14</b>)</h3><div class="NLM_p last">To a solution of methyl 2-butoxy-6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)nicotinate (<b>41</b>, 1.3 g, 2.88 mmol) in anhydrous THF (20 mL) at 0 °C was added a THF solution (3 M) of methylmagnesium chloride (10 mL, 30 mmol). The reaction mixture was stirred at room temperature overnight. The reaction was then quenched by aqueous saturated NH<sub>4</sub>Cl solution (50 mL). The resulting solution was extracted with ethyl acetate (3 × 20 mL). The combined organic extract was washed with brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash chromatography (25% ethyl acetate in petroleum ether as the eluent) to give the title compound as a white solid (330 mg, 25% yield). LCMS (ESI): mass calcd for C<sub>23</sub>H<sub>33</sub>NO<sub>6</sub>S, 451.2; <i>m</i>/<i>z</i> found, 452.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.00 (s, 1H), 7.95 (d, <i>J</i> = 8.7 Hz, 2H), 7.88 (d, <i>J</i> = 8.7 Hz, 2H), 5.11 (s, 1H), 4.61 (s, 1H), 4.38 (t, <i>J</i> = 6.3 Hz, 2H), 4.12 (s, 2H), 3.25 (s, 3H), 1.71–1.81 (m, 2H), 1.54 (s, 6H), 1.41–1.54 (m, 2H), 1.17 (s, 6H), 0.97 (t, <i>J</i> = 7.5 Hz, 3H) ppm.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Preparation of Ethyl 2-((2-Butoxy-6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methoxy)acetate (<b>42</b>)</h3><div class="NLM_p last">To a solution of 1-[[6-butoxy-5-(hydroxymethyl)-3-(4-methanesulfonylphenyl)pyridin-2-yl]oxy]-2-methylpropan-2-ol (<b>11</b>, 1.1 g, 2.60 mmol) in anhydrous THF (22 mL) at 0 °C was added NaH (60%, 417 mg, 10.4 mmol) in several batches. The mixture was stirred at 0 °C for 1 h, and then ethyl 2-bromoacetate (1.18 g, 7.06 mmol) was added dropwise. The reaction mixture was stirred at room temperature overnight. The mixture was quenched with acetic acid (10 mL) and water (50 mL). The mixture was extracted with ethyl acetate (3 × 30 mL). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a colorless oil (910 mg, 69% yield). LCMS (ESI): mass calcd for C<sub>25</sub>H<sub>35</sub>NO<sub>8</sub>S, 509.2; <i>m</i>/<i>z</i> found, 510.3 [M – H]<sup>+</sup>.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Preparation of 1-((6-Butoxy-5-((2-hydroxyethoxy)methyl)-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>15</b>)</h3><div class="NLM_p last">To a solution of ethyl 2-((2-butoxy-6-(2-hydroxy-2-methylpropoxy)-5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methoxy)acetate (<b>42</b>, 910 mg, 1.34 mmol) in anhydrous THF (20 mL) at 0 °C was added LiAlH<sub>4</sub> (102 mg, 2.7 mmol). The reaction mixture was stirred at 0 °C for 2 h. The mixture was quenched by Fieser workup (water, 0.1 mL, followed by 15% aqueous NaOH, 0.3 mL; and then stirred for 10 min). The mixture was filtered, and the filtrate was concentrated. The residue was purified by flash chromatography (33–50% ethyl acetate in petroleum ether as the eluent) to give the title compound as a white solid (441 mg, 53% yield). LCMS (ESI): mass calcd for C<sub>23</sub>H<sub>33</sub>NO<sub>7</sub>S, 467.2; <i>m</i>/<i>z</i> found, 468.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.95 (d, <i>J</i> = 8.7 Hz, 2H), 7.89 (d, <i>J</i> = 8.7 Hz, 2H), 7.86 (s, 1H), 4.62 (s, 2H), 4.45 (s, 2H), 4.35 (d, <i>J</i> = 6.0 Hz, 2H), 4.14 (s, 2H), 3.49–3.54 (m, 4H), 3.25 (s, 3H), 1.70–1.79 (m, 2H), 1.39–1.52 (m, 2H), 1.17 (s, 6H), 0.93 (d, <i>J</i> = 7.5 Hz, 3H) ppm.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Preparation of 2-Butoxy-6-(4-fluorophenyl)nicotinic Acid (<b>43</b>)</h3><div class="NLM_p last">To a mixture of 2-butoxy-6-chloronicotinic acid (<b>36c</b>, 4 g, 17.1 mmol), K<sub>2</sub>CO<sub>3</sub> (10.6 g, 76.9 mmol), and 4-fluorophenylboronic acid (3.6 g, 25.6 mmol) in 1,4-dioxane (80 mL) and water (16 mL) under nitrogen was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (2.0 g, 1.7 mmol). The reaction mixture was heated and stirred at 80 °C overnight. The mixture was cooled to room temperature and then quenched with water (200 mL). The mixture was acidified to “pH” 1 using aqueous HCl solution (1 M), and then extracted with ethyl acetate (3 × 50 mL). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (50–70% ethyl acetate in petroleum ether as the eluent) to give the title compound as a white solid (2.1 g, 40% yield). LCMS (ESI): mass calcd for C<sub>16</sub>H<sub>16</sub>FNO<sub>3</sub>, 289.1; <i>m</i>/<i>z</i> found, 288.2 [M – H]<sup>+</sup>.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Preparation of 5-Bromo-2-butoxy-6-(4-fluorophenyl)nicotinic Acid (<b>44</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-(4-fluorophenyl)nicotinic acid (2.1 g, 6.9 mmol) in acetonitrile (40 mL) and trifluoroacetic acid (40 mL) was added NBS (1.6 g, 9.0 mmol). The reaction mixture was stirred at room temperature overnight. Water (500 mL) was added. The precipitate was collected by filtration, washed with water (2 × 40 mL), and dried in vacuo to give the title compound as a white solid (1.5 g, 57% yield). LCMS (ESI): mass calcd for C<sub>16</sub>H<sub>15</sub>BrFNO<sub>3</sub>, 367.0; <i>m</i>/<i>z</i> found, 368.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Preparation of 2-Butoxy-6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)nicotinic Acid (<b>45</b>)</h3><div class="NLM_p last">To a mixture of 5-bromo-2-butoxy-6-(4-fluorophenyl)nicotinic acid (<b>44</b>, 1.1 g, 2.87 mmol), K<sub>2</sub>CO<sub>3</sub> (1.8 g, 12.9 mmol), and 4-(methylsulfonyl)phenylboronic acid (630 mg, 3.15 mmol) in 1,4-dioxane (20 mL) and water (4 mL) was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (331 mg, 0.29 mmol) under nitrogen. The reaction mixture was heated with stirring at 80 °C overnight. The mixture was cooled to room temperature and quenched with water (60 mL). The mixture was acidified to “pH” 1 using aqueous HCl solution (1 M) and then extracted with ethyl acetate (3 × 20 mL). The combined organic extract was washed with brine (30 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (70% ethyl acetate in petroleum ether as the eluent) to give the title compound as a white solid (810 mg, 56% yield). LCMS (ESI): mass calcd for C<sub>23</sub>H<sub>22</sub>FNO<sub>5</sub>S, 443.1; <i>m</i>/<i>z</i> found, 444.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Preparation of (2-Butoxy-6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methanol (<b>16</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)nicotinic acid (<b>45</b>, 810 mg, 1.6 mmol) in anhydrous THF (16 mL) at 0 °C was added a THF solution (1 M) of BH<sub>3</sub>·THF (4.7 mL, 4.7 mmol). The reaction mixture was stirred at room temperature for 3 h. The mixture was quenched with MeOH (10 mL) and water (50 mL), and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 × 20 mL). The combined organic extract was washed with saturated aqueous NaHCO<sub>3</sub> (20 mL), brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by reverse-phase prep-HPLC [Column, XBridge Prep C18 OBD column 19 × 150 mm 5umC-0013; mobile phase, phase A: water (10 mmol NH<sub>4</sub>HCO<sub>3</sub> solution; phase B: MeCN from 56 to 74% in 7 min; detector, 254 nm)] to give the title compound as a white solid (416 mg, 61% yield). LCMS (ESI): mass calcd for C<sub>23</sub>H<sub>24</sub>FNO<sub>4</sub>S, 429.1; <i>m</i>/<i>z</i> found, 430.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.86 (d, <i>J</i> = 8.4 Hz, 2H), 7.75 (s, 1H), 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 7.31–7.37 (m, 2H), 7.10–7.17 (m, 2H), 5.30 (t, <i>J</i> = 5.4 Hz, 1H), 4.56 (d, <i>J</i> = 5.4 Hz, 2H), 4.40 (t, <i>J</i> = 6.3 Hz, 2H), 3.23 (s, 3H), 1.70–1.79 (m, 2H), 1.42–1.49 (m, 2H), 0.95 (t, <i>J</i> = 7.2 Hz, 3H) ppm.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Preparation of 2-Butoxy-6-(oxetan-3-ylmethoxy)nicotinic Acid (<b>47a</b>)</h3><div class="NLM_p last">To a mixture of 2-butoxy-6-chloronicotinic acid (<b>36c</b>, 20 g, 85 mmol), Cs<sub>2</sub>CO<sub>3</sub> (83.1 g, 255 mmol), and oxetan-3-ylmethanol (18.7 g, 212 mmol) in toluene (600 mL) under nitrogen was added XPhos Pd G3 (1.4 g, 1.65 mmol). The reaction mixture was heated and stirred at 90 °C for 3 h. The mixture was cooled to room temperature and then quenched with water. The organic layer was separated, and the “pH” of the aqueous layer was adjusted to 1 using aqueous HCl solution (1 M). The aqueous solution was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a white solid (19 g, 80% yield). LCMS (ESI): mass calcd for C<sub>14</sub>H<sub>19</sub>NO<sub>5</sub>, 281.1; <i>m</i>/<i>z</i> found, 282.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Preparation of 2-Butoxy-6-((3-hydroxyoxetan-3-yl)methoxy)nicotinic Acid (<b>47b</b>)</h3><div class="NLM_p last">To a mixture of 2-butoxy-6-chloronicotinic acid (<b>36c</b>, 2 g, 8.7 mmol), Cs<sub>2</sub>CO<sub>3</sub> (8.6 g, 26.4 mmol), and 3-(hydroxymethyl)oxetan-3-ol (1.4 g, 13.4 mmol) in toluene (60 mL) under nitrogen was added XPhos Pd G3 (148 mg, 0.175 mmol). The reaction mixture was heated and stirred at 90 °C for 3 h. The mixture was cooled to room temperature and then quenched with water. The organic layer was separated, and the “pH” of the aqueous layer was adjusted to 1 using aqueous HCl solution (1 M). The aqueous solution was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a white solid (1.4 g, 54% yield). LCMS (ESI): mass calcd for C<sub>14</sub>H<sub>19</sub>NO<sub>6</sub>, 297.1; <i>m</i>/<i>z</i> found, 298.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Preparation of 2-Butoxy-6-((3-methyloxetan-3-yl)methoxy)nicotinic Acid (<b>47c</b>)</h3><div class="NLM_p last">To a mixture of 2-butoxy-6-chloronicotinic acid (<b>36c</b>, 4 g, 17.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (17 g, 52.2 mmol), and (3-methyloxetan-3-yl) methanol (4.4 g, 43.1 mmol) in toluene (120 mL) under nitrogen was added XPhos Pd G3 (295 mg, 0.349 mmol). The reaction mixture was heated and stirred at 90 °C for 3 h. The mixture was cooled to room temperature and then quenched with water. The organic layer was separated, and the “pH” of the aqueous layer was adjusted to 1 using aqueous HCl solution (1 M). The aqueous solution was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a white solid (4.1 g, 80% yield). LCMS (ESI): mass calcd for C<sub>15</sub>H<sub>21</sub>NO<sub>5</sub>, 295.1; <i>m</i>/<i>z</i> found, 296.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Preparation of 2-Butoxy-6-((1-hydroxycyclobutyl)methoxy)nicotinic Acid (<b>47d</b>)</h3><div class="NLM_p last">To a mixture of 2-butoxy-6-chloronicotinic acid (<b>36c</b>, 20 g, 87.0 mmol), Cs<sub>2</sub>CO<sub>3</sub> (85.1 g, 261 mmol), and 1-(hydroxymethyl) cyclobutan-1-ol (17.8 g, 174 mmol) in toluene (600 mL) under nitrogen was added XPhos Pd G3 (1.47 g, 1.74 mmol). The reaction mixture was heated and stirred at 90 °C overnight. The mixture was cooled to room temperature and then quenched with water (3 L). The organic layer was separated, and the “pH” of the aqueous layer was adjusted to 1 using aqueous HCl solution (1 M). The aqueous solution was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a brown oil (15 g, 45% yield). LCMS (ESI): mass calcd for C<sub>15</sub>H<sub>21</sub>NO<sub>5</sub>, 295.1; <i>m</i>/<i>z</i> found, 296.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Preparation of 5-Bromo-2-butoxy-6-(oxetan-3-ylmethoxy)nicotinic Acid (<b>48a</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-(oxetan-3-ylmethoxy)nicotinic acid (<b>47a</b>, 19 g, 60.8 mmol) and acetic acid (18.3 g, 305 mmol) in acetonitrile (400 mL) was added NBS (13 g, 73 mmol). The reaction mixture was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure. The residue was triturated in ethyl acetate to give the title compound as a white solid (19.5 g, 85% yield). LCMS (ESI): mass calcd for C<sub>14</sub>H<sub>18</sub>BrNO<sub>5</sub>, 359.0; <i>m</i>/<i>z</i> found, 360.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Preparation of 5-Bromo-2-butoxy-6-((3-hydroxyoxetan-3-yl)methoxy)nicotinic Acid (<b>48b</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-((3-hydroxyoxetan-3-yl)methoxy) nicotinic acid (<b>47b</b>, 1.4 g, 4.7 mmol) in acetonitrile (25 mL) and acetic acid (1.4 g, 23 mmol) was added NBS (1 g, 5.6 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated. The residue was purified by reversal-phase Combi-Flash [MeCN/water (0.05% NH<sub>4</sub>HCO<sub>3</sub>) from 10% to 60% in 45 min] to give the title compound as a white solid (1.3 g, 73% yield). LCMS (ESI): mass calcd for C<sub>14</sub>H<sub>18</sub>BrNO<sub>6</sub>, 375.0; <i>m</i>/<i>z</i> found, 376.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Preparation of 5-Bromo-2-butoxy-6-((3-methyloxetan-3-yl)methoxy)nicotinic Acid (<b>48c</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-((3-methyloxetan-3-yl)methoxy) nicotinic acid (<b>47c</b>, 4.1 g, 13.9 mmol) and acetic acid (4.2 g, 69.4 mmol) in acetonitrile (80 mL) was added NBS (3 g, 16.9 mmol). The reaction mixture was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure. The residue was triturated in ethyl acetate to give the title compound as a white solid (4.5 g, 87% yield). LCMS (ESI): mass calcd for C<sub>15</sub>H<sub>20</sub>BrNO<sub>5</sub>, 373.0; <i>m</i>/<i>z</i> found, 374.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Preparation of 5-Bromo-2-butoxy-6-((1-hydroxycyclobutyl)methoxy)nicotinic Acid (<b>48d</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-((1-hydroxycyclobutyl)methoxy)nicotinic acid (<b>47d</b>, 15 g, 39.1 mmol) in acetonitrile (375 mL) was added NBS (7.66 g, 43.0 mmol). The reaction mixture was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure. The residue was triturated in ethyl acetate to give the title compound as a white solid (8 g, 50% yield). LCMS (ESI): mass calcd for C<sub>15</sub>H<sub>20</sub>BrNO<sub>5</sub>, 373.0; <i>m</i>/<i>z</i> found, 374.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Preparation of 2-Butoxy-5-(4-(methylsulfonyl)phenyl)-6-(oxetan-3-ylmethoxy)nicotinic Acid (<b>49a</b>)</h3><div class="NLM_p last">To a mixture of 5-bromo-2-butoxy-6-(oxetan-3-ylmethoxy)nicotinic acid (<b>48a</b>, 10 g, 27.8 mmol), 4-(methylsulfonyl)phenylboronic acid (6.1 g, 30.5 mmol), and K<sub>2</sub>CO<sub>3</sub> (17.3 g, 125 mmol) in 1,4-dioxane (200 mL) and water (20 mL) was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (3.2 g, 2.76 mmol) under nitrogen. The reaction mixture was heated with stirring at 80 °C overnight. The mixture was cooled to room temperature and quenched with water. The mixture was filtered to remove the solids. The filtrate was acidified to “pH” 1 using aqueous HCl solution (1 M), and then extracted with ethyl acetate. The combined organic extract was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was triturated in ethyl acetate to give the title compound as a white solid (8 g, 66% yield). LCMS (ESI): mass calcd for C<sub>21</sub>H<sub>25</sub>NO<sub>7</sub>S, 435.1; <i>m</i>/<i>z</i> found, 436.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Preparation of 2-Butoxy-6-((3-hydroxyoxetan-3-yl)methoxy)-5-(4-(methylsulfonyl)phenyl)nicotinic Acid (<b>49b</b>)</h3><div class="NLM_p last">To a mixture of 5-bromo-2-butoxy-6-((3-hydroxyoxetan-3-yl)methoxy)nicotinic acid (<b>48b</b>, 1.3 g, 3.5 mmol), (4-(methylsulfonyl)phenyl)boronic acid (760 mg, 3.80 mmol), and K<sub>2</sub>CO<sub>3</sub> (2.15 g, 15.6 mmol) in 1,4-dioxane (30 mL) and water (3 mL) was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (400 mg, 0.346 mmol) under nitrogen. The reaction mixture was heated with stirring at 80 °C overnight. The mixture was cooled to room temperature and quenched with water. The mixture was filtered to remove the solids. The filtrate was acidified to “pH” 1 using aqueous HCl solution (1 M), and then extracted with ethyl acetate. The combined organic extract was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was triturated in ethyl acetate to give the title compound as a white solid (660 mg, 42% yield). LCMS (ESI): mass calcd for C<sub>21</sub>H<sub>25</sub>NO<sub>8</sub>S, 451.1; <i>m</i>/<i>z</i> found, 452.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Preparation of 2-Butoxy-6-((3-methyloxetan-3-yl)methoxy)-5-(4-(methylsulfonyl)phenyl)nicotinic Acid (<b>49c</b>)</h3><div class="NLM_p last">To a mixture of 5-bromo-2-butoxy-6-((3-methyloxetan-3-yl)methoxy)nicotinic acid (<b>48c</b>, 4.5 g, 12.0 mmol), 4-(methylsulfonyl)phenylboronic acid (2.6 g, 13.0 mmol), and K<sub>2</sub>CO<sub>3</sub> (7.5 g, 54.3 mmol) in 1,4-dioxane (90 mL) and water (9 mL) was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (1.4 g, 1.21 mmol) under nitrogen. The reaction mixture was heated with stirring at 80 °C overnight. The mixture was cooled to room temperature and quenched with water. The mixture was filtered to remove the solids. The filtrate was acidified to “pH” 1 using aqueous HCl solution (1 M), and then extracted with ethyl acetate. The combined organic extract was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by reverse-phase Combi-Flash [MeCN/water (0.05% NH<sub>4</sub>HCO<sub>3</sub>) from 10% to 40% in 45 min] to give the title compound as a white solid (2.2 g, 41% yield). LCMS (ESI): mass calcd for C<sub>22</sub>H<sub>27</sub>NO<sub>7</sub>S, 449.2; <i>m</i>/<i>z</i> found, 450.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Preparation of 2-Butoxy-6-((1-hydroxycyclobutyl)methoxy)-5-(4-(methylsulfonyl)phenyl)nicotinic Acid (<b>49d</b>)</h3><div class="NLM_p last">To a mixture of 5-bromo-2-butoxy-6-((1-hydroxycyclobutyl)methoxy)nicotinic acid (<b>48d</b>, 8 g, 19.5 mmol), 4-(methylsulfonyl)phenylboronic acid (4.28 g, 21.4 mmol), and K<sub>2</sub>CO<sub>3</sub> (12.1 g, 87.5 mmol) in 1,4-dioxane (160 mL) and water (16 mL) was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (2.25 g, 1.95 mmol) under nitrogen. The reaction mixture was heated with stirring at 80 °C overnight. The mixture was cooled to room temperature and quenched with water. The mixture was filtered to remove the solids. The filtrate was acidified to “pH” 1 using aqueous HCl solution (1 M), and then extracted with ethyl acetate. The combined organic extract was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by reverse-phase Combi-Flash [MeCN/water (0.05% NH<sub>4</sub>HCO<sub>3</sub>) from 10% to 40% in 45 min] to give the title compound as a white solid (4.1 g, 45% yield). LCMS (ESI): mass calcd for C<sub>22</sub>H<sub>27</sub>NO<sub>7</sub>S, 449.2; <i>m</i>/<i>z</i> found, 450.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Preparation of (2-Butoxy-5-(4-(methylsulfonyl)phenyl)-6-(oxetan-3-ylmethoxy)pyridin-3-yl)methanol (<b>17</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-5-(4-(methylsulfonyl) phenyl)-6-(oxetan-3-ylmethoxy)nicotinic acid (<b>49a</b>, 8 g, 18.4 mmol) and triethylamine (2.3 g, 22.7 mmol) in anhydrous THF (200 mL) at 0 °C was added isobutyl chloroformate (3 g, 22 mmol). The mixture was stirred at 0 °C for 0.5 h, and then an aqueous suspension (2 mL) of NaBH<sub>4</sub> (1.4 g, 37.0 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated. The residue was purified by reverse-phase prep-HPLC (column, C-18, mobile phase, water (a)/MeCN (b), b %: 30%–80%, 35 min; detector, UV 210 nm) to give the title compound as a white solid (3.41 g, 44% yield). LCMS (ESI): mass calcd for C<sub>21</sub>H<sub>27</sub>NO<sub>6</sub>S, 421.2; <i>m</i>/<i>z</i> found, 422.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.94 (d, <i>J</i> = 8.4 Hz, 2H), 7.82 (s, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 2H), 5.08 (t, <i>J</i> = 5.6 Hz, 1H), 4.65–4.74 (m, 2H), 4.57 (d, <i>J</i> = 6.4 Hz, 2H), 4.41–4.50 (m, 4H), 4.37 (t, <i>J</i> = 6.4 Hz, 2H), 3.32–3.49 (m, 1H), 3.24 (s, 3H), 1.65–1.80 (m, 2H), 1.36–1.53 (m, 2H), 0.95 (t, <i>J</i> = 7.4 Hz, 3H) ppm.</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Preparation of 3-(((6-Butoxy-5-(hydroxymethyl)-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)methyl)oxetan-3-ol (<b>18</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-((3-hydroxyoxetan-3-yl)methoxy)-5-(4-(methylsulfonyl)phenyl)nicotinic acid (<b>49b</b>, 660 mg, 1.46 mmol) and triethylamine (178 mg, 1.76 mmol) in anhydrous THF (18 mL) at 0 °C was added isobutyl chloroformate (240 mg, 1.76 mmol). The mixture was stirred at 0 °C for 0.5 h, and then an aqueous suspension (0.2 mL) of NaBH<sub>4</sub> (111 mg, 2.93 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated. The residue was purified by reverse-phase prep-HPLC (column, C-18, mobile phase, water (a)/MeCN (b), <i>b</i> %: 20–50%, 35 min; detector, UV 210 nm) to give the title compound as a white solid (350 mg, 54% yield). LCMS (ESI): mass calcd for C<sub>21</sub>H<sub>27</sub>NO<sub>7</sub>S, 437.2; <i>m</i>/<i>z</i> found, 438.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.97–7.87 (m, 4H), 7.85 (s, 1H), 4.57–4.48 (m, 8H), 4.38 (t, <i>J</i> = 6.5 Hz, 2H), 3.46 (br s, 2H), 3.25 (s, 3H), 1.80–1.68 (m, 2H), 1.54–1.36 (m, 2H), 0.95 (t, <i>J</i> = 7.4 Hz, 3H) ppm.</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Preparation of (2-Butoxy-6-((3-methyloxetan-3-yl)methoxy)-5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methanol (<b>19</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-((3-methyloxetan-3-yl)methoxy)-5-(4-(methylsulfonyl)phenyl)nicotinic acid (<b>49c</b>, 2.2 g, 4.9 mmol) and triethylamine (594 mg, 5.87 mmol) in anhydrous THF (55 mL) at 0 °C was added isobutyl chloroformate (802 mg, 5.87 mmol). The mixture was stirred at 0 °C for 0.5 h, and then an aqueous suspension (0.6 mL) of NaBH<sub>4</sub> (370 mg, 9.78 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated. The residue was purified by reverse-phase prep-HPLC (column, C-18, mobile phase, water (a)/MeCN (b), <i>b</i> %: 30–60%, 35 min; detector, UV 210 nm) to give the title compound as a white solid (746 mg, 35% yield). LCMS (ESI): mass calcd for C<sub>22</sub>H<sub>29</sub>NO<sub>6</sub>S, 435.2; <i>m</i>/<i>z</i> found, 436.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.95 (d, <i>J</i> = 8.7 Hz, 2H), 7.84 (s, 1 H), 7.82 (d, <i>J</i> = 8.7 Hz, 2H), 5.10 (t, <i>J</i> = 5.7 Hz, 1H), 4.50–4.48 (m, 6H), 4.46 (t, <i>J</i> = 6.5 Hz, 2H), 4.29 (d, <i>J</i> = 5.7 Hz, 2H), 3.25 (s, 3H), 1.80–1.65 (m, 2H), 1.51–1.39 (m, 2H), 1.29 (s, 3H), 0.95 (t, <i>J</i> = 7.4 Hz, 3H) ppm.</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Preparation of 1-(((6-Butoxy-5-(hydroxymethyl)-3-(4-(methylsulfonyl)phenyl)pyridin-2-yl)oxy)methyl)cyclobutan-1-ol (<b>20</b>)</h3><div class="NLM_p last">To a solution of 2-butoxy-6-((1-hydroxycyclobutyl)methoxy)-5-(4-(methylsulfonyl) phenyl) nicotinic acid (<b>49d</b>, 4.1 g, 8.8 mmol) in anhydrous THF (82 mL) at 0 °C was added a THF solution (1 M) of BH<sub>3</sub>·THF (27 mL, 27 mmol). The reaction mixture was stirred at room temperature for 5 h. The mixture was slowly quenched with MeOH (5 mL) dropwise and concentrated. The residue was purified by reverse-phase Combi-Flash chromatography [MeCN/water (0.05% NH<sub>4</sub>HCO<sub>3</sub>) from 45 to 65% in 30 min] to give the crude product (3.2 g). Then, SiliaMrtS DMT (0.5 g) and MeCN (100 mL) were added to the crude product. The mixture was stirred at room temperature for 2 h, and then filtered. The filtrate was concentrated to give the title compound as a white solid (2.85 g, 74% yield). LCMS (ESI): mass calcd for C<sub>22</sub>H<sub>29</sub>NO<sub>6</sub>S, 435.2; <i>m</i>/<i>z</i> found, 436.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.94–7.82 (m, 4H), 7.82 (s, 1H), 5.21 (s, 1H), 5.07 (t, <i>J</i> = 4.2 Hz, 1H), 4.45 (d, <i>J</i> = 4.2 Hz, 2H), 4.39–4.34 (m, 2H), 4.34 (s, 2H), 3.24 (s, 3H), 2.13–1.94 (m, 4H), 1.78–1.63 (m, 3H), 1.55–1.39 (m, 3H), 0.95 (t, <i>J</i> = 6.8 Hz, 3H) ppm; Anal. Calcd for C<sub>22</sub>H<sub>29</sub>NO<sub>6</sub>S: C, 60.67; H, 6.71; N, 3.22. Found: C, 60.32; H, 7.04; N, 3.17; Pd level 4.8 ppm.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Preparation of 1-((3-Bromo-6-butoxy-5-(hydroxymethyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>50</b>)</h3><div class="NLM_p last">To a solution of 5-bromo-2-butoxy-6-(2-hydroxy-2-methylpropoxy)nicotinic acid (<b>38c</b>, 100 g, 255 mmol) in anhydrous THF (2 L) at 0 °C was added a THF solution (1 M) of BH<sub>3</sub>·THF (575 mL, 575 mmol). The reaction mixture was stirred at room temperature for 5 h. The mixture was quenched with MeOH (300 mL) and water (2 L), and then extracted with ethyl acetate (3 × 600 mL). The combined organic extract was washed with saturated aqueous NaHCO<sub>3</sub> (600 mL) and brine (600 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the title compound as a white solid (82 g, 81% yield). LCMS (ESI): mass calcd for C<sub>14</sub>H<sub>22</sub>BrNO<sub>4</sub>, 347.1; <i>m</i>/<i>z</i> found, 348.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Preparation of 1-((6-Butoxy-5-(hydroxymethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>51</b>)</h3><div class="NLM_p last">To a mixture of 1-((3-bromo-6-butoxy-5-(hydroxymethyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol (<b>50</b>, 82 g, 208 mmol), bis(pinacolato)diboron (105.6 g, 416 mmol), and potassium acetate (40.8 g, 416 mmol) in anhydrous 1,4-dioxane (800 mL) was added Pd(dppf)Cl<sub>2</sub> (15.2 g, 20.8 mmol) under nitrogen. The reaction mixture was heated with stirring at 100 °C overnight. The mixture was cooled to room temperature and diluted with water (1 L), and then extracted with ethyl acetate (3 × 400 mL). The combined organic extract was washed with brine (400 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound as a crude product: a black solid (90 g, 67% yield). LCMS (ESI): mass calcd for C<sub>20</sub>H<sub>34</sub>BNO<sub>6</sub>, 395.2; <i>m</i>/<i>z</i> found, 396.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Preparation of 6′-Butoxy-2′-(2-hydroxy-2-methylpropoxy)-5′-(hydroxymethyl)-[2,3′-Bipyridine]-5-sulfonamide (<b>23</b>)</h3><div class="NLM_p last">To a mixture of 1-(6-butoxy-5-(hydroxymethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxa-borolan-2-yl)pyridin-2-yloxy)-2-methylpropan-2-ol (<b>51</b>, 70 g, 115 mmol), 6-chloropyridine-3-sulfonamide (26.5 g, 138 mmol), and Na<sub>2</sub>CO<sub>3</sub> (24.3 g, 229.5 mmol) in 1,4-dioxane (700 mL) and water (70 mL) was added Pd(dppf)Cl<sub>2</sub> (8.4 g, 11.5 mmol) under nitrogen. The reaction mixture was heated with stirring at 65 °C overnight. The mixture was cooled to room temperature and concentrated. The residue was diluted with water (500 mL), and then extracted with ethyl acetate (3 × 200 mL). The combined organic extract was washed with brine (200 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (50–80% ethyl acetate in petroleum ether as the eluent) to give a crude product. The crude product was dissolved in THF (200 mL) and SiliaMrtS DMT (3 g) was added. The mixture was stirred at room temperature overnight. The mixture was filtered, and the filtrate was concentrated. The residue was purified by reverse-phase prep-HPLC [Column, C-18, mobile phase, water (a, 0.1%TFA)/MeCN (b), <i>b</i> %: 20–57%, 12 min; detector, UV 254 nm] followed by recrystallization in acetonitrile to give the title compound as a white solid (15 g, 30% yield). LCMS (ESI): mass calcd for C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>S, 425.2; <i>m</i>/<i>z</i> found, 426.2 [M + H]<sup>+</sup>; <sup>1</sup>HNMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.00 (d, <i>J</i> = 2.0 Hz, 1H), 8.46 (s, 1H), 8.34 (d, <i>J</i> = 8.4 Hz, 1H), 8.18 (dd, <i>J</i> = 2.4, 8.4 Hz, 1H), 7.58 (s, 2H), 5.17 (t, <i>J</i> = 6.0 Hz, 1H), 4.73 (s, 1H), 4.46 (d, <i>J</i> = 5.6 Hz, 2H), 4.38 (t, <i>J</i> = 6.4 Hz, 2H), 4.21 (s, 2H), 1.71–1.78 (m, 2H), 1.40–1.49 (m, 2H), 1.22 (s, 6H), 0.95 (t, <i>J</i> = 6.8 Hz, 3H) ppm; Anal. Calcd for C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>S: C, 53.63; H, 6.40; N, 9.88. Found: C, 53.45; H, 6.41; N, 9.95; Pd level < 4.4 ppm.</div></div><div id="sec4_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Human COX-2/COX-1 Enzymatic Assays</h3><div class="NLM_p">COX-2 is a bifunctional enzyme that catalyzes two sequential reactions starting with a COX reaction that oxidizes arachidonic acid to PGG2 and followed by a peroxidase reaction that reduces PGG2 to PGH2. COX-2 activity was assessed in an in vitro assay through coupling of the peroxidase activity with oxidation of ADHP to form resurofin, which is highly fluorescent with an excitation wavelength between 530 and 540 nm and an emission wavelength between 585 and 595 nm. The final assay buffer consisted of 30 nM recombinant human COX-2 and 25 mM arachidonic acid in 100 mM Tris–HCl, pH 8, containing 2 mM heme, 20 μM ADHP, 10 nM catalase, 0.1 mg/mL BSA, and 0.002% Tween-20. The <i>K</i><sub>m</sub> value under these conditions was determined to be 13 ± 3 μM. Test compound concentrations ranged from 50 μM to 0.85 nM prepared using a 11-step serial dilution (1:3) in pure DMSO. The serially diluted test compounds were spotted per well of a black 384-Proxiplate (Perkin Elmer) with DMSO maintained at 1% of the total assay volume. The background signal was measured from control wells containing assay buffer without arachidonic acid, which functions as low control (LC). High control (HC) values were generated using the reaction with enzyme but no compound treatment. Compounds were preincubated with enzyme for 60 min at room temperature. The substrate was added to initiate the reaction and the reaction mixture was incubated for 20 s. The reaction was quenched by adding 10 mM ascorbic acid (diverting oxidation of ADHP to that of ascorbic acid). Fluorescence was then measured in PheraStar with excitation at 540 nm and emission at 590 nm.</div><div class="NLM_p last">The COX-1 enzyme assay was identical to the COX-2 enzyme assay as described above with the exception that the arachidonic acid concentration in the COX-1 enzyme assay was maintained at 10 μM rather than at 25 μM as in the COX-2 assay. The <i>K</i><sub>m</sub> value of COX-1 was determined to be 2.8 ± 0.4 μM under the assay conditions.</div></div><div id="sec4_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> COX-2/COX-1 RapidFire High-Throughput Mass Spectrometry Cellular Assay</h3><div class="NLM_p last">The COX-2/COX-1 RapidFire mass spectrometric cellular assay monitors the conversion of arachidonic acid to PGD2 by COX1 and COX2. Tetracycline-inducible HEK 293 T-Rex cells (Thermo) overexpressed COX-2 or COX-1 via overnight promotion. Cells were adjusted to a given concentration (COX-2, 80,000 cells/mL; Cox-1, 30,000 cells/mL) in cell media supplemented with 1 μg/mL tetracycline (Sigma, T7660) and dispensed into Poly-D lysine (PDL)-coated 384-well cell culture plates (Greiner #655940), 100 μL/well, using a ThermoFisher MultiDrop Combi liquid handler. The plates were incubated overnight at 37 °C, 5% CO<sub>2</sub>, 95% RH to induce COX-2 or COX-1 protein. Compounds were diluted fresh in DMSO (Sigma, 276855) and plated in Greiner 384-well PP plates (Greiner#781280). Using a Janus MDT liquid handler, a 3-fold titration was conducted for each compound (11pt. + vehicle control). 200 μL of tetracycline-free media (Life-Technologies 10566016) was dispensed into a 384-well deep well microplate (Greiner#781270) using the Combi. The Janus liquid handler was used to transfer 1 μL of each well from the compound plate (100% DMSO) and transfer it to the 200 μL of media and mix, creating 0.5% DMSO final concentrations of compounds in cell media. Spent media were removed from the overnight-induced PDL plates via plate flicking, and 30 μL of compound titrations in cell media were added atop PDL-attached cells. The plates were covered with a lid, centrifuged briefly (250<i>g</i>, 1 min), and incubated for 1 h at 37 °C. A MultiDrop Combi was used to dispense 30 μL/well of deuterated substrate (40 μM arachidonic acid-D11, AA-D11, Cayman Chemicals #10006758), which was diluted in tetracycline-free media. AA-D11 was dispensed with a small tube cassette due to the smaller tubing diameter and thus more vigorous mixing upon addition. Assay plates were covered with a lid, centrifuged, and incubated for 1 h at 37 °C. The Janus liquid handler was used to gently mix the media atop the cells now containing deuterated product PGD2-D11 and transfer 10 μL into 90 μL of Agilent RapidFire effluent containing internal standard PGD2-D4 (Cayman Chemicals #312010) (0.01% Formic Acid, 0.1% Tween 20, 0.025 μg/mL PGD2-D4). The assay plates were analyzed using a RapidFire high-throughput solid-phase extraction system (Agilent) coupled to a triple quadrupole mass spectrometer (AB SCIEX) to measure relative peak areas of PGD2-D11 and PGD2-D4. Due to the variable sip volume of the RF-MS system, quantification of product (PGD2-D11) via a relative peak area was divided by the relative peak area of internal control (PGD2-D4), for internal assay normalization. Peaks were integrated using the RapidFire integrator software. RF-MS sample loading was done on a miniature C4 column, Agilent “Cartridge A” (Agilent #G9303A). The RF-MS was tuned to capture the PGD2-D11 product at XIC 362.2/282.2 and the PGD2-d4 spiked in product at XIC 354.9/275.2 on a Sciex Triple Quad 4000 QTRAP.</div></div><div id="sec4_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Human Whole Blood COX-2/COX-1 Assays</h3><div class="NLM_p">The whole blood assay and related analytical procedure were previously described.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Briefly, DMSO solutions of test compounds (50,000, 33,300, 10,000, 3,000, 900, 270, 81.4, 24.4, 7.34, 2.20, 0.662, 0.199, and 0.0597 μM) were prepared. The test compound (1.8 μL) for each concentration was added into a 96 deep-well plate. Each of 300 μL freshly heparinized blood was used for COX-2 and COX-1 assays. The final compound concentrations ranged from 600 to 0.4 μM. The plate was covered with foil, vortexed at 800 rpm for 1 min, and then incubated at 37 °C/5% CO<sub>2</sub> for 1 h.</div><div class="NLM_p">For the COX-2 assay, 10 μL of 300 μg/mL LPS solution was added to COX-2 plate for a 10 μg/mL LPS final concentration. The plate was covered with foil, vortexed at 800 rpm for 1 min, and then incubated at 37 °C/5% CO<sub>2</sub> overnight. 100 μL ice-cold PBS buffer was added to the wells and mixed by using a pipet 10 times. The plates were centrifuged at 1400 rpm at 4 °C for 10 min. The supernatant aliquot (50 μL) was transferred into 150 μL ELISA buffer and vortexed. The samples were analyzed using PGE<sub>2</sub> ELISA kits from Cayman Chemical Inc.</div><div class="NLM_p last">For the COX-1 assay, 2 μL of 2.25 mM calcium ionophore solution was added to the COX-1 plate for a 15 μM calcium ionophore final concentration. The plate was covered with foil, vortexed at 800 rpm for 1 min, and then incubated at 37 °C/5% CO<sub>2</sub> for 1 h with continuous shaking at 175 rpm. 100 μL ice-cold PBS buffer was added to the wells and mixed by using a pipet 10 times. The plates were centrifuged at 1400 rpm at 4 °C for 10 min. The supernatant aliquot (20 μL) was transferred into 180 μL ELISA buffer and vortexed. The samples were analyzed using TXB<sub>2</sub> ELISA kits from Cayman Chemical Inc.</div></div><div id="sec4_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Mouse Cassette PK Studies Following IV or Oral Dosing</h3><div class="NLM_p last">The selected compounds were formulated together for the cassette dosing. Three fasted male C57BL/6J mice were administered a single intravenous (IV) bolus injection of 2 mg/kg in a solution of PEG400/water (70:30) at a dose volume of 2 mL/kg. Blood samples were collected at 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h postdose via dorsal metatarsal vein. Six fasted male C57BL/6J mice were administered a single oral dose of 10 mg/kg in a solution of PEG400/water (70:30) at a dose volume of 10 mL/kg. Blood samples were collected at 0.25, 0.5, 1, 2, 3, and 4 h postdose. Colon tissue was collected at 2 and 4 h postdose. For both studies, blood samples were collected into tubes containing the K<sub>2</sub>EDTA anticoagulant and placed on wet ice. The plasma fraction was separated by centrifugation and frozen at −20 °C or lower until analysis. Colon tissue was collected at 2 and 4 h postdose. For both studies, blood samples were collected into tubes containing K<sub>2</sub>EDTA anticoagulant and placed on wet ice. The plasma fraction was separated by centrifugation and frozen at −20 °C or lower until analysis. Colon tissue was homogenized with PBS at a ratio of 1:5 [colon weight (g) to PBS volume (mL)]. Plasma and colon samples were processed for analysis by protein precipitation using acetonitrile. The final compound concentration in colon (ng/mL) was corrected by multiplying by 6. Concentrations of the compound in plasma and colon were determined using a liquid chromatographic triple-quadrupole mass spectrometric method (Shimadzu HPLC coupled to an AAB API 5500 instrument; Quantification: MRM, Positive ion).</div></div><div id="sec4_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Metabolite Identifications from Incubations of Compound 11 with Human and Mouse Hepatocytes</h3><div class="NLM_p">The cryopreserved hepatocytes were thawed on ice and vials were placed in a 37 °C water bath for approximately 90 s and then immediately added to a prewarmed hepatocyte-thawing media. The cells were resuspended with the media and then centrifuged at 700<i>g</i> for 7 min at room temperature. The supernatant was discarded, and the cells were resuspended in 2 mL of Krebs–Henseleit buffer (KHB) containing 12.5 mM HEPES pH 7.4. Cell viability and yield were determined by Trypan Blue exclusion. The hepatocytes were then diluted in KHB to a cell concentration of 2 × 10<sup>6</sup> cells/mL (500 μL/well in 10 mL glass tubes). The tubes were placed on a rotary shaker in a humidifier incubator supplied with 5% CO<sub>2</sub> and allowed for 15 min acclimation at 37 °C prior to use. Compound <b>11</b> or positive control, diclofenac (10 μM), in KHB was then added to the hepatocytes to achieve a final compound concentration of 10 μM and a cell concentration of 1 × 10<sup>6</sup> cells/mL (1000 μL final incubation volume). Cells were incubated for 0 and 2 h. At the end of the incubation, cells were quenched with 3 volumes of ice-cold acetonitrile containing 0.02% formic acid, vortexed, and sonicated (3 min). Precipitated proteins were pelleted by centrifugation (3000 rpm, 10 min, 4 °C) and the supernatants were evaporated to dryness under a gentle stream of nitrogen. The resulting residues were reconstituted in 250 μL of water: acetonitrile (9:1) containing 0.01% formic acid with sonication and vortexing to aid solubilization of drug-derived materials prior to filtration using 0.45 μm nylon filter at 10,000<i>g</i> at room temperature for 10 min. The filtrate was transferred to a 96-well plate for liquid chromatography/tandem mass spectrometric (LC–MS/MS) analysis.</div><div class="NLM_p last">LC–MS/MS analysis: Accela HPLC coupled to LTQ-Orbitrap XL and operated in a positive ESI mode. Column: Betasil PHENYL-HEXYL (100 × 2.0 mm ID, 3 μm). Mobile phase A: 0.1% formic acid; mobile phase B: acetonitrile containing 0.1% formic acid. A nonlinear gradient with a flow rate of 0.2 mL/min was used throughout the analysis. Compound <b>11</b> underwent extensive metabolism in both species. The turnover at a 10 μM substrate concentration was 79.6% and ∼100% in mouse and human hepatocytes, respectively. The percentages of compound <b>11</b> and its derived metabolites in the incubation extracts were obtained based on the peak areas in LC/UV chromatograms.</div></div><div id="sec4_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Uptake of [<sup>18</sup>F]-FDG in Established Polyps/Adenomas Present in the GI-Tract of Aged Apc<sup>min/+</sup> Mice Using Ex Vivo PET Imaging</h3><div class="NLM_p last">The uptake of [<sup>18</sup>F]-FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism. After [<sup>18</sup>F]-FDG is injected into a patient (or animal), a PET scanner can form two-dimensional or three-dimensional images of the distribution of [<sup>18</sup>F]-FDG within the body. The spontaneous GI-tract tumor Apc<sup>min</sup> (C57BL/6J-Apc<sup>Min</sup>/J) was used that was approximately 16+ weeks of age. All mice were individually housed in IVC cages with 2 oz glass food hoppers (with metal food follower and lids) containing standard diet 5008 (powdered/meal form) and ad libitum water 4–5 days prior to the start of experiment. Day 1 (start of experiment), diet was changed to chow containing testing compound for 14 days (changed/topped off a minimum of 1× weekly). Body weights and food intake were measured at a minimum once weekly (more often if possible). Day 13, mice were fasted overnight for 12+ hour (for [<sup>18</sup>F]-FDG imaging). Day 14 (ex vivo imaging), for the [<sup>18</sup>F]-FDG imaging, mice were euthanized with CO<sub>2</sub>, death confirmed by no response of paw-pinch reflex. Cardiac puncture was carried out to draw blood, which was transferred into EDTA containing tubes that were placed onto a rocker for 10 min. Mice were opened up and GI-tract was removed and placed onto paper towel. Kidneys, liver, heart, and stomach (opened and pinned) were taken out and placed in formalin (10% neutral buffer saline; NBF) for histopathology. GI was sectioned in duodenum, jejunum, ileum, and colon and opened up longitudinally. One section at a time was washed with clean cold PBS (∼300 mL) in a glass beaker (a separated glass beaker for each mouse). The tissue was placed onto a black-coated cork board and flattened out (proximal at top, lumen surface facing upwards). Approximately 0.5–1.0 cm of the proximal portions of each tissue were cut and placed into separate reweighed Eppendorf tubes. The remainder was photographed. Fresh PBS was squirted over top of sections to keep them from drying out. These were imaged using a PET scanner—20 min static scan on an ice pack/cold cork board. During scan, instruments were cleaned with PBS and EtOH, wiped dry. Contents of the glass beakers were placed in large plastic containers, as all radioactive ([<sup>18</sup>F]) was kept for 24 h until it had decayed (10× half-life). Beakers were washed briefly with water, wiped, rinsed again, and wiped dry. After scanning, sections on board were carefully blotted to remove PBS, and formalin was added onto the sections (15–20 mL 10% NBF). After 3 h, each GI tract portion was swiss-rolled, pinned, and placed into a large white cassette and into formalin. Analyses were performed in R, version 3.3.2. ANOVA, adjusted for multiple comparisons in a linear regression model.</div></div><div id="sec4_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> In Vivo Polyp Growth/Formation Inhibition within the GI-Tract of 4–5 weeks of Age Apc<sup>min/+</sup> Mice in a Prophylactic Setting</h3><div class="NLM_p">Fifty 4- to 5-week-old female C57BL/6J-Apc<sup>Min</sup>/J mice were sourced from JAX labs and acclimated for 5–7 days. Mice were group housed in IVC-cages under a 12 h light: dark cycle at a temperature of 19 to 22 °C. Mice were fed an autoclaved powdered diet laboratory chow (5008) and water ad libitum. Mice were ear-tagged and tailed tattooed, which will be placed 5–7 days prior to the start of the study to identify each animal. The spontaneous GI-tract tumor Apc<sup>min</sup> (C57BL/6J-Apc<sup>Min</sup>/J) was used that was approximately 5+ weeks of age. Day 1 (start of experiment), diet was changed to chow containing testing compound for 84 days (12 weeks, with hoppers changed/topped off a minimum of 1× weekly). Body weights and food intake were measured at a minimum once weekly. On day 83, mice were fasted overnight for 12+ hour (for [<sup>18</sup>F]-FDG imaging). On day 84 (ex vivo imaging), for the [<sup>18</sup>F]-FDG imaging, mice were euthanized with CO<sub>2</sub>, with death confirmed by no response of paw-pinch reflex. Cardiac puncture was carried out to draw blood, which was transferred into EDTA-containing tubes that were placed onto a rocker for 10 min. Mice were opened up and GI-tract was removed and placed onto paper towel. Kidneys, liver, heart, and stomach (opened and pinned) were taken out and placed in formalin (10% neutral buffer saline; NBF) for histopathology. GI was sectioned in duodenum, jejunum, ileum and colon, and opened up longitudinally. One section at a time was washed in clean cold PBS (∼300 mL) in a glass beaker (separated glass beaker for each mouse). The tissue was placed onto a black-coated cork board and flattened out (proximal at the top, lumen surface facing upwards). Approximately 0.5–1.0 cm of the proximal portions of each tissue (duodenum, jejunum, ileum, and colon) were cut and placed into separate reweighed Eppendorf tubes. The remainder was photographed. Fresh PBS was squirted over top of sections to keep them from drying out. These were imaged using a PET scanner—20 min static scan on ice pack/cold cork board. During scan, instruments were cleaned with PBS and EtOH, and wiped dry. Contents of the glass beakers were placed in large plastic containers, as all radioactive ([<sup>18</sup>F]) was kept for 24 h until it had decayed (10 × half-life). Beakers were briefly washed with water, wiped, rinsed again, and wiped dry. After scan, sections on board were carefully blotted to remove PBS, and formalin was added onto of sections (15–20 mL 10% NBF). After 3 h, each GI tract portion was swiss-rolled, pinned, and placed into a large white cassette and into formalin.</div><div class="NLM_p last">Weight and tumor assessment: body weights were measured on a balance a minimum of once weekly. Mice were monitored daily for clinical signs of toxicity for the duration of the treatment. A sustained body weight loss greater than 15% of the initial body weight was considered as clinical toxicity, with the animal being humanely sacrificed. Tumor growth inhibition (TGI) values were determined from total ileum polyp area (sum of all polyp areas with diameter > 1 mm) following a daily oral dosing of 300 mg/kg as a suspension for 10–12 weeks, % TGI = 1 – (<i>T</i><sub><i>t</i></sub>/<i>C</i><sub><i>t</i></sub>), <i>T</i><sub><i>t</i></sub> = median tumor volume of treated at time <i>t</i>, and <i>C</i><sub><i>t</i></sub> = median tumor volume of control at time <i>t</i>. Analyses were performed in One-way ANOVA with Dunnett’s Multiple comparisons test; or Two-way ANOVA with the Dunnett’s Multiple Comparisons test using GraphPad Prism 7.0..</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i89"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00890" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00890?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00890</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular modeling; molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">(<a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Assays and protocols: chemistry; metabolite identifications; PK; UGT phenotyping; glucuronidation <i>K</i><sub>m</sub> determination; survival extension; plots for derived free unbound fraction (fu %) in vivo potency; and HPLC traces of compounds <b>10</b>, <b>11</b>, <b>20</b>, <b>21</b>, <b>22</b>, and <b>23</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb">jm1c00890_si_001.pdb (714.76 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_002.csv">jm1c00890_si_002.csv (3.83 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_003.pdf">jm1c00890_si_003.pdf (1.87 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00890" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18062" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18062" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhuming Zhang</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</span>; 
    <span>Present Address:
                        Deerfield Discovery & Development, New York, NY, USA</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-5638-5320" title="Orcid link">https://orcid.org/0000-0002-5638-5320</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c9b3b3b3a1a8a7ae96faf9f9f989b0a8a1a6a6e7aaa6a4"><span class="__cf_email__" data-cfemail="592323233138373e066a696969192038313636773a3634">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David C. Evans</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a5e1e6e0d3c4cbd6e5ccd1d68bcfcbcf8bc6cac8"><span class="__cf_email__" data-cfemail="fabeb9bf8c9b9489ba938e89d4909490d4999597">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Avijit Ghosh</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span>; 
    <span>Present Address:
                        Amgen Corporation, South San Francisco, CA, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter J. Connolly</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter King</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span>; 
    <span>Present Address:
                        Immuneering Corporation, San Diego, CA, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Wilde</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianyao Wang</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-2559-8849" title="Orcid link">https://orcid.org/0000-0003-2559-8849</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yawei Dong</span> - <span class="hlFld-Affiliation affiliation">Chemistry, Pharmaron
Beijing, Co. Ltd., No.
6, TaiHe Road, BDA Beijing 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xueliang Li</span> - <span class="hlFld-Affiliation affiliation">Chemistry, Pharmaron
Beijing, Co. Ltd., No.
6, TaiHe Road, BDA Beijing 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daohong Liao</span> - <span class="hlFld-Affiliation affiliation">Chemistry, Pharmaron
Beijing, Co. Ltd., No.
6, TaiHe Road, BDA Beijing 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Chen</span> - <span class="hlFld-Affiliation affiliation">Chemistry, Pharmaron
Beijing, Co. Ltd., No.
6, TaiHe Road, BDA Beijing 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gaochao Tian</span> - <span class="hlFld-Affiliation affiliation">Discovery
Technology and Molecular Pharmacology, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Javier Suarez</span> - <span class="hlFld-Affiliation affiliation">Discovery
Technology and Molecular Pharmacology, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William G. Bonnette</span> - <span class="hlFld-Affiliation affiliation">Discovery
Technology and Molecular Pharmacology, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vineet Pande</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Janssen Research and Development, Turnhoutseweg 30, B-2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen A. Diloreto</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yifan Shi</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shefali Patel</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beth Pietrak</span> - <span class="hlFld-Affiliation affiliation">Discovery
Technology and Molecular Pharmacology, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence Szewczuk</span> - <span class="hlFld-Affiliation affiliation">Discovery
Technology and Molecular Pharmacology, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlo Sensenhauser</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shannon Dallas</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Janssen
Research and Development, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James P. Edwards</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kurtis E. Bachman</span> - <span class="hlFld-Affiliation affiliation">Oncology
Discovery, Janssen Research and Development, Spring House, Pennsylvania 19477, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>This manuscript was written through contributions of all authors. Z.Z., A.G., and P.K. contributed to this work while employed at Janssen Research and Development.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46412" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46412" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Christopher Teleha (Janssen Research and Development) for his valuable insights into chemistry, and Karine Smans (Janssen Research and Development), Heather Murrey (Janssen Research and Development), and Kay Ahn (Janssen Research and Development) for their valuable insights into biology. We are also grateful to Wenqiong Wu (Pharmaron, Beijing, China) for her contributions to the synthesis of compounds described herein.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">NSAID</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drug</p></td></tr><tr><td class="NLM_term">CRC</td><td class="NLM_def"><p class="first last">colorectal cancer</p></td></tr><tr><td class="NLM_term">FDG</td><td class="NLM_def"><p class="first last">fluorodeoxyglucose</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">APC</td><td class="NLM_def"><p class="first last">adenomatous polyposis coli</p></td></tr><tr><td class="NLM_term">MIN</td><td class="NLM_def"><p class="first last">multiple intestinal neoplasia</p></td></tr><tr><td class="NLM_term">IVIVC</td><td class="NLM_def"><p class="first last">in vitro–in vivo correlation</p></td></tr><tr><td class="NLM_term">FAP</td><td class="NLM_def"><p class="first last">familial adenomatous polyposis</p></td></tr><tr><td class="NLM_term">PG</td><td class="NLM_def"><p class="first last">prostaglandin</p></td></tr><tr><td class="NLM_term">PGE<sub>2</sub></td><td class="NLM_def"><p class="first last">prostaglandin E<sub>2</sub></p></td></tr><tr><td class="NLM_term">RR</td><td class="NLM_def"><p class="first last">relative risk</p></td></tr><tr><td class="NLM_term">CV</td><td class="NLM_def"><p class="first last">cardiovascular</p></td></tr><tr><td class="NLM_term">PGI<sub>2</sub></td><td class="NLM_def"><p class="first last">prostacyclin</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">endoplasmic reticulum</p></td></tr><tr><td class="NLM_term">HEK</td><td class="NLM_def"><p class="first last">human embryonic kidney</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate hydrogen</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">SGF</td><td class="NLM_def"><p class="first last">simulated gastric fluid</p></td></tr><tr><td class="NLM_term">FaSSIF</td><td class="NLM_def"><p class="first last">fasted simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsomes</p></td></tr><tr><td class="NLM_term">MDCK-MDR1</td><td class="NLM_def"><p class="first last">Madin Darby canine kidney (MDCK) cells with the MDR1 gene (ABCB1)</p></td></tr><tr><td class="NLM_term">ADHP</td><td class="NLM_def"><p class="first last">10-acetyl-3,7-dihydroxyphenoxazine</p></td></tr><tr><td class="NLM_term">UGT</td><td class="NLM_def"><p class="first last">UDP-glucuronosyltransferases</p></td></tr><tr><td class="NLM_term">PV</td><td class="NLM_def"><p class="first last">portal vein</p></td></tr><tr><td class="NLM_term">HWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">ACN or MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">XPhos Pd G3</td><td class="NLM_def"><p class="first last">(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate</p></td></tr><tr><td class="NLM_term">Cy<sub>2</sub>NMe</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-dicyclohexyl-carbodiimide</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">LiHMDS</td><td class="NLM_def"><p class="first last">lithium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">Red-Al</td><td class="NLM_def"><p class="first last">sodium bis(2-methoxyethoxy)aluminum hydride, boron trichloride</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">CHCl<sub>3</sub></td><td class="NLM_def"><p class="first last">chloroform</p></td></tr><tr><td class="NLM_term">Pd(dppf)Cl<sub>2</sub></td><td class="NLM_def"><p class="first last">[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">Pd(Ph<sub>3</sub>P)<sub>4</sub></td><td class="NLM_def"><p class="first last">tetrakis(triphenylphosphine)palladium(0)</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03123" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03123" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 69 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2021</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.3322/caac.21654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.3322%2Fcaac.21654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=33433946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BB3svptVKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2021&pages=7-33&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=H.+E.+Fuchsauthor=A.+Jemal&title=Cancer+statistics%2C+2021&doi=10.3322%2Fcaac.21654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Statistics, 2021</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Fuchs Hannah E; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence.  Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.  Mortality data (through 2018) were collected by the National Center for Health Statistics.  In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States.  After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment.  This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted.  Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018.  The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall.  This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC).  For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%.  Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_jHscXVnJh1WTCLT8lX9SfW6udTcc2ebL55t-ITgLA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3svptVKhuw%253D%253D&md5=c65743e74b28b6c7dd1f912745f3edf1</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21654%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DFuchs%26aufirst%3DH.%2BE.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202021%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2021%26volume%3D71%26spage%3D7%26epage%3D33%26doi%3D10.3322%2Fcaac.21654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fearon, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span> <span> </span><span class="NLM_article-title">A genetic model for colorectal tumorigenesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(90)90186-i</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2F0092-8674%2890%2990186-I" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=2188735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADyaK3cXktlyhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1990&pages=759-767&author=E.+R.+Fearonauthor=B.+Vogelstein&title=A+genetic+model+for+colorectal+tumorigenesis&doi=10.1016%2F0092-8674%2890%2990186-i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A genetic model for colorectal tumorigenesis</span></div><div class="casAuthors">Fearon, Eric R.; Vogelstein, Bert</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">759-67</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">A review with 76 refs. on various genetic aspects of colonic neoplasia, including genetic alterations of oncogenes, clonal selection, allelic losses and tumor suppressor genes, multiple allelic losses, and accumulation and multistep tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe4CC_sLtNt7Vg90H21EOLACvtfcHk0lj_6LJ-YMlNUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktlyhtrg%253D&md5=d88588a58ce05a327c3e7ff8afccd3a7</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2890%2990186-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252890%252990186-I%26sid%3Dliteratum%253Aachs%26aulast%3DFearon%26aufirst%3DE.%2BR.%26aulast%3DVogelstein%26aufirst%3DB.%26atitle%3DA%2520genetic%2520model%2520for%2520colorectal%2520tumorigenesis%26jtitle%3DCell%26date%3D1990%26volume%3D61%26spage%3D759%26epage%3D767%26doi%3D10.1016%2F0092-8674%2890%2990186-i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Radtke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clevers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, O.</span></span> <span> </span><span class="NLM_article-title">From gut homeostasis to cancer</span>. <i>Curr. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.2174/156652406776894527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.2174%2F156652406776894527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16712475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=275-289&author=F.+Radtkeauthor=H.+Cleversauthor=O.+Riccio&title=From+gut+homeostasis+to+cancer&doi=10.2174%2F156652406776894527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">From gut homeostasis to cancer</span></div><div class="casAuthors">Radtke, Freddy; Clevers, Hans; Riccio, Orbicia</div><div class="citationInfo"><span class="NLM_cas:title">Current Molecular Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-289</span>CODEN:
                <span class="NLM_cas:coden">CMMUBP</span>;
        ISSN:<span class="NLM_cas:issn">1566-5240</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The mammalian intestine has one of the highest turnover rates in the body.  The intestinal epithelium is completely renewed in less than a week.  It is divided into spatially distinct compartments in the form of finger-like projections and invaginations that are dedicated to specific functions.  Intestinal cells are constantly produced from a stem cell reservoir that gives rise to proliferating transient amplifying cells, which subsequently differentiate and migrate to the correct compartment before dying after having fulfilled their physiol. function.  In recent years, a substantial body of evidence has accumulated to support the concept that signaling pathways known to be crucial for embryonic development of multiple organisms play a crit. role in tightly regulating and controlling the self-renewing process of the intestine.  Moreover, the same pathways appear to be deregulated in several hereditary and sporadic colorectal cancer syndromes due to activating and/or inactivating mutations of key components of such pathways.  In this review we discuss recent findings demonstrating that differentiation and homeostasis of the intestine are controlled by developmental pathways such as Wnt, Notch, TGF-β and Hedgehog, and illustrate how their deregulation contributes to intestinal neoplasia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr97XFU85BmQ7Vg90H21EOLACvtfcHk0ljkdKo6oElzAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVGmsbs%253D&md5=abb08789af40370f1ff99b2446e0bb72</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F156652406776894527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156652406776894527%26sid%3Dliteratum%253Aachs%26aulast%3DRadtke%26aufirst%3DF.%26aulast%3DClevers%26aufirst%3DH.%26aulast%3DRiccio%26aufirst%3DO.%26atitle%3DFrom%2520gut%2520homeostasis%2520to%2520cancer%26jtitle%3DCurr.%2520Mol.%2520Med.%26date%3D2006%26volume%3D6%26spage%3D275%26epage%3D289%26doi%3D10.2174%2F156652406776894527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranger, G. S.</span></span> <span> </span><span class="NLM_article-title">Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">6277</span>– <span class="NLM_lpage">6282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=25368225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2jtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=6277-6282&author=G.+S.+Ranger&title=Current+concepts+in+colorectal+cancer+prevention+with+cyclooxygenase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors</span></div><div class="casAuthors">Ranger, Gurpreet Singh</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6277-6282</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  Colorectal cancer is one of the commonest malignancies worldwide.  Recently, there has been much speculation regarding the role of cyclooxygenase-2 (COX-2) suppression in chemoprevention.  Drugs with the ability to inhibit COX-2 expression include aspirin, nonsteroidal anti-inflammatory drugs (NSAID) and selective COX-2 inhibitors.  Any strategy for chemoprevention must be able to quantify how effective the potential treatment is likely to be and which drugs will be most useful.  We would also need to know for how long the agent could be taken safely and if any side-effects could preclude long-term use.  Evidence from observational studies and recent updates of randomised controlled trials have been very encouraging - at least indicating benefit from the long term use of aspirin, even at low dose, with greatest impact on prevention of proximal colon cancers and adenomas.  Most studies do, however, also warn that risks of gastrointestinal bleeding increase with long-term use of aspirin and related drugs.  The risk-to-benefit ratio of a chemoprevention regimen using these medications needs to be carefully examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri3PhG0YSWkLVg90H21EOLACvtfcHk0ljkdKo6oElzAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2jtbzK&md5=d6fc0dec50ce1991b351de4e05054c0f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRanger%26aufirst%3DG.%2BS.%26atitle%3DCurrent%2520concepts%2520in%2520colorectal%2520cancer%2520prevention%2520with%2520cyclooxygenase%2520inhibitors%26jtitle%3DAnticancer%2520Res.%26date%3D2014%26volume%3D34%26spage%3D6277%26epage%3D6282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardiello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, P. M.</span></span> <span> </span><span class="NLM_article-title">Chemoprevention of hereditary colon cancers: time for new strategies</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1038/nrgastro.2016.56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fnrgastro.2016.56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=27095653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFCjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=352-361&author=L.+Ricciardielloauthor=D.+J.+Ahnenauthor=P.+M.+Lynch&title=Chemoprevention+of+hereditary+colon+cancers%3A+time+for+new+strategies&doi=10.1038%2Fnrgastro.2016.56"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoprevention of hereditary colon cancers: time for new strategies</span></div><div class="casAuthors">Ricciardiello, Luigi; Ahnen, Dennis J.; Lynch, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">352-361</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Colorectal cancer (CRC) is potentially preventable.  Chemoprevention, a focus of research for the past three decades, aims to prevent or delay the onset of cancer through the regression or prevention of colonic adenomas.  Ideal pharmacol. agents for chemoprevention should be cheap and nontoxic.  Although data indicate that aspirin can reduce the risk of CRC in the general population, the highest return from chemopreventive strategies would be expected in patients with the highest risk of developing the disease, particularly those with a defined hereditary predisposition.  Despite compelling data showing that a large no. of chemopreventive agents show promise in preclin. CRC models, clin. studies have yielded conflicting results.  This Review provides a historical and methodol. perspective of chemoprevention in familial adenomatous polyposis and Lynch syndrome, and summarizes the current status of CRC chemoprevention in humans.  Our goal is to critically focus on important issues of trial design, with particular attention on the choice of appropriate trial end points, how such end points should be measured, and which patients are the ideal candidates to be included in a chemopreventive trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMlS0TequWJrVg90H21EOLACvtfcHk0ljkdKo6oElzAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFCjt7o%253D&md5=49a6d6e0287e00f2e3efa8ae7de82ebb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2016.56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2016.56%26sid%3Dliteratum%253Aachs%26aulast%3DRicciardiello%26aufirst%3DL.%26aulast%3DAhnen%26aufirst%3DD.%2BJ.%26aulast%3DLynch%26aufirst%3DP.%2BM.%26atitle%3DChemoprevention%2520of%2520hereditary%2520colon%2520cancers%253A%2520time%2520for%2520new%2520strategies%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2016%26volume%3D13%26spage%3D352%26epage%3D361%26doi%3D10.1038%2Fnrgastro.2016.56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theisen, C.</span></span> <span> </span><span class="NLM_article-title">Chemoprevention: what’s in a name?</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">743</span>, <span class="refDoi"> DOI: 10.1093/jnci/93.10.743</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1093%2Fjnci%2F93.10.743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11353783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD3M3ls1ejsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=743&author=C.+Theisen&title=Chemoprevention%3A+what%E2%80%99s+in+a+name%3F&doi=10.1093%2Fjnci%2F93.10.743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoprevention: What's in a name?</span></div><div class="casAuthors">Theisen C</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">743</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRge04axPApWCsZ1x6zOs0vfW6udTcc2eaT_SY6tGlUvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3ls1ejsw%253D%253D&md5=61a3a0a66d255472eaf4cdd7b759c95f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.10.743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.10.743%26sid%3Dliteratum%253Aachs%26aulast%3DTheisen%26aufirst%3DC.%26atitle%3DChemoprevention%253A%2520what%25E2%2580%2599s%2520in%2520a%2520name%253F%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2001%26volume%3D93%26spage%3D743%26doi%3D10.1093%2Fjnci%2F93.10.743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadder, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüneburg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castells, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallenberg, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinicrope, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strassburg, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Cutsem, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalloo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willingham, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grady, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gryfe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syngal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A.</span></span> <span> </span><span class="NLM_article-title">Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1039</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1916063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJMoa1916063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=32905675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVeisr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2020&pages=1028-1039&author=C.+A.+Burkeauthor=E.+Dekkerauthor=P.+Lynchauthor=N.+J.+Samadderauthor=F.+Balaguerauthor=R.+H%C3%BCneburgauthor=J.+Burnauthor=A.+Castellsauthor=S.+Gallingerauthor=R.+Limauthor=E.+M.+Stoffelauthor=S.+Guptaauthor=A.+Hendersonauthor=F.+G.+Kallenbergauthor=P.+Kanthauthor=V.+H.+Roosauthor=G.+G.+Ginsbergauthor=F.+A.+Sinicropeauthor=C.+P.+Strassburgauthor=E.+van+Cutsemauthor=J.+Churchauthor=F.+Lallooauthor=F.+F.+Willinghamauthor=P.+E.+Wiseauthor=W.+M.+Gradyauthor=M.+Fordauthor=J.+M.+Weissauthor=R.+Gryfeauthor=A.+K.+Rustgiauthor=S.+Syngalauthor=A.+Cohen&title=Eflornithine+plus+sulindac+for+prevention+of+progression+in+familial+adenomatous+polyposis&doi=10.1056%2Fnejmoa1916063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis</span></div><div class="casAuthors">Burke, C. A.; Dekker, E.; Lynch, P.; Samadder, N. J.; Balaguer, F.; Huneburg, R.; Burn, J.; Castells, A.; Gallinger, S.; Lim, R.; Stoffel, E. M.; Gupta, S.; Henderson, A.; Kallenberg, F. G.; Kanth, P.; Roos, V. H.; Ginsberg, G. G.; Sinicrope, F. A.; Strassburg, C. P.; Van Cutsem, E.; Church, J.; Lalloo, F.; Willingham, F. F.; Wise, P. E.; Grady, W. M.; Ford, M.; Weiss, J. M.; Gryfe, R.; Rustgi, A. K.; Syngal, S.; Cohen, A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1028-1039</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The efficacy and safety of combination therapy with eflornithine and sulindac, as compared with either drug alone, in delaying disease progression in patients with familial adenomatous polyposis are unknown.  We evaluated the efficacy and safety of the combination of eflornithine and sulindac, as compared with either drug alone, in adults with familial adenomatous polyposis.  The patients were stratified on the basis of anatomical site with the highest polyp burden and surgical status; the strata were precolectomy (shortest projected time to disease progression), rectal or ileal pouch polyposis after colectomy and duodenal polyposis.  The patients were then randomly assigned in a 1:1:1 ratio to receive 750 mg of eflornithine, 150 mg of sulindac, or both once daily for up to 48 mo.  A total of 171 patients underwent randomization.  Disease progression occurred in 18 of 56 patients (32%) in the eflornithine-sulindac group, 22 of 58 (38%) in the sulindac group, and 23 of 57 (40%) in the eflornithine group, with a hazard ratio of 0.71 for eflornithine-sulindac as compared with sulindac for eflornithine-sulindac as compared with eflornithine.  Adverse and serious adverse events were similar across the treatment groups. conclusions: In this trial involving patients with familial adenomatous polyposis, the incidence of disease progression was not significantly lower with the combination of eflornithine and sulindac than with either drug alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqqma4qG6TKbVg90H21EOLACvtfcHk0ljh6sRXooCLQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVeisr%252FP&md5=6bf64c2705029dbe62098b0fd68fa2dd</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1916063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1916063%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DC.%2BA.%26aulast%3DDekker%26aufirst%3DE.%26aulast%3DLynch%26aufirst%3DP.%26aulast%3DSamadder%26aufirst%3DN.%2BJ.%26aulast%3DBalaguer%26aufirst%3DF.%26aulast%3DH%25C3%25BCneburg%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DJ.%26aulast%3DCastells%26aufirst%3DA.%26aulast%3DGallinger%26aufirst%3DS.%26aulast%3DLim%26aufirst%3DR.%26aulast%3DStoffel%26aufirst%3DE.%2BM.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DHenderson%26aufirst%3DA.%26aulast%3DKallenberg%26aufirst%3DF.%2BG.%26aulast%3DKanth%26aufirst%3DP.%26aulast%3DRoos%26aufirst%3DV.%2BH.%26aulast%3DGinsberg%26aufirst%3DG.%2BG.%26aulast%3DSinicrope%26aufirst%3DF.%2BA.%26aulast%3DStrassburg%26aufirst%3DC.%2BP.%26aulast%3Dvan%2BCutsem%26aufirst%3DE.%26aulast%3DChurch%26aufirst%3DJ.%26aulast%3DLalloo%26aufirst%3DF.%26aulast%3DWillingham%26aufirst%3DF.%2BF.%26aulast%3DWise%26aufirst%3DP.%2BE.%26aulast%3DGrady%26aufirst%3DW.%2BM.%26aulast%3DFord%26aufirst%3DM.%26aulast%3DWeiss%26aufirst%3DJ.%2BM.%26aulast%3DGryfe%26aufirst%3DR.%26aulast%3DRustgi%26aufirst%3DA.%2BK.%26aulast%3DSyngal%26aufirst%3DS.%26aulast%3DCohen%26aufirst%3DA.%26atitle%3DEflornithine%2520plus%2520sulindac%2520for%2520prevention%2520of%2520progression%2520in%2520familial%2520adenomatous%2520polyposis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D383%26spage%3D1028%26epage%3D1039%26doi%3D10.1056%2Fnejmoa1916063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J. A.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of non-steroidal anti-inflammatory drugs and cancer</span>. <i>Prog. Exp. Tumor Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1159/000071364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1159%2F000071364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=12795046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltlKisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2003&pages=1-24&author=J.+A.+Baron&title=Epidemiology+of+non-steroidal+anti-inflammatory+drugs+and+cancer&doi=10.1159%2F000071364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of non-steroidal anti-inflammatory drugs and cancer</span></div><div class="casAuthors">Baron, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Experimental Tumor Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">COX-2</span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">PEXTAR</span>;
        ISSN:<span class="NLM_cas:issn">0079-6263</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review, discussing epidemiol. of non-steroidal anti-inflammatory drugs and cancer risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppYph-OLsGA7Vg90H21EOLACvtfcHk0ljh6sRXooCLQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltlKisb4%253D&md5=28dc6dfa17a8f830eefebef794dead67</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1159%2F000071364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000071364%26sid%3Dliteratum%253Aachs%26aulast%3DBaron%26aufirst%3DJ.%2BA.%26atitle%3DEpidemiology%2520of%2520non-steroidal%2520anti-inflammatory%2520drugs%2520and%2520cancer%26jtitle%3DProg.%2520Exp.%2520Tumor%2520Res.%26date%3D2003%26volume%3D37%26spage%3D1%26epage%3D24%26doi%3D10.1159%2F000071364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsertsvadze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrowman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Code, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moher, D.</span></span>; <span class="NLM_contrib-group">U.S. Preventive Services Task Force</span> <span> </span><span class="NLM_article-title">The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-146-5-200703060-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.7326%2F0003-4819-146-5-200703060-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=17339622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD2s7jvFKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2007&pages=365-375&author=C.+Dub%C3%A9author=A.+Rostomauthor=G.+Lewinauthor=A.+Tsertsvadzeauthor=N.+Barrowmanauthor=C.+Codeauthor=M.+Sampsonauthor=D.+Moherauthor=U.S.+Preventive+Services+Task+Force&title=The+use+of+aspirin+for+primary+prevention+of+colorectal+cancer%3A+a+systematic+review+prepared+for+the+U.S.+Preventive+Services+Task+Force&doi=10.7326%2F0003-4819-146-5-200703060-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force</span></div><div class="casAuthors">Dube Catherine; Rostom Alaa; Lewin Gabriela; Tsertsvadze Alexander; Barrowman Nicholas; Code Catherine; Sampson Margaret; Moher David</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Aspirin for prevention of colorectal cancer is controversial.  PURPOSE:  To examine the benefits and harms of aspirin chemoprevention.  DATA SOURCES:  MEDLINE, 1966 to December 2006; EMBASE, 1980 to April 2005; CENTRAL, Cochrane Collaboration's registry of clinical trials; Cochrane Database of Systematic Reviews.  STUDY SELECTION:  Two independent reviewers conducted multilevel screening to identify randomized, controlled trials (RCTs), case-control studies, and cohort studies of aspirin chemoprophylaxis.  For harms, systematic reviews were sought.  DATA EXTRACTION:  In duplicate, data were abstracted and checked and quality was assessed.  DATA SYNTHESIS:  Regular use of aspirin reduced the incidence of colonic adenomas in RCTs (relative risk [RR], 0.82 [95% CI, 0.7 to 0.95]), case-control studies (RR, 0.87 [CI, 0.77 to 0.98]), and cohort studies (RR, 0.72 [CI, 0.61 to 0.85]).  In cohort studies, regular use of aspirin was associated with RR reductions of 22% for incidence of colorectal cancer.  Two RCTs of low-dose aspirin failed to show a protective effect.  Data for colorectal cancer mortality were limited.  Benefits from chemoprevention were more evident when aspirin was used at a high dose and for periods longer than 10 years.  Aspirin use was associated with a dose-related increase in incidence of gastrointestinal complications.  LIMITATIONS:  Important clinical and methodological heterogeneity in the definitions of regular use, dose, and duration of use of aspirin necessitated careful grouping for analysis.  CONCLUSIONS:  Aspirin appears to be effective at reducing the incidence of colonic adenoma and colorectal cancer, especially if used in high doses for more than 10 years.  However, the possible harms of such a practice require careful consideration.  Further evaluation of the cost-effectiveness of chemoprevention compared with, and in combination with, a screening strategy is required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvvW0G13y7DzQLBVDQn4bCfW6udTcc2ebQaHVL3IUJn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7jvFKlug%253D%253D&md5=33b3c3e01aa356da0a4e8d1f882bf01b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-146-5-200703060-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-146-5-200703060-00009%26sid%3Dliteratum%253Aachs%26aulast%3DDub%25C3%25A9%26aufirst%3DC.%26aulast%3DRostom%26aufirst%3DA.%26aulast%3DLewin%26aufirst%3DG.%26aulast%3DTsertsvadze%26aufirst%3DA.%26aulast%3DBarrowman%26aufirst%3DN.%26aulast%3DCode%26aufirst%3DC.%26aulast%3DSampson%26aufirst%3DM.%26aulast%3DMoher%26aufirst%3DD.%26aulast%3D%26atitle%3DThe%2520use%2520of%2520aspirin%2520for%2520primary%2520prevention%2520of%2520colorectal%2520cancer%253A%2520a%2520systematic%2520review%2520prepared%2520for%2520the%2520U.S.%2520Preventive%2520Services%2520Task%2520Force%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2007%26volume%3D146%26spage%3D365%26epage%3D375%26doi%3D10.7326%2F0003-4819-146-5-200703060-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rostom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsertsvadze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrowman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Code, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moher, D.</span></span>; <span class="NLM_contrib-group">U.S. Preventive Services Task Force</span> <span> </span><span class="NLM_article-title">Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-146-5-200703060-00010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.7326%2F0003-4819-146-5-200703060-00010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=17339623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD2s7jvFKluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2007&pages=376-389&author=A.+Rostomauthor=C.+Dub%C3%A9author=G.+Lewinauthor=A.+Tsertsvadzeauthor=N.+Barrowmanauthor=C.+Codeauthor=M.+Sampsonauthor=D.+Moherauthor=U.S.+Preventive+Services+Task+Force&title=Nonsteroidal+anti-inflammatory+drugs+and+cyclooxygenase-2+inhibitors+for+primary+prevention+of+colorectal+cancer%3A+a+systematic+review+prepared+for+the+U.S.+Preventive+Services+Task+Force&doi=10.7326%2F0003-4819-146-5-200703060-00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force</span></div><div class="casAuthors">Rostom Alaa; Dube Catherine; Lewin Gabriela; Tsertsvadze Alexander; Barrowman Nicholas; Code Catherine; Sampson Margaret; Moher David</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">376-89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To examine the benefits and harms of nonaspirin (non-ASA) nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX-2) inhibitors for the prevention of colorectal cancer (CRC) and adenoma.  DATA SOURCES:  MEDLINE (1966 to 2006), EMBASE (1980 to 2006), Cochrane Central Register of Controlled Trials, Cochrane Collaboration's registry of clinical trials, Cochrane Database of Systematic Reviews.  STUDY SELECTION:  Randomized, controlled trials and case-control and cohort studies of the effectiveness of NSAIDs for the prevention of CRC and colorectal adenoma were identified by multilevel screening by 2 independent reviewers.  Systematic reviews of harms were sought.  DATA EXTRACTION:  Data abstraction, checking, and quality assessment were completed in duplicate.  DATA SYNTHESIS:  A single cohort study showed no effect of non-ASA NSAIDs on death due to CRC.  Colorectal cancer incidence was reduced with non-ASA NSAIDs in cohort studies (relative risk, 0.61 [95% CI, 0.48 to 0.77]) and case-control studies (relative risk, 0.70 [CI, 0.63 to 0.78]).  Colorectal adenoma incidence was also reduced with non-ASA NSAID use in cohort studies (relative risk, 0.64 [CI, 0.48 to 0.85]) and case-control studies (relative risk, 0.54 [CI, 0.4 to 0.74]) and by COX-2 inhibitors in randomized, controlled trials (relative risk, 0.72 [CI, 0.68 to 0.77]).  The ulcer complication rate associated with non-ASA NSAIDs is 1.5% per year.  Compared with non-ASA NSAIDs, COX-2 inhibitors reduce this risk but, in multiyear use, have a higher ulcer complication rate than placebo.  Cyclooxygenase-2 inhibitors and nonnaproxen NSAIDs increase the risk for serious cardiovascular events (relative risk, 1.86 [CI, 1.33 to 2.59] for COX-2 inhibitors vs. placebo).  LIMITATIONS:  Heterogeneity in the dose, duration and frequency of use necessitated careful grouping for analysis.  CONCLUSIONS:  Cyclooxygenase-2 inhibitors and NSAIDs reduce the incidence of colonic adenomas.  Nonsteroidal anti-inflammatory drugs also reduce the incidence of CRC.  However, these agents are associated with important cardiovascular events and gastrointestinal harms.  The balance of benefits to risk does not favor chemoprevention in average-risk individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvvW0G13y7D8kU0YCbOU3EfW6udTcc2ebQaHVL3IUJn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7jvFKluw%253D%253D&md5=ab1c062c621f671f5e0faa0d380f2a17</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-146-5-200703060-00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-146-5-200703060-00010%26sid%3Dliteratum%253Aachs%26aulast%3DRostom%26aufirst%3DA.%26aulast%3DDub%25C3%25A9%26aufirst%3DC.%26aulast%3DLewin%26aufirst%3DG.%26aulast%3DTsertsvadze%26aufirst%3DA.%26aulast%3DBarrowman%26aufirst%3DN.%26aulast%3DCode%26aufirst%3DC.%26aulast%3DSampson%26aufirst%3DM.%26aulast%3DMoher%26aufirst%3DD.%26aulast%3D%26atitle%3DNonsteroidal%2520anti-inflammatory%2520drugs%2520and%2520cyclooxygenase-2%2520inhibitors%2520for%2520primary%2520prevention%2520of%2520colorectal%2520cancer%253A%2520a%2520systematic%2520review%2520prepared%2520for%2520the%2520U.S.%2520Preventive%2520Services%2520Task%2520Force%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2007%26volume%3D146%26spage%3D376%26epage%3D389%26doi%3D10.7326%2F0003-4819-146-5-200703060-00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mecklin, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möslein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McRonald, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertario, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerdes, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindblom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashbass, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seppälä, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pylvänäinen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthwick, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathers, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussioutas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porteous, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Side, L.</span></span>; <span class="NLM_contrib-group">CAPP2 Investigators</span> <span> </span><span class="NLM_article-title">Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1863</span>, <span class="refDoi"> DOI: 10.1016/s0140-6736(20)30366-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2FS0140-6736%2820%2930366-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=32534647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGgsrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1855-1863&author=J.+Burnauthor=H.+Shethauthor=F.+Elliottauthor=L.+Reedauthor=F.+Macraeauthor=J.-P.+Mecklinauthor=G.+M%C3%B6sleinauthor=F.+E.+McRonaldauthor=L.+Bertarioauthor=D.+G.+Evansauthor=A.-M.+Gerdesauthor=J.+W.+C.+Hoauthor=A.+Lindblomauthor=P.+J.+Morrisonauthor=J.+Rashbassauthor=R.+Ramesarauthor=T.+Sepp%C3%A4l%C3%A4author=H.+J.+W.+Thomasauthor=K.+Pylv%C3%A4n%C3%A4inenauthor=G.+M.+Borthwickauthor=J.+C.+Mathersauthor=D.+T.+Bishopauthor=A.+Boussioutasauthor=C.+Brewerauthor=J.+Cookauthor=D.+Ecclesauthor=A.+Ellisauthor=S.+V.+Hodgsonauthor=J.+Lubinskiauthor=E.+R.+Maherauthor=M.+E.+Porteousauthor=J.+Sampsonauthor=R.+J.+Scottauthor=L.+Sideauthor=CAPP2+Investigators&title=Cancer+prevention+with+aspirin+in+hereditary+colorectal+cancer+%28Lynch+syndrome%29%2C+10-year+follow-up+and+registry-based+20-year+data+in+the+CAPP2+study%3A+a+double-blind%2C+randomised%2C+placebo-controlled+trial&doi=10.1016%2Fs0140-6736%2820%2930366-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial</span></div><div class="casAuthors">Burn, John; Sheth, Harsh; Elliott, Faye; Reed, Lynn; Macrae, Finlay; Mecklin, Jukka-Pekka; Moslein, Gabriela; McRonald, Fiona E.; Bertario, Lucio; Evans, D. Gareth; Gerdes, Anne-Marie; Ho, Judy W. C.; Lindblom, Annika; Morrison, Patrick J.; Rashbass, Jem; Ramesar, Raj; Seppala, Toni; Thomas, Huw J. W.; Pylvanainen, Kirsi; Borthwick, Gillian M.; Mathers, John C.; Bishop, D. Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10240</span>),
    <span class="NLM_cas:pages">1855-1863</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lynch syndrome is assocd. with an increased risk of colorectal cancer and with a broader spectrum of cancers, esp. endometrial cancer.  In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 mo [SD 31·4]) for participants with Lynch syndrome enrolled into a randomised trial of daily aspirin vs. placebo.  This report completes the planned 10-yr follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population.  In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centers worldwide (707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [<1%] from The Americas) with Lynch syndrome were randomly assigned to receive 600 mg aspirin daily or placebo.  Cancer outcomes were monitored for at least 10 years from recruitment with English, Finnish, and Welsh participants being monitored for up to 20 years.  The primary endpoint was development of colorectal cancer.  Anal. was by intention to treat and per protocol.  The trial is registered with the ISRCTN registry, no. ISRCTN59521990.  Between Jan., 1999, and March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, commenced treatment, of whom 861 agreed to be randomly assigned to the aspirin group or placebo; 427 (50%) participants received aspirin and 434 (50%) placebo.  Participants were followed for a mean of 10 years approximating 8500 person-years. 40 (9%) of 427 participants who received aspirin developed colorectal cancer compared with 58 (13%) of 434 who received placebo.  Intention-to-treat Cox proportional hazards anal. revealed a significantly reduced hazard ratio (HR) of 0·65 (95% CI 0·43-0·97; p=0·035) for aspirin vs. placebo.  Neg. binomial regression to account for multiple primary events gave an incidence rate ratio of 0·58 (0·39-0·87; p=0·0085).  Per-protocol analyses restricted to 509 who achieved 2 years' intervention gave an HR of 0·56 (0·34-0·91; p=0·019) and an incidence rate ratio of 0·50 (0·31-0·82; p=0·0057).  Non-colorectal Lynch syndrome cancers were reported in 36 participants who received aspirin and 36 participants who received placebo.  Intention-to-treat and per-protocol analyses showed no effect.  For all Lynch syndrome cancers combined, the intention-to-treat anal. did not reach significance but per-protocol anal. showed significantly reduced overall risk for the aspirin group (HR=0·63, 0·43-0·92; p=0·018).  Adverse events during the intervention phase between aspirin and placebo groups were similar, and no significant difference in compliance between intervention groups was obsd. for participants with complete intervention phase data; details reported previously.  The case for prevention of colorectal cancer with aspirin in Lynch syndrome is supported by our results.  Cancer Research UK, European Union, MRC, NIHR, Bayer Pharma AG, Barbour Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2QsSPBQpP_rVg90H21EOLACvtfcHk0lgDSCVL6T2ErA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGgsrjI&md5=a11f499bf6be45a8168f927b0bd07433</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930366-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930366-4%26sid%3Dliteratum%253Aachs%26aulast%3DBurn%26aufirst%3DJ.%26aulast%3DSheth%26aufirst%3DH.%26aulast%3DElliott%26aufirst%3DF.%26aulast%3DReed%26aufirst%3DL.%26aulast%3DMacrae%26aufirst%3DF.%26aulast%3DMecklin%26aufirst%3DJ.-P.%26aulast%3DM%25C3%25B6slein%26aufirst%3DG.%26aulast%3DMcRonald%26aufirst%3DF.%2BE.%26aulast%3DBertario%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DD.%2BG.%26aulast%3DGerdes%26aufirst%3DA.-M.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLindblom%26aufirst%3DA.%26aulast%3DMorrison%26aufirst%3DP.%2BJ.%26aulast%3DRashbass%26aufirst%3DJ.%26aulast%3DRamesar%26aufirst%3DR.%26aulast%3DSepp%25C3%25A4l%25C3%25A4%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DH.%2BJ.%2BW.%26aulast%3DPylv%25C3%25A4n%25C3%25A4inen%26aufirst%3DK.%26aulast%3DBorthwick%26aufirst%3DG.%2BM.%26aulast%3DMathers%26aufirst%3DJ.%2BC.%26aulast%3DBishop%26aufirst%3DD.%2BT.%26aulast%3DBoussioutas%26aufirst%3DA.%26aulast%3DBrewer%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DEccles%26aufirst%3DD.%26aulast%3DEllis%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%2BV.%26aulast%3DLubinski%26aufirst%3DJ.%26aulast%3DMaher%26aufirst%3DE.%2BR.%26aulast%3DPorteous%26aufirst%3DM.%2BE.%26aulast%3DSampson%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DR.%2BJ.%26aulast%3DSide%26aufirst%3DL.%26aulast%3D%26atitle%3DCancer%2520prevention%2520with%2520aspirin%2520in%2520hereditary%2520colorectal%2520cancer%2520%2528Lynch%2520syndrome%2529%252C%252010-year%2520follow-up%2520and%2520registry-based%252020-year%2520data%2520in%2520the%2520CAPP2%2520study%253A%2520a%2520double-blind%252C%2520randomised%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1855%26epage%3D1863%26doi%3D10.1016%2Fs0140-6736%2820%2930366-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bresalier, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognese, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxenius, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horgan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loftus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, D. G.</span></span>; <span class="NLM_contrib-group">APPROVe Trial Investigators</span> <span> </span><span class="NLM_article-title">A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1674</span>– <span class="NLM_lpage">1682</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2006.08.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1053%2Fj.gastro.2006.08.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=17087947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2006&pages=1674-1682&author=J.+A.+Baronauthor=R.+S.+Sandlerauthor=R.+S.+Bresalierauthor=H.+Quanauthor=R.+Riddellauthor=A.+Lanasauthor=J.+A.+Bologneseauthor=B.+Oxeniusauthor=K.+Horganauthor=S.+Loftusauthor=D.+G.+Mortonauthor=APPROVe+Trial+Investigators&title=A+randomized+trial+of+rofecoxib+for+the+chemoprevention+of+colorectal+adenomas&doi=10.1053%2Fj.gastro.2006.08.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas</span></div><div class="casAuthors">Baron, John A.; Sandler, Robert S.; Bresalier, Robert S.; Quan, Hui; Riddell, Robert; Lanas, Angel; Bolognese, James A.; Oxenius, Bettina; Horgan, Kevin; Loftus, Susan; Morton, Dion G.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1674-1682</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background & Aims: In human and animal studies, nonsteroidal anti-inflammatory drugs have been assocd. with a reduced risk of colorectal neoplasia.  Although the underlying mechanisms are unknown, inhibition of cyclooxygenase (COX), particularly COX-2, is thought to play a role.  We conducted a randomized, placebo-controlled, double-blind trial to assess whether use of the selective COX-2 inhibitor rofecoxib would reduce the risk of colorectal adenomas.  Methods: We randomized 2587 subjects with a recent history of histol. confirmed adenomas to receive daily placebo or 25 mg rofecoxib.  Randomization was stratified by baseline use of cardioprotective aspirin.  Colonoscopic follow-up evaluation was planned for 1 and 3 years after randomization.  The primary end point was all adenomas diagnosed during 3 years' treatment.  In a modified intent-to-treat anal., we computed the relative risk of any adenoma after randomization, using Mantel-Haenszel statistics stratified by low-dose aspirin use at baseline.  Results: Adenoma recurrence was less frequent for rofecoxib subjects than for those randomized to placebo (41% vs 55%; P < .0001; relative risk [RR], 0.76; 95% confidence interval [CI], 0.69 - 0.83).  Rofecoxib also conferred a redn. in risk of advanced adenomas (P < .01).  The chemopreventive effect was more pronounced in the first year (RR, 0.65; 95% CI, 0.57 - 0.73) than in the subsequent 2 years (RR, 0.81; 95% CI, 0.71 - 0.93).  As reported previously, rofecoxib was assocd. with increased risks of significant upper gastrointestinal events and serious thrombotic cardiovascular events.  Conclusions: In this randomized trial, rofecoxib significantly reduced the risk of colorectal adenomas, but also had serious toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroWzbUDSkG27Vg90H21EOLACvtfcHk0lgCdvkjkCw8wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFyltL8%253D&md5=f510a7e4de6ff726ecd7da7de7396022</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2006.08.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2006.08.079%26sid%3Dliteratum%253Aachs%26aulast%3DBaron%26aufirst%3DJ.%2BA.%26aulast%3DSandler%26aufirst%3DR.%2BS.%26aulast%3DBresalier%26aufirst%3DR.%2BS.%26aulast%3DQuan%26aufirst%3DH.%26aulast%3DRiddell%26aufirst%3DR.%26aulast%3DLanas%26aufirst%3DA.%26aulast%3DBolognese%26aufirst%3DJ.%2BA.%26aulast%3DOxenius%26aufirst%3DB.%26aulast%3DHorgan%26aufirst%3DK.%26aulast%3DLoftus%26aufirst%3DS.%26aulast%3DMorton%26aufirst%3DD.%2BG.%26aulast%3D%26atitle%3DA%2520randomized%2520trial%2520of%2520rofecoxib%2520for%2520the%2520chemoprevention%2520of%2520colorectal%2520adenomas%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D131%26spage%3D1674%26epage%3D1682%26doi%3D10.1053%2Fj.gastro.2006.08.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyooka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketo, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, K.</span></span> <span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4756</span>– <span class="NLM_lpage">4760</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=14581346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVGjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=4756-4760&author=T.+Higuchiauthor=T.+Iwamaauthor=K.+Yoshinagaauthor=M.+Toyookaauthor=M.+M.+Taketoauthor=K.+Sugihara&title=A+randomized%2C+double-blind%2C+placebo-controlled+trial+of+the+effects+of+rofecoxib%2C+a+selective+cyclooxygenase-2+inhibitor%2C+on+rectal+polyps+in+familial+adenomatous+polyposis+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients</span></div><div class="casAuthors">Higuchi, Tetsuro; Iwama, Takeo; Yoshinaga, Keigo; Toyooka, Masahiro; Taketo, Makoto M.; Sugihara, Kenichi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4756-4760</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The aim of this study was to examine the effect of a specific cyclooxygenase-2 inhibitor, rofecoxib, on rectal polyps in familial adenomatous polyposis patients.  E This was a randomized, double-blind, placebo-controlled study of the efficacy and safety of rofecoxib in the rectum.  Initially, 21 patients were assigned randomly in a 1:1 ratio to receive either 25 mg rofecoxib once a day or a placebo p.o. for 9 mo.  Patients underwent endoscopy at the beginning of the study and then every 3 mo thereafter.  We reviewed the videotapes to measure the no. and size of polyps in the same area throughout the study period in each individual patient.  The polyp no., measured as the percentage of change from the baseline values, was significantly decreased in the rofecoxib group at 3, 6, and 9 mo.  At 9 mo, the polyp no. in the rofecoxib group decreased by 6.8% from the baseline values, whereas that in the placebo group increased by 3.1%.  The 9.9% difference between the rofecoxib and placebo groups was statistically significant (P = 0.004).  At 9 mo, the rofecoxib group showed a significant redn. from the baseline in polyp size as compared with the placebo group (-16.2% vs. 1.5%; P < 0.001).  There was no statistically significant increase in the incidence of any adverse events in treatment with rofecoxib compared with placebo (P = 0.922).  In this study, once-daily treatment with 25 mg rofecoxib, a cyclooxygenase 2-specific inhibitor, significantly decreased the no. and size of rectal polyps in familial adenomatous polyposis patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp7t8XSgc4ibVg90H21EOLACvtfcHk0lgCdvkjkCw8wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVGjsLs%253D&md5=2155960fa91e6abca93a9289fa8792dc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHiguchi%26aufirst%3DT.%26aulast%3DIwama%26aufirst%3DT.%26aulast%3DYoshinaga%26aufirst%3DK.%26aulast%3DToyooka%26aufirst%3DM.%26aulast%3DTaketo%26aufirst%3DM.%2BM.%26aulast%3DSugihara%26aufirst%3DK.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520the%2520effects%2520of%2520rofecoxib%252C%2520a%2520selective%2520cyclooxygenase-2%2520inhibitor%252C%2520on%2520rectal%2520polyps%2520in%2520familial%2520adenomatous%2520polyposis%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D4756%26epage%3D4760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eagle, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rácz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dite, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavoral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechuga, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstein, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhadra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zauber, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, B.</span></span>; <span class="NLM_contrib-group">PreSAP Trial Investigators</span> <span> </span><span class="NLM_article-title">Celecoxib for the prevention of colorectal adenomatous polyps</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1056/nejmoa061652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJMoa061652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16943401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28XovFehurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=885-895&author=N.+Arberauthor=C.+J.+Eagleauthor=J.+Spicakauthor=I.+R%C3%A1czauthor=P.+Diteauthor=J.+Hajerauthor=M.+Zavoralauthor=M.+J.+Lechugaauthor=P.+Gerlettiauthor=J.+Tangauthor=R.+B.+Rosensteinauthor=K.+Macdonaldauthor=P.+Bhadraauthor=R.+Fowlerauthor=J.+Wittesauthor=A.+G.+Zauberauthor=S.+D.+Solomonauthor=B.+Levinauthor=PreSAP+Trial+Investigators&title=Celecoxib+for+the+prevention+of+colorectal+adenomatous+polyps&doi=10.1056%2Fnejmoa061652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib for the prevention of colorectal adenomatous polyps</span></div><div class="casAuthors">Arber, Nadir; Eagle, Craig J.; Spicak, Julius; Racz, Istvan; Diet, Petr; Hajer, Jan; Zavoral, Miroslav; Lechuga, Maria J.; Gerletti, Paola; Tang, Jie; Rosenstein, Rebecca B.; Macdonald, Katie; Bhadra, Pritha; Fowler, Robert; Wittes, Janet; Zauber, Ann G.; Solomon, Scott D.; Levin, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">885-895</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Over-expression of cyclooxygenase 2 (COX-2) has been assocd. with colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition as a chemopreventive intervention.  METHODS: The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose.  At 107 centers in 32 countries, we randomly assigned 1561 subjects who had adenomas removed before enrollment to receive celecoxib (933 subjects) or placebo (628 subjects) daily, after stratification according to the use or nonuse of low-dose aspirin.  The primary outcome was detection of adenomas at either year 1 or year 3 by colonoscopy and was compared among the groups with the use of the Mantel-Cox test.  RESULTS: Colonoscopies were performed at year 1 on 88.7 % of the subjects who had under- gone randomization and at year 3 on 79.2 %.  Of the 557 subjects in the placebo group and the 840 subjects in the celecoxib group who were included in the efficacy anal., 264 and 270, resp., were found to have at least one adenoma at year 1, at year 3, or both.  The cumulative rate of adenomas detected through year 3 was 33.6 % in the celecoxib group and 49.3 % in the placebo group (relative risk, 0.64; 95 % confidence interval, 0.56 to 0.75; P < 0.001).  The cumulative rate of advanced adenomas detected through year 3 was 5.3 % in the celecoxib group and 10.4 % in the placebo group (relative risk, 0.49; 95 % confidence interval, 0.33 to 0.73; P < 0.001).  Adjudicated serious cardiovascular events occurred in 2.5 % of subjects in the celecoxib group and 1.9 % of those in the placebo group (relative risk, 1.30; 95 % confidence interval, 0.65 to 2.62).  CONCLUSIONS: The use of 400 mg of celecoxib once daily significantly reduced the occurrence of colorectal adenomas within three years after polypectomy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYauG8XTOtrVg90H21EOLACvtfcHk0ljW1uwgMRlm6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovFehurc%253D&md5=28500d74b851ea3d9b03c3956c2867cb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa061652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa061652%26sid%3Dliteratum%253Aachs%26aulast%3DArber%26aufirst%3DN.%26aulast%3DEagle%26aufirst%3DC.%2BJ.%26aulast%3DSpicak%26aufirst%3DJ.%26aulast%3DR%25C3%25A1cz%26aufirst%3DI.%26aulast%3DDite%26aufirst%3DP.%26aulast%3DHajer%26aufirst%3DJ.%26aulast%3DZavoral%26aufirst%3DM.%26aulast%3DLechuga%26aufirst%3DM.%2BJ.%26aulast%3DGerletti%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DRosenstein%26aufirst%3DR.%2BB.%26aulast%3DMacdonald%26aufirst%3DK.%26aulast%3DBhadra%26aufirst%3DP.%26aulast%3DFowler%26aufirst%3DR.%26aulast%3DWittes%26aufirst%3DJ.%26aulast%3DZauber%26aufirst%3DA.%2BG.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DLevin%26aufirst%3DB.%26aulast%3D%26atitle%3DCelecoxib%2520for%2520the%2520prevention%2520of%2520colorectal%2520adenomatous%2520polyps%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D885%26epage%3D895%26doi%3D10.1056%2Fnejmoa061652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, R. K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawk, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Bigas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jester, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruzzese, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hittelman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelloff, G.</span></span> <span> </span><span class="NLM_article-title">The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1952</span>, <span class="refDoi"> DOI: 10.1056/nejm200006293422603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJM200006293422603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10874062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVCnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2000&pages=1946-1952&author=G.+Steinbachauthor=P.+M.+Lynchauthor=R.+K.+S.+Phillipsauthor=M.+H.+Wallaceauthor=E.+Hawkauthor=G.+B.+Gordonauthor=N.+Wakabayashiauthor=B.+Saundersauthor=Y.+Shenauthor=T.+Fujimuraauthor=L.-K.+Suauthor=B.+Levinauthor=L.+Godioauthor=S.+Pattersonauthor=M.+A.+Rodriguez-Bigasauthor=S.+L.+Jesterauthor=K.+L.+Kingauthor=M.+Schumacherauthor=J.+Abbruzzeseauthor=R.+N.+DuBoisauthor=W.+N.+Hittelmanauthor=S.+Zimmermanauthor=J.+W.+Shermanauthor=G.+Kelloff&title=The+effect+of+celecoxib%2C+a+cyclooxygenase-2+inhibitor%2C+in+familial+adenomatous+polyposis&doi=10.1056%2Fnejm200006293422603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis</span></div><div class="casAuthors">Steinbach, Gideon; Lynch, Patrick M.; Phillips, Robin K. S.; Wallace, Marina H.; Hawk, Ernest; Gordon, Gary B.; Wakabayashi, Naoki; Saunders, Brian; Shen, Yu; Fujimura, Takashi; Su, Li-Kuo; Levin, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">1946-1952</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer.  In this disease, the chemopreventive effects of nonsteroidal antiinflammatory drugs may be related to their inhibition of cyclooxygenase-2.  We studied the effect of celecoxib, a selective cyclooxygenase-2 inhibitor, on colorectal polyps in patients with familial adenomatous polyposis.  In a double-blind, placebo-controlled study, we randomly assigned 77 patients to treatment with celecoxib (100 or 400 mg twice daily) or placebo for six months.  Patients underwent endoscopy at the beginning and end of the study.  We detd. the no. and size of polyps from photographs and videotapes; the response to treatment was expressed as the mean percent change from base line.  At base line, the mean (±SD) no. of polyps in focal areas where polyps were counted was 15.5±13.4 in the 15 patients assigned to placebo, 11.5±8.5 in the 32 patients assigned to 100 mg of celecoxib twice a day, and 12.3±8.2 in the 30 patients assigned to 400 mg of celecoxib twice a day (P = 0.66 for the comparison among groups).  After six months, the patients receiving 400 mg of celecoxib twice a day had a 28.0 percent redn. in the mean no. of colorectal polyps (P = 0.003 for the comparison with placebo) and a 30.7 percent redn. in the polyp burden (the sum of polyp diams.) (P = 0.001), as compared with redns. of 4.5 and 4.9 percent, resp., in the placebo group.  The improvement in the extent of colorectal polyposis in the group receiving 400 mg twice a day was confirmed by a panel of endoscopists who reviewed the videotapes.  The redns. in the group receiving 100 mg of celecoxib twice a day were 11.9 percent (P = 0.33 for the comparison with placebo) and 14.6 percent (P = 0.09), resp.  The incidence of adverse events was similar among the groups.  In patients with familial adenomatous polyposis, six months of twice-daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant redn. in the no. of colorectal polyps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPgVvRxhzKO7Vg90H21EOLACvtfcHk0ljW1uwgMRlm6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVCnu7Y%253D&md5=bb03a12f34d846350fec8e45c1467c82</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJM200006293422603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200006293422603%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbach%26aufirst%3DG.%26aulast%3DLynch%26aufirst%3DP.%2BM.%26aulast%3DPhillips%26aufirst%3DR.%2BK.%2BS.%26aulast%3DWallace%26aufirst%3DM.%2BH.%26aulast%3DHawk%26aufirst%3DE.%26aulast%3DGordon%26aufirst%3DG.%2BB.%26aulast%3DWakabayashi%26aufirst%3DN.%26aulast%3DSaunders%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DL.-K.%26aulast%3DLevin%26aufirst%3DB.%26aulast%3DGodio%26aufirst%3DL.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DRodriguez-Bigas%26aufirst%3DM.%2BA.%26aulast%3DJester%26aufirst%3DS.%2BL.%26aulast%3DKing%26aufirst%3DK.%2BL.%26aulast%3DSchumacher%26aufirst%3DM.%26aulast%3DAbbruzzese%26aufirst%3DJ.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26aulast%3DHittelman%26aufirst%3DW.%2BN.%26aulast%3DZimmerman%26aufirst%3DS.%26aulast%3DSherman%26aufirst%3DJ.%2BW.%26aulast%3DKelloff%26aufirst%3DG.%26atitle%3DThe%2520effect%2520of%2520celecoxib%252C%2520a%2520cyclooxygenase-2%2520inhibitor%252C%2520in%2520familial%2520adenomatous%2520polyposis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D342%26spage%3D1946%26epage%3D1952%26doi%3D10.1056%2Fnejm200006293422603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertagnolli, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eagle, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zauber, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstein, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woloj, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisserie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagheri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruitt, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylwestrowicz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawk, E. T.</span></span>; <span class="NLM_contrib-group">APC Study Investigators</span> <span> </span><span class="NLM_article-title">Celecoxib for the prevention of sporadic colorectal adenomas</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1056/nejmoa061355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJMoa061355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16943400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28XovFaju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=873-884&author=M.+M.+Bertagnolliauthor=C.+J.+Eagleauthor=A.+G.+Zauberauthor=M.+Redstonauthor=S.+D.+Solomonauthor=K.+Kimauthor=J.+Tangauthor=R.+B.+Rosensteinauthor=J.+Wittesauthor=D.+Corleauthor=T.+M.+Hessauthor=G.+M.+Wolojauthor=F.+Boisserieauthor=W.+F.+Andersonauthor=J.+L.+Vinerauthor=D.+Bagheriauthor=J.+Burnauthor=D.+C.+Chungauthor=T.+Dewarauthor=T.+R.+Foleyauthor=N.+Hoffmanauthor=F.+Macraeauthor=R.+E.+Pruittauthor=J.+R.+Saltzmanauthor=B.+Salzbergauthor=T.+Sylwestrowiczauthor=G.+B.+Gordonauthor=E.+T.+Hawkauthor=APC+Study+Investigators&title=Celecoxib+for+the+prevention+of+sporadic+colorectal+adenomas&doi=10.1056%2Fnejmoa061355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib for the prevention of sporadic colorectal adenomas</span></div><div class="casAuthors">Bertagnolli, Monica M.; Eagle, Craig J.; Zauber, Ann G.; Redston, Mark; Solomon, Scott D.; Kim, KyungMann; Tang, Jie; Rosenstein, Rebecca B.; Wittes, Janet; Corle, Donald; Hess, Timothy M.; Woloj, Mabel; Boisserie, Frederic; Anderson, William F.; Viner, Jaye L.; Bagheri, Donya; Burn, John; Chung, Daniel C.; Dewar, Thomas; Foley, T. Raymond; Hoffman, Neville; Macrae, Finlay; Pruitt, Ronald E.; Saltzman, John R.; Salzberg, Bruce; Sylwestrowicz, Thomas; Gordon, Gary B.; Hawk, Ernest T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">873-884</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the no. of colorectal adenomas in animals and patients with familial adenomatous polyposis suggest that COX-2 inhibitors may also prevent sporadic colorectal neoplasia.  METHODS: We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily.  Randomization was stratified for the use of low-dose aspirin.  Follow-up colonoscopies were performed at one and three years after randomization.  The occurrence of newly detected colorectal adenomas was compared among the groups with the life-table extension of the Mantel-Haenszel test.  RESULTS: Follow-up colonoscopies were completed at year 1 in 89.5 % of randomized patients, and at year 3 in 75.7 %.  The estd. cumulative incidence of the detection of one or more adenomas by year 3 was 60.7 % for patients receiving placebo, as compared with 43.2 % for those receiving 200 mg of celecoxib twice a day (risk ratio, 0.67; 95 % confidence interval, 0.59 to 0.77; P < 0.001) and 37.5 % for those receiving 400 mg of celecoxib twice a day (risk ratio, 0.55; 95 % confidence interval, 0.48 to 0.64; P < 0.001).  Serious adverse events occurred in 18.8 % of patients in the placebo group, as compared with 20.4 % of those in the low-dose celecoxib group (risk ratio, 1.1; 95 % confidence interval, 0.9 to 1.3; P = 0.5) and 23.0 % of those in the high-dose group (risk ratio, 1.2; 95 % confidence interval, 1.0 to 1.5; P = 0.06).  As compared with placebo, celecoxib was assocd. with an increased risk of cardiovascular events (risk ratio for the low dose, 2.6; 95 % confidence interval, 1.1 to 6.1; and risk ratio for the high dose, 3.4; 95 % confidence interval, 1.5 to 7.9).  CONCLUSIONS: These findings indicate that celecoxib is an effective agent for the prevention of colorectal adenomas but, because of potential cardiovascular events, cannot be routinely recommended for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnWgcYRoN-LLVg90H21EOLACvtfcHk0lg-Lj4f2x7fzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovFaju7Y%253D&md5=b650c8d861c7f5bd0b14f92b6cdc2140</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa061355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa061355%26sid%3Dliteratum%253Aachs%26aulast%3DBertagnolli%26aufirst%3DM.%2BM.%26aulast%3DEagle%26aufirst%3DC.%2BJ.%26aulast%3DZauber%26aufirst%3DA.%2BG.%26aulast%3DRedston%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DRosenstein%26aufirst%3DR.%2BB.%26aulast%3DWittes%26aufirst%3DJ.%26aulast%3DCorle%26aufirst%3DD.%26aulast%3DHess%26aufirst%3DT.%2BM.%26aulast%3DWoloj%26aufirst%3DG.%2BM.%26aulast%3DBoisserie%26aufirst%3DF.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DBagheri%26aufirst%3DD.%26aulast%3DBurn%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DD.%2BC.%26aulast%3DDewar%26aufirst%3DT.%26aulast%3DFoley%26aufirst%3DT.%2BR.%26aulast%3DHoffman%26aufirst%3DN.%26aulast%3DMacrae%26aufirst%3DF.%26aulast%3DPruitt%26aufirst%3DR.%2BE.%26aulast%3DSaltzman%26aufirst%3DJ.%2BR.%26aulast%3DSalzberg%26aufirst%3DB.%26aulast%3DSylwestrowicz%26aufirst%3DT.%26aulast%3DGordon%26aufirst%3DG.%2BB.%26aulast%3DHawk%26aufirst%3DE.%2BT.%26aulast%3D%26atitle%3DCelecoxib%2520for%2520the%2520prevention%2520of%2520sporadic%2520colorectal%2520adenomas%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D873%26epage%3D884%26doi%3D10.1056%2Fnejmoa061355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrono, C.</span></span> <span> </span><span class="NLM_article-title">The coxibs, selective inhibitors of cyclooxygenase-2</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1056/nejm200108093450607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJM200108093450607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11496855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsV2ls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2001&pages=433-442&author=G.+A.+FitzGeraldauthor=C.+Patrono&title=The+coxibs%2C+selective+inhibitors+of+cyclooxygenase-2&doi=10.1056%2Fnejm200108093450607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The coxibs, selective inhibitors of cyclooxygenase-2</span></div><div class="casAuthors">Wood, Alastair J. J.; FitzGerald, Garret A.; Patrono, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">433-442</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on the development of coxibs as an alternative to nonsteroidal antiinflammatory drugs (NSAID) for treating arthritis, menstrual pain, and headache.  Both groups of drugs inhibit prostaglandin G/H synthase, the enzyme that catalyzes the transformation of arachidonic acid to a range of lipid mediators, termed prostaglandins and thromboxanes.  However, whereas NSAIDs inhibit the two recognized forms of the enzyme, referred to as cyclooxygenase-1 and cyclooxygenase-2, the coxibs are selective inhibitors of cyclooxygenase-2.  Since the inhibition of cyclooxygenase-2 has been more directly implicated in ameliorating inflammation, it was hoped that coxibs would be better tolerated than nonselective NSAIDs but equally efficacious.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5jaFALK8yjbVg90H21EOLACvtfcHk0lg-Lj4f2x7fzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsV2ls7k%253D&md5=d7b7cbeadd4801a3a5105f370f93c1c3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJM200108093450607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200108093450607%26sid%3Dliteratum%253Aachs%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26aulast%3DPatrono%26aufirst%3DC.%26atitle%3DThe%2520coxibs%252C%2520selective%2520inhibitors%2520of%2520cyclooxygenase-2%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D345%26spage%3D433%26epage%3D442%26doi%3D10.1056%2Fnejm200108093450607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botting, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1124/pr.56.3.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1124%2Fpr.56.3.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=15317910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotVKjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=387-437&author=D.+L.+Simmonsauthor=R.+M.+Bottingauthor=T.+Hla&title=Cyclooxygenase+isozymes%3A+the+biology+of+prostaglandin+synthesis+and+inhibition&doi=10.1124%2Fpr.56.3.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition</span></div><div class="casAuthors">Simmons, Daniel L.; Botting, Regina M.; Hla, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-437</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Nonsteroidal anti-inflammatory drugs (NSAIDs) represent one of the most highly utilized classes of pharmaceutical agents in medicine.  All NSAIDs act through inhibiting prostaglandin synthesis, a catalytic activity possessed by two distinct cyclooxygenase (COX) isoenzymes encoded by sep. genes.  The discovery of COX-2 launched a new era in NSAID pharmacol., resulting in the synthesis, marketing, and widespread use of COX-2 selective drugs.  These pharmaceutical agents have quickly become established as important therapeutic medications with potentially fewer side effects than traditional NSAIDs.  Addnl., characterization of the two COX isoenzymes is allowing the discrimination of the roles each play in physiol. processes such as homeostatic maintenance of the gastrointestinal tract, renal function, blood clotting, embryonic implantation, parturition, pain, and fever.  Of particular importance has been the investigation of COX-1 and -2 isoenzymic functions in cancer, dysregulation of inflammation, and Alzheimer's disease.  More recently, addnl. heterogeneity in COX-related proteins has been described, with the finding of variants of COX-1 and COX-2 enzymes.  These variants may function in tissue-specific physiol. and pathophysiol. processes and may represent important new targets for drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgI1sKLwTNi7Vg90H21EOLACvtfcHk0lg-Lj4f2x7fzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotVKjtbY%253D&md5=75abc6304f28a60fbfb2a950ed200612</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fpr.56.3.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.56.3.3%26sid%3Dliteratum%253Aachs%26aulast%3DSimmons%26aufirst%3DD.%2BL.%26aulast%3DBotting%26aufirst%3DR.%2BM.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DCyclooxygenase%2520isozymes%253A%2520the%2520biology%2520of%2520prostaglandin%2520synthesis%2520and%2520inhibition%26jtitle%3DPharmacol.%2520Rev.%26date%3D2004%26volume%3D56%26spage%3D387%26epage%3D437%26doi%3D10.1124%2Fpr.56.3.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, R. N.</span></span> <span> </span><span class="NLM_article-title">Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1038/35094017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2F35094017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11900248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD387mvVOhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=11-21&author=R.+A.+Guptaauthor=R.+N.+Dubois&title=Colorectal+cancer+prevention+and+treatment+by+inhibition+of+cyclooxygenase-2&doi=10.1038%2F35094017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2</span></div><div class="casAuthors">Gupta R A; Dubois R N</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-21</span>
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    </div><div class="casAbstract">Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer.  These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression.  Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-LChZ0ggVnrrIbt-tGZmxfW6udTcc2eawh6cjXTygxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387mvVOhsA%253D%253D&md5=68870f346eed4159e3363e38454d1cb9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2F35094017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35094017%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DR.%2BA.%26aulast%3DDubois%26aufirst%3DR.%2BN.%26atitle%3DColorectal%2520cancer%2520prevention%2520and%2520treatment%2520by%2520inhibition%2520of%2520cyclooxygenase-2%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D11%26epage%3D21%26doi%3D10.1038%2F35094017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sankaranarayanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altinoz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, G. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of colorectal cancer Prevention by aspirin-a literature review and perspective on the role of COX-dependent and -independent pathways</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">9018</span>, <span class="refDoi"> DOI: 10.3390/ijms21239018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.3390%2Fijms21239018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3MXotFSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=9018&author=R.+Sankaranarayananauthor=D.+R.+Kumarauthor=M.+A.+Altinozauthor=G.+J.+Bhat&title=Mechanisms+of+colorectal+cancer+Prevention+by+aspirin-a+literature+review+and+perspective+on+the+role+of+COX-dependent+and+-independent+pathways&doi=10.3390%2Fijms21239018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of colorectal cancer prevention by aspirin-a literature review and perspective on the role of COX-dependent and -independent pathways</span></div><div class="casAuthors">Sankaranarayanan, Ranjini; Ramesh Kumar, D.; Altinoz, Meric A.; Jayarama Bhat, G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9018</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Aspirin, synthesized and marketed in 1897 by Bayer, is one of the most widely used drugs in the world.  It has a well-recognized role in decreasing inflammation, pain and fever, and in the prevention of thrombotic cardiovascular diseases.  Its anti-inflammatory and cardio-protective actions have been well studied and occur through inhibition of cyclooxygenases (COX).  Interestingly, a vast amt. of epidemiol., preclin. and clin. studies have revealed aspirin as a promising chemopreventive agent, particularly against colorectal cancers (CRC); however, the primary mechanism by which it decreases the occurrences of CRC has still not been established.  Numerous mechanisms have been proposed for aspirin's chemopreventive properties among which the inhibition of COX enzymes has been widely discussed.  Despite the wide attention COX-inhibition has received as the most probable mechanism of cancer prevention by aspirin, it is clear that aspirin targets many other proteins and pathways, suggesting that these extra-COX targets may also be equally important in preventing CRC.  In this review, we discuss the COX-dependent and -independent pathways described in literature for aspirin's anti-cancer effects and highlight the strengths and limitations of the proposed mechanisms.  Addnl., we emphasize the potential role of the metabolites of aspirin and salicylic acid (generated in the gut through microbial biotransformation) in contributing to aspirin's chemopreventive actions.  We suggest that the preferential chemopreventive effect of aspirin against CRC may be related to direct exposure of aspirin/salicylic acid or its metabolites to the colorectal tissues.  Future investigations should shed light on the role of aspirin, its metabolites and the role of the gut microbiota in cancer prevention against CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4sYLSZVDDB7Vg90H21EOLACvtfcHk0lhQp-rf5aPkkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXotFSmuw%253D%253D&md5=595bbf9da93434724924d34aa59c0871</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Fijms21239018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21239018%26sid%3Dliteratum%253Aachs%26aulast%3DSankaranarayanan%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DD.%2BR.%26aulast%3DAltinoz%26aufirst%3DM.%2BA.%26aulast%3DBhat%26aufirst%3DG.%2BJ.%26atitle%3DMechanisms%2520of%2520colorectal%2520cancer%2520Prevention%2520by%2520aspirin-a%2520literature%2520review%2520and%2520perspective%2520on%2520the%2520role%2520of%2520COX-dependent%2520and%2520-independent%2520pathways%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D9018%26doi%3D10.3390%2Fijms21239018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venè, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, N.</span></span> <span> </span><span class="NLM_article-title">Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy</span>. <i>Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.trsl.2018.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2Fj.trsl.2018.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=29421522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1OhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2018&pages=42-61&author=R.+Benelliauthor=R.+Ven%C3%A8author=N.+Ferrari&title=Prostaglandin-endoperoxide+synthase+2+%28cyclooxygenase-2%29%2C+a+complex+target+for+colorectal+cancer+prevention+and+therapy&doi=10.1016%2Fj.trsl.2018.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy</span></div><div class="casAuthors">Benelli, Roberto; Vene, Roberta; Ferrari, Nicoletta</div><div class="citationInfo"><span class="NLM_cas:title">Translational Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42-61</span>CODEN:
                <span class="NLM_cas:coden">TRRECL</span>;
        ISSN:<span class="NLM_cas:issn">1878-1810</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A plentiful literature has linked colorectal cancer (CRC) to inflammation and prostaglandin-endoperoxide synthase (PTGS)2 expression.  Accordingly, several nonsteroidal antiinflammatory drugs (NSAIDs) have been tested often successfully in CRC chemoprevention despite their different ability to specifically target PTGS2 and the low or null expression of PTGS2 in early colon adenomas.  Some observational studies showed an increased survival for patients with CRC assuming NSAIDs after diagnosis, but no clin. trial has yet demonstrated the efficacy of NSAIDs against established CRC, where PTGS2 is expressed at high levels.  The major limits for the application of NSAIDs, or specific PTGS2 inhibitors, as adjuvant drugs in CRC are (1) a frequent confusion about the physiol. role of PTGS1 and PTGS2, reflecting in CRC pathol. and therapy; (2) the presence of unavoidable side effects linked to the intrinsic function of these enzymes; (3) the need of established criteria and markers for patient selection; and (4) the evaluation of the immunomodulatory potential of PTGS2 inhibitors as possible adjuvants for immunotherapy.  This review has been written to rediscover the multifaceted potential of PTGS2 targeting, hoping it could act as a starting point for a new and more aware application of NSAIDs against CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ1c3Zqhe__rVg90H21EOLACvtfcHk0lhQp-rf5aPkkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1OhtL8%253D&md5=0245a1dbac369f0b02acc9f08a11321b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2018.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2018.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DBenelli%26aufirst%3DR.%26aulast%3DVen%25C3%25A8%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DN.%26atitle%3DProstaglandin-endoperoxide%2520synthase%25202%2520%2528cyclooxygenase-2%2529%252C%2520a%2520complex%2520target%2520for%2520colorectal%2520cancer%2520prevention%2520and%2520therapy%26jtitle%3DTransl.%2520Res.%26date%3D2018%26volume%3D196%26spage%3D42%26epage%3D61%26doi%3D10.1016%2Fj.trsl.2018.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sigthorsson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotz-Behoftsitz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palizban, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pombo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morham, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjarnason, I.</span></span> <span> </span><span class="NLM_article-title">COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">1913</span>– <span class="NLM_lpage">1923</span>, <span class="refDoi"> DOI: 10.1053/gast.2002.33647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1053%2Fgast.2002.33647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=12055598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt12gsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2002&pages=1913-1923&author=G.+Sigthorssonauthor=R.+J.+Simpsonauthor=M.+Walleyauthor=A.+Anthonyauthor=R.+Fosterauthor=C.+Hotz-Behoftsitzauthor=A.+Palizbanauthor=J.+Pomboauthor=J.+Wattsauthor=S.+G.+Morhamauthor=I.+Bjarnason&title=COX-1+and+2%2C+intestinal+integrity%2C+and+pathogenesis+of+nonsteroidal+anti-inflammatory+drug+enteropathy+in+mice&doi=10.1053%2Fgast.2002.33647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice</span></div><div class="casAuthors">Sigthorsson, Gudmundur; Simpson, Robert J.; Walley, Matthew; Anthony, Andrew; Foster, Russell; Hotz-Behoftsitz, Christoph; Palizban, Abbas; Pombo, Joaquim; Watts, Jo; Morham, Scott G.; Bjarnason, Ingvar</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1913-1923</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">Background & Aims: The pathogenesis of nonsteroidal anti-inflammatory drug-induced enteropathy is controversial, but it is thought that cyclooxygenase-1 (COX-1) inhibition is of pivotal importance.  We compared small intestinal function and morphol. in untreated wild-type, COX-1- and COX-2-deficient mice and the effect of indomethacin, selective COX-1 (SC-560), and COX-2 (celecoxib) inhibition.  Methods: Intestinal permeability (51CrEDTA), inflammation (fecal granulocyte marker protein), prostaglandin E2 (PGE2) levels, and macroscopic and microscopic appearances were assessed at baseline and after the drugs.  Results: COX-1-/- animals were normal except for a 97% decrease in intestinal PGE2 levels.  COX-1+/+ and COX-1-/- animals reacted in a similar way to indomethacin.  However, celecoxib, having caused no damage in COX-1+/+ animals, caused small bowel ulcers in COX-1-/- animals.  Selective inhibition of COX-1 decreased intestinal PGE2 levels in COX-2+/+ and COX-2-/- animals by 95%-97%, but caused only small bowel ulcers in the latter group.  Dual inhibition of COX-1 and COX-2 in wild-type animals resulted in similar small bowel damage.  Between 40% and 50% of untreated COX-2-/- animals had increased intestinal permeability and inflammation.  Some had ileal ulcers that were distinctively different from indomethacin-induced ulcers.  Furthermore, long-term celecoxib administration in wild-type animals was assocd. with similar damage as in the COX-2-/- mice.  Conclusions: COX-1 deficiency or inhibition and short-term COX-2 inhibition are compatible with normal small intestinal integrity.  Dual inhibition of the COX enzymes leads to damage similar to that seen with indomethacin.  Long-term COX-2 deficiency or inhibition is assocd. with significant intestinal pathol. despite normal intestinal PGE2 levels, suggesting a role for COX-2 in the maintenance of small intestinal integrity in the mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcqSGtUvxOVLVg90H21EOLACvtfcHk0lhQp-rf5aPkkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt12gsL8%253D&md5=e0a1c7c320b5dffe3c2e0d7a34ca05ae</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1053%2Fgast.2002.33647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fgast.2002.33647%26sid%3Dliteratum%253Aachs%26aulast%3DSigthorsson%26aufirst%3DG.%26aulast%3DSimpson%26aufirst%3DR.%2BJ.%26aulast%3DWalley%26aufirst%3DM.%26aulast%3DAnthony%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DR.%26aulast%3DHotz-Behoftsitz%26aufirst%3DC.%26aulast%3DPalizban%26aufirst%3DA.%26aulast%3DPombo%26aufirst%3DJ.%26aulast%3DWatts%26aufirst%3DJ.%26aulast%3DMorham%26aufirst%3DS.%2BG.%26aulast%3DBjarnason%26aufirst%3DI.%26atitle%3DCOX-1%2520and%25202%252C%2520intestinal%2520integrity%252C%2520and%2520pathogenesis%2520of%2520nonsteroidal%2520anti-inflammatory%2520drug%2520enteropathy%2520in%2520mice%26jtitle%3DGastroenterology%26date%3D2002%26volume%3D122%26spage%3D1913%26epage%3D1923%26doi%3D10.1053%2Fgast.2002.33647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bjarnason, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpignato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmgren, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainsford, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanas, A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-Inflammatory drugs</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">500</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2017.10.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1053%2Fj.gastro.2017.10.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=29221664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Slurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=500-514&author=I.+Bjarnasonauthor=C.+Scarpignatoauthor=E.+Holmgrenauthor=M.+Olszewskiauthor=K.+D.+Rainsfordauthor=A.+Lanas&title=Mechanisms+of+damage+to+the+gastrointestinal+tract+from+nonsteroidal+anti-Inflammatory+drugs&doi=10.1053%2Fj.gastro.2017.10.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs</span></div><div class="casAuthors">Bjarnason, Ingvar; Scarpignato, Carmelo; Holmgren, Erik; Olszewski, Michael; Rainsford, Kim D.; Lanas, Angel</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">500-514</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Nonsteroidal anti-inflammatory drugs (NSAIDs) can damage the gastrointestinal tract, causing widespread morbidity and mortality.  Although mechanisms of damage involve the activities of prostaglandin-endoperoxide synthase 1 (PTGS1 or cyclooxygenase [COX] 1) and PTGS1 (COX2), other factors are involved.  We review the mechanisms of gastrointestinal damage induction by NSAIDs via COX-mediated and COX-independent processes.  NSAIDs interact with phospholipids and uncouple mitochondrial oxidative phosphorylation, which initiates biochem. changes that impair function of the gastrointestinal barrier.  The resulting increase in intestinal permeability leads to low-grade inflammation.  NSAID inhibition of COX enzymes, along with luminal aggressors, results in erosions and ulcers, with potential complications of bleeding, protein loss, stricture formation, and perforation.  We propose a model for NSAID-induced damage to the gastrointestinal tract that includes these complex, interacting, and inter-dependent factors.  This model highlights the obstacles for the development of safer NSAIDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp7Sis01AebLVg90H21EOLACvtfcHk0lgZ8JkZro8m5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Slurk%253D&md5=5dc660ecf3b4919bfad9281bf0f077c2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2017.10.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2017.10.049%26sid%3Dliteratum%253Aachs%26aulast%3DBjarnason%26aufirst%3DI.%26aulast%3DScarpignato%26aufirst%3DC.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DOlszewski%26aufirst%3DM.%26aulast%3DRainsford%26aufirst%3DK.%2BD.%26aulast%3DLanas%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520damage%2520to%2520the%2520gastrointestinal%2520tract%2520from%2520nonsteroidal%2520anti-Inflammatory%2520drugs%26jtitle%3DGastroenterology%26date%3D2018%26volume%3D154%26spage%3D500%26epage%3D514%26doi%3D10.1053%2Fj.gastro.2017.10.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fornai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giustarini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matarangasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderone, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpignato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span> <span> </span><span class="NLM_article-title">NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.207118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1124%2Fjpet.113.207118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=24135073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=86-95&author=M.+Fornaiauthor=L.+Antonioliauthor=R.+Colucciauthor=C.+Pellegriniauthor=G.+Giustariniauthor=L.+Testaiauthor=A.+Martelliauthor=A.+Matarangasiauthor=G.+Nataleauthor=V.+Calderoneauthor=M.+Tuccoriauthor=C.+Scarpignatoauthor=C.+Blandizzi&title=NSAID-induced+enteropathy%3A+are+the+currently+available+selective+COX-2+inhibitors+all+the+same%3F&doi=10.1124%2Fjpet.113.207118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same</span></div><div class="casAuthors">Fornai, Matteo; Antonioli, Luca; Colucci, Rocchina; Pellegrini, Carolina; Giustarini, Giulio; Testai, Lara; Martelli, Alma; Matarangasi, Antuela; Natale, Gianfranco; Calderone, Vincenzo; Tuccori, Marco; Scarpignato, Carmelo; Blandizzi, Corrado</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-95, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Nonsteroidal anti-inflammatory drugs (NSAIDs) can induce intestinal mucosal damage, but the underlying mechanisms remain poorly understood.  The present study investigated the effects of celecoxib, etoricoxib, indomethacin, and diclofenac on small bowel integrity in rats.  Male rats were treated orally with test drugs for 14 days.  Animals were processed for assessment of blood Hb levels and hepatic mitochondrial functions, microscopic evaluation of small intestinal damage, Western blot anal. of cyclooxygenase-1 and -2 (COX-1, COX-2) expression, and assay of malondialdehyde (MDA), myeloperoxidase (MPO), and prostaglandin E2 (PGE2) levels in small intestine.  Indomethacin and diclofenac decreased blood Hb levels, whereas etoricoxib and celecoxib were without effects.  Celecoxib caused a lower degree of intestinal damage in comparison with the other test drugs.  Indomethacin and diclofenac, but not etoricoxib or celecoxib, reduced intestinal PGE2 levels.  Test drugs did not modify intestinal COX-1 expression, although they enhanced COX-2, with the exception of celecoxib, which downregulated COX-2.  Indomethacin, diclofenac, and etoricoxib altered mitochondrial respiratory parameters, although celecoxib was without effects.  Indomethacin or diclofenac increased MDA and MPO levels in both jejunum and ileum.  In the jejunum, etoricoxib or celecoxib did not modify such parameters, whereas in the ileum, etoricoxib, but not celecoxib, increased both MDA and MPO levels.  These findings suggest that nonselective NSAIDs and etoricoxib can induce enteropathy through a topic action, whereas celecoxib lacks relevant detrimental actions.  The selectivity profile of COX-1/COX-2 inhibition by test drugs and the related effects on prostaglandin prodn. do not appear to play a major role in the pathogenesis of enteropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1N7U0V8iLeLVg90H21EOLACvtfcHk0lgZ8JkZro8m5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKjuro%253D&md5=b79f005b0aa8fe078c28478e48e74971</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207118%26sid%3Dliteratum%253Aachs%26aulast%3DFornai%26aufirst%3DM.%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DColucci%26aufirst%3DR.%26aulast%3DPellegrini%26aufirst%3DC.%26aulast%3DGiustarini%26aufirst%3DG.%26aulast%3DTestai%26aufirst%3DL.%26aulast%3DMartelli%26aufirst%3DA.%26aulast%3DMatarangasi%26aufirst%3DA.%26aulast%3DNatale%26aufirst%3DG.%26aulast%3DCalderone%26aufirst%3DV.%26aulast%3DTuccori%26aufirst%3DM.%26aulast%3DScarpignato%26aufirst%3DC.%26aulast%3DBlandizzi%26aufirst%3DC.%26atitle%3DNSAID-induced%2520enteropathy%253A%2520are%2520the%2520currently%2520available%2520selective%2520COX-2%2520inhibitors%2520all%2520the%2520same%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D86%26epage%3D95%26doi%3D10.1124%2Fjpet.113.207118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seibert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masferrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakson, P.</span></span> <span> </span><span class="NLM_article-title">Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">12013</span>– <span class="NLM_lpage">12017</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.25.12013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1073%2Fpnas.91.25.12013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=7991575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADyaK2MXisFyqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=12013-12017&author=K.+Seibertauthor=Y.+Zhangauthor=K.+Leahyauthor=S.+Hauserauthor=J.+Masferrerauthor=W.+Perkinsauthor=L.+Leeauthor=P.+Isakson&title=Pharmacological+and+biochemical+demonstration+of+the+role+of+cyclooxygenase+2+in+inflammation+and+pain&doi=10.1073%2Fpnas.91.25.12013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain</span></div><div class="casAuthors">Seibert, Karen; Zhang, Yan; Leahy, Kathleen; Hauser, Scott; Masferrer, Jaime; Perkins, William; Lee, Len; Isakson, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">12013-17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used for the treatment of inflammatory diseases, but significant side effects such as gastrointestinal erosion and renal damage limit their use.  NSAIDs inhibit the enzyme cyclooxygenase (COX), which catalyzes the conversion of arachidonic acid to prostaglandins (PGs) and thromboxane.  Two forms of COX has been identified - COX-1, which is constitutively expressed in most tissues and organs, and the inducible enzyme, COX-2, which has been localized primarily to inflammatory cells and tissues.  In an animal model of acute inflammation (injection of carrageenan into the footpad), edema was produced that was assocd. with marked accumulation of COX-2 mRNA and thromboxane.  A selective inhibitor of COX-2 (SC-58125) inhibited edema at the inflammatory site and was analgesic but had no effect on PG prodn. in the stomach and did not cause gastric toxicity.  These data suggest that selective inhibition of COX-2 may produce superior antiinflammatory drugs with substantial safety advantages over existing NSAIDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSANLo1WFaz7Vg90H21EOLACvtfcHk0lgZ8JkZro8m5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisFyqtb0%253D&md5=431b3b433ad20ad2bdac4807e9d758da</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.25.12013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.25.12013%26sid%3Dliteratum%253Aachs%26aulast%3DSeibert%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLeahy%26aufirst%3DK.%26aulast%3DHauser%26aufirst%3DS.%26aulast%3DMasferrer%26aufirst%3DJ.%26aulast%3DPerkins%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DIsakson%26aufirst%3DP.%26atitle%3DPharmacological%2520and%2520biochemical%2520demonstration%2520of%2520the%2520role%2520of%2520cyclooxygenase%25202%2520in%2520inflammation%2520and%2520pain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D12013%26epage%3D12017%26doi%3D10.1073%2Fpnas.91.25.12013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, R. N.</span></span> <span> </span><span class="NLM_article-title">Role of prostanoids in gastrointestinal cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2732</span>– <span class="NLM_lpage">2742</span>, <span class="refDoi"> DOI: 10.1172/jci97953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1172%2FJCI97953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=29733297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BC1MfgsVOqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=2732-2742&author=D.+Wangauthor=R.+N.+DuBois&title=Role+of+prostanoids+in+gastrointestinal+cancer&doi=10.1172%2Fjci97953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Role of prostanoids in gastrointestinal cancer</span></div><div class="casAuthors">Wang Dingzhi; DuBois Raymond N; DuBois Raymond N</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2732-2742</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic inflammation is a risk factor for gastrointestinal cancer and other diseases.  Most studies have focused on cytokines and chemokines as mediators connecting chronic inflammation to cancer, whereas the involvement of lipid mediators, including prostanoids, has not been extensively investigated.  Prostanoids are among the earliest signaling molecules released in response to inflammation.  Multiple lines of evidence suggest that prostanoids are involved in gastrointestinal cancer.  In this Review, we discuss how prostanoids impact gastrointestinal cancer development.  In particular, we highlight recent advances in our understanding of how prostaglandin E2 induces the immunosuppressive microenvironment in gastrointestinal cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7h5aD28C1RmgRQsDqrjW_fW6udTcc2eZtp3xsDYW2srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfgsVOqtQ%253D%253D&md5=e8d770a5bf709f801b0fc1146e4655bb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1172%2FJCI97953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI97953%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DRole%2520of%2520prostanoids%2520in%2520gastrointestinal%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D2732%26epage%3D2742%26doi%3D10.1172%2Fjci97953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, R. N.</span></span> <span> </span><span class="NLM_article-title">The role of COX-2 in intestinal inflammation and colorectal cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">788</span>, <span class="refDoi"> DOI: 10.1038/onc.2009.421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fonc.2009.421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=19946329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2gtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=781-788&author=D.+Wangauthor=R.+N.+Dubois&title=The+role+of+COX-2+in+intestinal+inflammation+and+colorectal+cancer&doi=10.1038%2Fonc.2009.421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The role of COX-2 in intestinal inflammation and colorectal cancer</span></div><div class="casAuthors">Wang, D.; Du Bois, R. N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">781-788</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms: hereditary, sporadic and colitis-assocd. CRC.  A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are the risk factors for CRC.  As elevated cyclooxygenase-2 (COX-2) expression was found in most CRC tissue and is assocd. with worse survival among CRC patients, investigators have sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) on CRC.  The epidemiol. studies, clin. trials and animal expts. indicate that NSAIDs are among the most promising chemopreventive agents for this disease.  NSAIDs exert their anti-inflammatory and antitumor effects primarily by reducing prostaglandin prodn. by inhibition of COX-2 activity.  In this review, we highlight breakthroughs in our understanding of the roles of COX-2 in CRC and inflammatory bowel disease.  These recent data provide a rationale for re-evaluating COX-2 as both the prognostic and the predictive marker in a wide variety of malignancies and for renewing the interest in evaluating relative benefits and risk of COXIBs in appropriately selected patients for cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYCBy3ymdCiLVg90H21EOLACvtfcHk0li12yo-9gL36A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2gtrfF&md5=a860e703faa4759550d28f68d4400c7e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.421%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DDubois%26aufirst%3DR.%2BN.%26atitle%3DThe%2520role%2520of%2520COX-2%2520in%2520intestinal%2520inflammation%2520and%2520colorectal%2520cancer%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D781%26epage%3D788%26doi%3D10.1038%2Fonc.2009.421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kömhoff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shappell, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jack, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyr, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shappell, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breyer, M. D.</span></span> <span> </span><span class="NLM_article-title">Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/s0002-9440(10)64513-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2FS0002-9440%2810%2964513-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10880372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlsVGmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2000&pages=29-35&author=M.+K%C3%B6mhoffauthor=Y.+Guanauthor=H.+W.+Shappellauthor=L.+Davisauthor=G.+Jackauthor=Y.+Shyrauthor=M.+O.+Kochauthor=S.+B.+Shappellauthor=M.+D.+Breyer&title=Enhanced+expression+of+cyclooxygenase-2+in+high+grade+human+transitional+cell+bladder+carcinomas&doi=10.1016%2Fs0002-9440%2810%2964513-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas</span></div><div class="casAuthors">Komhoff, Martin; Guan, Youfei; Shappell, Heidi W.; Davis, Linda; Jack, Greg; Shyr, Yu; Koch, Michael O.; Shappell, Scott B.; Breyer, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-35</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Studies in human and animal models have shown that cyclooxygenase (COX)-2 is up-regulated in several epithelial carcinomas including colon, breast, and lung.  To elucidate the possible involvement of COX-2 in human bladder cancer we examd. the expression of COX isoforms in benign tissue and in bladder carcinoma specimens.  Paraffin embedded tissues from 75 patients with urothelial carcinomas were immunostained with specific antibodies raised against COX-1 and COX-2.  COX-1 expression was detected in smooth muscle cells in both benign and malignant bladders.  COX-2 immunoreactivity was absent in benign tissue and in specimens with low-grade urothelial carcinoma (0/23).  In contrast, expression of COX-2 was detected in malignant epithelial cells in 38% (17/47) of specimens with high-grade urothelial carcinomas.  Expression of COX-2 in high-grade bladder cancer was confirmed by radioactive in situ hybridization using a COX-2-selective riboprobe.  Both immunohistochem. and in situ hybridization showed COX-2 expression in a small subset of malignant cells.  COX-2 mRNA was also expressed in three out of seven malignant urothelial cell lines.  These data demonstrate elevated expression of COX-2 in a high percentage of high-grade bladder carcinomas, suggesting a possible role of COX-2 in the progression of bladder urothelial carcinoma and supporting its potential as a therapeutic target in human bladder carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT4KEYR4r_wLVg90H21EOLACvtfcHk0li12yo-9gL36A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlsVGmtr0%253D&md5=9b04d8d5610e89f3cf2cbee015addfeb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2964513-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252964513-0%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6mhoff%26aufirst%3DM.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DShappell%26aufirst%3DH.%2BW.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DJack%26aufirst%3DG.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DKoch%26aufirst%3DM.%2BO.%26aulast%3DShappell%26aufirst%3DS.%2BB.%26aulast%3DBreyer%26aufirst%3DM.%2BD.%26atitle%3DEnhanced%2520expression%2520of%2520cyclooxygenase-2%2520in%2520high%2520grade%2520human%2520transitional%2520cell%2520bladder%2520carcinomas%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2000%26volume%3D157%26spage%3D29%26epage%3D35%26doi%3D10.1016%2Fs0002-9440%2810%2964513-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagmohan-Changur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodde, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alman, B. A.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fsj.onc.1204107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11313976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsVKjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=451-460&author=R.+Poonauthor=R.+Smitsauthor=C.+Liauthor=S.+Jagmohan-Changurauthor=M.+Kongauthor=S.+Cheonauthor=C.+Yuauthor=R.+Foddeauthor=B.+A.+Alman&title=Cyclooxygenase-two+%28COX-2%29+modulates+proliferation+in+aggressive+fibromatosis+%28desmoid+tumor%29&doi=10.1038%2Fsj.onc.1204107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor)</span></div><div class="casAuthors">Poon, Raymond; Smits, Ron; Li, Catherine; Jagmohan-Changur, Shantie; Kong, Michael; Cheon, Sophia; Yu, Chunying; Fodde, Riccardo; Alman, Benjamin A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">451-460</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aggressive fibromatosis is a locally invasive soft tissue lesion.  Seventy-five per cent of cases harbor a somatic mutation in either the APC or β-catenin genes, resulting in β-catenin protein stabilization.  Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin synthesis that modulates the formation of colonic neoplasia, esp. in cases due to mutations resulting in β-catenin stabilization.  Human aggressive fibromatoses and lesions from the Apc+ / Apc1638N mouse (a murine model for Apc-driven fibromatosis) demonstrated elevated COX-2 levels.  COX-2 blockade either by the selective agent DFU or by non-selective COX blocking agents results in reduced proliferation in human tumor cell cultures.  Breeding mice with Cox-2-/- mice resulted in no difference in no. of aggressive fibromatoses formed, but in a smaller tumor size, while there was a decrease in no. of GI lesions by 50%.  Mice fed various COX blocking agents also showed a decline in tumor size.  COX-2 expression was regulated by tcf-dependent transcription in this lesion.  COX-2 partially regulates proliferation due to β-catenin stabilization in aggressive fibromatosis.  Although COX blockade alone does not cause tumor regression, this data suggests that it may have a role as an adjuvant therapy to slow tumor growth in this lesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVUl1nYn85kLVg90H21EOLACvtfcHk0lgVVp7C0K1a3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsVKjtLo%253D&md5=8c524ab0cb80b0e00913fafcae0b3f98</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204107%26sid%3Dliteratum%253Aachs%26aulast%3DPoon%26aufirst%3DR.%26aulast%3DSmits%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DJagmohan-Changur%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DM.%26aulast%3DCheon%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DFodde%26aufirst%3DR.%26aulast%3DAlman%26aufirst%3DB.%2BA.%26atitle%3DCyclooxygenase-two%2520%2528COX-2%2529%2520modulates%2520proliferation%2520in%2520aggressive%2520fibromatosis%2520%2528desmoid%2520tumor%2529%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D451%26epage%3D460%26doi%3D10.1038%2Fsj.onc.1204107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benamouzig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzzan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deyra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaussade, S.</span></span>; <span class="NLM_contrib-group">APACC Study Group</span> <span> </span><span class="NLM_article-title">Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1136/gut.2008.175406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1136%2Fgut.2008.175406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=20427397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvFKhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2010&pages=622-629&author=R.+Benamouzigauthor=B.+Uzzanauthor=A.+Martinauthor=J.+Deyraauthor=J.+Littleauthor=B.+Girardauthor=S.+Chaussadeauthor=APACC+Study+Group&title=Cyclooxygenase-2+expression+and+recurrence+of+colorectal+adenomas%3A+effect+of+aspirin+chemoprevention&doi=10.1136%2Fgut.2008.175406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention</span></div><div class="casAuthors">Benamouzig, Robert; Uzzan, Bernard; Martin, Antoine; Deyra, Jacques; Little, Julian; Girard, Bernard; Chaussade, Stanislas</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-629</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background: Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas.  Cyclooxygenase-2 (COX-2), one of its main target enzymes, is reportedly over-expressed in colorectal adenomas.  Aim: To assess COX-2 expression, in relation to adenoma recurrence and the protective effect of aspirin, in a large series of colorectal adenomas, recruited from a double-blind randomised controlled trial comparing recurrences after low-dose aspirin or placebo.  Methods: Follow-up colonoscopies were performed after 1 and 4 years to assess adenoma recurrence.  COX-2 expression was assessed by immunohistochem. for each adenoma obtained at baseline colonoscopy, sep. for epithelium, deep stroma and overall.  Architecture, grade of dysplasia, K-ras mutation, p53 and cyclin D1 expression were studied.  Results: COX-2 expression could be assessed in 219 adenomas from 136 patients: 128 adenomas (58%) from 59 patients strongly expressed COX-2.  Strong COX-2 expression predominated in adenomas larger than 10 mm (84/129 vs 44/90; p=0.02) and in adenomas showing high-grade dysplasia (22/29 vs 104/188; p=0.04).  Deep stromal but not epithelial initial expression of COX-2 predicted adenoma recurrence in the whole population (30/72 patients or 42% strongly expressed deep stromal COX-2 compared with 16/64 or 25% without recurrent adenoma; p=0.04).  The protective effect of aspirin was mainly obsd. in patients in whom COX-2 initial expression was low (RR for recurrence in patients taking aspirin with low COX-2 expression: 0.59; 95% CI 0.39 to 0.90; p=0.02).  There was no significant effect of aspirin at the end of the trial.  Conclusion: Over-expression of COX-2 was frequent and predominated in large and high-grade dysplasia adenomas.  Deep stromal but not epithelial initial expression of COX-2 predicted recurrence of adenomas.  Aspirin did not act preferentially on patients whose initial adenomas strongly expressed COX-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqexHP2P0a_xLVg90H21EOLACvtfcHk0lgVVp7C0K1a3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvFKhsrw%253D&md5=e5b0d1409ea022eebbec145b1a461f2e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1136%2Fgut.2008.175406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.2008.175406%26sid%3Dliteratum%253Aachs%26aulast%3DBenamouzig%26aufirst%3DR.%26aulast%3DUzzan%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DDeyra%26aufirst%3DJ.%26aulast%3DLittle%26aufirst%3DJ.%26aulast%3DGirard%26aufirst%3DB.%26aulast%3DChaussade%26aufirst%3DS.%26aulast%3D%26atitle%3DCyclooxygenase-2%2520expression%2520and%2520recurrence%2520of%2520colorectal%2520adenomas%253A%2520effect%2520of%2520aspirin%2520chemoprevention%26jtitle%3DGut%26date%3D2010%26volume%3D59%26spage%3D622%26epage%3D629%26doi%3D10.1136%2Fgut.2008.175406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomozawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuno, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitayama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagawa, H.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1054/bjoc.2000.1270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1054%2Fbjoc.2000.1270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10917546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslens74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2000&pages=324-328&author=S.+Tomozawaauthor=N.+H.+Tsunoauthor=E.+Sunamiauthor=K.+Hatanoauthor=J.+Kitayamaauthor=T.+Osadaauthor=S.+Saitoauthor=T.+Tsuruoauthor=Y.+Shibataauthor=H.+Nagawa&title=Cyclooxygenase-2+overexpression+correlates+with+tumour+recurrence%2C+especially+haematogenous+metastasis%2C+of+colorectal+cancer&doi=10.1054%2Fbjoc.2000.1270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially hematogenous metastasis, of colorectal cancer</span></div><div class="casAuthors">Tomozawa, S.; Tsuno, N. H.; Sunami, E.; Hatano, K.; Kitayama, J.; Osada, T.; Saito, S.; Tsuruo, T.; Shibata, Y.; Nagawa, H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">324-328</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Epidemiol. studies have demonstrated that nonsteroidal anti-inflammatory drugs (NSAIDs), known to inhibit cyclooxygenase (COX), reduce the risk of colorectal cancer.  COX is a key enzyme in prostaglandin biosynthesis, and two isoforms of COX, COX-1 and COX-2, have been identified.  Recently COX-2 has been reported to frequently overexpress in colorectal neoplasms and to play a role in colorectal tumorigenesis and tumor progression.  In this study, using immunohistochem., we examd. COX-2 expression in advanced human colorectal cancer and its correlation with clinicopathol. features.  COX-2 expression was obsd. mainly in the cytoplasm of cancer cells in all the specimens examd., but some stromal cells and endothelial cells were also stained.  According to the grade of COX-2 expression of the cancer cells, patients were divided into high- and low-COX-2 expression groups.  High-COX-2 expression significantly correlated with tumor recurrence, esp. hematogenous metastasis.  These results suggest that a selective COX-2 inhibitor can be a novel class of therapeutic agents not only for tumorigenesis but also for hematogenous metastasis of cololectal cancer.  To our knowledge, this is the first report on the correlation between COX-2 overexpression and recurrence of colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE3FvAVoPF-rVg90H21EOLACvtfcHk0lgVVp7C0K1a3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslens74%253D&md5=b430293923b4e27e76605915629a807f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2000.1270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2000.1270%26sid%3Dliteratum%253Aachs%26aulast%3DTomozawa%26aufirst%3DS.%26aulast%3DTsuno%26aufirst%3DN.%2BH.%26aulast%3DSunami%26aufirst%3DE.%26aulast%3DHatano%26aufirst%3DK.%26aulast%3DKitayama%26aufirst%3DJ.%26aulast%3DOsada%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DTsuruo%26aufirst%3DT.%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DNagawa%26aufirst%3DH.%26atitle%3DCyclooxygenase-2%2520overexpression%2520correlates%2520with%2520tumour%2520recurrence%252C%2520especially%2520haematogenous%2520metastasis%252C%2520of%2520colorectal%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2000%26volume%3D83%26spage%3D324%26epage%3D328%26doi%3D10.1054%2Fbjoc.2000.1270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cha, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, R. N.</span></span> <span> </span><span class="NLM_article-title">NSAIDs and cancer prevention: targets downstream of COX-2</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1146/annurev.med.57.121304.131253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1146%2Fannurev.med.57.121304.131253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=17100552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisV2jsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2007&pages=239-252&author=Y.+I.+Chaauthor=R.+N.+DuBois&title=NSAIDs+and+cancer+prevention%3A+targets+downstream+of+COX-2&doi=10.1146%2Fannurev.med.57.121304.131253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">NSAIDs and cancer prevention: targets downstream of COX-2</span></div><div class="casAuthors">Cha, Yong I.; DuBois, Raymond N.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">239-252, 2 plates</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Preclin. and clin. studies have clearly shown a benefit of non-steroidal anti-inflammatory drug (NSAID) use in reducing cancer risk.  However, the adverse gastrointestinal and cardiovascular side effects assocd. with NSAIDs and COX-2 selective inhibitors (coxibs) have provoked more scrutiny of the precise role of specific downstream mediators in the prostaglandin (PG) signaling cascade.  NSAIDs and coxibs inhibit PG biosynthesis.  One of the PGs produced at high levels in the tumor microenvironment is PGE2, which is thought to play a major role in cancer progression.  Thus, a better understanding of PGE2 signaling could enable identification of novel and safer therapeutic targets downstream of the cyclooxygenase enzymes.  We review the emerging mol. mechanisms by which COX-2-derived PGE2 is involved in cancer progression and delineate potential opportunities for development of novel pharmacol. approaches utilizing this pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ3LRrVwjZILVg90H21EOLACvtfcHk0lhLj0dCvXI1tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisV2jsbc%253D&md5=169e6750f118f6b449b792b8563370d0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.57.121304.131253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.57.121304.131253%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DY.%2BI.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DNSAIDs%2520and%2520cancer%2520prevention%253A%2520targets%2520downstream%2520of%2520COX-2%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2007%26volume%3D58%26spage%3D239%26epage%3D252%26doi%3D10.1146%2Fannurev.med.57.121304.131253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, R. N.</span></span> <span> </span><span class="NLM_article-title">Eicosanoids and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/nrc2809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fnrc2809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=20168319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFemsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=181-193&author=D.+Wangauthor=R.+N.+DuBois&title=Eicosanoids+and+cancer&doi=10.1038%2Fnrc2809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Eicosanoids and cancer</span></div><div class="casAuthors">Wang, Dingzhi; DuBois, Raymond N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-193</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Eicosanoids, including prostaglandins and leukotrienes, are biol. active lipids that have been implicated in various pathol. processes, such as inflammation and cancer.  This Review highlights our understanding of the intricate roles of eicosanoids in epithelial-derived tumors and their microenvironment.  The knowledge of how these lipids orchestrate the complex interactions between transformed epithelial cells and the surrounding stromal cells is crucial for understanding tumor evolution, progression and metastasis.  Understanding the mol. mechanisms underlying the role of prostaglandins and other eicosanoids in cancer progression will help to develop more effective cancer chemopreventive and/or therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq_oPm3Qm5n7Vg90H21EOLACvtfcHk0lhLj0dCvXI1tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFemsbs%253D&md5=7a8cb25f2a7a8884439fdcfe7452d40a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrc2809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2809%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DEicosanoids%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D181%26epage%3D193%26doi%3D10.1038%2Fnrc2809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, R. N.</span></span> <span> </span><span class="NLM_article-title">Prostaglandins and cancer</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1136/gut.2004.047100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1136%2Fgut.2004.047100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16118353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1yquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2006&pages=115-122&author=D.+Wangauthor=R.+N.+Dubois&title=Prostaglandins+and+cancer&doi=10.1136%2Fgut.2004.047100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Prostaglandins and cancer</span></div><div class="casAuthors">Wang, D.; DuBois, R. N.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-122</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemoprevention has been considered as a possible approach for cancer prevention.  A significant effort has been made in the development of novel drugs for both cancer prevention and treatment over the past decade.  Recent epidemiol. studies and clin. trials indicate that long term use of aspirin and similar agents, also called non-steroidal anti-inflammatory drugs (NSAIDs), can decrease the incidence of certain malignancies, including colorectal, esophageal, breast, lung, and bladder cancers.  The best known targets of NSAIDs are cyclooxygenase (COX) enzymes, which convert arachidonic acid to prostaglandins (PGs) and thromboxane.  COX-2 derived prostaglandin E2 (PGE2) can promote tumor growth by binding its receptors and activating signaling pathways which control cell proliferation, migration, apoptosis, and/or angiogenesis.  However, the prolonged use of high dosages of COX-2 selective inhibitors (COXIBs) is assocd. with unacceptable cardiovascular side effects.  Thus it is crucial to develop more effective chemopreventive agents with minimal toxicity.  Recent efforts to identify the mol. mechanisms by which PGE2 promotes tumor growth and metastasis may provide opportunities for the development of safer strategies for cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozLiBOa60XjbVg90H21EOLACvtfcHk0lhLj0dCvXI1tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1yquw%253D%253D&md5=deb3293aa36c14a2ded00aa3a9fa7cf0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1136%2Fgut.2004.047100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.2004.047100%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DDubois%26aufirst%3DR.%2BN.%26atitle%3DProstaglandins%2520and%2520cancer%26jtitle%3DGut%26date%3D2006%26volume%3D55%26spage%3D115%26epage%3D122%26doi%3D10.1136%2Fgut.2004.047100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, R. N.</span></span> <span> </span><span class="NLM_article-title">Prostaglandin E2 promotes intestinal tumor growth via DNA methylation</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1038/nm.2608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fnm.2608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=22270723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFSmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=224-226&author=D.+Xiaauthor=D.+Wangauthor=S.-H.+Kimauthor=H.+Katohauthor=R.+N.+DuBois&title=Prostaglandin+E2+promotes+intestinal+tumor+growth+via+DNA+methylation&doi=10.1038%2Fnm.2608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Prostaglandin E2 promotes intestinal tumor growth via DNA methylation</span></div><div class="casAuthors">Xia, Dianren; Wang, Dingzhi; Kim, Sun-Hee; Katoh, Hiroshi; DuBois, Raymond N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-226</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although aberrant DNA methylation is considered to be one of the key ways by which tumor-suppressor and DNA-repair genes are silenced during tumor initiation and progression, the mechanisms underlying DNA methylation alterations in cancer remain unclear.  Here we show that prostaglandin E2 (PGE2) silences certain tumor-suppressor and DNA-repair genes through DNA methylation to promote tumor growth.  These findings uncover a previously unrecognized role for PGE2 in the promotion of tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTr1SGHi4NNbVg90H21EOLACvtfcHk0lhLj0dCvXI1tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFSmurk%253D&md5=fc7251a005fc2424129255e6d5638d71</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnm.2608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2608%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DKatoh%26aufirst%3DH.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DProstaglandin%2520E2%2520promotes%2520intestinal%2520tumor%2520growth%2520via%2520DNA%2520methylation%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D224%26epage%3D226%26doi%3D10.1038%2Fnm.2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohnai, N.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase isozymes and their gene structures and expression</span>. <i>Prostaglandins Other Lipid Mediators</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>68–69</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/s0090-6980(02)00024-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2FS0090-6980%2802%2900024-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=12432912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvV2nsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68%E2%80%9369&publication_year=2002&pages=95-114&author=T.+Tanabeauthor=N.+Tohnai&title=Cyclooxygenase+isozymes+and+their+gene+structures+and+expression&doi=10.1016%2Fs0090-6980%2802%2900024-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase isozymes and their gene structures and expression</span></div><div class="casAuthors">Tanabe, Tadashi; Tohnai, Norimitsu</div><div class="citationInfo"><span class="NLM_cas:title">Prostaglandins & Other Lipid Mediators</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">68-69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-114</span>CODEN:
                <span class="NLM_cas:coden">POLMFL</span>;
        ISSN:<span class="NLM_cas:issn">1098-8823</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The cyclooxygenase (COX, prostaglandin endoperoxide synthase) is a key enzyme in prostaglandin biosynthesis.  Two isoforms of COX, COX-1 and COX-2, have been identified by mol. biol. methods.  The amino acid sequence homol. between COX-1 and COX-2 is about 60% for the human enzymes.  COX-1 is constitutively expressed in most tissues and cells in animal species.  The COX-1 promoter region lacks a canonical TATA or CAAT box and is GC-rich.  These features are consistent with those of a housekeeping gene.  On the other hand, COX-2 is an inducible enzyme and is induced by various cytokines and mitogenic factors.  The induction of COX-2 is suppressed by dexamethasone and PGJ2.  There are many consensus cis-elements in the 5'-flanking region to regulate the expression of COX-2.  Among them, a CRE, an NF-κB site, a NF-IL6 motif and an E-box, regulate transcription independently or synergistically.  Most of the transcriptional signaling pathways require activation of the mitogen-activated protein kinase (MAPK) cascade.  Moreover, MAPK signaling pathways are involved in regulating COX-2 gene expression at the post-transcriptional level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqFxhemLq53rVg90H21EOLACvtfcHk0liBItxOUU6xVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvV2nsLs%253D&md5=98a5d784f864e819abd1c5b8a17d6004</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0090-6980%2802%2900024-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0090-6980%252802%252900024-2%26sid%3Dliteratum%253Aachs%26aulast%3DTanabe%26aufirst%3DT.%26aulast%3DTohnai%26aufirst%3DN.%26atitle%3DCyclooxygenase%2520isozymes%2520and%2520their%2520gene%2520structures%2520and%2520expression%26jtitle%3DProstaglandins%2520Other%2520Lipid%2520Mediators%26date%3D2002%26volume%3D68%25E2%2580%259369%26spage%3D95%26epage%3D114%26doi%3D10.1016%2Fs0090-6980%2802%2900024-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinchuk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzaskos, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketo, M. M.</span></span> <span> </span><span class="NLM_article-title">Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1016/s0092-8674(00)81988-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2FS0092-8674%2800%2981988-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=8945508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADyaK28XntlymsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1996&pages=803-809&author=M.+Oshimaauthor=J.+E.+Dinchukauthor=S.+L.+Kargmanauthor=H.+Oshimaauthor=B.+Hancockauthor=E.+Kwongauthor=J.+M.+Trzaskosauthor=J.+F.+Evansauthor=M.+M.+Taketo&title=Suppression+of+intestinal+polyposis+in+Apc+delta716+knockout+mice+by+inhibition+of+cyclooxygenase+2+%28COX-2%29&doi=10.1016%2Fs0092-8674%2800%2981988-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)</span></div><div class="casAuthors">Oshima, Masanobu; Dinchuk, Joseph E.; Kargman, Stacia L.; Oshima, Hiroko; Hancock, Bruno; Kwong, Elizabeth; Trzaskos, James M.; Evans, Jilly F.; Taketo, Makoto M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">803-809</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Two cyclooxygenase isoenzymes catalyze conversion of arachidonic acid to prostaglandin H2: constitutive COX-1 and inducible COX-2.  To assess the role of COX-2 in colorectal tumorigenesis, we detd. the effects of COX-2 gene (Ptgs2) knockouts and a novel COX-2 inhibitor on ApcΔ716 knockout mice, a model of human familial adenomatous polyposis.  A Ptgs2 null mutation reduced the no. and size of the intestinal polyps dramatically.  Furthermore, treating ApcΔ716 mice with a novel COX-2 inhibitor reduced the polyp no. more significantly than with sulindac, which inhibits both isoenzymes.  These results provide direct genetic evidence that COX-2 plays a key role in tumorigenesis and indicate that COX-2-selective inhibitors can be a novel class of therapeutic agents for colorectal polyposis and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3SIHZ--FNr7Vg90H21EOLACvtfcHk0liBItxOUU6xVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntlymsLc%253D&md5=f6fc36452bd2085932025aaa025936f5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981988-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981988-1%26sid%3Dliteratum%253Aachs%26aulast%3DOshima%26aufirst%3DM.%26aulast%3DDinchuk%26aufirst%3DJ.%2BE.%26aulast%3DKargman%26aufirst%3DS.%2BL.%26aulast%3DOshima%26aufirst%3DH.%26aulast%3DHancock%26aufirst%3DB.%26aulast%3DKwong%26aufirst%3DE.%26aulast%3DTrzaskos%26aufirst%3DJ.%2BM.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DTaketo%26aufirst%3DM.%2BM.%26atitle%3DSuppression%2520of%2520intestinal%2520polyposis%2520in%2520Apc%2520delta716%2520knockout%2520mice%2520by%2520inhibition%2520of%2520cyclooxygenase%25202%2520%2528COX-2%2529%26jtitle%3DCell%26date%3D1996%26volume%3D87%26spage%3D803%26epage%3D809%26doi%3D10.1016%2Fs0092-8674%2800%2981988-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukutake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatsugi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, K.</span></span> <span> </span><span class="NLM_article-title">Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1939</span>– <span class="NLM_lpage">1942</span>, <span class="refDoi"> DOI: 10.1093/carcin/19.11.1939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1093%2Fcarcin%2F19.11.1939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=9855006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADyaK1cXnvVCnu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1998&pages=1939-1942&author=M.+Fukutakeauthor=S.+Nakatsugiauthor=T.+Isoiauthor=M.+Takahashiauthor=T.+Ohtaauthor=S.+Mamiyaauthor=Y.+Taniguchiauthor=H.+Satoauthor=K.+Fukudaauthor=T.+Sugimuraauthor=K.+Wakabayashi&title=Suppressive+effects+of+nimesulide%2C+a+selective+inhibitor+of+cyclooxygenase-2%2C+on+azoxymethane-induced+colon+carcinogenesis+in+mice&doi=10.1093%2Fcarcin%2F19.11.1939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice</span></div><div class="casAuthors">Fukutake, Masato; Nakatsugi, Seiichi; Isoi, Takashi; Takahashi, Mami; Ohta, Toshihisa; Mamiya, Souichi; Taniguchi, Yasuaki; Sato, Hidetaka; Fukuda, Kazunori; Sugimura, Takashi; Wakabayashi, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1939-1942</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The effects of nimesulide, a selective inhibitor of cyclooxygenase-2 (COX-2) on azoxymethane (AOM)-induced colon carcinogenesis were investigated in mice.  AOM at a dose of 10 mg/kg body wt was administered to male ICR mice once a week for 6 wk.  The animals were fed on AIN-76A powder diet contg. nimesulide at doses of 200 or 400 p.p.m., starting the day before the first carcinogen treatment until the end of the expt., at week 30.  Administration of nimesulide reduced the incidence of colon carcinomas to 32 and 25% for the AOM + 200 and 400 p.p.m. nimesulide groups, resp., compared with the AOM + basal diet group (50%).  Multiplicities of colon carcinomas in the 200 and 400 p.p.m. nimesulide-treated groups were 0.70 ± 0.28 and 0.35 ± 0.11, resp., being significantly smaller than the AOM alone value (1.79 ± 0.47).  The sizes of the colon carcinomas in the nimesulide-treated groups were also decreased.  No significant influence on liver and lung tumor development was apparent.  Thus, nimesulide exerted a suppressive effect on AOM-induced colon carcinogenesis in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-A6HxAiQGsLVg90H21EOLACvtfcHk0liBItxOUU6xVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvVCnu74%253D&md5=483d5eb26bab6d5721c686372b937076</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2F19.11.1939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252F19.11.1939%26sid%3Dliteratum%253Aachs%26aulast%3DFukutake%26aufirst%3DM.%26aulast%3DNakatsugi%26aufirst%3DS.%26aulast%3DIsoi%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DT.%26aulast%3DMamiya%26aufirst%3DS.%26aulast%3DTaniguchi%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DSugimura%26aufirst%3DT.%26aulast%3DWakabayashi%26aufirst%3DK.%26atitle%3DSuppressive%2520effects%2520of%2520nimesulide%252C%2520a%2520selective%2520inhibitor%2520of%2520cyclooxygenase-2%252C%2520on%2520azoxymethane-induced%2520colon%2520carcinogenesis%2520in%2520mice%26jtitle%3DCarcinogenesis%26date%3D1998%26volume%3D19%26spage%3D1939%26epage%3D1942%26doi%3D10.1093%2Fcarcin%2F19.11.1939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arguello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketo, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1733</span>– <span class="NLM_lpage">1740</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11245490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvVeksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=1733-1740&author=M.+Oshimaauthor=N.+Muraiauthor=S.+Kargmanauthor=M.+Arguelloauthor=P.+Lukauthor=E.+Kwongauthor=M.+M.+Taketoauthor=J.+F.+Evans&title=Chemoprevention+of+intestinal+polyposis+in+the+Apcdelta716+mouse+by+rofecoxib%2C+a+specific+cyclooxygenase-2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoprevention of intestinal polyposis in the ApcΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor</span></div><div class="casAuthors">Oshima, Masanobu; Murai, Naomi; Kargman, Stacia; Arguello, Meztli; Luk, Pauline; Kwong, Elizabeth; Taketo, Makoto M.; Evans, Jilly F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1733-1740</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations in the human adenomatous polyposis (APC) gene are causative for familial adenomatous polyposis (FAP), a rare condition in which numerous colonic polyps arise during puberty and, if left untreated, lead to colon cancer.  The APC gene is a tumor suppressor that has been termed the "gatekeeper gene" for colon cancer.  In addn. to the 100% mutation rate in FAP patients, the APC gene is mutated in >80% of sporadic colon and intestinal cancers.  The Apc gene in mice has been mutated either by chem. carcinogenesis, resulting in the Min mouse ApcΔ850, or by heterologous recombination, resulting in the ApcΔ716 or ApcΔ1368 mice.  Although homozygote Apc-/- mice are embryonically lethal, the heterozygotes are viable but develop numerous intestinal polyps with loss of Apc heterozygosity within the polyps.  The proinflammatory, prooncogenic protein cyclooxygenase (COX)-2 has been shown to be markedly induced in the ApcΔ716 polyps at an early stage of polyp development.  We demonstrate here that treatment with the specific COX-2 inhibitor rofecoxib results in a dose-dependent redn. in the no. and size of intestinal and colonic polyps in the ApcΔ716 mouse.  The plasma concn. of rofecoxib that resulted in a 55% inhibition of polyp no. and an 80% inhibition of polyps > 1 mm in size is comparable with the human clin. steady-state concn. of 25 mg rofecoxib (Vioxx) taken once daily.  Polyps from both untreated and rofecoxib- or sulindac-treated ApcΔ716 mice expressed COX-1 and -2, whereas normal epithelium from all mice expressed COX-1 but minimal amts. of COX-2.  Polyps from either rofecoxib- or sulindac-treated mice had lower rates of DNA replication, expressed less proangiogenic vascular endothelial-derived growth factor and more membrane-bound β-catenin, but showed unchanged nuclear localization of this transcription factor.  This study showing the inhibition of polyposis in the ApcΔ716 mouse suggests that the specific COX-2 inhibitor rofecoxib (Vioxx) has potential as a chemopreventive agent in human intestinal and colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruBvlEU33JU7Vg90H21EOLACvtfcHk0ljg6QFxr0RFBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvVeksr4%253D&md5=9399fcfc94603a0b95564bae11d2e349</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOshima%26aufirst%3DM.%26aulast%3DMurai%26aufirst%3DN.%26aulast%3DKargman%26aufirst%3DS.%26aulast%3DArguello%26aufirst%3DM.%26aulast%3DLuk%26aufirst%3DP.%26aulast%3DKwong%26aufirst%3DE.%26aulast%3DTaketo%26aufirst%3DM.%2BM.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DChemoprevention%2520of%2520intestinal%2520polyposis%2520in%2520the%2520Apcdelta716%2520mouse%2520by%2520rofecoxib%252C%2520a%2520specific%2520cyclooxygenase-2%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D1733%26epage%3D1740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span> <span> </span><span class="NLM_article-title">Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">46</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-5-46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1186%2F1471-2407-5-46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=15892897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD2MzhsFWhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=46&author=H.+Kohnoauthor=R.+Suzukiauthor=S.+Sugieauthor=T.+Tanaka&title=Suppression+of+colitis-related+mouse+colon+carcinogenesis+by+a+COX-2+inhibitor+and+PPAR+ligands&doi=10.1186%2F1471-2407-5-46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands</span></div><div class="casAuthors">Kohno Hiroyuki; Suzuki Rikako; Sugie Shigeyuki; Tanaka Takuji</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  It is generally assumed that inflammatory bowel disease (IBD)-related carcinogenesis occurs as a result of chronic inflammation.  We previously developed a novel colitis-related mouse colon carcinogenesis model initiated with azoxymethane (AOM) and followed by dextran sodium sulfate (DSS).  In the present study we investigated whether a cyclooxygenase (COX)-2 inhibitor nimesulide and ligands for peroxisome proliferator-activated receptors (PPARs), troglitazone (a PPARgamma ligand) and bezafibrate (a PPARalpha ligand) inhibit colitis-related colon carcinogenesis using our model to evaluate the efficacy of these drugs in prevention of IBD-related colon carcinogenesis.  METHODS:  Female CD-1 (ICR) mice were given a single intraperitoneal administration of AOM (10 mg/kg body weight) and followed by one-week oral exposure of 2% (w/v) DSS in drinking water, and then maintained on the basal diets mixed with or without nimesulide (0.04%, w/w), troglitazone (0.05%, w/w), and bezafibrate (0.05%, w/w) for 14 weeks.  The inhibitory effects of dietary administration of these compounds were determined by histopathological and immunohistochemical analyses.  RESULTS:  Feeding with nimesulide and troglitazone significantly inhibited both the incidence and multiplicity of colonic adenocarcinoma induced by AOM/DSS in mice.  Bezafibrate feeding significantly reduced the incidence of colonic adenocarcinoma, but did not significantly lower the multiplicity.  Feeding with nimesulide and troglitazone decreased the proliferating cell nuclear antigen (PCNA)-labeling index and expression of beta-catenin, COX-2, inducible nitric oxide synthase (iNOS) and nitrotyrosine.  The treatments increased the apoptosis index in the colonic adenocarcinoma.  Feeding with bezafibrate also affected these parameters except for beta-catenin expression in the colonic malignancy.  CONCLUSION:  Dietary administration of nimesulide, troglitazone and bezafibrate effectively suppressed the development of colonic epithelial malignancy induced by AOM/DSS in female ICR mice.  The results suggest that COX-2 inhibitor and PPAR ligands could serve as an effective agent against colitis-related colon cancer development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyAfRYtKH1_UHdcurJClFcfW6udTcc2eYYC7QIwBLJ7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzhsFWhug%253D%253D&md5=2a61a3291a0b0f39beea1b21832a61cd</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-5-46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-5-46%26sid%3Dliteratum%253Aachs%26aulast%3DKohno%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DSugie%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DT.%26atitle%3DSuppression%2520of%2520colitis-related%2520mouse%2520colon%2520carcinogenesis%2520by%2520a%2520COX-2%2520inhibitor%2520and%2520PPAR%2520ligands%26jtitle%3DBMC%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D46%26doi%3D10.1186%2F1471-2407-5-46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rácz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavoral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breazna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechuga, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstein, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eagle, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, B.</span></span> <span> </span><span class="NLM_article-title">Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1135</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1038/ajg.2011.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fajg.2011.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=21503000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BC3MrntVSjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2011&pages=1135-1146&author=N.+Arberauthor=J.+Spicakauthor=I.+R%C3%A1czauthor=M.+Zavoralauthor=A.+Breaznaauthor=P.+Gerlettiauthor=M.+J.+Lechugaauthor=N.+Collinsauthor=R.+B.+Rosensteinauthor=C.+J.+Eagleauthor=B.+Levin&title=Five-year+analysis+of+the+prevention+of+colorectal+sporadic+adenomatous+polyps+trial&doi=10.1038%2Fajg.2011.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial</span></div><div class="casAuthors">Arber Nadir; Spicak Julius; Racz Istvan; Zavoral Miroslav; Breazna Aurora; Gerletti Paola; Lechuga Maria J; Collins Neal; Rosenstein Rebecca B; Eagle Craig J; Levin Bernard</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of gastroenterology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1135-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Subjects in the Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trial (PRESAP/NCT00141193/www.clinicaltrials.gov) were studied to determine efficacy and safety at a year 5 assessment.  METHODS:  In this randomized, placebo-controlled, double-blind trial, 1,561 subjects with diagnosed colorectal adenomas removed within 3 months of the study's initiation were assessed after ~ 3 years on celecoxib followed by 2 years off.  Studied in 107 primary and secondary care settings, subjects were stratified by cardioprotective aspirin use and randomized to receive orally 400 ng celecoxib (933 subjects) or placebo (628 subjects) once daily.  Efficacy was measured by colonoscopy at years 1, 3, and 5, and safety was measured by investigators for the on-treatment period and collected by subject self-report over 2 years post-treatment.  RESULTS:  At year 5, the primary outcome measure was the rate of new adenomas measured cumulatively from baseline.  This rate was statistically significantly lower in the celecoxib group (51.4%) than in the placebo group (57.5%; P<0.001).  Similarly, the cumulative rate of new advanced adenomas was significantly lower in the celecoxib group (10.0%) than in the placebo group (13.8%; P=0.007).  However, the year 5 interval measure, which was not cumulative and did not take the rates of previous years into account, showed that after 2 years off treatment, the celecoxib group (27.0%) was 1.66 times more likely to have new adenomas than the placebo group (16.3%; P<0.0001).  Similarly, the percentage of patients with new advanced adenomas was significantly higher in the celecoxib group (5.0%) than in the placebo group (3.8%) (P=0.0072).  The evaluation of safety from baseline through year 5 indicated that the risks of serious cardiac disorders (relative risk (RR) 1.66; 95% confidence interval (CI) 1.01-2.73), selected renal/hypertension events (RR 1.35; 95% CI 1.09-1.68), and general vascular (RR 1.34; 95% CI 1.08-1.68) and cardiac disorders (RR 1.59; 95% CI 1.12-2.26) were higher in those taking celecoxib than in those on placebo.  CONCLUSIONS:  The year 5 cumulative measures of the incidence of new and advanced adenomas were significantly lower in the celecoxib group than in the placebo group, but the year 5 interval rates of these measures were significantly lower in the placebo group than the celecoxib group, perhaps suggesting a release of cyclooxygenase-2 inhibition.  Consistent with what has been previously reported, increased risk of renal/hypertension events and cardiac disorders associated with celecoxib therapy mandates caution in patient selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbWOm5UyaukMkU0YCbOU3EfW6udTcc2eYYC7QIwBLJ7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrntVSjtw%253D%253D&md5=9c1087c8453feaad12169fb57afe6079</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fajg.2011.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajg.2011.116%26sid%3Dliteratum%253Aachs%26aulast%3DArber%26aufirst%3DN.%26aulast%3DSpicak%26aufirst%3DJ.%26aulast%3DR%25C3%25A1cz%26aufirst%3DI.%26aulast%3DZavoral%26aufirst%3DM.%26aulast%3DBreazna%26aufirst%3DA.%26aulast%3DGerletti%26aufirst%3DP.%26aulast%3DLechuga%26aufirst%3DM.%2BJ.%26aulast%3DCollins%26aufirst%3DN.%26aulast%3DRosenstein%26aufirst%3DR.%2BB.%26aulast%3DEagle%26aufirst%3DC.%2BJ.%26aulast%3DLevin%26aufirst%3DB.%26atitle%3DFive-year%2520analysis%2520of%2520the%2520prevention%2520of%2520colorectal%2520sporadic%2520adenomatous%2520polyps%2520trial%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2011%26volume%3D106%26spage%3D1135%26epage%3D1146%26doi%3D10.1038%2Fajg.2011.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zauber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawk, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertagnolli, M.</span></span> <span> </span><span class="NLM_article-title">Adenoma prevention with celecoxib (APC) study investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1071</span>– <span class="NLM_lpage">1080</span>, <span class="refDoi"> DOI: 10.1056/nejmoa050405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJMoa050405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=15713944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Kqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1071-1080&author=S.+D.+Solomonauthor=J.+J.+V.+McMurrayauthor=M.+A.+Pfefferauthor=J.+Wittesauthor=R.+Fowlerauthor=P.+Finnauthor=W.+F.+Andersonauthor=A.+Zauberauthor=E.+Hawkauthor=M.+Bertagnolli&title=Adenoma+prevention+with+celecoxib+%28APC%29+study+investigators.+Cardiovascular+risk+associated+with+celecoxib+in+a+clinical+trial+for+colorectal+adenoma+prevention&doi=10.1056%2Fnejmoa050405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention</span></div><div class="casAuthors">Solomon, Scott D.; McMurray, John J. V.; Pfeffer, Marc A.; Wittes, Janet; Fowler, Robert; Finn, Peter; Anderson, William F.; Zauber, Ann; Hawk, Ernest; Bertagnolli, Monica</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1071-1080</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Selective cyclooxygenase-2(COX-2) inhibitors have come under scrutiny because of reports suggesting an increased cardiovascular risk assocd. with their use.  Exptl. research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern.  We reviewed all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who were enrolled in a trial comparing two doses of celecoxib (200 mg or 400 mg twice daily) with placebo for the prevention of colorectal adenomas.  All deaths were categorized as cardiovascular or noncardiovascular, and nonfatal cardiovascular events were categorized in a blinded fashion according to a prespecified scheme.  For all patients except those who died, 2.8 to 3.1 years of follow-up data were available.  A composite cardiovascular end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure was reached in 7 of 679 patients in the placebo group (1.0 %), as compared with 16 of 685 patients receiving 200 mg of celecoxib twice daily (2.3 %; hazard ratio, 2.3; 95 % confidence interval, 0.9 to 5.5) and with 23 of 671 patients receiving 400 mg of celecoxib twice daily (3.4 %; hazard ratio, 3.4; 95 % confidence interval, 1.4 to 7.8).  Similar trends were obsd. for other composite end points.  On the basis of these observations, the data and safety monitoring board recommended early discontinuation of the study drug.  Celecoxib use was assocd. with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure.  In light of recent reports of cardiovascular harm assocd. with treatment with other agents in this class, these data provide further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2PPDnO2tXU7Vg90H21EOLACvtfcHk0ljxDLt0jNOnSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Kqur4%253D&md5=5df251ddfc12b7d625c888ec7b09606b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050405%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DPfeffer%26aufirst%3DM.%2BA.%26aulast%3DWittes%26aufirst%3DJ.%26aulast%3DFowler%26aufirst%3DR.%26aulast%3DFinn%26aufirst%3DP.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DZauber%26aufirst%3DA.%26aulast%3DHawk%26aufirst%3DE.%26aulast%3DBertagnolli%26aufirst%3DM.%26atitle%3DAdenoma%2520prevention%2520with%2520celecoxib%2520%2528APC%2529%2520study%2520investigators.%2520Cardiovascular%2520risk%2520associated%2520with%2520celecoxib%2520in%2520a%2520clinical%2520trial%2520for%2520colorectal%2520adenoma%2520prevention%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1071%26epage%3D1080%26doi%3D10.1056%2Fnejmoa050405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y.</span></span> <span> </span><span class="NLM_article-title">N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">1831</span>– <span class="NLM_lpage">1842</span>, <span class="refDoi"> DOI: 10.1002/jps.23082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1002%2Fjps.23082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=22334096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1WhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2012&pages=1831-1842&author=Y.+Leeauthor=J.+Kimauthor=H.+Kimauthor=S.+Kangauthor=J.-H.+Yoonauthor=D.-D.+Kimauthor=Y.+M.+Kimauthor=Y.+Jung&title=N-succinylaspart-1-yl+celecoxib+is+a+potential+colon-specific+prodrug+of+celecoxib+with+improved+therapeutic+properties&doi=10.1002%2Fjps.23082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties</span></div><div class="casAuthors">Lee, Yonghyun; Kim, Jeongyun; Kim, Hyunjeong; Kang, Sookjin; Yoon, Jeong-Hyun; Kim, Dae-Duk; Kim, Young Mi; Jung, Yunjin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1831-1842</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To develop a colon-specific prodrug of celecoxib, a cyclooxygenase-2 selective inhibitor, which could improve cardiovascular toxicity and therapeutic effectiveness for chemoprevention of colorectal cancer, aspart-1-yl celecoxib (A1C) or aspart-4-yl celecoxib (A4C), succinyl celecoxib (SC), and N-succinylaspart-1-yl celecoxib (SA1C) or N-succinylaspart-4-yl celecoxib (SA4C) were prepd. and evaluated as a prodrug with such beneficial properties.  On incubation with the small intestinal contents while SC, SA1C, and SA4C were stable, A1C and A4C were degraded to liberate celecoxib.  In the cecal contents, the other conjugates except for SC and SA4C were cleaved to release celecoxib.  These results suggest the colon-specific delivery and activation of SA1C.  On oral administration of SA1C or celecoxib, no SA1C was detected in the blood and urine, indicating the limited absorption of SA1C.  SA1C delivered a much greater amt. of celecoxib to the large intestine while keeping the plasma concn. of celecoxib at much lower level, which is consistent with no change of the serum level of 6-ketoprostaglandin F1α whose decrease is assocd. with the cardiovascular toxicity of celecoxib.  Moreover, SA1C administered orally supplied a greater concn. of celecoxib for the whole colonic tissue.  Taken together, SA1C may be a colon-specific prodrug of celecoxib with improved therapeutic properties.  © 2012 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH8q8MLsDG3LVg90H21EOLACvtfcHk0ljxDLt0jNOnSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1WhsLY%253D&md5=2bed14ce990dcbe5f7b77d138d04d08c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fjps.23082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23082%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DYoon%26aufirst%3DJ.-H.%26aulast%3DKim%26aufirst%3DD.-D.%26aulast%3DKim%26aufirst%3DY.%2BM.%26aulast%3DJung%26aufirst%3DY.%26atitle%3DN-succinylaspart-1-yl%2520celecoxib%2520is%2520a%2520potential%2520colon-specific%2520prodrug%2520of%2520celecoxib%2520with%2520improved%2520therapeutic%2520properties%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D101%26spage%3D1831%26epage%3D1842%26doi%3D10.1002%2Fjps.23082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y.</span></span> <span> </span><span class="NLM_article-title">Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis</span>. <i>J. Drug Targeting</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.3109/1061186x.2012.693498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.3109%2F1061186X.2012.693498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=22632102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns1yqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=524-534&author=Y.+Leeauthor=H.+Kimauthor=W.+Kimauthor=J.-H.+Yoonauthor=S.+H.+Jeongauthor=Y.+Jung&title=Colon-specific+delivery+of+celecoxib+is+a+potential+strategy+to+improve+toxicological+and+pharmacological+properties+of+the+selective+Cox-2+inhibitor%3A+implication+in+treatment+of+familiar+adenomatous+polyposis&doi=10.3109%2F1061186x.2012.693498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis</span></div><div class="casAuthors">Lee, Yonghyun; Kim, Hyunjeong; Kim, Wooseong; Yoon, Jeong-Hyun; Jeong, Seong Hoon; Jung, Yunjin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">524-534</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1026-7158</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">In general, colon-specific delivery of a drug decreases systemic absorption and increases therapeutic concn. of the drug at the target site.  N-succinylglutam-1 or 5-yl celecoxib (SG1C and SG5C) were prepd. as a colon-specific prodrug of celecoxib, a selective Cox-2 inhibitor, and investigated whether the celecoxib derivs. could deliver celecoxib to the target site and improve cardiovascular toxicity and therapeutic effectiveness for the treatment of familiar adenomatous polyposis.  SG1C and SA5C were cleaved to release celecoxib in the cecal contents while stable in small intestinal contents.  The cecal release of celecoxib was much greater for SG1C than SG5C.  SG1C administered orally was barely detected in the blood and urine.  SG1C delivered much greater amt. of celecoxib to the large intestine while keeping the plasma concn. of celecoxib at much lower level compared with oral administration of free celecoxib.  Consistent with these pharmacokinetic results, SG1C supplied a greater concn. of celecoxib for the entire colonic tissue and did not change the serum level of 6-keto-PGF1α whose decrease is assocd. with the cardiovascular toxicity of celecoxib.  Taken together, colon-specific delivery of celecoxib using a prodrug approach may be a useful strategy to improve toxicol. and pharmacol. properties of celecoxib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR3Vyh3Q_nNbVg90H21EOLACvtfcHk0ljxDLt0jNOnSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns1yqu70%253D&md5=c38a57f47b7e9d7558ba471c7f6be296</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3109%2F1061186X.2012.693498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F1061186X.2012.693498%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DYoon%26aufirst%3DJ.-H.%26aulast%3DJeong%26aufirst%3DS.%2BH.%26aulast%3DJung%26aufirst%3DY.%26atitle%3DColon-specific%2520delivery%2520of%2520celecoxib%2520is%2520a%2520potential%2520strategy%2520to%2520improve%2520toxicological%2520and%2520pharmacological%2520properties%2520of%2520the%2520selective%2520Cox-2%2520inhibitor%253A%2520implication%2520in%2520treatment%2520of%2520familiar%2520adenomatous%2520polyposis%26jtitle%3DJ.%2520Drug%2520Targeting%26date%3D2012%26volume%3D20%26spage%3D524%26epage%3D534%26doi%3D10.3109%2F1061186x.2012.693498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filipski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span> <span> </span><span class="NLM_article-title">Intestinal targeting of drugs: rational design approaches and challenges</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.2174/1568026611313070002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.2174%2F1568026611313070002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=23578023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsVaqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=776-802&author=K.+J.+Filipskiauthor=M.+V.+Varmaauthor=A.+F.+El-Kattanauthor=C.+M.+Amblerauthor=R.+B.+Ruggeriauthor=T.+C.+Goosenauthor=K.+O.+Cameron&title=Intestinal+targeting+of+drugs%3A+rational+design+approaches+and+challenges&doi=10.2174%2F1568026611313070002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal targeting of drugs: rational design approaches and challenges</span></div><div class="casAuthors">Filipski, Kevin J.; Varma, Manthena V.; El-Kattan, Ayman F.; Ambler, Catherine M.; Ruggeri, Roger B.; Goosen, Theunis C.; Cameron, Kimberly O.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">776-802</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting drugs to the gastrointestinal tract has been and continues to be an active area of research.  Guttargeting is an effective means of increasing the local concn. of active substance at the desired site of action while minimizing concns. elsewhere in the body that could lead to unwanted side-effects.  Several approaches to intestinal targeting exist.  Physicochem. property manipulation can drive mols. to large, polar, low absorption space or alternatively to lipophilic, high clearance space in order to minimize systemic exposure.  Design of compds. that are substrates for transporters within the gastrointestinal tract, either uptake or efflux, or at the hepato-biliary interface, may help to increase intestinal concn.  Prodrug strategies have been shown to be effective particularly for colon targeting, and several different technol. formulation approaches are currently being researched.  This review provides examples of various approaches to intestinal targeting, and discusses challenges and areas in need of future scientific advances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn5CowmF-p-LVg90H21EOLACvtfcHk0lgbfvBwKVTUew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsVaqt7w%253D&md5=b950400c76b8d955ebd39e6cad4a20aa</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.2174%2F1568026611313070002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313070002%26sid%3Dliteratum%253Aachs%26aulast%3DFilipski%26aufirst%3DK.%2BJ.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26atitle%3DIntestinal%2520targeting%2520of%2520drugs%253A%2520rational%2520design%2520approaches%2520and%2520challenges%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D776%26epage%3D802%26doi%3D10.2174%2F1568026611313070002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span> <span> </span><span class="NLM_article-title">Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">524</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.00524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.3389%2Ffphar.2020.00524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=32425781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFKktbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=524&author=S.+Hua&title=Advances+in+oral+drug+delivery+for+regional+targeting+in+the+gastrointestinal+tract+-+influence+of+physiological%2C+pathophysiological+and+pharmaceutical+factors&doi=10.3389%2Ffphar.2020.00524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors</span></div><div class="casAuthors">Hua, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">00524</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The oral route is by far the most common route of drug administration in the gastrointestinal tract and can be used for both systemic drug delivery and for treating local gastrointestinal diseases.  It is the most preferred route by patients, due to its advantages, such as ease of use, non-invasiveness, and convenience for self administration.  Formulations can also be designed to enhance drug delivery to specific regions in the upper or lower gastrointestinal tract.  Despite the clear advantages offered by the oral route, drug delivery can be challenging as the human gastrointestinal tract is complex and displays a no. of physiol. barriers that affect drug delivery.  Among these challenges are poor drug stability, poor drug soly., and low drug permeability across the mucosal barriers.  Attempts to overcome these issues have focused on improved understanding of the physiol. of the gastrointestinal tract in both healthy and diseased states.  Innovative pharmaceutical approaches have also been explored to improve regional drug targeting in the gastrointestinal tract, including nanoparticulate formulations.  This review will discuss the physiol., pathophysiol., and pharmaceutical considerations influencing drug delivery for the oral route of administration, as well as the conventional and novel drug delivery approaches.  The translational challenges and development aspects of novel formulations will also be addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9AssynyIctbVg90H21EOLACvtfcHk0lgbfvBwKVTUew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFKktbfP&md5=178306800c1f4256026282dffc97c354</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.00524%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26atitle%3DAdvances%2520in%2520oral%2520drug%2520delivery%2520for%2520regional%2520targeting%2520in%2520the%2520gastrointestinal%2520tract%2520-%2520influence%2520of%2520physiological%252C%2520pathophysiological%2520and%2520pharmaceutical%2520factors%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D524%26doi%3D10.3389%2Ffphar.2020.00524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madge, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawczuk, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreutter, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacani, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichenor, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaviya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seierstad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzolio, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a gut-restricted JAK inhibitor for the treatment of inflammatory bowel disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2915</span>– <span class="NLM_lpage">2929</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01439</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01439" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlOmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2915-2929&author=K.+A.+Leonardauthor=L.+A.+Madgeauthor=P.+J.+Krawczukauthor=A.+Wangauthor=K.+D.+Kreutterauthor=G.+M.+Bacaniauthor=W.+Chaiauthor=R.+C.+Smithauthor=M.+S.+Tichenorauthor=M.+C.+Harrisauthor=R.+Malaviyaauthor=M.+Seierstadauthor=M.+E.+Johnsonauthor=J.+D.+Venableauthor=S.+Kimauthor=G.+C.+Hirstauthor=A.+S.+Mathurauthor=T.+S.+Raoauthor=J.+P.+Edwardsauthor=M.+C.+Rizzolioauthor=T.+Koudriakova&title=Discovery+of+a+gut-restricted+JAK+inhibitor+for+the+treatment+of+inflammatory+bowel+disease&doi=10.1021%2Facs.jmedchem.9b01439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease</span></div><div class="casAuthors">Leonard, Kristi A.; Madge, Lisa A.; Krawczuk, Paul J.; Wang, Aihua; Kreutter, Kevin D.; Bacani, Genesis M.; Chai, Wenying; Smith, Russell C.; Tichenor, Mark S.; Harris, Michael C.; Malaviya, Ravi; Seierstad, Mark; Johnson, Marguerite E.; Venable, Jennifer D.; Kim, Suzie; Hirst, Gavin C.; Mathur, Ashok S.; Rao, Tadimeti S.; Edwards, James P.; Rizzolio, Michele C.; Koudriakova, Tatiana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2915-2929</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To identify Janus kinase (JAK) inhibitors that selectively target gastrointestinal tissues with limited systemic exposures, a class of imidazopyrrolopyridines with a range of phys. properties was prepd. and evaluated.  We identified compds. with low intrinsic permeability and detd. a correlation between permeability and physicochem. properties, clogP and tPSA, for a subset of compds.  This low intrinsic permeability translated into compds. displaying high colonic exposure and low systemic exposure after oral dosing at 25 mg/kg in mouse.  In a mouse PK/PD model, oral dosing of lead compd. 2 demonstrated dose-dependent inhibition of pSTAT phosphorylation in colonic explants post-oral dose but low systemic exposure and no measurable systemic pharmacodynamic activity.  We thus demonstrate the utility of JAK inhibitors with low intrinsic permeability as a feasible approach to develop gut-restricted, pharmacol. active mols. with a potential advantage over systemically available compds. that are limited by systemic on-target adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD40Yr_F26I7Vg90H21EOLACvtfcHk0lhjY43ASLvCbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlOmsLY%253D&md5=83d9007f45ba0c4d9c9dc00abfb49f9e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01439%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DK.%2BA.%26aulast%3DMadge%26aufirst%3DL.%2BA.%26aulast%3DKrawczuk%26aufirst%3DP.%2BJ.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DKreutter%26aufirst%3DK.%2BD.%26aulast%3DBacani%26aufirst%3DG.%2BM.%26aulast%3DChai%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DR.%2BC.%26aulast%3DTichenor%26aufirst%3DM.%2BS.%26aulast%3DHarris%26aufirst%3DM.%2BC.%26aulast%3DMalaviya%26aufirst%3DR.%26aulast%3DSeierstad%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26aulast%3DVenable%26aufirst%3DJ.%2BD.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26aulast%3DMathur%26aufirst%3DA.%2BS.%26aulast%3DRao%26aufirst%3DT.%2BS.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DRizzolio%26aufirst%3DM.%2BC.%26aulast%3DKoudriakova%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520gut-restricted%2520JAK%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520bowel%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2915%26epage%3D2929%26doi%3D10.1021%2Facs.jmedchem.9b01439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanwar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piplani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, S.</span></span> <span> </span><span class="NLM_article-title">Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis</span>. <i>Asian Pac. J. Cancer Prev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1329</span>– <span class="NLM_lpage">1333</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=21198287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FotlGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1329-1333&author=L.+Tanwarauthor=H.+Piplaniauthor=S.+Sanyal&title=Anti-proliferative+and+apoptotic+effects+of+etoricoxib%2C+a+selective+COX-2+inhibitor%2C+on+1%2C2-dimethylhydrazine+dihydrochloride-induced+colon+carcinogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis</span></div><div class="casAuthors">Tanwar Lalita; Piplani Honit; Sanyal Sn</div><div class="citationInfo"><span class="NLM_cas:title">Asian Pacific journal of cancer prevention : APJCP</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1329-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the present study, we assessed effects of etoricoxib, a non-steroidal anti-inflammatory drug, on proliferation and apoptosis in 1,2-dimethylhydrazine dihydrochloride (DMH) induced colon lesion development.  Male SD rats were divided into four groups: Group 1 controls receiving the vehicle treatment; Group 2 administered DMH weekly (30 mg/kg body weight, subcutaneously) alone; Group 3, DMH weekly plus etoricoxib (0.64 mg/kg body weight, orally) daily; and Group 4, etoricoxib alone.  After six weeks of treatment, animals were sacrificed and colons were analysed for morphological and histopathological features.  Well characterized pre-neoplastic aberrations such as multiple plaque lesions, hyperplasia and dysplasia were found in the DMH treated group whereas these features were reduced with co-administration of etoricoxib.  To study apoptosis, colonocytes were isolated by metal chelation from colonic sacs and studied by fluorescent staining and further confirmed by DNA fragmentation.  The DMH treated animals had fewer apoptotic nuclei as compared to the controls, but numbers were higher with DMH+etoricoxib as well as etoricoxib alone.  Expression of proliferative cell nuclear antigen (PCNA), assessed by Western blot analysis and immunohistochemistry, was found to be elevated by DMH treatment group and again reduced by etoricoxib.  Results for bromodeoxyuridine incorporation (BrdU) were in agreement.  It may be concluded that the drug, etoricoxib, has the potential to act as an anti-apoptotic and anti- proliferative agent in the colon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0e2HGwvlkQvtos8R3JUhXfW6udTcc2eYjehswE27GlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FotlGqsQ%253D%253D&md5=280c999372ebedfd43b8cdafaca558b7</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTanwar%26aufirst%3DL.%26aulast%3DPiplani%26aufirst%3DH.%26aulast%3DSanyal%26aufirst%3DS.%26atitle%3DAnti-proliferative%2520and%2520apoptotic%2520effects%2520of%2520etoricoxib%252C%2520a%2520selective%2520COX-2%2520inhibitor%252C%2520on%25201%252C2-dimethylhydrazine%2520dihydrochloride-induced%2520colon%2520carcinogenesis%26jtitle%3DAsian%2520Pac.%2520J.%2520Cancer%2520Prev.%26date%3D2010%26volume%3D11%26spage%3D1329%26epage%3D1333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Miedany, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youssef, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Gaafary, M.</span></span> <span> </span><span class="NLM_article-title">The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1111/j.1572-0241.2006.00384.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1111%2Fj.1572-0241.2006.00384.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16454836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28XitFSgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2006&pages=311-317&author=Y.+El%0AMiedanyauthor=S.+Youssefauthor=I.+Ahmedauthor=M.+El+Gaafary&title=The+gastrointestinal+safety+and+effect+on+disease+activity+of+etoricoxib%2C+a+selective+cox-2+inhibitor+in+inflammatory+bowel+diseases&doi=10.1111%2Fj.1572-0241.2006.00384.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases</span></div><div class="casAuthors">El Miedany, Yasser; Youssef, Sally; Ahmed, Ihab; El Gaafary, Maha</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">While traditional nonsteroidal antiinflammatory drugs (t-NSAIDs) are relatively contraindicated in patients with inflammatory bowel disease (IBD) for fear of disease aggravation, controlled clin. trials showed that cyclo-oxygenase-2 inhibitors have fewer gastrointestinal side effects than the t-NSAIDs.  Etoricoxib is a new antiinflammatory inhibitor that has high Cox-2 selectivity.  To assess the safety of etoricoxib and effect on disease activity in patients with IBD in a multicenter, double-blind, placebo-control study.  Study group included 76 patients suffering from IBD (ulcerative colitis (DC), and Crohn's disease (CD)).  The control group included 70 patients known to have UC and CD.  Patients of both groups were referred to the rheumatol. clinic for rheumatic manifestations that require antiinflammatory therapy and were intolerable to the t-NSAIDs.  The level of the IBD activity at the baseline visit, when drug/placebo therapy was initiated, was scored for all subjects included in the study.  In the study group the dose of etoricoxib ranged from 60 to 120 mg tablet once a day according to their rheumatic condition.  The control group received a placebo tablet once a day.  Adverse events related to the use of the study medication in 1 and 3 mo time were documented.  Etoricoxib/placebo therapy was stopped once the patient experience flare up of their IBD.  There was no significant difference between the patients and the control groups.  After 3 mo of etoricoxib therapy, 8 of 76 (10.53%) of the study group had aggravation of their underlying IBD and stopped the drug therapy, while 68 of 76 (89.5%) completed the study.  The mean disease activity index before etoricoxib therapy was 1.15 + 0.794, whereas it was 1.19 + 0.683 after therapy.  In the control group 8 of 70 (11.43%) experienced exacerbation of their symptoms while 62 of 70 (88.6%) completed the study.  In the control group the mean disease activity before treatment was 1.16 + 0.253, whereas after placebo therapy was 1.20 + 0.481.  Six-seven of 76 (88.2%) of the study group and 62 of 70 (88.6%) of the control group gave history of using t-NSAID therapy in addn. to PPI that caused flare up of their IBD.  For the patients who had to stop their drug therapy, all the adverse events occurred in the first month of drug/placebo challenge and all symptoms were reversible.  Etoricoxib therapy is safe and beneficial in most patients with IBD treatment with etoricoxib was not assocd. with exacerbation of the underlying IBD- and GI-related complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7mYyZQNQXWrVg90H21EOLACvtfcHk0lhZsrbiJd9zlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitFSgtrw%253D&md5=f848fd270519bbeef45c06488c4144bc</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fj.1572-0241.2006.00384.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1572-0241.2006.00384.x%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BMiedany%26aufirst%3DY.%26aulast%3DYoussef%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DI.%26aulast%3DEl%2BGaafary%26aufirst%3DM.%26atitle%3DThe%2520gastrointestinal%2520safety%2520and%2520effect%2520on%2520disease%2520activity%2520of%2520etoricoxib%252C%2520a%2520selective%2520cox-2%2520inhibitor%2520in%2520inflammatory%2520bowel%2520diseases%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2006%26volume%3D101%26spage%3D311%26epage%3D317%26doi%3D10.1111%2Fj.1572-0241.2006.00384.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G.</span>; <span class="NLM_string-name">Suarez, J.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Connolly, P.</span>; <span class="NLM_string-name">Ahn, K.</span></span> <span> </span><span class="NLM_article-title">Potent phenylpyridine and oxodihydrofuran inhibitors of cyclooxygenase-2: optimization towards long residence time with balanced internal energetics</span>.  <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, in press.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=32930576" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=G.+Tian&author=J.+Suarez&author=Z.+Zhang&author=P.+Connolly&author=K.+Ahn&title=Potent+phenylpyridine+and+oxodihydrofuran+inhibitors+of+cyclooxygenase-2%3A+optimization+towards+long+residence+time+with+balanced+internal+energetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DG.%26atitle%3DPotent%2520phenylpyridine%2520and%2520oxodihydrofuran%2520inhibitors%2520of%2520cyclooxygenase-2%253A%2520optimization%2520towards%2520long%2520residence%2520time%2520with%2520balanced%2520internal%2520energetics%26jtitle%3DBiochemistry%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00936.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1111%2Fj.1476-5381.2010.00936.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=20880390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=488-508&author=G.+Vauquelinauthor=S.+J.+Charlton&title=Long-lasting+target+binding+and+rebinding+as+mechanisms+to+prolong+in+vivo+drug+action&doi=10.1111%2Fj.1476-5381.2010.00936.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span></div><div class="casAuthors">Vauquelin, Georges; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-508</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  An increasing no. of examples in the literature suggest that the in vivo duration of drug action not only depends on macroscopic pharmacokinetic properties like plasma half-life and the time needed to equilibrate between the plasma and the effect compartments, but is also influenced by long-lasting target binding and rebinding.  The present review combines information from different research areas and simulations to explore the nature of these mechanisms and the conditions in which they are most prevalent.  Simulations reveal that these latter phenomena become esp. influential when there is no longer sufficient free drug around to maintain high levels of receptor occupancy.  There is not always a direct link between slow dissocn. and long-lasting in vivo target protection, as the rate of free drug elimination from the effect compartment is also a key influencing factor.  Local phenomena that hinder the diffusion of free drug mols. away from their target may allow them to consecutively bind to the same target and/or targets nearby (denoted as 'rebinding') even when their concn. in the bulk phase has already dropped to insignificant levels.  The micro-anat. properties of many effect compartments are likely to intensify this phenomenon.  By mimicking the complexity of tissues, intact cells offer the opportunity to investigate both mechanisms under the same, physiol. relevant conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzSGNmKeaTzrVg90H21EOLACvtfcHk0lhZsrbiJd9zlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE&md5=bd91e09a0fd79a2de6bf9ef0cfd3443e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00936.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00936.x%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DLong-lasting%2520target%2520binding%2520and%2520rebinding%2520as%2520mechanisms%2520to%2520prolong%2520in%2520vivo%2520drug%2520action%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D488%26epage%3D508%26doi%3D10.1111%2Fj.1476-5381.2010.00936.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krey, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Situ, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandvik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido-Rios, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighton, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganeshappa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abhyankar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinschek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panes, J.</span></span> <span> </span><span class="NLM_article-title">Development of gut-selective pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme</span>. <i>J. Crohns Colitis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1202</span>– <span class="NLM_lpage">1213</span>, <span class="refDoi"> DOI: 10.1093/ecco-jcc/jjaa049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1093%2Fecco-jcc%2Fjjaa049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=32161949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BB383isVartQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=1202-1213&author=W.+J.+Sandbornauthor=D.+D.+Nguyenauthor=D.+T.+Beattieauthor=P.+Brassilauthor=W.+Kreyauthor=J.+Wooauthor=E.+Situauthor=R.+Sanaauthor=E.+Sandvikauthor=M.+T.+Pulido-Riosauthor=R.+Bhandariauthor=J.+A.+Leightonauthor=R.+Ganeshappaauthor=D.+L.+Boyleauthor=B.+Abhyankarauthor=M.+A.+Kleinschekauthor=R.+A.+Grahamauthor=J.+Panes&title=Development+of+gut-selective+pan-Janus+kinase+inhibitor+TD-1473+for+ulcerative+colitis%3A+a+translational+medicine+programme&doi=10.1093%2Fecco-jcc%2Fjjaa049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme</span></div><div class="casAuthors">Sandborn William J; Nguyen Deanna D; Beattie David T; Brassil Patrick; Krey Whitney; Woo Jacky; Situ Eva; Sana Reuben; Sandvik Erik; Pulido-Rios M Teresa; Kleinschek Melanie A; Graham Richard A; Bhandari Raj; Leighton Jonathan A; Ganeshappa Ravi; Boyle David L; Abhyankar Brihad; Panes Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Crohn's & colitis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1202-1213</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND AIMS:  Oral systemic pan-Janus kinase [JAK] inhibition is effective for ulcerative colitis [UC] but is limited by toxicities.  We describe preclinical to clinical translation of TD-1473-an oral gut-selective pan-JAK inhibitor-from in vitro characterization through a Phase 1b study in patients with UC.  METHODS:  TD-1473 JAK inhibition potency was evaluated in vitro; plasma pharmacokinetics, safety and efficacy were assessed in mice.  In a first-time-in-human study, plasma pharmacokinetics and safety were assessed after single and multiple [14 days] ascending doses administered orally to healthy subjects.  The Phase 1b study randomized patients with moderately to severely active UC to receive once-daily oral TD-1473 20, 80 or 270 mg, or placebo for 28 days.  Plasma and colonic tissue concentrations were measured; safety was assessed; and efficacy was evaluated by UC clinical parameters, disease-surrogate biomarkers, endoscopy, histology and colonic tissue JAK signalling.  RESULTS:  TD-1473 exhibited potent pan-JAK inhibitory activity in vitro.  Oral TD-1473 administration to mice achieved high, biologically active colonic tissue concentrations with low plasma exposure and decreased oxazolone-induced colitis activity without reducing blood cell counts vs placebo.  TD-1473 administration in healthy human subjects and patients with UC yielded low plasma exposure and was generally well tolerated; treatment in patients with UC resulted in biologically active colonic tissue concentrations and descriptive trends toward reduced clinical, endoscopic and histological disease activity vs placebo.  CONCLUSION:  Gut-selective pan-JAK inhibition with TD-1473 administration resulted in high intestinal vs plasma drug exposure, local target engagement, and trends toward reduced UC disease activity. [Clinicaltrials.gov NCT02657122, NCT02818686].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfnFMNcI5A1mK_SFaaT9INfW6udTcc2ebqfamZD3Aiobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383isVartQ%253D%253D&md5=d954d19b2d5f046326ae7608a6e01180</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjaa049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjaa049%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DNguyen%26aufirst%3DD.%2BD.%26aulast%3DBeattie%26aufirst%3DD.%2BT.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DKrey%26aufirst%3DW.%26aulast%3DWoo%26aufirst%3DJ.%26aulast%3DSitu%26aufirst%3DE.%26aulast%3DSana%26aufirst%3DR.%26aulast%3DSandvik%26aufirst%3DE.%26aulast%3DPulido-Rios%26aufirst%3DM.%2BT.%26aulast%3DBhandari%26aufirst%3DR.%26aulast%3DLeighton%26aufirst%3DJ.%2BA.%26aulast%3DGaneshappa%26aufirst%3DR.%26aulast%3DBoyle%26aufirst%3DD.%2BL.%26aulast%3DAbhyankar%26aufirst%3DB.%26aulast%3DKleinschek%26aufirst%3DM.%2BA.%26aulast%3DGraham%26aufirst%3DR.%2BA.%26aulast%3DPanes%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520gut-selective%2520pan-Janus%2520kinase%2520inhibitor%2520TD-1473%2520for%2520ulcerative%2520colitis%253A%2520a%2520translational%2520medicine%2520programme%26jtitle%3DJ.%2520Crohns%2520Colitis.%26date%3D2020%26volume%3D14%26spage%3D1202%26epage%3D1213%26doi%3D10.1093%2Fecco-jcc%2Fjjaa049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plount
Price, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Analysis of binding affinities for celecoxib analogues with COX-1 and COX-2 from combined docking and monte carlo simulations and insight into the COX-2/COX-1 Selectivity</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">9455</span>– <span class="NLM_lpage">9466</span>, <span class="refDoi"> DOI: 10.1021/ja001018c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja001018c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=9455-9466&author=M.+L.+Plount%0APriceauthor=W.+L.+Jorgensen&title=Analysis+of+binding+affinities+for+celecoxib+analogues+with+COX-1+and+COX-2+from+combined+docking+and+monte+carlo+simulations+and+insight+into+the+COX-2%2FCOX-1+Selectivity&doi=10.1021%2Fja001018c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fja001018c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja001018c%26sid%3Dliteratum%253Aachs%26aulast%3DPlount%2BPrice%26aufirst%3DM.%2BL.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DAnalysis%2520of%2520binding%2520affinities%2520for%2520celecoxib%2520analogues%2520with%2520COX-1%2520and%2520COX-2%2520from%2520combined%2520docking%2520and%2520monte%2520carlo%2520simulations%2520and%2520insight%2520into%2520the%2520COX-2%252FCOX-1%2520Selectivity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D9455%26epage%3D9466%26doi%3D10.1021%2Fja001018c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graneto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamper, J. R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlitz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurumbail, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maziasz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talley, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, J.</span></span> <span> </span><span class="NLM_article-title">The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">7159</span>– <span class="NLM_lpage">7163</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2Fj.bmcl.2010.07.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=20709553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7159-7163&author=J.+L.+Wangauthor=D.+Limburgauthor=M.+J.+Granetoauthor=J.+Springerauthor=J.+R.+B.+Hamperauthor=S.+Liaoauthor=J.+L.+Pawlitzauthor=R.+G.+Kurumbailauthor=T.+Maziaszauthor=J.+J.+Talleyauthor=J.+R.+Kieferauthor=J.+Carter&title=The+novel+benzopyran+class+of+selective+cyclooxygenase-2+inhibitors.+Part+2%3A+the+second+clinical+candidate+having+a+shorter+and+favorable+human+half-life&doi=10.1016%2Fj.bmcl.2010.07.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life</span></div><div class="casAuthors">Wang, Jane L.; Limburg, David; Graneto, Matthew J.; Springer, John; Hamper, Joseph Rogier Bruce; Liao, Subo; Pawlitz, Jennifer L.; Kurumbail, Ravi G.; Maziasz, Timothy; Talley, John J.; Kiefer, James R.; Carter, Jeffery</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7159-7163</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this Letter, we provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data for a series of selective COX-2 inhibitors.  During the course of our structure-based drug design efforts, we discovered two distinct binding modes within the COX-2 active site for differently substituted members of this class.  The challenge of a undesirably long human half-life for the first clin. candidate 1 t 1/2 = 360 h was addressed by multiple strategies, leading to the discovery of 29b-(S) (SC-75416) with t 1/2 = 34 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3MuS8lF7TabVg90H21EOLACvtfcHk0lgEUZYk9W60TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtb7O&md5=63eb8c45901f27b6d94669e834b26f95</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.054%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BL.%26aulast%3DLimburg%26aufirst%3DD.%26aulast%3DGraneto%26aufirst%3DM.%2BJ.%26aulast%3DSpringer%26aufirst%3DJ.%26aulast%3DHamper%26aufirst%3DJ.%2BR.%2BB.%26aulast%3DLiao%26aufirst%3DS.%26aulast%3DPawlitz%26aufirst%3DJ.%2BL.%26aulast%3DKurumbail%26aufirst%3DR.%2BG.%26aulast%3DMaziasz%26aufirst%3DT.%26aulast%3DTalley%26aufirst%3DJ.%2BJ.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DJ.%26atitle%3DThe%2520novel%2520benzopyran%2520class%2520of%2520selective%2520cyclooxygenase-2%2520inhibitors.%2520Part%25202%253A%2520the%2520second%2520clinical%2520candidate%2520having%2520a%2520shorter%2520and%2520favorable%2520human%2520half-life%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7159%26epage%3D7163%26doi%3D10.1016%2Fj.bmcl.2010.07.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malkowski, M. G.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of rofecoxib bound to human cyclooxygenase-2</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">772</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1107/s2053230x16014230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1107%2FS2053230X16014230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=27710942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1aktrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=772-776&author=B.+J.+Orlandoauthor=M.+G.+Malkowski&title=Crystal+structure+of+rofecoxib+bound+to+human+cyclooxygenase-2&doi=10.1107%2Fs2053230x16014230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of rofecoxib bound to human cyclooxygenase-2</span></div><div class="casAuthors">Orlando, Benjamin J.; Malkowski, Michael G.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">772-776</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Rofecoxib (Vioxx) was one of the first selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) to be approved for use in humans.  Within five years after its release to the public, Vioxx was withdrawn from the market owing to the adverse cardiovascular effects of the drug.  Despite the widespread knowledge of the development and withdrawal of Vioxx, relatively little is known at the mol. level about how the inhibitor binds to COX-2.  Vioxx is unique in that the inhibitor contains a Me sulfone moiety in place of the sulfonamide moiety found in other coxibs such as celecoxib and valdecoxib.  Here, new crystn. conditions were identified that allowed the structural detn. of human COX-2 in complex with Vioxx and the structure was subsequently detd. to 2.7 Å resoln.  The crystal structure provides the first at. level details of the binding of Vioxx to COX-2.  As anticipated, Vioxx binds with its Me sulfone moiety located in the side pocket of the cyclooxygenase channel, providing support for the isoform selectivity of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOl7fUeSagZrVg90H21EOLACvtfcHk0lgEUZYk9W60TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1aktrrK&md5=43095603b1bd2dc112b6fb3990ee056e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1107%2FS2053230X16014230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X16014230%26sid%3Dliteratum%253Aachs%26aulast%3DOrlando%26aufirst%3DB.%2BJ.%26aulast%3DMalkowski%26aufirst%3DM.%2BG.%26atitle%3DCrystal%2520structure%2520of%2520rofecoxib%2520bound%2520to%2520human%2520cyclooxygenase-2%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2016%26volume%3D72%26spage%3D772%26epage%3D776%26doi%3D10.1107%2Fs2053230x16014230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. L.</span></span> <span> </span><span class="NLM_article-title">A cyclooxygenase-2-dependent prostaglandin E2 biosynthetic system in the Golgi apparatus</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">5606</span>– <span class="NLM_lpage">5620</span>, <span class="refDoi"> DOI: 10.1074/jbc.m114.632463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1074%2Fjbc.M114.632463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=25548276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsF2nurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=5606-5620&author=C.+Yuanauthor=W.+L.+Smith&title=A+cyclooxygenase-2-dependent+prostaglandin+E2+biosynthetic+system+in+the+Golgi+apparatus&doi=10.1074%2Fjbc.m114.632463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A Cyclooxygenase-2-dependent Prostaglandin E2 Biosynthetic System in the Golgi Apparatus</span></div><div class="casAuthors">Yuan, Chong; Smith, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5606-5620</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cyclooxygenases (COXs) catalyze the committed step in prostaglandin (PG) biosynthesis.  COX-1 is constitutively expressed and stable, whereas COX-2 is inducible and short lived.  COX-2 is degraded via endoplasmic reticulum (ER)-assocd. degrdn. (ERAD) following post-translational glycosylation of Asn-594.  COX-1 and COX-2 are found in abundance on the luminal surfaces of the ER and inner membrane of the nuclear envelope.  Using confocal immunocytofluorescence, we detected both COX-2 and microsomal PGE synthase-1 (mPGES-1) but not COX-1 in the Golgi app.  Inhibition of trafficking between the ER and Golgi retarded COX-2 ERAD.  COX-2 has a C-terminal STEL sequence, which is an inefficient ER retention signal.  Substituting this sequence with KDEL, a robust ER retention signal, concd. COX-2 in the ER where it was stable and slowly glycosylated on Asn-594.  Native COX-2 and a recombinant COX-2 having a Golgi targeting signal but not native COX-1 exhibited efficient catalytic coupling to mPGES-1.  We conclude that N-glycosylation of Asn-594 of COX-2 occurs in the ER, leading to anterograde movement of COX-2 to the Golgi where the Asn-594-linked glycan is trimmed prior to retrograde COX-2 transport to the ER for ERAD.  Having an inefficient ER retention signal leads to sluggish Golgi to ER transit of COX-2.  This permits significant Golgi residence time during which COX-2 can function catalytically.  Cytosolic phospholipase A2α, which mobilizes arachidonic acid for PG synthesis, preferentially translocates to the Golgi in response to physiol. Ca2+ mobilization.  We propose that cytosolic phospholipase A2α, COX-2, and mPGES-1 in the Golgi comprise a dedicated system for COX-2-dependent PGE2 biosynthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSs0vog1ec2LVg90H21EOLACvtfcHk0lhd1OejR_J20A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsF2nurk%253D&md5=20c3616bdc0f950b6a5cd77f50f8a178</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.632463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.632463%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DW.%2BL.%26atitle%3DA%2520cyclooxygenase-2-dependent%2520prostaglandin%2520E2%2520biosynthetic%2520system%2520in%2520the%2520Golgi%2520apparatus%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D5606%26epage%3D5620%26doi%3D10.1074%2Fjbc.m114.632463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Troberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sneitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosorin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagström, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finel, M.</span></span> <span> </span><span class="NLM_article-title">Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.059303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1124%2Fdmd.114.059303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=25301937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=107-118&author=J.+Trobergauthor=E.+J%C3%A4rvinenauthor=M.+Munizauthor=N.+Sneitzauthor=J.+Mosorinauthor=M.+Hagstr%C3%B6mauthor=M.+Finel&title=Dog+UDP-glucuronosyltransferase+enzymes+of+subfamily+1A%3A+cloning%2C+expression%2C+and+activity&doi=10.1124%2Fdmd.114.059303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity</span></div><div class="casAuthors">Troberg, Johanna; Jarvinen, Erkka; Muniz, Maria; Sneitz, Nina; Mosorin, Johanna; Hagstrom, Marja; Finel, Moshe</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-118, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Understanding drug glucuronidation in the dog, a preclin. animal, is important but currently poorly characterized at the level of individual enzymes.  We have constructed cDNAs for the 10 dog UDP-glucuronosyltransferases of subfamily 1A (dUGT1As), expressed them in insect cells, and assayed their activity as well as the activity of the nine human UGT1As, toward 14 compds.  The goal was to find out whether individual dUGT1As and individual human UGT1As have similar substrate specificities.  The results revealed similarities but also many differences.  For example, similarly to the human UGT1A10, dUGT1A11 exhibited high glucuronidation activity toward the 3-OH of 17-β-estradiol, 17-α-estradiol, and ethinylestradiol, and also conjugated the drug entacapone.  Unlike the human UGT1A10, however, it failed to catalyze considerable rates of R-propranolol, diclofenac, and indomethacin glucuronidation.  The estrogen glucuronidation assays revealed that dUGT1A8 and dUGT1A10 have a capacity to catalyze the formation of (linked) diglucuronides, an activity no human UGT1A exhibited.  DUGT1A2-dUGT1A4 are homologs of the human UGT1A4, but none of them catalyzed N-glucuronidation of dexmedetomidine.  Contrary to the human UGT1A4, however, dUGT1A2-dUGT1A4 catalyzed indomethacin and diclofenac glucuronidation.  It may be concluded that, perhaps with the exception of UGT1A6, high similarities in substrate specificity between individual dog and human UGTs of subfamily 1A are rare or partial.  Activity assays with liver and intestine microsomes of both dog and human further revealed interspecies differences, particularly in glucuronidation rates.  In the dog, the microsomes assays also strongly suggested important roles for dUGTs of other subfamilies, mainly in the liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3TLXzGFFl5rVg90H21EOLACvtfcHk0lhd1OejR_J20A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7jO&md5=ff07227c57d689d3b8b75dc83f962b6e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.059303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.059303%26sid%3Dliteratum%253Aachs%26aulast%3DTroberg%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DE.%26aulast%3DMuniz%26aufirst%3DM.%26aulast%3DSneitz%26aufirst%3DN.%26aulast%3DMosorin%26aufirst%3DJ.%26aulast%3DHagstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DFinel%26aufirst%3DM.%26atitle%3DDog%2520UDP-glucuronosyltransferase%2520enzymes%2520of%2520subfamily%25201A%253A%2520cloning%252C%2520expression%252C%2520and%2520activity%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D107%26epage%3D118%26doi%3D10.1124%2Fdmd.114.059303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haston, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimble, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peppard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintavalla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toscano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, P. J.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fsj.bjp.0706078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=15655513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVOmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2005&pages=538-550&author=R.+Esserauthor=C.+Berryauthor=Z.+Duauthor=J.+Dawsonauthor=A.+Foxauthor=R.+A.+Fujimotoauthor=W.+Hastonauthor=E.+F.+Kimbleauthor=J.+Koehlerauthor=J.+Peppardauthor=E.+Quadrosauthor=J.+Quintavallaauthor=K.+Toscanoauthor=L.+Urbanauthor=J.+van+Duzerauthor=X.+Zhangauthor=S.+Zhouauthor=P.+J.+Marshall&title=Preclinical+pharmacology+of+lumiracoxib%3A+a+novel+selective+inhibitor+of+cyclooxygenase-2&doi=10.1038%2Fsj.bjp.0706078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2</span></div><div class="casAuthors">Esser, Ronald; Berry, Carol; Du, Zhengming; Dawson, Janet; Fox, Alyson; Fujimoto, Roger A.; Haston, William; Kimble, Earl F.; Koehler, Julie; Peppard, Jane; Quadros, Elizabeth; Quintavalla, Joseph; Toscano, Karen; Urban, Laszlo; van Duzer, John; Zhang, Xiaoli; Zhou, Siyuan; Marshall, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">538-550</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This manuscript presents the preclin. profile of lumiracoxib, a novel cyclooxygenase-2 (COX-2) selective inhibitor.  Lumiracoxib inhibited purified COX-1 and COX-2 with Ki values of 3 and 0.06 μM, resp.  In cellular assays, lumiracoxib had an IC50 of 0.14 μM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concns. up to 30 μM (HEK 293 cells transfected with human COX-1).  In a human whole blood assay, IC50 values for lumiracoxib were 0.13 μM for COX-2 and 67 μM for COX-1 (COX-1/COX-2 selectivity ratio 515).  Lumiracoxib was rapidly absorbed following oral administration in rats with peak plasma levels being reached between 0.5 and 1 h.  Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B2 (TxB2) generation with an ID50 of 33 mg kg-1, whereas COX-2-derived prodn. of prostaglandin E2 (PGE2) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID50 value of 0.24 mg kg-1.  Efficacy of lumiracoxib in rat models of hyperalgesia, edema, pyresis and arthritis was dose-dependent and similar to diclofenac.  However, consistent with its low COX-1 inhibitory activity, lumiracoxib at a dose of 100 mg kg-1 orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).  Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the ref. NSAID, but with much improved gastrointestinal safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGFkSVhj6hjbVg90H21EOLACvtfcHk0lhd1OejR_J20A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVOmsbk%253D&md5=c56dbbee7e3bc394087d2cc450c24d47</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706078%26sid%3Dliteratum%253Aachs%26aulast%3DEsser%26aufirst%3DR.%26aulast%3DBerry%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DFox%26aufirst%3DA.%26aulast%3DFujimoto%26aufirst%3DR.%2BA.%26aulast%3DHaston%26aufirst%3DW.%26aulast%3DKimble%26aufirst%3DE.%2BF.%26aulast%3DKoehler%26aufirst%3DJ.%26aulast%3DPeppard%26aufirst%3DJ.%26aulast%3DQuadros%26aufirst%3DE.%26aulast%3DQuintavalla%26aufirst%3DJ.%26aulast%3DToscano%26aufirst%3DK.%26aulast%3DUrban%26aufirst%3DL.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DMarshall%26aufirst%3DP.%2BJ.%26atitle%3DPreclinical%2520pharmacology%2520of%2520lumiracoxib%253A%2520a%2520novel%2520selective%2520inhibitor%2520of%2520cyclooxygenase-2%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D144%26spage%3D538%26epage%3D550%26doi%3D10.1038%2Fsj.bjp.0706078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span> <span> </span><span class="NLM_article-title">LC-MS/MS assay for the simultaneous quantitation of thromboxane B2 and prostaglandin E2 to evaluate cyclooxygenase inhibition in human whole blood</span>. <i>J. Appl. Bioanal.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.17145/jab.20.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.17145%2Fjab.20.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1GmtLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=131-144&author=Y.+Shiauthor=H.+E.+Murreyauthor=K.+Ahnauthor=N.+Wengauthor=S.+Patel&title=LC-MS%2FMS+assay+for+the+simultaneous+quantitation+of+thromboxane+B2+and+prostaglandin+E2+to+evaluate+cyclooxygenase+inhibition+in+human+whole+blood&doi=10.17145%2Fjab.20.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">LC-MS/MS assay for the simultaneous quantitation of thromboxane B2 and prostaglandin E2 to evaluate cyclooxygenase inhibition in human whole blood</span></div><div class="casAuthors">Shi, Yifan; Murrey, Heather E.; Ahn, Kay; Weng, Naidong; Patel, Shefali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Bioanalysis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-144</span>CODEN:
                <span class="NLM_cas:coden">JABODF</span>;
        ISSN:<span class="NLM_cas:issn">2405-710X</span>.
    
            (<span class="NLM_cas:orgname">Betasciencepress Publishing</span>)
        </div><div class="casAbstract">Objectives: A high-throughput LC-MS method for TXB2 and PGE2 was developed for human whole blood assay for COX inhibition.  Methods: A surrogate analyte approach was used for the quantitation of TXB2 and PGE2 by LC-MS.  Fifty microliters plasma was processed using solidphase extn.  TXB2-d4 and PGE2-d4 were used as surrogate analytes.  The calibration curves were established for TXB2 from 0.1 to 500 ng/mL and for PGE2 from 0.05 to 500 ng/mL.  TXB1 was used as internal std.  Results: The response factor and parallelism between surrogate and authentic analyte were verified.  Heparinized whole blood assay for COX inhibition was optimized for sample pretreatment, stimulant concn. and incubation time.  Conclusion: The LC-MS assay was successfully used to analyze inhibitory activity of four com. available COX inhibitors.  The presented method offers a sensitive, high throughput and low-cost alternative to ELISA for human whole blood assay for COX inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoodLQBsztKc7Vg90H21EOLACvtfcHk0linOMSAIpVlRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1GmtLrF&md5=ab3155d7669e1992e42a84a333077e19</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.17145%2Fjab.20.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17145%252Fjab.20.014%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DMurrey%26aufirst%3DH.%2BE.%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DWeng%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DS.%26atitle%3DLC-MS%252FMS%2520assay%2520for%2520the%2520simultaneous%2520quantitation%2520of%2520thromboxane%2520B2%2520and%2520prostaglandin%2520E2%2520to%2520evaluate%2520cyclooxygenase%2520inhibition%2520in%2520human%2520whole%2520blood%26jtitle%3DJ.%2520Appl.%2520Bioanal.%26date%3D2020%26volume%3D6%26spage%3D131%26epage%3D144%26doi%3D10.17145%2Fjab.20.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heijink, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleibeuker, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagengast, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosterhuis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koornstra, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G. E.</span></span> <span> </span><span class="NLM_article-title">Total abdominal 18F-FDG uptake reflects intestinal adenoma burden in Apc mutant mice</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.2967/jnumed.110.083956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.2967%2Fjnumed.110.083956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=21321272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BC3M3hsVGgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=431-436&author=D.+M.+Heijinkauthor=J.+H.+Kleibeukerauthor=W.+B.+Nagengastauthor=D.+Oosterhuisauthor=A.+H.+Brouwersauthor=J.+J.+Koornstraauthor=S.+de+Jongauthor=E.+G.+E.+de+Vries&title=Total+abdominal+18F-FDG+uptake+reflects+intestinal+adenoma+burden+in+Apc+mutant+mice&doi=10.2967%2Fjnumed.110.083956"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Total abdominal 18F-FDG uptake reflects intestinal adenoma burden in Apc mutant mice</span></div><div class="casAuthors">Heijink Dianne M; Kleibeuker Jan H; Nagengast Wouter B; Oosterhuis Dorenda; Brouwers Adrienne H; Koornstra Jan J; de Jong Steven; de Vries Elisabeth G E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">431-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Apc mutant (Apc(Min)) mice develop multiple adenomas in their intestines and are widely used to study colorectal carcinogenesis and chemopreventive approaches.  Molecular imaging of intestinal adenomas could potentially provide noninvasive longitudinal evaluation of these lesions in living mice.  Therefore, the aim of this study was to investigate the role of (18)F-FDG PET in the Apc(Min) mouse model.  METHODS:  Apc(Min) mice (n = 8) fed a purified diet were imaged serially after injection of (18)F-FDG at age 9 and 12 wk using a small-animal PET scanner.  Abdominal uptake of the tracer was quantified.  After dissection, intestines were imaged separately, and intestinal tracer uptake was quantified.  Tracer distribution was compared with results from microscopic examination regarding adenoma number and size.  Thereafter, findings were validated serially in 20 Apc(Min) mice aged 6, 8, 10, and 12 wk that received standard chow to increase adenoma numbers.  In vivo abdominal (18)F-FDG uptake was correlated with microscopy results.  RESULTS:  Microscopic examination showed that the mice developed 25-35 intestinal adenomas at age 12 wk.  Ex vivo (18)F-FDG PET of the dissected intestines visualized all large adenomas and most small adenomas.  Ex vivo total intestinal (18)F-FDG uptake correlated with in vivo total abdominal uptake and with the number of large adenomas at age 9 and 12 wk.  At 12 wk, there was a clear correlation between in vivo abdominal tracer uptake and the number of large adenomas but not the total number of lesions.  CONCLUSION:  Intestinal adenomas in Apc(Min) mice are metabolically active lesions that take up (18)F-FDG.  Abdominal (18)F-FDG uptake at age 12 wk serves as a readout modality for large intestinal adenomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhSdcYVQxSi6x48Rj5GnGofW6udTcc2eaI_2eKsalLFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3hsVGgtw%253D%253D&md5=364983634028a7a108a7ca13fc8f89ef</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.110.083956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.110.083956%26sid%3Dliteratum%253Aachs%26aulast%3DHeijink%26aufirst%3DD.%2BM.%26aulast%3DKleibeuker%26aufirst%3DJ.%2BH.%26aulast%3DNagengast%26aufirst%3DW.%2BB.%26aulast%3DOosterhuis%26aufirst%3DD.%26aulast%3DBrouwers%26aufirst%3DA.%2BH.%26aulast%3DKoornstra%26aufirst%3DJ.%2BJ.%26aulast%3Dde%2BJong%26aufirst%3DS.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%2BE.%26atitle%3DTotal%2520abdominal%252018F-FDG%2520uptake%2520reflects%2520intestinal%2520adenoma%2520burden%2520in%2520Apc%2520mutant%2520mice%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2011%26volume%3D52%26spage%3D431%26epage%3D436%26doi%3D10.2967%2Fjnumed.110.083956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka-Kogo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onouchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimomura, A.</span></span> <span> </span><span class="NLM_article-title">Adenomatous polyposis coli (APC) plays multiple roles in the intestinal and colorectal epithelia</span>. <i>Med. Mol. Morphol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1007/s00795-006-0352-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1007%2Fs00795-006-0352-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=17572842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD2szlvFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=68-81&author=T.+Sendaauthor=A.+Iizuka-Kogoauthor=T.+Onouchiauthor=A.+Shimomura&title=Adenomatous+polyposis+coli+%28APC%29+plays+multiple+roles+in+the+intestinal+and+colorectal+epithelia&doi=10.1007%2Fs00795-006-0352-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Adenomatous polyposis coli (APC) plays multiple roles in the intestinal and colorectal epithelia</span></div><div class="casAuthors">Senda Takao; Iizuka-Kogo Akiko; Onouchi Takanori; Shimomura Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Medical molecular morphology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">68-81</span>
        ISSN:<span class="NLM_cas:issn">1860-1480</span>.
    </div><div class="casAbstract">The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis and in most sporadic colorectal tumors.  During both embryonic and postnatal periods, APC is widely expressed in a variety of tissues, including the brain and gastrointestinal tract.  The APC gene product (APC) is a large multidomain protein consisting of 2843 amino acids.  APC downregulates the Wnt signaling pathway through its binding to beta-catenin and Axin.  Most mutated APC proteins in colorectal tumors lack the beta-catenin-binding regions and fail to inhibit Wnt signaling, leading to the overproliferation of tumor cells.  Several mouse models (APC580D, APCDelta716, APC1309, APCMin, APC1638T) have been established to investigate carcinogenesis caused by APC mutations.  APC also binds to APC-stimulated guanine nucleotide exchange factor, the kinesin superfamily-associated protein 3, IQGAP1, microtubules, EB1, and discs large (DLG).  APC has both nuclear localization signals and nuclear export signals in its molecule, suggesting its occasional nuclear localization and export of beta-catenin from the nucleus.  APC is highly expressed in the intestinal and colorectal epithelia and may be involved in homeostasis of the enterocyte renewal phenomena, in which proliferation, migration, differentiation, and apoptosis are highly regulated both temporally and spatially.  Through the many binding proteins mentioned, APC can exert multiple functions involved in epithelial homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-4MRnRLUCxEPI-fCgwosgfW6udTcc2eaI_2eKsalLFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szlvFCjtQ%253D%253D&md5=a4470cce4b39a3eb09296bbfafa1459c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs00795-006-0352-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00795-006-0352-5%26sid%3Dliteratum%253Aachs%26aulast%3DSenda%26aufirst%3DT.%26aulast%3DIizuka-Kogo%26aufirst%3DA.%26aulast%3DOnouchi%26aufirst%3DT.%26aulast%3DShimomura%26aufirst%3DA.%26atitle%3DAdenomatous%2520polyposis%2520coli%2520%2528APC%2529%2520plays%2520multiple%2520roles%2520in%2520the%2520intestinal%2520and%2520colorectal%2520epithelia%26jtitle%3DMed.%2520Mol.%2520Morphol.%26date%3D2007%26volume%3D40%26spage%3D68%26epage%3D81%26doi%3D10.1007%2Fs00795-006-0352-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickaryous, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, A.</span></span> <span> </span><span class="NLM_article-title">Apc mice: models, modifiers and mutants</span>. <i>Pathol., Res. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1016/j.prp.2008.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2Fj.prp.2008.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=18538487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD1cvks1ajtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2008&pages=479-490&author=A.+E.+McCartauthor=N.+K.+Vickaryousauthor=A.+Silver&title=Apc+mice%3A+models%2C+modifiers+and+mutants&doi=10.1016%2Fj.prp.2008.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Apc mice: models, modifiers and mutants</span></div><div class="casAuthors">McCart Amy E; Vickaryous Nicola K; Silver Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Pathology, research and practice</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">479-90</span>
        ISSN:<span class="NLM_cas:issn">0344-0338</span>.
    </div><div class="casAbstract">The mouse provides an excellent in vivo system with which to model human diseases and to test therapies.  Mutations in the Adenomatous polyposis coli (APC) gene are required to initiate familial adenomatous polyposis (FAP) and are also important in sporadic colorectal cancer tumorigenesis.  The (multiple intestinal neoplasia Min) mouse contains a point mutation in the Apc gene, develops numerous adenomas and was the first model used to study the involvement of the Apc gene in intestinal tumorigenesis.  The model has provided examples of modifying loci (called Modifiers of Min: Mom) in mice, demonstrating the principle of genetic modulation of disease severity.  A spectrum of Apc mutant mice has since been developed, each with defining characteristics, some more able to accurately model human polyposis and colon cancer.  We will focus our review on Apc mutant mouse models, the advent of models with concurrent or compound mutations and the importance of genetic background when modeling polyposis and cancer.  Brief consideration will be given to the use of these models in drug testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuLqm-nKM-kNbHMBt0mMIXfW6udTcc2ebDsjhG0k4bWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvks1ajtQ%253D%253D&md5=cf1f5603d54884e41710a3392b549e99</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.prp.2008.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prp.2008.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DMcCart%26aufirst%3DA.%2BE.%26aulast%3DVickaryous%26aufirst%3DN.%2BK.%26aulast%3DSilver%26aufirst%3DA.%26atitle%3DApc%2520mice%253A%2520models%252C%2520modifiers%2520and%2520mutants%26jtitle%3DPathol.%252C%2520Res.%2520Pract.%26date%3D2008%26volume%3D204%26spage%3D479%26epage%3D490%26doi%3D10.1016%2Fj.prp.2008.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corpet, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span> <span> </span><span class="NLM_article-title">How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2005.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2Fj.ejca.2005.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16084718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslyitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=1911-1922&author=D.+E.+Corpetauthor=F.+Pierre&title=How+good+are+rodent+models+of+carcinogenesis+in+predicting+efficacy+in+humans%3F+A+systematic+review+and+meta-analysis+of+colon+chemoprevention+in+rats%2C+mice+and+men&doi=10.1016%2Fj.ejca.2005.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men</span></div><div class="casAuthors">Corpet, Denis E.; Pierre, Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1911-1922</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumors in rodent and human colon share many histol. and genetic features.  To know if rodent models of colon carcinogenesis are good predictors of chemopreventive efficacy in humans, we conducted a meta-anal. of aspirin, β-carotene, calcium, and wheat bran studies.  Controlled intervention studies of adenoma recurrence in human volunteers were compared with chemoprevention studies of carcinogen-induced tumors in rats, and of polyps in Min (Apc(+/-)) mice: 6714 volunteers, 3911 rats and 458 mice were included in the meta-analyses.  Difference between models was small since most global relative risks were between 0.76 and 1.00.  A closer look showed that carcinogen-induced rat studies matched human trials for aspirin, calcium, carotene, and were compatible for wheat bran.  Min mice results were compatible with human results for aspirin, but discordant for calcium and wheat bran (no carotene study).  These few results suggest that rodent models roughly predict effect in humans, but the prediction is not accurate for all agents.  Based on three cases only, the carcinogen-induced rat model seems better than the Min mouse model.  However, rodent studies are useful to screen potential chemopreventive agents, and to study mechanisms of carcinogenesis and chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH3KBhHmna9LVg90H21EOLACvtfcHk0lhELLFsPAdlDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslyitrk%253D&md5=dea93026b2eff3a750356b347210f3bb</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2005.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2005.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DCorpet%26aufirst%3DD.%2BE.%26aulast%3DPierre%26aufirst%3DF.%26atitle%3DHow%2520good%2520are%2520rodent%2520models%2520of%2520carcinogenesis%2520in%2520predicting%2520efficacy%2520in%2520humans%253F%2520A%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520colon%2520chemoprevention%2520in%2520rats%252C%2520mice%2520and%2520men%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D1911%26epage%3D1922%26doi%3D10.1016%2Fj.ejca.2005.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacoby, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelloff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubet, R. A.</span></span> <span> </span><span class="NLM_article-title">The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5040</span>– <span class="NLM_lpage">5044</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11016626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntVamtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=5040-5044&author=R.+F.+Jacobyauthor=K.+Seibertauthor=C.+E.+Coleauthor=G.+Kelloffauthor=R.+A.+Lubet&title=The+cyclooxygenase-2+inhibitor+celecoxib+is+a+potent+preventive+and+therapeutic+agent+in+the+min+mouse+model+of+adenomatous+polyposis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis</span></div><div class="casAuthors">Jacoby, Russell F.; Seibert, Karen; Cole, Carolyn E.; Kelloff, Gary; Lubet, Ronald A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5040-5044</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidemiol. and animal studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce colon cancer risk.  NSAIDs nonselectively inhibit both the constitutive cyclooxygenase (COX) 1 assocd. with side effects and the desired therapeutic target COX-2, which is induced in inflammation and neoplasia.  We used the adenomatous polyposis coli (Apc) mutant Min mouse model to det. whether the selective COX-2 inhibitor celecoxib is effective for adenoma prevention and/or regression, and whether it might be safer than the nonselective NSAID previously shown to be most effective in this model, piroxicam.  Min mice (n = 120) were randomized to treatment with celecoxib (0, 150, 500, or 1500 ppm celecoxib mixed in the diet) or piroxicam.  To distinguish prevention from regression effects, groups were treated either "early" (before adenomas develop) or "late" (after most adenomas are established).  Celecoxib caused dramatic redns. in both the multiplicity and size of tumors in a dose-dependent manner (P < 0.01).  Early treatment with 1500 ppm of celecoxib was effective for prevention, decreasing tumor multiplicity to 29% and tumor size to only 17% of controls (P < 0.01).  Late treatment demonstrated regression effects, reducing tumor multiplicity and size by about half.  In contrast to the significant toxicity of piroxicam, which caused ulcers complicated by perforation and bleeding, celecoxib caused no gastrointestinal side effects and did not inhibit platelet thromboxane B2 at plasma drug levels similar to those obtained in early clin. trials in humans.  These results provide the first evidence that selective inhibitors of COX-2 are safe and effective for the prevention and regression of adenomas in a mouse model of adenomatous polyposis and strongly support ongoing clin. trials in humans with the same syndrome.  The broader population of patients with common sporadic adenomas that have somatic mutations of the same gene (APC) may also benefit from this treatment approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCWIaZxzkH37Vg90H21EOLACvtfcHk0lhELLFsPAdlDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntVamtLs%253D&md5=8b63c8502278215654f1215c981beb65</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJacoby%26aufirst%3DR.%2BF.%26aulast%3DSeibert%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DC.%2BE.%26aulast%3DKelloff%26aufirst%3DG.%26aulast%3DLubet%26aufirst%3DR.%2BA.%26atitle%3DThe%2520cyclooxygenase-2%2520inhibitor%2520celecoxib%2520is%2520a%2520potent%2520preventive%2520and%2520therapeutic%2520agent%2520in%2520the%2520min%2520mouse%2520model%2520of%2520adenomatous%2520polyposis%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D5040%26epage%3D5044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wieder, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lordick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummeny, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siewer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, W. A.</span></span> <span> </span><span class="NLM_article-title">Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2029</span>– <span class="NLM_lpage">2034</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16330567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=2029-2034&author=H.+A.+Wiederauthor=A.+J.+Beerauthor=F.+Lordickauthor=K.+Ottauthor=M.+Fischerauthor=E.+J.+Rummenyauthor=S.+Zieglerauthor=J.+R.+Siewerauthor=M.+Schwaigerauthor=W.+A.+Weber&title=Comparison+of+changes+in+tumor+metabolic+activity+and+tumor+size+during+chemotherapy+of+adenocarcinomas+of+the+esophagogastric+junction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction</span></div><div class="casAuthors">Wieder, Hinrich A.; Beer, Ambros J.; Lordick, Florian; Ott, Katja; Fischer, Michael; Rummeny, Ernst J.; Ziegler, Sibylle; Siewer, Joerg R.; Schwaiger, Markus; Weber, Wolfgang A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2029-2034</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">We evaluated the temporal relationship between chemotherapy-induced changes in tumor glucose use and tumor size.  Methods: Twenty patients with adenocarcinoma of the esophagogastric junction (AEG) were studied by 18F-FDG PET and CT scans before neoadjuvant chemotherapy, 14 d after the initiation of therapy, and 4 wk after the completion of therapy.  Results: The relative change in 18F-FDG uptake was more than 2 times larger than the decrease in tumor size at all time points (P < 0.01).  At 14 d after the initiation of chemotherapy, there was no correlation between the redn. in 18F-FDG uptake and tumor wall thickness.  The change in 18F-FDG uptake after 14 d of therapy was significantly correlated with the redn. in tumor size after the completion of therapy.  Conclusion: In AEG, changes in tumor metab. are a more sensitive parameter for assessing the effects of chemotherapy than are changes in tumor size.  Early changes in metabolic activity predict the subsequent redn. in tumor size.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroiwJywC8BirVg90H21EOLACvtfcHk0ljxiUdb1VJEBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVSrsQ%253D%253D&md5=45a50c535b2b5825c653c88f6665339c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWieder%26aufirst%3DH.%2BA.%26aulast%3DBeer%26aufirst%3DA.%2BJ.%26aulast%3DLordick%26aufirst%3DF.%26aulast%3DOtt%26aufirst%3DK.%26aulast%3DFischer%26aufirst%3DM.%26aulast%3DRummeny%26aufirst%3DE.%2BJ.%26aulast%3DZiegler%26aufirst%3DS.%26aulast%3DSiewer%26aufirst%3DJ.%2BR.%26aulast%3DSchwaiger%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DW.%2BA.%26atitle%3DComparison%2520of%2520changes%2520in%2520tumor%2520metabolic%2520activity%2520and%2520tumor%2520size%2520during%2520chemotherapy%2520of%2520adenocarcinomas%2520of%2520the%2520esophagogastric%2520junction%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2005%26volume%3D46%26spage%3D2029%26epage%3D2034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egashira, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi-Yanaga, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arioka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomooka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabeppu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaguri, T.</span></span> <span> </span><span class="NLM_article-title">Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">108</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1111/cas.13106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1111%2Fcas.13106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=27761963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKnu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=108-115&author=I.+Egashiraauthor=F.+Takahashi-Yanagaauthor=R.+Nishidaauthor=M.+Ariokaauthor=K.+Igawaauthor=K.+Tomookaauthor=Y.+Nakatsuauthor=T.+Tsuzukiauthor=Y.+Nakabeppuauthor=T.+Kitazonoauthor=T.+Sasaguri&title=Celecoxib+and+2%2C5-dimethylcelecoxib+inhibit+intestinal+cancer+growth+by+suppressing+the+Wnt%2F%CE%B2-catenin+signaling+pathway&doi=10.1111%2Fcas.13106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway</span></div><div class="casAuthors">Egashira, Issei; Takahashi-Yanaga, Fumi; Nishida, Risa; Arioka, Masaki; Igawa, Kazunobu; Tomooka, Katsuhiko; Nakatsu, Yoshimichi; Tsuzuki, Teruhisa; Nakabeppu, Yusaku; Kitazono, Takanari; Sasaguri, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">108-115</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We previously reported that celecoxib, a selective COX-2 inhibitor, strongly inhibited human colon cancer cell proliferation by suppressing the Wnt/β-catenin signaling pathway. 2,5-Dimethylcelecoxib (DM-celecoxib), a celecoxib analog that does not inhibit COX-2, has also been reported to have an antitumor effect.  In the present study, we elucidated whether DM-celecoxib inhibits intestinal cancer growth, and its underlying mechanism of action.  First, we compared the effect of DM-celecoxib with that of celecoxib on the human colon cancer cell lines HCT-116 and DLD-1. 2,5-Dimethylcelecoxib suppressed cell proliferation and inhibited T-cell factor 7-like 2 expression with almost the same strength as celecoxib. 2,5-Dimethylcelecoxib also inhibited the T-cell factor-dependent transcription activity and suppressed the expression of Wnt/β-catenin target gene products cyclin D1 and survivin.  Subsequently, we compared the in vivo effects of celecoxib and DM-celecoxib using the Mutyh-/- mouse model, in which oxidative stress induces multiple intestinal carcinomas.  Serum concns. of orally administered celecoxib and DM-celecoxib elevated to the levels enough to suppress cancer cell proliferation.  Repeated treatment with celecoxib and DM-celecoxib markedly reduced the no. and size of the carcinomas without showing toxicity.  These results suggest that the central mechanism for the anticancer effect of celecoxib derivs. is the suppression of the Wnt/β-catenin signaling pathway but not the inhibition of COX-2, and that DM-celecoxib might be a better lead compd. candidate than celecoxib for the development of novel anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbu-BBe6MiirVg90H21EOLACvtfcHk0ljxiUdb1VJEBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKnu7zJ&md5=8852e33d3a40bed0706e1dfa4a6b5c73</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fcas.13106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13106%26sid%3Dliteratum%253Aachs%26aulast%3DEgashira%26aufirst%3DI.%26aulast%3DTakahashi-Yanaga%26aufirst%3DF.%26aulast%3DNishida%26aufirst%3DR.%26aulast%3DArioka%26aufirst%3DM.%26aulast%3DIgawa%26aufirst%3DK.%26aulast%3DTomooka%26aufirst%3DK.%26aulast%3DNakatsu%26aufirst%3DY.%26aulast%3DTsuzuki%26aufirst%3DT.%26aulast%3DNakabeppu%26aufirst%3DY.%26aulast%3DKitazono%26aufirst%3DT.%26aulast%3DSasaguri%26aufirst%3DT.%26atitle%3DCelecoxib%2520and%25202%252C5-dimethylcelecoxib%2520inhibit%2520intestinal%2520cancer%2520growth%2520by%2520suppressing%2520the%2520Wnt%252F%25CE%25B2-catenin%2520signaling%2520pathway%26jtitle%3DCancer%2520Sci.%26date%3D2017%26volume%3D108%26spage%3D108%26epage%3D115%26doi%3D10.1111%2Fcas.13106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montrose, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sue, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yantiss, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leve, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoly, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suen, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benezra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamer, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannenberg, A. J.</span></span> <span> </span><span class="NLM_article-title">Celecoxib alters the intestinal microbiota and metabolome in association with reducing polyp burden</span>. <i>Cancer Prev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1158/1940-6207.capr-16-0095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1158%2F1940-6207.CAPR-16-0095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=27432344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyju73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=721-731&author=D.+C.+Montroseauthor=X.+K.+Zhouauthor=E.+M.+McNallyauthor=E.+Sueauthor=R.+K.+Yantissauthor=S.+S.+Grossauthor=N.+D.+Leveauthor=E.+D.+Karolyauthor=C.+S.+Suenauthor=L.+Lingauthor=R.+Benezraauthor=E.+G.+Pamerauthor=A.+J.+Dannenberg&title=Celecoxib+alters+the+intestinal+microbiota+and+metabolome+in+association+with+reducing+polyp+burden&doi=10.1158%2F1940-6207.capr-16-0095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden</span></div><div class="casAuthors">Montrose, David C.; Zhou, Xi Kathy; McNally, Erin M.; Sue, Erika; Yantiss, Rhonda K.; Gross, Steven S.; Leve, Nitai D.; Karoly, Edward D.; Suen, Chen S.; Ling, Lilan; Benezra, Robert; Pamer, Eric G.; Dannenberg, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Prevention Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">721-731</span>CODEN:
                <span class="NLM_cas:coden">CPRACC</span>;
        ISSN:<span class="NLM_cas:issn">1940-6207</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Treatment with celecoxib, a selective COX-2 inhibitor, reduces formation of premalignant adenomatous polyps in the gastrointestinal tracts of humans and mice.  In addn. to its chemopreventive activity, celecoxib can exhibit antimicrobial activity.  Differing bacterial profiles have been found in feces from colon cancer patients compared with those of normal subjects.  Moreover, preclin. studies suggest that bacteria can modulate intestinal tumorigenesis by secreting specific metabolites.  In the current study, we detd. whether celecoxib treatment altered the luminal microbiota and metabolome in assocn. with reducing intestinal polyp burden in mice.  Administration of celecoxib for 10 wk markedly reduced intestinal polyp burden in APCMin/+ mice.  Treatment with celecoxib also altered select luminal bacterial populations in both APCMin/+ and wild-type mice, including decreased Lactobacillaceae and Bifidobacteriaceae as well as increased Coriobacteriaceae.  Metabolomic anal. demonstrated that celecoxib caused a strong redn. in many fecal metabolites linked to carcinogenesis, including glucose, amino acids, nucleotides, and lipids.  Ingenuity Pathway Anal. suggested that these changes in metabolites may contribute to reduced cell proliferation.  To this end, we showed that celecoxib reduced cell proliferation in the base of normal appearing ileal and colonic crypts of APCMin/+ mice.  Consistent with this finding, lineage tracing indicated that celecoxib treatment reduced the rate at which Lgr5-pos. stem cells gave rise to differentiated cell types in the crypts.  Taken together, these results demonstrate that celecoxib alters the luminal microbiota and metabolome along with reducing epithelial cell proliferation in mice.  We hypothesize that these actions contribute to its chemopreventive activity.  Cancer Prev Res; 9(9); 721-31. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPJQWx8cqn7bVg90H21EOLACvtfcHk0ljxiUdb1VJEBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyju73K&md5=215d84e8c53026a9b74a862dc86cab0f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F1940-6207.CAPR-16-0095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1940-6207.CAPR-16-0095%26sid%3Dliteratum%253Aachs%26aulast%3DMontrose%26aufirst%3DD.%2BC.%26aulast%3DZhou%26aufirst%3DX.%2BK.%26aulast%3DMcNally%26aufirst%3DE.%2BM.%26aulast%3DSue%26aufirst%3DE.%26aulast%3DYantiss%26aufirst%3DR.%2BK.%26aulast%3DGross%26aufirst%3DS.%2BS.%26aulast%3DLeve%26aufirst%3DN.%2BD.%26aulast%3DKaroly%26aufirst%3DE.%2BD.%26aulast%3DSuen%26aufirst%3DC.%2BS.%26aulast%3DLing%26aufirst%3DL.%26aulast%3DBenezra%26aufirst%3DR.%26aulast%3DPamer%26aufirst%3DE.%2BG.%26aulast%3DDannenberg%26aufirst%3DA.%2BJ.%26atitle%3DCelecoxib%2520alters%2520the%2520intestinal%2520microbiota%2520and%2520metabolome%2520in%2520association%2520with%2520reducing%2520polyp%2520burden%26jtitle%3DCancer%2520Prev.%2520Res.%26date%3D2016%26volume%3D9%26spage%3D721%26epage%3D731%26doi%3D10.1158%2F1940-6207.capr-16-0095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brideau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschênes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesen, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riendeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.-C.</span></span> <span> </span><span class="NLM_article-title">2-Heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1720</span>, <span class="refDoi"> DOI: 10.1016/s0960-894x(99)00264-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2FS0960-894X%2899%2900264-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10397507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADyaK1MXktVCis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=1715-1720&author=D.+Dub%C3%A9author=C.+Brideauauthor=D.+Desch%C3%AAnesauthor=R.+Fortinauthor=R.+W.+Friesenauthor=R.+Gordonauthor=Y.+Girardauthor=D.+Riendeauauthor=C.+Savoieauthor=C.-C.+Chan&title=2-Heterosubstituted-3-%284-methylsulfonyl%29phenyl-5-trifluoromethyl+pyridines+as+selective+and+orally+active+cyclooxygenase-2+inhibitors&doi=10.1016%2Fs0960-894x%2899%2900264-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">2-Heterosubstituted 3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)pyridines as selective and orally active cyclooxygenase-2 inhibitors</span></div><div class="casAuthors">Dube, Daniel; Brideau, Christine; Deschenes, Denis; Fortin, Rejean; Friesen, Richard W.; Gordon, Robert; Girard, Yves; Riendeau, Denis; Savoie, Chantal; Chan, Chi-Chung</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1715-1720</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">2-Alkoxy-, 2-(alkylthio)-, and 2-amino-3-[4-(methylsulfonyl)phenyl]pyridines were synthesized and shown to be highly potent and selective cyclooxygenase-2 (COX-2) inhibitors.  Structure-activity relationship studies demonstrated that the pyridine ring substituents play an important role in the COX-2 potency, selectivity vs. the COX-1 enzyme, and oral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_1P4ZDqcdBrVg90H21EOLACvtfcHk0liEq5F8ywtGSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVCis78%253D&md5=9c64d7a78971e5908a914aff6641a788</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900264-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900264-4%26sid%3Dliteratum%253Aachs%26aulast%3DDub%25C3%25A9%26aufirst%3DD.%26aulast%3DBrideau%26aufirst%3DC.%26aulast%3DDesch%25C3%25AAnes%26aufirst%3DD.%26aulast%3DFortin%26aufirst%3DR.%26aulast%3DFriesen%26aufirst%3DR.%2BW.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DGirard%26aufirst%3DY.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DSavoie%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DC.-C.%26atitle%3D2-Heterosubstituted-3-%25284-methylsulfonyl%2529phenyl-5-trifluoromethyl%2520pyridines%2520as%2520selective%2520and%2520orally%2520active%2520cyclooxygenase-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26spage%3D1715%26epage%3D1720%26doi%3D10.1016%2Fs0960-894x%2899%2900264-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drennen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheenstra, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanning, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilder, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">Structural re-engineering of the α-helix mimetic JY-1-106 into small molecules: disruption of the Mcl-1-Bak-BH3 protein-protein interaction with 2,6-di-substituted nicotinates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1002%2Fcmdc.201500461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=26844930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=827-833&author=B.+Drennenauthor=J.+A.+Scheenstraauthor=J.+L.+Yapauthor=L.+Chenauthor=M.+E.+Lanningauthor=B.+M.+Rothauthor=P.+T.+Wilderauthor=S.+Fletcher&title=Structural+re-engineering+of+the+%CE%B1-helix+mimetic+JY-1-106+into+small+molecules%3A+disruption+of+the+Mcl-1-Bak-BH3+protein-protein+interaction+with+2%2C6-di-substituted+nicotinates&doi=10.1002%2Fcmdc.201500461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates</span></div><div class="casAuthors">Drennen, Brandon; Scheenstra, Jacob A.; Yap, Jeremy L.; Chen, Lijia; Lanning, Maryanna E.; Roth, Braden M.; Wilder, Paul T.; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">827-833</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The disruption of aberrant protein-protein interactions (PPIs) with synthetic agents remains a challenging goal in contemporary medicinal chem. but some progress has been made.  One such dysregulated PPI is that between the anti-apoptotic Bcl-2 proteins, including myeloid cell leukemia-1 (Mcl-1), and the α-helical Bcl-2 homol.-3 (BH3) domains of its pro-apoptotic counterparts, such as Bak.  Herein, we describe the discovery of small-mol. inhibitors of the Mcl-1 oncoprotein based on a novel chemotype.  Particularly, re-engineering of our α-helix mimetic JY-1-106 into 2,6-di-substituted nicotinates afforded inhibitors of comparable potencies but with significantly decreased mol. wts.  The most potent inhibitor 2-(benzyloxy)-6-(4-chloro-3,5-dimethylphenoxy)nicotinic acid (1 r: Ki=2.90 μm) likely binds in the p2 pocket of Mcl-1 and engages R263 in a salt bridge through its carboxylic acid, as supported by 2D 1H-15N HSQC NMR data.  Significantly, inhibitors were easily accessed in just four steps, which will facilitate future optimization efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop4jh0-PJZwrVg90H21EOLACvtfcHk0liEq5F8ywtGSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWjtbk%253D&md5=1a9f2e38a7653888b32ceb067a3dc270</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500461%26sid%3Dliteratum%253Aachs%26aulast%3DDrennen%26aufirst%3DB.%26aulast%3DScheenstra%26aufirst%3DJ.%2BA.%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLanning%26aufirst%3DM.%2BE.%26aulast%3DRoth%26aufirst%3DB.%2BM.%26aulast%3DWilder%26aufirst%3DP.%2BT.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DStructural%2520re-engineering%2520of%2520the%2520%25CE%25B1-helix%2520mimetic%2520JY-1-106%2520into%2520small%2520molecules%253A%2520disruption%2520of%2520the%2520Mcl-1-Bak-BH3%2520protein-protein%2520interaction%2520with%25202%252C6-di-substituted%2520nicotinates%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D827%26epage%3D833%26doi%3D10.1002%2Fcmdc.201500461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of celecoxib (<b>1</b>) and etoricoxib (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking model of compound <b>11</b> (balls and sticks) in complex with COX-2 (side chains as sticks and binding pocket depicted as an electrostatic surface map—blue: positive and red: negative potential). Celecoxib (<b>1</b>, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LN1">3LN1</a>) is superimposed as purple sticks for reference.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Evolution of etoricoxib (<b>3</b>) and analogues <b>4–12</b> for local enteric delivery.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Analogues <b>13–20</b> with modifications at R<sup>2</sup> or R<sup>3</sup> on the pyridine ring sites of compound <b>11</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Correlation between cellular PGE<sub>2</sub> COX-2 potency (pIC<sub>50</sub>) and clog <i>P</i> with human COX-2 enzymatic potency (pIC<sub>50</sub>, color coding) [pIC<sub>50</sub> = −log<sub>10</sub> (IC<sub>50</sub> μM)].</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison of the mouse exposure colon/plasma ratio to the colon/PV plasma ratio (both measured at 4 h) in cassette PK following an oral dosing of 10 mg/kg in C57BL mice. All points were color coded in relation to clog <i>P</i>. Logarithmic scale was used on all axes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Analogues <b>21–23</b> as selected representatives with modifications at various sites of compounds <b>11</b> (or <b>10</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Side-by-side comparison of the [<sup>18</sup>F]-FDG PET signal (expressed as average injected dose per gram (% ID/g, 20% threshold) in 2-week curative setting) and polyp area attenuation in APC<sup>Min/+</sup> mice in prophylactic setting (12 weeks) for compound <b>10</b>. Vehicle and celecoxib groups (300 mg/kg/daily in chow diet) served as negative and positive controls, respectively. Analyses were performed in R, version 3.3.2. ANOVA, adjusted for multiple comparisons in a linear regression model. *<i>P</i> < 0.05; **<i>P</i> < 0.01; ***<i>P</i> < 0.001; and ****<i>P</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compounds <b>11</b>, <b>20</b>, and <b>23</b> for [<sup>18</sup>F]-FDG PET in curative setting (dosing in chow diet, mice received daily doses of 3, 10, 30, 100, and 300 mg/kg for 2 weeks from the age of >16 weeks) compared to compound <b>10</b>. <sup>18</sup>F-FDG PET signal expressed as average injected dose per gram (% ID/g, 20% threshold). The percentage injected dose per gram (% ID/g) was calculated as follows: % ID/g = ROI activity divided by injected dose multiplied by 100%. Vehicle and celecoxib (300 mg/kg/daily) served as negative and positive controls, respectively. Analyses were performed in R, version 3.3.2. ANOVA, adjusted for multiple comparisons in a linear regression model. *<i>P</i> < 0.05; **<i>P</i> < 0.01; ***<i>P</i> < 0.001; and ****<i>P</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Oral in vivo efficacy of compound <b>21</b> in prophylactic setting (dosing as a suspension by gavage, mice received doses of 30, 100, and 300 mg/kg for 10 weeks from the age of 5–6 weeks). Celecoxib (300 mg/kg/daily in a suspension by gavage) served as a positive control. Polyp area/number in treatment: One-way ANOVA with Dunnett’s multiple comparison test; polyp number vs polyp size: Two-way ANOVA with Dunnett’s multiple comparison test. GraphPad Prism 7.0.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Compounds <b>5</b>, <b>6</b>, and <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) <i>tert</i>-BuOK, DMF, rt; (b) Pd(dppf)Cl<sub>2</sub> (cat) or Pd(dppf)Cl<sub>2</sub>·DCM (cat), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; (c) Red-Al, THF, rt; (d) NBS, DMF, 70 °C; (e) Pd(dppf)Cl<sub>2</sub> (cat), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; and (f) Pd–C (10%), H<sub>2</sub>, EtOH, rt.</p></p></figure><figure data-id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Compounds <b>8</b> and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) SOCl<sub>2</sub>, DMF, CHCl<sub>3</sub>, 80 °C; (b) CH<sub>3</sub>NHOCH<sub>3</sub>·HCl, TEA, DCM, rt; (c) <i>tert</i>-BuOK, DMF, 60 °C; (d) Br<sub>2</sub>, NaOAc, AcOH, 80 °C; (e) NaBH<sub>4</sub>, MeOH, rt; (f) Pd(dppf)Cl<sub>2</sub> (cat), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 60 °C; and (g) NaH, DMF, rt.</p></p></figure><figure data-id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route for Preparation of Compounds <b>9</b>, <b>10</b>, <b>11</b>, <b>21</b>, and <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) NaH, DMF or THF; (b) Xphos Pd G3 (cat), Cs<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C; (c) NBS, MeCN, rt; (d) Pd(PPh<sub>3</sub>)<sub>4</sub> (cat), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; and (e) BH<sub>3</sub>·THF, THF.</p></p></figure><figure data-id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of Compounds <b>13</b>, <b>14</b>, and <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) BH<sub>3</sub>·THF, THF; (b) Dess–Martin periodinane, DCM, rt; (c) MeMgCl, THF, rt; (d) TMSCHN<sub>2</sub>, MeOH, toluene, rt; (e) MeMgCl, THF, rt; (f) NaH, THF, rt; and (g) LiAlH<sub>4</sub>, THF, 0 °C.</p></p></figure><figure data-id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub> (cat), K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; (b) NBS, TFA, MeCN, rt; (c) Pd(PPh<sub>3</sub>)<sub>4</sub> (cat), K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; and (d) BH<sub>3</sub>·THF, THF.</p></p></figure><figure data-id="sch6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Route for Preparation of Compounds <b>17</b>, <b>18</b>, <b>19</b>, and <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) Xphos Pd G3 (cat), Cs<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C; (b) NBS, AcOH, MeCN, rt; (c) Pd(PPh<sub>3</sub>)<sub>4</sub> (cat), K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 80 °C; and (d) (i) TEA, ClC(═O)O–iBu, THF; then NaBH<sub>4</sub>; or (ii) BH<sub>3</sub>·THF, THF.</p></p></figure><figure data-id="sch7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/medium/jm1c00890_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compound <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00890/20210722/images/large/jm1c00890_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00890&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BH<sub>3</sub>·THF, THF; (b) Pd(dppf)Cl<sub>2</sub> (cat), KOAc, 1,4-dioxane, 100 °C; and (c) Pd(dppf)Cl<sub>2</sub> (cat), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 65 °C.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84727" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84727" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 69 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2021</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.3322/caac.21654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.3322%2Fcaac.21654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=33433946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BB3svptVKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2021&pages=7-33&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=H.+E.+Fuchsauthor=A.+Jemal&title=Cancer+statistics%2C+2021&doi=10.3322%2Fcaac.21654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Statistics, 2021</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Fuchs Hannah E; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence.  Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.  Mortality data (through 2018) were collected by the National Center for Health Statistics.  In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States.  After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment.  This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted.  Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018.  The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall.  This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC).  For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%.  Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_jHscXVnJh1WTCLT8lX9SfW6udTcc2eajgpGKw90UDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3svptVKhuw%253D%253D&md5=c65743e74b28b6c7dd1f912745f3edf1</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21654%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DFuchs%26aufirst%3DH.%2BE.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202021%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2021%26volume%3D71%26spage%3D7%26epage%3D33%26doi%3D10.3322%2Fcaac.21654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fearon, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span> <span> </span><span class="NLM_article-title">A genetic model for colorectal tumorigenesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(90)90186-i</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2F0092-8674%2890%2990186-I" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=2188735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADyaK3cXktlyhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1990&pages=759-767&author=E.+R.+Fearonauthor=B.+Vogelstein&title=A+genetic+model+for+colorectal+tumorigenesis&doi=10.1016%2F0092-8674%2890%2990186-i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A genetic model for colorectal tumorigenesis</span></div><div class="casAuthors">Fearon, Eric R.; Vogelstein, Bert</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">759-67</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">A review with 76 refs. on various genetic aspects of colonic neoplasia, including genetic alterations of oncogenes, clonal selection, allelic losses and tumor suppressor genes, multiple allelic losses, and accumulation and multistep tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe4CC_sLtNt7Vg90H21EOLACvtfcHk0lgI7kMbvRNCMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktlyhtrg%253D&md5=d88588a58ce05a327c3e7ff8afccd3a7</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2890%2990186-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252890%252990186-I%26sid%3Dliteratum%253Aachs%26aulast%3DFearon%26aufirst%3DE.%2BR.%26aulast%3DVogelstein%26aufirst%3DB.%26atitle%3DA%2520genetic%2520model%2520for%2520colorectal%2520tumorigenesis%26jtitle%3DCell%26date%3D1990%26volume%3D61%26spage%3D759%26epage%3D767%26doi%3D10.1016%2F0092-8674%2890%2990186-i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Radtke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clevers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, O.</span></span> <span> </span><span class="NLM_article-title">From gut homeostasis to cancer</span>. <i>Curr. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.2174/156652406776894527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.2174%2F156652406776894527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16712475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=275-289&author=F.+Radtkeauthor=H.+Cleversauthor=O.+Riccio&title=From+gut+homeostasis+to+cancer&doi=10.2174%2F156652406776894527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">From gut homeostasis to cancer</span></div><div class="casAuthors">Radtke, Freddy; Clevers, Hans; Riccio, Orbicia</div><div class="citationInfo"><span class="NLM_cas:title">Current Molecular Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-289</span>CODEN:
                <span class="NLM_cas:coden">CMMUBP</span>;
        ISSN:<span class="NLM_cas:issn">1566-5240</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The mammalian intestine has one of the highest turnover rates in the body.  The intestinal epithelium is completely renewed in less than a week.  It is divided into spatially distinct compartments in the form of finger-like projections and invaginations that are dedicated to specific functions.  Intestinal cells are constantly produced from a stem cell reservoir that gives rise to proliferating transient amplifying cells, which subsequently differentiate and migrate to the correct compartment before dying after having fulfilled their physiol. function.  In recent years, a substantial body of evidence has accumulated to support the concept that signaling pathways known to be crucial for embryonic development of multiple organisms play a crit. role in tightly regulating and controlling the self-renewing process of the intestine.  Moreover, the same pathways appear to be deregulated in several hereditary and sporadic colorectal cancer syndromes due to activating and/or inactivating mutations of key components of such pathways.  In this review we discuss recent findings demonstrating that differentiation and homeostasis of the intestine are controlled by developmental pathways such as Wnt, Notch, TGF-β and Hedgehog, and illustrate how their deregulation contributes to intestinal neoplasia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr97XFU85BmQ7Vg90H21EOLACvtfcHk0litwW-DIEb8Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVGmsbs%253D&md5=abb08789af40370f1ff99b2446e0bb72</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F156652406776894527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156652406776894527%26sid%3Dliteratum%253Aachs%26aulast%3DRadtke%26aufirst%3DF.%26aulast%3DClevers%26aufirst%3DH.%26aulast%3DRiccio%26aufirst%3DO.%26atitle%3DFrom%2520gut%2520homeostasis%2520to%2520cancer%26jtitle%3DCurr.%2520Mol.%2520Med.%26date%3D2006%26volume%3D6%26spage%3D275%26epage%3D289%26doi%3D10.2174%2F156652406776894527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranger, G. S.</span></span> <span> </span><span class="NLM_article-title">Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">6277</span>– <span class="NLM_lpage">6282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=25368225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2jtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=6277-6282&author=G.+S.+Ranger&title=Current+concepts+in+colorectal+cancer+prevention+with+cyclooxygenase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors</span></div><div class="casAuthors">Ranger, Gurpreet Singh</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6277-6282</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  Colorectal cancer is one of the commonest malignancies worldwide.  Recently, there has been much speculation regarding the role of cyclooxygenase-2 (COX-2) suppression in chemoprevention.  Drugs with the ability to inhibit COX-2 expression include aspirin, nonsteroidal anti-inflammatory drugs (NSAID) and selective COX-2 inhibitors.  Any strategy for chemoprevention must be able to quantify how effective the potential treatment is likely to be and which drugs will be most useful.  We would also need to know for how long the agent could be taken safely and if any side-effects could preclude long-term use.  Evidence from observational studies and recent updates of randomised controlled trials have been very encouraging - at least indicating benefit from the long term use of aspirin, even at low dose, with greatest impact on prevention of proximal colon cancers and adenomas.  Most studies do, however, also warn that risks of gastrointestinal bleeding increase with long-term use of aspirin and related drugs.  The risk-to-benefit ratio of a chemoprevention regimen using these medications needs to be carefully examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri3PhG0YSWkLVg90H21EOLACvtfcHk0litwW-DIEb8Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2jtbzK&md5=d6fc0dec50ce1991b351de4e05054c0f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRanger%26aufirst%3DG.%2BS.%26atitle%3DCurrent%2520concepts%2520in%2520colorectal%2520cancer%2520prevention%2520with%2520cyclooxygenase%2520inhibitors%26jtitle%3DAnticancer%2520Res.%26date%3D2014%26volume%3D34%26spage%3D6277%26epage%3D6282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardiello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, P. M.</span></span> <span> </span><span class="NLM_article-title">Chemoprevention of hereditary colon cancers: time for new strategies</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1038/nrgastro.2016.56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fnrgastro.2016.56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=27095653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFCjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=352-361&author=L.+Ricciardielloauthor=D.+J.+Ahnenauthor=P.+M.+Lynch&title=Chemoprevention+of+hereditary+colon+cancers%3A+time+for+new+strategies&doi=10.1038%2Fnrgastro.2016.56"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoprevention of hereditary colon cancers: time for new strategies</span></div><div class="casAuthors">Ricciardiello, Luigi; Ahnen, Dennis J.; Lynch, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">352-361</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Colorectal cancer (CRC) is potentially preventable.  Chemoprevention, a focus of research for the past three decades, aims to prevent or delay the onset of cancer through the regression or prevention of colonic adenomas.  Ideal pharmacol. agents for chemoprevention should be cheap and nontoxic.  Although data indicate that aspirin can reduce the risk of CRC in the general population, the highest return from chemopreventive strategies would be expected in patients with the highest risk of developing the disease, particularly those with a defined hereditary predisposition.  Despite compelling data showing that a large no. of chemopreventive agents show promise in preclin. CRC models, clin. studies have yielded conflicting results.  This Review provides a historical and methodol. perspective of chemoprevention in familial adenomatous polyposis and Lynch syndrome, and summarizes the current status of CRC chemoprevention in humans.  Our goal is to critically focus on important issues of trial design, with particular attention on the choice of appropriate trial end points, how such end points should be measured, and which patients are the ideal candidates to be included in a chemopreventive trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMlS0TequWJrVg90H21EOLACvtfcHk0litwW-DIEb8Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFCjt7o%253D&md5=49a6d6e0287e00f2e3efa8ae7de82ebb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2016.56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2016.56%26sid%3Dliteratum%253Aachs%26aulast%3DRicciardiello%26aufirst%3DL.%26aulast%3DAhnen%26aufirst%3DD.%2BJ.%26aulast%3DLynch%26aufirst%3DP.%2BM.%26atitle%3DChemoprevention%2520of%2520hereditary%2520colon%2520cancers%253A%2520time%2520for%2520new%2520strategies%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2016%26volume%3D13%26spage%3D352%26epage%3D361%26doi%3D10.1038%2Fnrgastro.2016.56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theisen, C.</span></span> <span> </span><span class="NLM_article-title">Chemoprevention: what’s in a name?</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">743</span>, <span class="refDoi"> DOI: 10.1093/jnci/93.10.743</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1093%2Fjnci%2F93.10.743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11353783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD3M3ls1ejsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=743&author=C.+Theisen&title=Chemoprevention%3A+what%E2%80%99s+in+a+name%3F&doi=10.1093%2Fjnci%2F93.10.743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoprevention: What's in a name?</span></div><div class="casAuthors">Theisen C</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">743</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRge04axPApWCsZ1x6zOs0vfW6udTcc2eaT1S6frp74Tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3ls1ejsw%253D%253D&md5=61a3a0a66d255472eaf4cdd7b759c95f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.10.743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.10.743%26sid%3Dliteratum%253Aachs%26aulast%3DTheisen%26aufirst%3DC.%26atitle%3DChemoprevention%253A%2520what%25E2%2580%2599s%2520in%2520a%2520name%253F%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2001%26volume%3D93%26spage%3D743%26doi%3D10.1093%2Fjnci%2F93.10.743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadder, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaguer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüneburg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castells, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallenberg, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinicrope, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strassburg, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Cutsem, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalloo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willingham, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grady, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gryfe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syngal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A.</span></span> <span> </span><span class="NLM_article-title">Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1039</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1916063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJMoa1916063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=32905675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVeisr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2020&pages=1028-1039&author=C.+A.+Burkeauthor=E.+Dekkerauthor=P.+Lynchauthor=N.+J.+Samadderauthor=F.+Balaguerauthor=R.+H%C3%BCneburgauthor=J.+Burnauthor=A.+Castellsauthor=S.+Gallingerauthor=R.+Limauthor=E.+M.+Stoffelauthor=S.+Guptaauthor=A.+Hendersonauthor=F.+G.+Kallenbergauthor=P.+Kanthauthor=V.+H.+Roosauthor=G.+G.+Ginsbergauthor=F.+A.+Sinicropeauthor=C.+P.+Strassburgauthor=E.+van+Cutsemauthor=J.+Churchauthor=F.+Lallooauthor=F.+F.+Willinghamauthor=P.+E.+Wiseauthor=W.+M.+Gradyauthor=M.+Fordauthor=J.+M.+Weissauthor=R.+Gryfeauthor=A.+K.+Rustgiauthor=S.+Syngalauthor=A.+Cohen&title=Eflornithine+plus+sulindac+for+prevention+of+progression+in+familial+adenomatous+polyposis&doi=10.1056%2Fnejmoa1916063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis</span></div><div class="casAuthors">Burke, C. A.; Dekker, E.; Lynch, P.; Samadder, N. J.; Balaguer, F.; Huneburg, R.; Burn, J.; Castells, A.; Gallinger, S.; Lim, R.; Stoffel, E. M.; Gupta, S.; Henderson, A.; Kallenberg, F. G.; Kanth, P.; Roos, V. H.; Ginsberg, G. G.; Sinicrope, F. A.; Strassburg, C. P.; Van Cutsem, E.; Church, J.; Lalloo, F.; Willingham, F. F.; Wise, P. E.; Grady, W. M.; Ford, M.; Weiss, J. M.; Gryfe, R.; Rustgi, A. K.; Syngal, S.; Cohen, A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1028-1039</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The efficacy and safety of combination therapy with eflornithine and sulindac, as compared with either drug alone, in delaying disease progression in patients with familial adenomatous polyposis are unknown.  We evaluated the efficacy and safety of the combination of eflornithine and sulindac, as compared with either drug alone, in adults with familial adenomatous polyposis.  The patients were stratified on the basis of anatomical site with the highest polyp burden and surgical status; the strata were precolectomy (shortest projected time to disease progression), rectal or ileal pouch polyposis after colectomy and duodenal polyposis.  The patients were then randomly assigned in a 1:1:1 ratio to receive 750 mg of eflornithine, 150 mg of sulindac, or both once daily for up to 48 mo.  A total of 171 patients underwent randomization.  Disease progression occurred in 18 of 56 patients (32%) in the eflornithine-sulindac group, 22 of 58 (38%) in the sulindac group, and 23 of 57 (40%) in the eflornithine group, with a hazard ratio of 0.71 for eflornithine-sulindac as compared with sulindac for eflornithine-sulindac as compared with eflornithine.  Adverse and serious adverse events were similar across the treatment groups. conclusions: In this trial involving patients with familial adenomatous polyposis, the incidence of disease progression was not significantly lower with the combination of eflornithine and sulindac than with either drug alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqqma4qG6TKbVg90H21EOLACvtfcHk0ljmjeWbKrDjbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVeisr%252FP&md5=6bf64c2705029dbe62098b0fd68fa2dd</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1916063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1916063%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DC.%2BA.%26aulast%3DDekker%26aufirst%3DE.%26aulast%3DLynch%26aufirst%3DP.%26aulast%3DSamadder%26aufirst%3DN.%2BJ.%26aulast%3DBalaguer%26aufirst%3DF.%26aulast%3DH%25C3%25BCneburg%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DJ.%26aulast%3DCastells%26aufirst%3DA.%26aulast%3DGallinger%26aufirst%3DS.%26aulast%3DLim%26aufirst%3DR.%26aulast%3DStoffel%26aufirst%3DE.%2BM.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DHenderson%26aufirst%3DA.%26aulast%3DKallenberg%26aufirst%3DF.%2BG.%26aulast%3DKanth%26aufirst%3DP.%26aulast%3DRoos%26aufirst%3DV.%2BH.%26aulast%3DGinsberg%26aufirst%3DG.%2BG.%26aulast%3DSinicrope%26aufirst%3DF.%2BA.%26aulast%3DStrassburg%26aufirst%3DC.%2BP.%26aulast%3Dvan%2BCutsem%26aufirst%3DE.%26aulast%3DChurch%26aufirst%3DJ.%26aulast%3DLalloo%26aufirst%3DF.%26aulast%3DWillingham%26aufirst%3DF.%2BF.%26aulast%3DWise%26aufirst%3DP.%2BE.%26aulast%3DGrady%26aufirst%3DW.%2BM.%26aulast%3DFord%26aufirst%3DM.%26aulast%3DWeiss%26aufirst%3DJ.%2BM.%26aulast%3DGryfe%26aufirst%3DR.%26aulast%3DRustgi%26aufirst%3DA.%2BK.%26aulast%3DSyngal%26aufirst%3DS.%26aulast%3DCohen%26aufirst%3DA.%26atitle%3DEflornithine%2520plus%2520sulindac%2520for%2520prevention%2520of%2520progression%2520in%2520familial%2520adenomatous%2520polyposis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D383%26spage%3D1028%26epage%3D1039%26doi%3D10.1056%2Fnejmoa1916063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J. A.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of non-steroidal anti-inflammatory drugs and cancer</span>. <i>Prog. Exp. Tumor Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1159/000071364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1159%2F000071364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=12795046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltlKisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2003&pages=1-24&author=J.+A.+Baron&title=Epidemiology+of+non-steroidal+anti-inflammatory+drugs+and+cancer&doi=10.1159%2F000071364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of non-steroidal anti-inflammatory drugs and cancer</span></div><div class="casAuthors">Baron, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Experimental Tumor Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">COX-2</span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">PEXTAR</span>;
        ISSN:<span class="NLM_cas:issn">0079-6263</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review, discussing epidemiol. of non-steroidal anti-inflammatory drugs and cancer risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppYph-OLsGA7Vg90H21EOLACvtfcHk0ljmjeWbKrDjbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltlKisb4%253D&md5=28dc6dfa17a8f830eefebef794dead67</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1159%2F000071364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000071364%26sid%3Dliteratum%253Aachs%26aulast%3DBaron%26aufirst%3DJ.%2BA.%26atitle%3DEpidemiology%2520of%2520non-steroidal%2520anti-inflammatory%2520drugs%2520and%2520cancer%26jtitle%3DProg.%2520Exp.%2520Tumor%2520Res.%26date%3D2003%26volume%3D37%26spage%3D1%26epage%3D24%26doi%3D10.1159%2F000071364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsertsvadze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrowman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Code, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moher, D.</span></span>; <span class="NLM_contrib-group">U.S. Preventive Services Task Force</span> <span> </span><span class="NLM_article-title">The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-146-5-200703060-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.7326%2F0003-4819-146-5-200703060-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=17339622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD2s7jvFKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2007&pages=365-375&author=C.+Dub%C3%A9author=A.+Rostomauthor=G.+Lewinauthor=A.+Tsertsvadzeauthor=N.+Barrowmanauthor=C.+Codeauthor=M.+Sampsonauthor=D.+Moherauthor=U.S.+Preventive+Services+Task+Force&title=The+use+of+aspirin+for+primary+prevention+of+colorectal+cancer%3A+a+systematic+review+prepared+for+the+U.S.+Preventive+Services+Task+Force&doi=10.7326%2F0003-4819-146-5-200703060-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force</span></div><div class="casAuthors">Dube Catherine; Rostom Alaa; Lewin Gabriela; Tsertsvadze Alexander; Barrowman Nicholas; Code Catherine; Sampson Margaret; Moher David</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Aspirin for prevention of colorectal cancer is controversial.  PURPOSE:  To examine the benefits and harms of aspirin chemoprevention.  DATA SOURCES:  MEDLINE, 1966 to December 2006; EMBASE, 1980 to April 2005; CENTRAL, Cochrane Collaboration's registry of clinical trials; Cochrane Database of Systematic Reviews.  STUDY SELECTION:  Two independent reviewers conducted multilevel screening to identify randomized, controlled trials (RCTs), case-control studies, and cohort studies of aspirin chemoprophylaxis.  For harms, systematic reviews were sought.  DATA EXTRACTION:  In duplicate, data were abstracted and checked and quality was assessed.  DATA SYNTHESIS:  Regular use of aspirin reduced the incidence of colonic adenomas in RCTs (relative risk [RR], 0.82 [95% CI, 0.7 to 0.95]), case-control studies (RR, 0.87 [CI, 0.77 to 0.98]), and cohort studies (RR, 0.72 [CI, 0.61 to 0.85]).  In cohort studies, regular use of aspirin was associated with RR reductions of 22% for incidence of colorectal cancer.  Two RCTs of low-dose aspirin failed to show a protective effect.  Data for colorectal cancer mortality were limited.  Benefits from chemoprevention were more evident when aspirin was used at a high dose and for periods longer than 10 years.  Aspirin use was associated with a dose-related increase in incidence of gastrointestinal complications.  LIMITATIONS:  Important clinical and methodological heterogeneity in the definitions of regular use, dose, and duration of use of aspirin necessitated careful grouping for analysis.  CONCLUSIONS:  Aspirin appears to be effective at reducing the incidence of colonic adenoma and colorectal cancer, especially if used in high doses for more than 10 years.  However, the possible harms of such a practice require careful consideration.  Further evaluation of the cost-effectiveness of chemoprevention compared with, and in combination with, a screening strategy is required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvvW0G13y7DzQLBVDQn4bCfW6udTcc2eYopV9bOhV2lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7jvFKlug%253D%253D&md5=33b3c3e01aa356da0a4e8d1f882bf01b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-146-5-200703060-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-146-5-200703060-00009%26sid%3Dliteratum%253Aachs%26aulast%3DDub%25C3%25A9%26aufirst%3DC.%26aulast%3DRostom%26aufirst%3DA.%26aulast%3DLewin%26aufirst%3DG.%26aulast%3DTsertsvadze%26aufirst%3DA.%26aulast%3DBarrowman%26aufirst%3DN.%26aulast%3DCode%26aufirst%3DC.%26aulast%3DSampson%26aufirst%3DM.%26aulast%3DMoher%26aufirst%3DD.%26aulast%3D%26atitle%3DThe%2520use%2520of%2520aspirin%2520for%2520primary%2520prevention%2520of%2520colorectal%2520cancer%253A%2520a%2520systematic%2520review%2520prepared%2520for%2520the%2520U.S.%2520Preventive%2520Services%2520Task%2520Force%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2007%26volume%3D146%26spage%3D365%26epage%3D375%26doi%3D10.7326%2F0003-4819-146-5-200703060-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rostom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsertsvadze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrowman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Code, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moher, D.</span></span>; <span class="NLM_contrib-group">U.S. Preventive Services Task Force</span> <span> </span><span class="NLM_article-title">Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-146-5-200703060-00010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.7326%2F0003-4819-146-5-200703060-00010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=17339623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD2s7jvFKluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2007&pages=376-389&author=A.+Rostomauthor=C.+Dub%C3%A9author=G.+Lewinauthor=A.+Tsertsvadzeauthor=N.+Barrowmanauthor=C.+Codeauthor=M.+Sampsonauthor=D.+Moherauthor=U.S.+Preventive+Services+Task+Force&title=Nonsteroidal+anti-inflammatory+drugs+and+cyclooxygenase-2+inhibitors+for+primary+prevention+of+colorectal+cancer%3A+a+systematic+review+prepared+for+the+U.S.+Preventive+Services+Task+Force&doi=10.7326%2F0003-4819-146-5-200703060-00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force</span></div><div class="casAuthors">Rostom Alaa; Dube Catherine; Lewin Gabriela; Tsertsvadze Alexander; Barrowman Nicholas; Code Catherine; Sampson Margaret; Moher David</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">376-89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To examine the benefits and harms of nonaspirin (non-ASA) nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX-2) inhibitors for the prevention of colorectal cancer (CRC) and adenoma.  DATA SOURCES:  MEDLINE (1966 to 2006), EMBASE (1980 to 2006), Cochrane Central Register of Controlled Trials, Cochrane Collaboration's registry of clinical trials, Cochrane Database of Systematic Reviews.  STUDY SELECTION:  Randomized, controlled trials and case-control and cohort studies of the effectiveness of NSAIDs for the prevention of CRC and colorectal adenoma were identified by multilevel screening by 2 independent reviewers.  Systematic reviews of harms were sought.  DATA EXTRACTION:  Data abstraction, checking, and quality assessment were completed in duplicate.  DATA SYNTHESIS:  A single cohort study showed no effect of non-ASA NSAIDs on death due to CRC.  Colorectal cancer incidence was reduced with non-ASA NSAIDs in cohort studies (relative risk, 0.61 [95% CI, 0.48 to 0.77]) and case-control studies (relative risk, 0.70 [CI, 0.63 to 0.78]).  Colorectal adenoma incidence was also reduced with non-ASA NSAID use in cohort studies (relative risk, 0.64 [CI, 0.48 to 0.85]) and case-control studies (relative risk, 0.54 [CI, 0.4 to 0.74]) and by COX-2 inhibitors in randomized, controlled trials (relative risk, 0.72 [CI, 0.68 to 0.77]).  The ulcer complication rate associated with non-ASA NSAIDs is 1.5% per year.  Compared with non-ASA NSAIDs, COX-2 inhibitors reduce this risk but, in multiyear use, have a higher ulcer complication rate than placebo.  Cyclooxygenase-2 inhibitors and nonnaproxen NSAIDs increase the risk for serious cardiovascular events (relative risk, 1.86 [CI, 1.33 to 2.59] for COX-2 inhibitors vs. placebo).  LIMITATIONS:  Heterogeneity in the dose, duration and frequency of use necessitated careful grouping for analysis.  CONCLUSIONS:  Cyclooxygenase-2 inhibitors and NSAIDs reduce the incidence of colonic adenomas.  Nonsteroidal anti-inflammatory drugs also reduce the incidence of CRC.  However, these agents are associated with important cardiovascular events and gastrointestinal harms.  The balance of benefits to risk does not favor chemoprevention in average-risk individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvvW0G13y7D8kU0YCbOU3EfW6udTcc2eYopV9bOhV2lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7jvFKluw%253D%253D&md5=ab1c062c621f671f5e0faa0d380f2a17</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-146-5-200703060-00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-146-5-200703060-00010%26sid%3Dliteratum%253Aachs%26aulast%3DRostom%26aufirst%3DA.%26aulast%3DDub%25C3%25A9%26aufirst%3DC.%26aulast%3DLewin%26aufirst%3DG.%26aulast%3DTsertsvadze%26aufirst%3DA.%26aulast%3DBarrowman%26aufirst%3DN.%26aulast%3DCode%26aufirst%3DC.%26aulast%3DSampson%26aufirst%3DM.%26aulast%3DMoher%26aufirst%3DD.%26aulast%3D%26atitle%3DNonsteroidal%2520anti-inflammatory%2520drugs%2520and%2520cyclooxygenase-2%2520inhibitors%2520for%2520primary%2520prevention%2520of%2520colorectal%2520cancer%253A%2520a%2520systematic%2520review%2520prepared%2520for%2520the%2520U.S.%2520Preventive%2520Services%2520Task%2520Force%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2007%26volume%3D146%26spage%3D376%26epage%3D389%26doi%3D10.7326%2F0003-4819-146-5-200703060-00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mecklin, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möslein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McRonald, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertario, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerdes, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindblom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashbass, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seppälä, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pylvänäinen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthwick, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathers, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussioutas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porteous, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Side, L.</span></span>; <span class="NLM_contrib-group">CAPP2 Investigators</span> <span> </span><span class="NLM_article-title">Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1863</span>, <span class="refDoi"> DOI: 10.1016/s0140-6736(20)30366-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2FS0140-6736%2820%2930366-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=32534647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGgsrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1855-1863&author=J.+Burnauthor=H.+Shethauthor=F.+Elliottauthor=L.+Reedauthor=F.+Macraeauthor=J.-P.+Mecklinauthor=G.+M%C3%B6sleinauthor=F.+E.+McRonaldauthor=L.+Bertarioauthor=D.+G.+Evansauthor=A.-M.+Gerdesauthor=J.+W.+C.+Hoauthor=A.+Lindblomauthor=P.+J.+Morrisonauthor=J.+Rashbassauthor=R.+Ramesarauthor=T.+Sepp%C3%A4l%C3%A4author=H.+J.+W.+Thomasauthor=K.+Pylv%C3%A4n%C3%A4inenauthor=G.+M.+Borthwickauthor=J.+C.+Mathersauthor=D.+T.+Bishopauthor=A.+Boussioutasauthor=C.+Brewerauthor=J.+Cookauthor=D.+Ecclesauthor=A.+Ellisauthor=S.+V.+Hodgsonauthor=J.+Lubinskiauthor=E.+R.+Maherauthor=M.+E.+Porteousauthor=J.+Sampsonauthor=R.+J.+Scottauthor=L.+Sideauthor=CAPP2+Investigators&title=Cancer+prevention+with+aspirin+in+hereditary+colorectal+cancer+%28Lynch+syndrome%29%2C+10-year+follow-up+and+registry-based+20-year+data+in+the+CAPP2+study%3A+a+double-blind%2C+randomised%2C+placebo-controlled+trial&doi=10.1016%2Fs0140-6736%2820%2930366-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial</span></div><div class="casAuthors">Burn, John; Sheth, Harsh; Elliott, Faye; Reed, Lynn; Macrae, Finlay; Mecklin, Jukka-Pekka; Moslein, Gabriela; McRonald, Fiona E.; Bertario, Lucio; Evans, D. Gareth; Gerdes, Anne-Marie; Ho, Judy W. C.; Lindblom, Annika; Morrison, Patrick J.; Rashbass, Jem; Ramesar, Raj; Seppala, Toni; Thomas, Huw J. W.; Pylvanainen, Kirsi; Borthwick, Gillian M.; Mathers, John C.; Bishop, D. Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10240</span>),
    <span class="NLM_cas:pages">1855-1863</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lynch syndrome is assocd. with an increased risk of colorectal cancer and with a broader spectrum of cancers, esp. endometrial cancer.  In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 mo [SD 31·4]) for participants with Lynch syndrome enrolled into a randomised trial of daily aspirin vs. placebo.  This report completes the planned 10-yr follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population.  In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centers worldwide (707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [<1%] from The Americas) with Lynch syndrome were randomly assigned to receive 600 mg aspirin daily or placebo.  Cancer outcomes were monitored for at least 10 years from recruitment with English, Finnish, and Welsh participants being monitored for up to 20 years.  The primary endpoint was development of colorectal cancer.  Anal. was by intention to treat and per protocol.  The trial is registered with the ISRCTN registry, no. ISRCTN59521990.  Between Jan., 1999, and March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, commenced treatment, of whom 861 agreed to be randomly assigned to the aspirin group or placebo; 427 (50%) participants received aspirin and 434 (50%) placebo.  Participants were followed for a mean of 10 years approximating 8500 person-years. 40 (9%) of 427 participants who received aspirin developed colorectal cancer compared with 58 (13%) of 434 who received placebo.  Intention-to-treat Cox proportional hazards anal. revealed a significantly reduced hazard ratio (HR) of 0·65 (95% CI 0·43-0·97; p=0·035) for aspirin vs. placebo.  Neg. binomial regression to account for multiple primary events gave an incidence rate ratio of 0·58 (0·39-0·87; p=0·0085).  Per-protocol analyses restricted to 509 who achieved 2 years' intervention gave an HR of 0·56 (0·34-0·91; p=0·019) and an incidence rate ratio of 0·50 (0·31-0·82; p=0·0057).  Non-colorectal Lynch syndrome cancers were reported in 36 participants who received aspirin and 36 participants who received placebo.  Intention-to-treat and per-protocol analyses showed no effect.  For all Lynch syndrome cancers combined, the intention-to-treat anal. did not reach significance but per-protocol anal. showed significantly reduced overall risk for the aspirin group (HR=0·63, 0·43-0·92; p=0·018).  Adverse events during the intervention phase between aspirin and placebo groups were similar, and no significant difference in compliance between intervention groups was obsd. for participants with complete intervention phase data; details reported previously.  The case for prevention of colorectal cancer with aspirin in Lynch syndrome is supported by our results.  Cancer Research UK, European Union, MRC, NIHR, Bayer Pharma AG, Barbour Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2QsSPBQpP_rVg90H21EOLACvtfcHk0lhKKTsLYzDjvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGgsrjI&md5=a11f499bf6be45a8168f927b0bd07433</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930366-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930366-4%26sid%3Dliteratum%253Aachs%26aulast%3DBurn%26aufirst%3DJ.%26aulast%3DSheth%26aufirst%3DH.%26aulast%3DElliott%26aufirst%3DF.%26aulast%3DReed%26aufirst%3DL.%26aulast%3DMacrae%26aufirst%3DF.%26aulast%3DMecklin%26aufirst%3DJ.-P.%26aulast%3DM%25C3%25B6slein%26aufirst%3DG.%26aulast%3DMcRonald%26aufirst%3DF.%2BE.%26aulast%3DBertario%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DD.%2BG.%26aulast%3DGerdes%26aufirst%3DA.-M.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLindblom%26aufirst%3DA.%26aulast%3DMorrison%26aufirst%3DP.%2BJ.%26aulast%3DRashbass%26aufirst%3DJ.%26aulast%3DRamesar%26aufirst%3DR.%26aulast%3DSepp%25C3%25A4l%25C3%25A4%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DH.%2BJ.%2BW.%26aulast%3DPylv%25C3%25A4n%25C3%25A4inen%26aufirst%3DK.%26aulast%3DBorthwick%26aufirst%3DG.%2BM.%26aulast%3DMathers%26aufirst%3DJ.%2BC.%26aulast%3DBishop%26aufirst%3DD.%2BT.%26aulast%3DBoussioutas%26aufirst%3DA.%26aulast%3DBrewer%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DEccles%26aufirst%3DD.%26aulast%3DEllis%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%2BV.%26aulast%3DLubinski%26aufirst%3DJ.%26aulast%3DMaher%26aufirst%3DE.%2BR.%26aulast%3DPorteous%26aufirst%3DM.%2BE.%26aulast%3DSampson%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DR.%2BJ.%26aulast%3DSide%26aufirst%3DL.%26aulast%3D%26atitle%3DCancer%2520prevention%2520with%2520aspirin%2520in%2520hereditary%2520colorectal%2520cancer%2520%2528Lynch%2520syndrome%2529%252C%252010-year%2520follow-up%2520and%2520registry-based%252020-year%2520data%2520in%2520the%2520CAPP2%2520study%253A%2520a%2520double-blind%252C%2520randomised%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1855%26epage%3D1863%26doi%3D10.1016%2Fs0140-6736%2820%2930366-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bresalier, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognese, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxenius, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horgan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loftus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, D. G.</span></span>; <span class="NLM_contrib-group">APPROVe Trial Investigators</span> <span> </span><span class="NLM_article-title">A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1674</span>– <span class="NLM_lpage">1682</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2006.08.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1053%2Fj.gastro.2006.08.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=17087947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2006&pages=1674-1682&author=J.+A.+Baronauthor=R.+S.+Sandlerauthor=R.+S.+Bresalierauthor=H.+Quanauthor=R.+Riddellauthor=A.+Lanasauthor=J.+A.+Bologneseauthor=B.+Oxeniusauthor=K.+Horganauthor=S.+Loftusauthor=D.+G.+Mortonauthor=APPROVe+Trial+Investigators&title=A+randomized+trial+of+rofecoxib+for+the+chemoprevention+of+colorectal+adenomas&doi=10.1053%2Fj.gastro.2006.08.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas</span></div><div class="casAuthors">Baron, John A.; Sandler, Robert S.; Bresalier, Robert S.; Quan, Hui; Riddell, Robert; Lanas, Angel; Bolognese, James A.; Oxenius, Bettina; Horgan, Kevin; Loftus, Susan; Morton, Dion G.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1674-1682</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background & Aims: In human and animal studies, nonsteroidal anti-inflammatory drugs have been assocd. with a reduced risk of colorectal neoplasia.  Although the underlying mechanisms are unknown, inhibition of cyclooxygenase (COX), particularly COX-2, is thought to play a role.  We conducted a randomized, placebo-controlled, double-blind trial to assess whether use of the selective COX-2 inhibitor rofecoxib would reduce the risk of colorectal adenomas.  Methods: We randomized 2587 subjects with a recent history of histol. confirmed adenomas to receive daily placebo or 25 mg rofecoxib.  Randomization was stratified by baseline use of cardioprotective aspirin.  Colonoscopic follow-up evaluation was planned for 1 and 3 years after randomization.  The primary end point was all adenomas diagnosed during 3 years' treatment.  In a modified intent-to-treat anal., we computed the relative risk of any adenoma after randomization, using Mantel-Haenszel statistics stratified by low-dose aspirin use at baseline.  Results: Adenoma recurrence was less frequent for rofecoxib subjects than for those randomized to placebo (41% vs 55%; P < .0001; relative risk [RR], 0.76; 95% confidence interval [CI], 0.69 - 0.83).  Rofecoxib also conferred a redn. in risk of advanced adenomas (P < .01).  The chemopreventive effect was more pronounced in the first year (RR, 0.65; 95% CI, 0.57 - 0.73) than in the subsequent 2 years (RR, 0.81; 95% CI, 0.71 - 0.93).  As reported previously, rofecoxib was assocd. with increased risks of significant upper gastrointestinal events and serious thrombotic cardiovascular events.  Conclusions: In this randomized trial, rofecoxib significantly reduced the risk of colorectal adenomas, but also had serious toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroWzbUDSkG27Vg90H21EOLACvtfcHk0ljD8kGKeWEblA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFyltL8%253D&md5=f510a7e4de6ff726ecd7da7de7396022</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2006.08.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2006.08.079%26sid%3Dliteratum%253Aachs%26aulast%3DBaron%26aufirst%3DJ.%2BA.%26aulast%3DSandler%26aufirst%3DR.%2BS.%26aulast%3DBresalier%26aufirst%3DR.%2BS.%26aulast%3DQuan%26aufirst%3DH.%26aulast%3DRiddell%26aufirst%3DR.%26aulast%3DLanas%26aufirst%3DA.%26aulast%3DBolognese%26aufirst%3DJ.%2BA.%26aulast%3DOxenius%26aufirst%3DB.%26aulast%3DHorgan%26aufirst%3DK.%26aulast%3DLoftus%26aufirst%3DS.%26aulast%3DMorton%26aufirst%3DD.%2BG.%26aulast%3D%26atitle%3DA%2520randomized%2520trial%2520of%2520rofecoxib%2520for%2520the%2520chemoprevention%2520of%2520colorectal%2520adenomas%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D131%26spage%3D1674%26epage%3D1682%26doi%3D10.1053%2Fj.gastro.2006.08.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyooka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketo, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, K.</span></span> <span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4756</span>– <span class="NLM_lpage">4760</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=14581346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVGjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=4756-4760&author=T.+Higuchiauthor=T.+Iwamaauthor=K.+Yoshinagaauthor=M.+Toyookaauthor=M.+M.+Taketoauthor=K.+Sugihara&title=A+randomized%2C+double-blind%2C+placebo-controlled+trial+of+the+effects+of+rofecoxib%2C+a+selective+cyclooxygenase-2+inhibitor%2C+on+rectal+polyps+in+familial+adenomatous+polyposis+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients</span></div><div class="casAuthors">Higuchi, Tetsuro; Iwama, Takeo; Yoshinaga, Keigo; Toyooka, Masahiro; Taketo, Makoto M.; Sugihara, Kenichi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4756-4760</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The aim of this study was to examine the effect of a specific cyclooxygenase-2 inhibitor, rofecoxib, on rectal polyps in familial adenomatous polyposis patients.  E This was a randomized, double-blind, placebo-controlled study of the efficacy and safety of rofecoxib in the rectum.  Initially, 21 patients were assigned randomly in a 1:1 ratio to receive either 25 mg rofecoxib once a day or a placebo p.o. for 9 mo.  Patients underwent endoscopy at the beginning of the study and then every 3 mo thereafter.  We reviewed the videotapes to measure the no. and size of polyps in the same area throughout the study period in each individual patient.  The polyp no., measured as the percentage of change from the baseline values, was significantly decreased in the rofecoxib group at 3, 6, and 9 mo.  At 9 mo, the polyp no. in the rofecoxib group decreased by 6.8% from the baseline values, whereas that in the placebo group increased by 3.1%.  The 9.9% difference between the rofecoxib and placebo groups was statistically significant (P = 0.004).  At 9 mo, the rofecoxib group showed a significant redn. from the baseline in polyp size as compared with the placebo group (-16.2% vs. 1.5%; P < 0.001).  There was no statistically significant increase in the incidence of any adverse events in treatment with rofecoxib compared with placebo (P = 0.922).  In this study, once-daily treatment with 25 mg rofecoxib, a cyclooxygenase 2-specific inhibitor, significantly decreased the no. and size of rectal polyps in familial adenomatous polyposis patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp7t8XSgc4ibVg90H21EOLACvtfcHk0ljD8kGKeWEblA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVGjsLs%253D&md5=2155960fa91e6abca93a9289fa8792dc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHiguchi%26aufirst%3DT.%26aulast%3DIwama%26aufirst%3DT.%26aulast%3DYoshinaga%26aufirst%3DK.%26aulast%3DToyooka%26aufirst%3DM.%26aulast%3DTaketo%26aufirst%3DM.%2BM.%26aulast%3DSugihara%26aufirst%3DK.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520the%2520effects%2520of%2520rofecoxib%252C%2520a%2520selective%2520cyclooxygenase-2%2520inhibitor%252C%2520on%2520rectal%2520polyps%2520in%2520familial%2520adenomatous%2520polyposis%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D4756%26epage%3D4760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eagle, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rácz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dite, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavoral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechuga, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstein, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhadra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zauber, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, B.</span></span>; <span class="NLM_contrib-group">PreSAP Trial Investigators</span> <span> </span><span class="NLM_article-title">Celecoxib for the prevention of colorectal adenomatous polyps</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1056/nejmoa061652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJMoa061652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16943401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28XovFehurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=885-895&author=N.+Arberauthor=C.+J.+Eagleauthor=J.+Spicakauthor=I.+R%C3%A1czauthor=P.+Diteauthor=J.+Hajerauthor=M.+Zavoralauthor=M.+J.+Lechugaauthor=P.+Gerlettiauthor=J.+Tangauthor=R.+B.+Rosensteinauthor=K.+Macdonaldauthor=P.+Bhadraauthor=R.+Fowlerauthor=J.+Wittesauthor=A.+G.+Zauberauthor=S.+D.+Solomonauthor=B.+Levinauthor=PreSAP+Trial+Investigators&title=Celecoxib+for+the+prevention+of+colorectal+adenomatous+polyps&doi=10.1056%2Fnejmoa061652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib for the prevention of colorectal adenomatous polyps</span></div><div class="casAuthors">Arber, Nadir; Eagle, Craig J.; Spicak, Julius; Racz, Istvan; Diet, Petr; Hajer, Jan; Zavoral, Miroslav; Lechuga, Maria J.; Gerletti, Paola; Tang, Jie; Rosenstein, Rebecca B.; Macdonald, Katie; Bhadra, Pritha; Fowler, Robert; Wittes, Janet; Zauber, Ann G.; Solomon, Scott D.; Levin, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">885-895</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Over-expression of cyclooxygenase 2 (COX-2) has been assocd. with colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition as a chemopreventive intervention.  METHODS: The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose.  At 107 centers in 32 countries, we randomly assigned 1561 subjects who had adenomas removed before enrollment to receive celecoxib (933 subjects) or placebo (628 subjects) daily, after stratification according to the use or nonuse of low-dose aspirin.  The primary outcome was detection of adenomas at either year 1 or year 3 by colonoscopy and was compared among the groups with the use of the Mantel-Cox test.  RESULTS: Colonoscopies were performed at year 1 on 88.7 % of the subjects who had under- gone randomization and at year 3 on 79.2 %.  Of the 557 subjects in the placebo group and the 840 subjects in the celecoxib group who were included in the efficacy anal., 264 and 270, resp., were found to have at least one adenoma at year 1, at year 3, or both.  The cumulative rate of adenomas detected through year 3 was 33.6 % in the celecoxib group and 49.3 % in the placebo group (relative risk, 0.64; 95 % confidence interval, 0.56 to 0.75; P < 0.001).  The cumulative rate of advanced adenomas detected through year 3 was 5.3 % in the celecoxib group and 10.4 % in the placebo group (relative risk, 0.49; 95 % confidence interval, 0.33 to 0.73; P < 0.001).  Adjudicated serious cardiovascular events occurred in 2.5 % of subjects in the celecoxib group and 1.9 % of those in the placebo group (relative risk, 1.30; 95 % confidence interval, 0.65 to 2.62).  CONCLUSIONS: The use of 400 mg of celecoxib once daily significantly reduced the occurrence of colorectal adenomas within three years after polypectomy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYauG8XTOtrVg90H21EOLACvtfcHk0ljD8kGKeWEblA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovFehurc%253D&md5=28500d74b851ea3d9b03c3956c2867cb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa061652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa061652%26sid%3Dliteratum%253Aachs%26aulast%3DArber%26aufirst%3DN.%26aulast%3DEagle%26aufirst%3DC.%2BJ.%26aulast%3DSpicak%26aufirst%3DJ.%26aulast%3DR%25C3%25A1cz%26aufirst%3DI.%26aulast%3DDite%26aufirst%3DP.%26aulast%3DHajer%26aufirst%3DJ.%26aulast%3DZavoral%26aufirst%3DM.%26aulast%3DLechuga%26aufirst%3DM.%2BJ.%26aulast%3DGerletti%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DRosenstein%26aufirst%3DR.%2BB.%26aulast%3DMacdonald%26aufirst%3DK.%26aulast%3DBhadra%26aufirst%3DP.%26aulast%3DFowler%26aufirst%3DR.%26aulast%3DWittes%26aufirst%3DJ.%26aulast%3DZauber%26aufirst%3DA.%2BG.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DLevin%26aufirst%3DB.%26aulast%3D%26atitle%3DCelecoxib%2520for%2520the%2520prevention%2520of%2520colorectal%2520adenomatous%2520polyps%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D885%26epage%3D895%26doi%3D10.1056%2Fnejmoa061652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, R. K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawk, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Bigas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jester, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruzzese, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hittelman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelloff, G.</span></span> <span> </span><span class="NLM_article-title">The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1952</span>, <span class="refDoi"> DOI: 10.1056/nejm200006293422603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJM200006293422603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10874062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVCnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2000&pages=1946-1952&author=G.+Steinbachauthor=P.+M.+Lynchauthor=R.+K.+S.+Phillipsauthor=M.+H.+Wallaceauthor=E.+Hawkauthor=G.+B.+Gordonauthor=N.+Wakabayashiauthor=B.+Saundersauthor=Y.+Shenauthor=T.+Fujimuraauthor=L.-K.+Suauthor=B.+Levinauthor=L.+Godioauthor=S.+Pattersonauthor=M.+A.+Rodriguez-Bigasauthor=S.+L.+Jesterauthor=K.+L.+Kingauthor=M.+Schumacherauthor=J.+Abbruzzeseauthor=R.+N.+DuBoisauthor=W.+N.+Hittelmanauthor=S.+Zimmermanauthor=J.+W.+Shermanauthor=G.+Kelloff&title=The+effect+of+celecoxib%2C+a+cyclooxygenase-2+inhibitor%2C+in+familial+adenomatous+polyposis&doi=10.1056%2Fnejm200006293422603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis</span></div><div class="casAuthors">Steinbach, Gideon; Lynch, Patrick M.; Phillips, Robin K. S.; Wallace, Marina H.; Hawk, Ernest; Gordon, Gary B.; Wakabayashi, Naoki; Saunders, Brian; Shen, Yu; Fujimura, Takashi; Su, Li-Kuo; Levin, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">1946-1952</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer.  In this disease, the chemopreventive effects of nonsteroidal antiinflammatory drugs may be related to their inhibition of cyclooxygenase-2.  We studied the effect of celecoxib, a selective cyclooxygenase-2 inhibitor, on colorectal polyps in patients with familial adenomatous polyposis.  In a double-blind, placebo-controlled study, we randomly assigned 77 patients to treatment with celecoxib (100 or 400 mg twice daily) or placebo for six months.  Patients underwent endoscopy at the beginning and end of the study.  We detd. the no. and size of polyps from photographs and videotapes; the response to treatment was expressed as the mean percent change from base line.  At base line, the mean (±SD) no. of polyps in focal areas where polyps were counted was 15.5±13.4 in the 15 patients assigned to placebo, 11.5±8.5 in the 32 patients assigned to 100 mg of celecoxib twice a day, and 12.3±8.2 in the 30 patients assigned to 400 mg of celecoxib twice a day (P = 0.66 for the comparison among groups).  After six months, the patients receiving 400 mg of celecoxib twice a day had a 28.0 percent redn. in the mean no. of colorectal polyps (P = 0.003 for the comparison with placebo) and a 30.7 percent redn. in the polyp burden (the sum of polyp diams.) (P = 0.001), as compared with redns. of 4.5 and 4.9 percent, resp., in the placebo group.  The improvement in the extent of colorectal polyposis in the group receiving 400 mg twice a day was confirmed by a panel of endoscopists who reviewed the videotapes.  The redns. in the group receiving 100 mg of celecoxib twice a day were 11.9 percent (P = 0.33 for the comparison with placebo) and 14.6 percent (P = 0.09), resp.  The incidence of adverse events was similar among the groups.  In patients with familial adenomatous polyposis, six months of twice-daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant redn. in the no. of colorectal polyps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPgVvRxhzKO7Vg90H21EOLACvtfcHk0lgbgw3-gDhpkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVCnu7Y%253D&md5=bb03a12f34d846350fec8e45c1467c82</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJM200006293422603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200006293422603%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbach%26aufirst%3DG.%26aulast%3DLynch%26aufirst%3DP.%2BM.%26aulast%3DPhillips%26aufirst%3DR.%2BK.%2BS.%26aulast%3DWallace%26aufirst%3DM.%2BH.%26aulast%3DHawk%26aufirst%3DE.%26aulast%3DGordon%26aufirst%3DG.%2BB.%26aulast%3DWakabayashi%26aufirst%3DN.%26aulast%3DSaunders%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DL.-K.%26aulast%3DLevin%26aufirst%3DB.%26aulast%3DGodio%26aufirst%3DL.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DRodriguez-Bigas%26aufirst%3DM.%2BA.%26aulast%3DJester%26aufirst%3DS.%2BL.%26aulast%3DKing%26aufirst%3DK.%2BL.%26aulast%3DSchumacher%26aufirst%3DM.%26aulast%3DAbbruzzese%26aufirst%3DJ.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26aulast%3DHittelman%26aufirst%3DW.%2BN.%26aulast%3DZimmerman%26aufirst%3DS.%26aulast%3DSherman%26aufirst%3DJ.%2BW.%26aulast%3DKelloff%26aufirst%3DG.%26atitle%3DThe%2520effect%2520of%2520celecoxib%252C%2520a%2520cyclooxygenase-2%2520inhibitor%252C%2520in%2520familial%2520adenomatous%2520polyposis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D342%26spage%3D1946%26epage%3D1952%26doi%3D10.1056%2Fnejm200006293422603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertagnolli, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eagle, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zauber, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstein, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woloj, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisserie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagheri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruitt, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylwestrowicz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawk, E. T.</span></span>; <span class="NLM_contrib-group">APC Study Investigators</span> <span> </span><span class="NLM_article-title">Celecoxib for the prevention of sporadic colorectal adenomas</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1056/nejmoa061355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJMoa061355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16943400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28XovFaju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=873-884&author=M.+M.+Bertagnolliauthor=C.+J.+Eagleauthor=A.+G.+Zauberauthor=M.+Redstonauthor=S.+D.+Solomonauthor=K.+Kimauthor=J.+Tangauthor=R.+B.+Rosensteinauthor=J.+Wittesauthor=D.+Corleauthor=T.+M.+Hessauthor=G.+M.+Wolojauthor=F.+Boisserieauthor=W.+F.+Andersonauthor=J.+L.+Vinerauthor=D.+Bagheriauthor=J.+Burnauthor=D.+C.+Chungauthor=T.+Dewarauthor=T.+R.+Foleyauthor=N.+Hoffmanauthor=F.+Macraeauthor=R.+E.+Pruittauthor=J.+R.+Saltzmanauthor=B.+Salzbergauthor=T.+Sylwestrowiczauthor=G.+B.+Gordonauthor=E.+T.+Hawkauthor=APC+Study+Investigators&title=Celecoxib+for+the+prevention+of+sporadic+colorectal+adenomas&doi=10.1056%2Fnejmoa061355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib for the prevention of sporadic colorectal adenomas</span></div><div class="casAuthors">Bertagnolli, Monica M.; Eagle, Craig J.; Zauber, Ann G.; Redston, Mark; Solomon, Scott D.; Kim, KyungMann; Tang, Jie; Rosenstein, Rebecca B.; Wittes, Janet; Corle, Donald; Hess, Timothy M.; Woloj, Mabel; Boisserie, Frederic; Anderson, William F.; Viner, Jaye L.; Bagheri, Donya; Burn, John; Chung, Daniel C.; Dewar, Thomas; Foley, T. Raymond; Hoffman, Neville; Macrae, Finlay; Pruitt, Ronald E.; Saltzman, John R.; Salzberg, Bruce; Sylwestrowicz, Thomas; Gordon, Gary B.; Hawk, Ernest T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">873-884</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the no. of colorectal adenomas in animals and patients with familial adenomatous polyposis suggest that COX-2 inhibitors may also prevent sporadic colorectal neoplasia.  METHODS: We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily.  Randomization was stratified for the use of low-dose aspirin.  Follow-up colonoscopies were performed at one and three years after randomization.  The occurrence of newly detected colorectal adenomas was compared among the groups with the life-table extension of the Mantel-Haenszel test.  RESULTS: Follow-up colonoscopies were completed at year 1 in 89.5 % of randomized patients, and at year 3 in 75.7 %.  The estd. cumulative incidence of the detection of one or more adenomas by year 3 was 60.7 % for patients receiving placebo, as compared with 43.2 % for those receiving 200 mg of celecoxib twice a day (risk ratio, 0.67; 95 % confidence interval, 0.59 to 0.77; P < 0.001) and 37.5 % for those receiving 400 mg of celecoxib twice a day (risk ratio, 0.55; 95 % confidence interval, 0.48 to 0.64; P < 0.001).  Serious adverse events occurred in 18.8 % of patients in the placebo group, as compared with 20.4 % of those in the low-dose celecoxib group (risk ratio, 1.1; 95 % confidence interval, 0.9 to 1.3; P = 0.5) and 23.0 % of those in the high-dose group (risk ratio, 1.2; 95 % confidence interval, 1.0 to 1.5; P = 0.06).  As compared with placebo, celecoxib was assocd. with an increased risk of cardiovascular events (risk ratio for the low dose, 2.6; 95 % confidence interval, 1.1 to 6.1; and risk ratio for the high dose, 3.4; 95 % confidence interval, 1.5 to 7.9).  CONCLUSIONS: These findings indicate that celecoxib is an effective agent for the prevention of colorectal adenomas but, because of potential cardiovascular events, cannot be routinely recommended for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnWgcYRoN-LLVg90H21EOLACvtfcHk0lgbgw3-gDhpkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovFaju7Y%253D&md5=b650c8d861c7f5bd0b14f92b6cdc2140</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa061355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa061355%26sid%3Dliteratum%253Aachs%26aulast%3DBertagnolli%26aufirst%3DM.%2BM.%26aulast%3DEagle%26aufirst%3DC.%2BJ.%26aulast%3DZauber%26aufirst%3DA.%2BG.%26aulast%3DRedston%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DRosenstein%26aufirst%3DR.%2BB.%26aulast%3DWittes%26aufirst%3DJ.%26aulast%3DCorle%26aufirst%3DD.%26aulast%3DHess%26aufirst%3DT.%2BM.%26aulast%3DWoloj%26aufirst%3DG.%2BM.%26aulast%3DBoisserie%26aufirst%3DF.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DBagheri%26aufirst%3DD.%26aulast%3DBurn%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DD.%2BC.%26aulast%3DDewar%26aufirst%3DT.%26aulast%3DFoley%26aufirst%3DT.%2BR.%26aulast%3DHoffman%26aufirst%3DN.%26aulast%3DMacrae%26aufirst%3DF.%26aulast%3DPruitt%26aufirst%3DR.%2BE.%26aulast%3DSaltzman%26aufirst%3DJ.%2BR.%26aulast%3DSalzberg%26aufirst%3DB.%26aulast%3DSylwestrowicz%26aufirst%3DT.%26aulast%3DGordon%26aufirst%3DG.%2BB.%26aulast%3DHawk%26aufirst%3DE.%2BT.%26aulast%3D%26atitle%3DCelecoxib%2520for%2520the%2520prevention%2520of%2520sporadic%2520colorectal%2520adenomas%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D873%26epage%3D884%26doi%3D10.1056%2Fnejmoa061355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrono, C.</span></span> <span> </span><span class="NLM_article-title">The coxibs, selective inhibitors of cyclooxygenase-2</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1056/nejm200108093450607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJM200108093450607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11496855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsV2ls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2001&pages=433-442&author=G.+A.+FitzGeraldauthor=C.+Patrono&title=The+coxibs%2C+selective+inhibitors+of+cyclooxygenase-2&doi=10.1056%2Fnejm200108093450607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The coxibs, selective inhibitors of cyclooxygenase-2</span></div><div class="casAuthors">Wood, Alastair J. J.; FitzGerald, Garret A.; Patrono, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">433-442</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on the development of coxibs as an alternative to nonsteroidal antiinflammatory drugs (NSAID) for treating arthritis, menstrual pain, and headache.  Both groups of drugs inhibit prostaglandin G/H synthase, the enzyme that catalyzes the transformation of arachidonic acid to a range of lipid mediators, termed prostaglandins and thromboxanes.  However, whereas NSAIDs inhibit the two recognized forms of the enzyme, referred to as cyclooxygenase-1 and cyclooxygenase-2, the coxibs are selective inhibitors of cyclooxygenase-2.  Since the inhibition of cyclooxygenase-2 has been more directly implicated in ameliorating inflammation, it was hoped that coxibs would be better tolerated than nonselective NSAIDs but equally efficacious.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5jaFALK8yjbVg90H21EOLACvtfcHk0lh4Ascz-ZSHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsV2ls7k%253D&md5=d7b7cbeadd4801a3a5105f370f93c1c3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJM200108093450607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200108093450607%26sid%3Dliteratum%253Aachs%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26aulast%3DPatrono%26aufirst%3DC.%26atitle%3DThe%2520coxibs%252C%2520selective%2520inhibitors%2520of%2520cyclooxygenase-2%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D345%26spage%3D433%26epage%3D442%26doi%3D10.1056%2Fnejm200108093450607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botting, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1124/pr.56.3.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1124%2Fpr.56.3.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=15317910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotVKjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=387-437&author=D.+L.+Simmonsauthor=R.+M.+Bottingauthor=T.+Hla&title=Cyclooxygenase+isozymes%3A+the+biology+of+prostaglandin+synthesis+and+inhibition&doi=10.1124%2Fpr.56.3.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition</span></div><div class="casAuthors">Simmons, Daniel L.; Botting, Regina M.; Hla, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-437</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Nonsteroidal anti-inflammatory drugs (NSAIDs) represent one of the most highly utilized classes of pharmaceutical agents in medicine.  All NSAIDs act through inhibiting prostaglandin synthesis, a catalytic activity possessed by two distinct cyclooxygenase (COX) isoenzymes encoded by sep. genes.  The discovery of COX-2 launched a new era in NSAID pharmacol., resulting in the synthesis, marketing, and widespread use of COX-2 selective drugs.  These pharmaceutical agents have quickly become established as important therapeutic medications with potentially fewer side effects than traditional NSAIDs.  Addnl., characterization of the two COX isoenzymes is allowing the discrimination of the roles each play in physiol. processes such as homeostatic maintenance of the gastrointestinal tract, renal function, blood clotting, embryonic implantation, parturition, pain, and fever.  Of particular importance has been the investigation of COX-1 and -2 isoenzymic functions in cancer, dysregulation of inflammation, and Alzheimer's disease.  More recently, addnl. heterogeneity in COX-related proteins has been described, with the finding of variants of COX-1 and COX-2 enzymes.  These variants may function in tissue-specific physiol. and pathophysiol. processes and may represent important new targets for drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgI1sKLwTNi7Vg90H21EOLACvtfcHk0lh4Ascz-ZSHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotVKjtbY%253D&md5=75abc6304f28a60fbfb2a950ed200612</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fpr.56.3.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.56.3.3%26sid%3Dliteratum%253Aachs%26aulast%3DSimmons%26aufirst%3DD.%2BL.%26aulast%3DBotting%26aufirst%3DR.%2BM.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DCyclooxygenase%2520isozymes%253A%2520the%2520biology%2520of%2520prostaglandin%2520synthesis%2520and%2520inhibition%26jtitle%3DPharmacol.%2520Rev.%26date%3D2004%26volume%3D56%26spage%3D387%26epage%3D437%26doi%3D10.1124%2Fpr.56.3.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, R. N.</span></span> <span> </span><span class="NLM_article-title">Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1038/35094017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2F35094017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11900248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD387mvVOhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=11-21&author=R.+A.+Guptaauthor=R.+N.+Dubois&title=Colorectal+cancer+prevention+and+treatment+by+inhibition+of+cyclooxygenase-2&doi=10.1038%2F35094017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2</span></div><div class="casAuthors">Gupta R A; Dubois R N</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-21</span>
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    </div><div class="casAbstract">Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer.  These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression.  Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-LChZ0ggVnrrIbt-tGZmxfW6udTcc2eblTX_D3b4k_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387mvVOhsA%253D%253D&md5=68870f346eed4159e3363e38454d1cb9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2F35094017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35094017%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DR.%2BA.%26aulast%3DDubois%26aufirst%3DR.%2BN.%26atitle%3DColorectal%2520cancer%2520prevention%2520and%2520treatment%2520by%2520inhibition%2520of%2520cyclooxygenase-2%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D11%26epage%3D21%26doi%3D10.1038%2F35094017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sankaranarayanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altinoz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, G. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of colorectal cancer Prevention by aspirin-a literature review and perspective on the role of COX-dependent and -independent pathways</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">9018</span>, <span class="refDoi"> DOI: 10.3390/ijms21239018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.3390%2Fijms21239018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3MXotFSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=9018&author=R.+Sankaranarayananauthor=D.+R.+Kumarauthor=M.+A.+Altinozauthor=G.+J.+Bhat&title=Mechanisms+of+colorectal+cancer+Prevention+by+aspirin-a+literature+review+and+perspective+on+the+role+of+COX-dependent+and+-independent+pathways&doi=10.3390%2Fijms21239018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of colorectal cancer prevention by aspirin-a literature review and perspective on the role of COX-dependent and -independent pathways</span></div><div class="casAuthors">Sankaranarayanan, Ranjini; Ramesh Kumar, D.; Altinoz, Meric A.; Jayarama Bhat, G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9018</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Aspirin, synthesized and marketed in 1897 by Bayer, is one of the most widely used drugs in the world.  It has a well-recognized role in decreasing inflammation, pain and fever, and in the prevention of thrombotic cardiovascular diseases.  Its anti-inflammatory and cardio-protective actions have been well studied and occur through inhibition of cyclooxygenases (COX).  Interestingly, a vast amt. of epidemiol., preclin. and clin. studies have revealed aspirin as a promising chemopreventive agent, particularly against colorectal cancers (CRC); however, the primary mechanism by which it decreases the occurrences of CRC has still not been established.  Numerous mechanisms have been proposed for aspirin's chemopreventive properties among which the inhibition of COX enzymes has been widely discussed.  Despite the wide attention COX-inhibition has received as the most probable mechanism of cancer prevention by aspirin, it is clear that aspirin targets many other proteins and pathways, suggesting that these extra-COX targets may also be equally important in preventing CRC.  In this review, we discuss the COX-dependent and -independent pathways described in literature for aspirin's anti-cancer effects and highlight the strengths and limitations of the proposed mechanisms.  Addnl., we emphasize the potential role of the metabolites of aspirin and salicylic acid (generated in the gut through microbial biotransformation) in contributing to aspirin's chemopreventive actions.  We suggest that the preferential chemopreventive effect of aspirin against CRC may be related to direct exposure of aspirin/salicylic acid or its metabolites to the colorectal tissues.  Future investigations should shed light on the role of aspirin, its metabolites and the role of the gut microbiota in cancer prevention against CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4sYLSZVDDB7Vg90H21EOLACvtfcHk0lgHlD1XlZP2bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXotFSmuw%253D%253D&md5=595bbf9da93434724924d34aa59c0871</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Fijms21239018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21239018%26sid%3Dliteratum%253Aachs%26aulast%3DSankaranarayanan%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DD.%2BR.%26aulast%3DAltinoz%26aufirst%3DM.%2BA.%26aulast%3DBhat%26aufirst%3DG.%2BJ.%26atitle%3DMechanisms%2520of%2520colorectal%2520cancer%2520Prevention%2520by%2520aspirin-a%2520literature%2520review%2520and%2520perspective%2520on%2520the%2520role%2520of%2520COX-dependent%2520and%2520-independent%2520pathways%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D9018%26doi%3D10.3390%2Fijms21239018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venè, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, N.</span></span> <span> </span><span class="NLM_article-title">Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy</span>. <i>Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.trsl.2018.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2Fj.trsl.2018.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=29421522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1OhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2018&pages=42-61&author=R.+Benelliauthor=R.+Ven%C3%A8author=N.+Ferrari&title=Prostaglandin-endoperoxide+synthase+2+%28cyclooxygenase-2%29%2C+a+complex+target+for+colorectal+cancer+prevention+and+therapy&doi=10.1016%2Fj.trsl.2018.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy</span></div><div class="casAuthors">Benelli, Roberto; Vene, Roberta; Ferrari, Nicoletta</div><div class="citationInfo"><span class="NLM_cas:title">Translational Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42-61</span>CODEN:
                <span class="NLM_cas:coden">TRRECL</span>;
        ISSN:<span class="NLM_cas:issn">1878-1810</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A plentiful literature has linked colorectal cancer (CRC) to inflammation and prostaglandin-endoperoxide synthase (PTGS)2 expression.  Accordingly, several nonsteroidal antiinflammatory drugs (NSAIDs) have been tested often successfully in CRC chemoprevention despite their different ability to specifically target PTGS2 and the low or null expression of PTGS2 in early colon adenomas.  Some observational studies showed an increased survival for patients with CRC assuming NSAIDs after diagnosis, but no clin. trial has yet demonstrated the efficacy of NSAIDs against established CRC, where PTGS2 is expressed at high levels.  The major limits for the application of NSAIDs, or specific PTGS2 inhibitors, as adjuvant drugs in CRC are (1) a frequent confusion about the physiol. role of PTGS1 and PTGS2, reflecting in CRC pathol. and therapy; (2) the presence of unavoidable side effects linked to the intrinsic function of these enzymes; (3) the need of established criteria and markers for patient selection; and (4) the evaluation of the immunomodulatory potential of PTGS2 inhibitors as possible adjuvants for immunotherapy.  This review has been written to rediscover the multifaceted potential of PTGS2 targeting, hoping it could act as a starting point for a new and more aware application of NSAIDs against CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ1c3Zqhe__rVg90H21EOLACvtfcHk0lgHlD1XlZP2bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1OhtL8%253D&md5=0245a1dbac369f0b02acc9f08a11321b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2018.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2018.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DBenelli%26aufirst%3DR.%26aulast%3DVen%25C3%25A8%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DN.%26atitle%3DProstaglandin-endoperoxide%2520synthase%25202%2520%2528cyclooxygenase-2%2529%252C%2520a%2520complex%2520target%2520for%2520colorectal%2520cancer%2520prevention%2520and%2520therapy%26jtitle%3DTransl.%2520Res.%26date%3D2018%26volume%3D196%26spage%3D42%26epage%3D61%26doi%3D10.1016%2Fj.trsl.2018.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sigthorsson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotz-Behoftsitz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palizban, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pombo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morham, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjarnason, I.</span></span> <span> </span><span class="NLM_article-title">COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">1913</span>– <span class="NLM_lpage">1923</span>, <span class="refDoi"> DOI: 10.1053/gast.2002.33647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1053%2Fgast.2002.33647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=12055598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt12gsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2002&pages=1913-1923&author=G.+Sigthorssonauthor=R.+J.+Simpsonauthor=M.+Walleyauthor=A.+Anthonyauthor=R.+Fosterauthor=C.+Hotz-Behoftsitzauthor=A.+Palizbanauthor=J.+Pomboauthor=J.+Wattsauthor=S.+G.+Morhamauthor=I.+Bjarnason&title=COX-1+and+2%2C+intestinal+integrity%2C+and+pathogenesis+of+nonsteroidal+anti-inflammatory+drug+enteropathy+in+mice&doi=10.1053%2Fgast.2002.33647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice</span></div><div class="casAuthors">Sigthorsson, Gudmundur; Simpson, Robert J.; Walley, Matthew; Anthony, Andrew; Foster, Russell; Hotz-Behoftsitz, Christoph; Palizban, Abbas; Pombo, Joaquim; Watts, Jo; Morham, Scott G.; Bjarnason, Ingvar</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1913-1923</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">Background & Aims: The pathogenesis of nonsteroidal anti-inflammatory drug-induced enteropathy is controversial, but it is thought that cyclooxygenase-1 (COX-1) inhibition is of pivotal importance.  We compared small intestinal function and morphol. in untreated wild-type, COX-1- and COX-2-deficient mice and the effect of indomethacin, selective COX-1 (SC-560), and COX-2 (celecoxib) inhibition.  Methods: Intestinal permeability (51CrEDTA), inflammation (fecal granulocyte marker protein), prostaglandin E2 (PGE2) levels, and macroscopic and microscopic appearances were assessed at baseline and after the drugs.  Results: COX-1-/- animals were normal except for a 97% decrease in intestinal PGE2 levels.  COX-1+/+ and COX-1-/- animals reacted in a similar way to indomethacin.  However, celecoxib, having caused no damage in COX-1+/+ animals, caused small bowel ulcers in COX-1-/- animals.  Selective inhibition of COX-1 decreased intestinal PGE2 levels in COX-2+/+ and COX-2-/- animals by 95%-97%, but caused only small bowel ulcers in the latter group.  Dual inhibition of COX-1 and COX-2 in wild-type animals resulted in similar small bowel damage.  Between 40% and 50% of untreated COX-2-/- animals had increased intestinal permeability and inflammation.  Some had ileal ulcers that were distinctively different from indomethacin-induced ulcers.  Furthermore, long-term celecoxib administration in wild-type animals was assocd. with similar damage as in the COX-2-/- mice.  Conclusions: COX-1 deficiency or inhibition and short-term COX-2 inhibition are compatible with normal small intestinal integrity.  Dual inhibition of the COX enzymes leads to damage similar to that seen with indomethacin.  Long-term COX-2 deficiency or inhibition is assocd. with significant intestinal pathol. despite normal intestinal PGE2 levels, suggesting a role for COX-2 in the maintenance of small intestinal integrity in the mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcqSGtUvxOVLVg90H21EOLACvtfcHk0lgHlD1XlZP2bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt12gsL8%253D&md5=e0a1c7c320b5dffe3c2e0d7a34ca05ae</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1053%2Fgast.2002.33647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fgast.2002.33647%26sid%3Dliteratum%253Aachs%26aulast%3DSigthorsson%26aufirst%3DG.%26aulast%3DSimpson%26aufirst%3DR.%2BJ.%26aulast%3DWalley%26aufirst%3DM.%26aulast%3DAnthony%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DR.%26aulast%3DHotz-Behoftsitz%26aufirst%3DC.%26aulast%3DPalizban%26aufirst%3DA.%26aulast%3DPombo%26aufirst%3DJ.%26aulast%3DWatts%26aufirst%3DJ.%26aulast%3DMorham%26aufirst%3DS.%2BG.%26aulast%3DBjarnason%26aufirst%3DI.%26atitle%3DCOX-1%2520and%25202%252C%2520intestinal%2520integrity%252C%2520and%2520pathogenesis%2520of%2520nonsteroidal%2520anti-inflammatory%2520drug%2520enteropathy%2520in%2520mice%26jtitle%3DGastroenterology%26date%3D2002%26volume%3D122%26spage%3D1913%26epage%3D1923%26doi%3D10.1053%2Fgast.2002.33647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bjarnason, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpignato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmgren, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainsford, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanas, A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-Inflammatory drugs</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">500</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2017.10.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1053%2Fj.gastro.2017.10.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=29221664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Slurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=500-514&author=I.+Bjarnasonauthor=C.+Scarpignatoauthor=E.+Holmgrenauthor=M.+Olszewskiauthor=K.+D.+Rainsfordauthor=A.+Lanas&title=Mechanisms+of+damage+to+the+gastrointestinal+tract+from+nonsteroidal+anti-Inflammatory+drugs&doi=10.1053%2Fj.gastro.2017.10.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs</span></div><div class="casAuthors">Bjarnason, Ingvar; Scarpignato, Carmelo; Holmgren, Erik; Olszewski, Michael; Rainsford, Kim D.; Lanas, Angel</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">500-514</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Nonsteroidal anti-inflammatory drugs (NSAIDs) can damage the gastrointestinal tract, causing widespread morbidity and mortality.  Although mechanisms of damage involve the activities of prostaglandin-endoperoxide synthase 1 (PTGS1 or cyclooxygenase [COX] 1) and PTGS1 (COX2), other factors are involved.  We review the mechanisms of gastrointestinal damage induction by NSAIDs via COX-mediated and COX-independent processes.  NSAIDs interact with phospholipids and uncouple mitochondrial oxidative phosphorylation, which initiates biochem. changes that impair function of the gastrointestinal barrier.  The resulting increase in intestinal permeability leads to low-grade inflammation.  NSAID inhibition of COX enzymes, along with luminal aggressors, results in erosions and ulcers, with potential complications of bleeding, protein loss, stricture formation, and perforation.  We propose a model for NSAID-induced damage to the gastrointestinal tract that includes these complex, interacting, and inter-dependent factors.  This model highlights the obstacles for the development of safer NSAIDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp7Sis01AebLVg90H21EOLACvtfcHk0ljh3Ec5nyWDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Slurk%253D&md5=5dc660ecf3b4919bfad9281bf0f077c2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2017.10.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2017.10.049%26sid%3Dliteratum%253Aachs%26aulast%3DBjarnason%26aufirst%3DI.%26aulast%3DScarpignato%26aufirst%3DC.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DOlszewski%26aufirst%3DM.%26aulast%3DRainsford%26aufirst%3DK.%2BD.%26aulast%3DLanas%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520damage%2520to%2520the%2520gastrointestinal%2520tract%2520from%2520nonsteroidal%2520anti-Inflammatory%2520drugs%26jtitle%3DGastroenterology%26date%3D2018%26volume%3D154%26spage%3D500%26epage%3D514%26doi%3D10.1053%2Fj.gastro.2017.10.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fornai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giustarini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matarangasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderone, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpignato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span> <span> </span><span class="NLM_article-title">NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.207118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1124%2Fjpet.113.207118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=24135073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=86-95&author=M.+Fornaiauthor=L.+Antonioliauthor=R.+Colucciauthor=C.+Pellegriniauthor=G.+Giustariniauthor=L.+Testaiauthor=A.+Martelliauthor=A.+Matarangasiauthor=G.+Nataleauthor=V.+Calderoneauthor=M.+Tuccoriauthor=C.+Scarpignatoauthor=C.+Blandizzi&title=NSAID-induced+enteropathy%3A+are+the+currently+available+selective+COX-2+inhibitors+all+the+same%3F&doi=10.1124%2Fjpet.113.207118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same</span></div><div class="casAuthors">Fornai, Matteo; Antonioli, Luca; Colucci, Rocchina; Pellegrini, Carolina; Giustarini, Giulio; Testai, Lara; Martelli, Alma; Matarangasi, Antuela; Natale, Gianfranco; Calderone, Vincenzo; Tuccori, Marco; Scarpignato, Carmelo; Blandizzi, Corrado</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-95, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Nonsteroidal anti-inflammatory drugs (NSAIDs) can induce intestinal mucosal damage, but the underlying mechanisms remain poorly understood.  The present study investigated the effects of celecoxib, etoricoxib, indomethacin, and diclofenac on small bowel integrity in rats.  Male rats were treated orally with test drugs for 14 days.  Animals were processed for assessment of blood Hb levels and hepatic mitochondrial functions, microscopic evaluation of small intestinal damage, Western blot anal. of cyclooxygenase-1 and -2 (COX-1, COX-2) expression, and assay of malondialdehyde (MDA), myeloperoxidase (MPO), and prostaglandin E2 (PGE2) levels in small intestine.  Indomethacin and diclofenac decreased blood Hb levels, whereas etoricoxib and celecoxib were without effects.  Celecoxib caused a lower degree of intestinal damage in comparison with the other test drugs.  Indomethacin and diclofenac, but not etoricoxib or celecoxib, reduced intestinal PGE2 levels.  Test drugs did not modify intestinal COX-1 expression, although they enhanced COX-2, with the exception of celecoxib, which downregulated COX-2.  Indomethacin, diclofenac, and etoricoxib altered mitochondrial respiratory parameters, although celecoxib was without effects.  Indomethacin or diclofenac increased MDA and MPO levels in both jejunum and ileum.  In the jejunum, etoricoxib or celecoxib did not modify such parameters, whereas in the ileum, etoricoxib, but not celecoxib, increased both MDA and MPO levels.  These findings suggest that nonselective NSAIDs and etoricoxib can induce enteropathy through a topic action, whereas celecoxib lacks relevant detrimental actions.  The selectivity profile of COX-1/COX-2 inhibition by test drugs and the related effects on prostaglandin prodn. do not appear to play a major role in the pathogenesis of enteropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1N7U0V8iLeLVg90H21EOLACvtfcHk0ljh3Ec5nyWDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKjuro%253D&md5=b79f005b0aa8fe078c28478e48e74971</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207118%26sid%3Dliteratum%253Aachs%26aulast%3DFornai%26aufirst%3DM.%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DColucci%26aufirst%3DR.%26aulast%3DPellegrini%26aufirst%3DC.%26aulast%3DGiustarini%26aufirst%3DG.%26aulast%3DTestai%26aufirst%3DL.%26aulast%3DMartelli%26aufirst%3DA.%26aulast%3DMatarangasi%26aufirst%3DA.%26aulast%3DNatale%26aufirst%3DG.%26aulast%3DCalderone%26aufirst%3DV.%26aulast%3DTuccori%26aufirst%3DM.%26aulast%3DScarpignato%26aufirst%3DC.%26aulast%3DBlandizzi%26aufirst%3DC.%26atitle%3DNSAID-induced%2520enteropathy%253A%2520are%2520the%2520currently%2520available%2520selective%2520COX-2%2520inhibitors%2520all%2520the%2520same%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D86%26epage%3D95%26doi%3D10.1124%2Fjpet.113.207118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seibert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masferrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakson, P.</span></span> <span> </span><span class="NLM_article-title">Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">12013</span>– <span class="NLM_lpage">12017</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.25.12013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1073%2Fpnas.91.25.12013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=7991575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADyaK2MXisFyqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=12013-12017&author=K.+Seibertauthor=Y.+Zhangauthor=K.+Leahyauthor=S.+Hauserauthor=J.+Masferrerauthor=W.+Perkinsauthor=L.+Leeauthor=P.+Isakson&title=Pharmacological+and+biochemical+demonstration+of+the+role+of+cyclooxygenase+2+in+inflammation+and+pain&doi=10.1073%2Fpnas.91.25.12013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain</span></div><div class="casAuthors">Seibert, Karen; Zhang, Yan; Leahy, Kathleen; Hauser, Scott; Masferrer, Jaime; Perkins, William; Lee, Len; Isakson, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">12013-17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used for the treatment of inflammatory diseases, but significant side effects such as gastrointestinal erosion and renal damage limit their use.  NSAIDs inhibit the enzyme cyclooxygenase (COX), which catalyzes the conversion of arachidonic acid to prostaglandins (PGs) and thromboxane.  Two forms of COX has been identified - COX-1, which is constitutively expressed in most tissues and organs, and the inducible enzyme, COX-2, which has been localized primarily to inflammatory cells and tissues.  In an animal model of acute inflammation (injection of carrageenan into the footpad), edema was produced that was assocd. with marked accumulation of COX-2 mRNA and thromboxane.  A selective inhibitor of COX-2 (SC-58125) inhibited edema at the inflammatory site and was analgesic but had no effect on PG prodn. in the stomach and did not cause gastric toxicity.  These data suggest that selective inhibition of COX-2 may produce superior antiinflammatory drugs with substantial safety advantages over existing NSAIDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSANLo1WFaz7Vg90H21EOLACvtfcHk0ljh3Ec5nyWDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisFyqtb0%253D&md5=431b3b433ad20ad2bdac4807e9d758da</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.25.12013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.25.12013%26sid%3Dliteratum%253Aachs%26aulast%3DSeibert%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLeahy%26aufirst%3DK.%26aulast%3DHauser%26aufirst%3DS.%26aulast%3DMasferrer%26aufirst%3DJ.%26aulast%3DPerkins%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DIsakson%26aufirst%3DP.%26atitle%3DPharmacological%2520and%2520biochemical%2520demonstration%2520of%2520the%2520role%2520of%2520cyclooxygenase%25202%2520in%2520inflammation%2520and%2520pain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D12013%26epage%3D12017%26doi%3D10.1073%2Fpnas.91.25.12013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, R. N.</span></span> <span> </span><span class="NLM_article-title">Role of prostanoids in gastrointestinal cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2732</span>– <span class="NLM_lpage">2742</span>, <span class="refDoi"> DOI: 10.1172/jci97953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1172%2FJCI97953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=29733297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BC1MfgsVOqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=2732-2742&author=D.+Wangauthor=R.+N.+DuBois&title=Role+of+prostanoids+in+gastrointestinal+cancer&doi=10.1172%2Fjci97953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Role of prostanoids in gastrointestinal cancer</span></div><div class="casAuthors">Wang Dingzhi; DuBois Raymond N; DuBois Raymond N</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2732-2742</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic inflammation is a risk factor for gastrointestinal cancer and other diseases.  Most studies have focused on cytokines and chemokines as mediators connecting chronic inflammation to cancer, whereas the involvement of lipid mediators, including prostanoids, has not been extensively investigated.  Prostanoids are among the earliest signaling molecules released in response to inflammation.  Multiple lines of evidence suggest that prostanoids are involved in gastrointestinal cancer.  In this Review, we discuss how prostanoids impact gastrointestinal cancer development.  In particular, we highlight recent advances in our understanding of how prostaglandin E2 induces the immunosuppressive microenvironment in gastrointestinal cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7h5aD28C1RmgRQsDqrjW_fW6udTcc2ebihKXningjp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfgsVOqtQ%253D%253D&md5=e8d770a5bf709f801b0fc1146e4655bb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1172%2FJCI97953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI97953%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DRole%2520of%2520prostanoids%2520in%2520gastrointestinal%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D2732%26epage%3D2742%26doi%3D10.1172%2Fjci97953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, R. N.</span></span> <span> </span><span class="NLM_article-title">The role of COX-2 in intestinal inflammation and colorectal cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">788</span>, <span class="refDoi"> DOI: 10.1038/onc.2009.421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fonc.2009.421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=19946329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2gtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=781-788&author=D.+Wangauthor=R.+N.+Dubois&title=The+role+of+COX-2+in+intestinal+inflammation+and+colorectal+cancer&doi=10.1038%2Fonc.2009.421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The role of COX-2 in intestinal inflammation and colorectal cancer</span></div><div class="casAuthors">Wang, D.; Du Bois, R. N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">781-788</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms: hereditary, sporadic and colitis-assocd. CRC.  A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are the risk factors for CRC.  As elevated cyclooxygenase-2 (COX-2) expression was found in most CRC tissue and is assocd. with worse survival among CRC patients, investigators have sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) on CRC.  The epidemiol. studies, clin. trials and animal expts. indicate that NSAIDs are among the most promising chemopreventive agents for this disease.  NSAIDs exert their anti-inflammatory and antitumor effects primarily by reducing prostaglandin prodn. by inhibition of COX-2 activity.  In this review, we highlight breakthroughs in our understanding of the roles of COX-2 in CRC and inflammatory bowel disease.  These recent data provide a rationale for re-evaluating COX-2 as both the prognostic and the predictive marker in a wide variety of malignancies and for renewing the interest in evaluating relative benefits and risk of COXIBs in appropriately selected patients for cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYCBy3ymdCiLVg90H21EOLACvtfcHk0lg712u7Fht-CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2gtrfF&md5=a860e703faa4759550d28f68d4400c7e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.421%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DDubois%26aufirst%3DR.%2BN.%26atitle%3DThe%2520role%2520of%2520COX-2%2520in%2520intestinal%2520inflammation%2520and%2520colorectal%2520cancer%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D781%26epage%3D788%26doi%3D10.1038%2Fonc.2009.421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kömhoff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shappell, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jack, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyr, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shappell, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breyer, M. D.</span></span> <span> </span><span class="NLM_article-title">Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/s0002-9440(10)64513-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2FS0002-9440%2810%2964513-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10880372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlsVGmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2000&pages=29-35&author=M.+K%C3%B6mhoffauthor=Y.+Guanauthor=H.+W.+Shappellauthor=L.+Davisauthor=G.+Jackauthor=Y.+Shyrauthor=M.+O.+Kochauthor=S.+B.+Shappellauthor=M.+D.+Breyer&title=Enhanced+expression+of+cyclooxygenase-2+in+high+grade+human+transitional+cell+bladder+carcinomas&doi=10.1016%2Fs0002-9440%2810%2964513-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas</span></div><div class="casAuthors">Komhoff, Martin; Guan, Youfei; Shappell, Heidi W.; Davis, Linda; Jack, Greg; Shyr, Yu; Koch, Michael O.; Shappell, Scott B.; Breyer, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-35</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Studies in human and animal models have shown that cyclooxygenase (COX)-2 is up-regulated in several epithelial carcinomas including colon, breast, and lung.  To elucidate the possible involvement of COX-2 in human bladder cancer we examd. the expression of COX isoforms in benign tissue and in bladder carcinoma specimens.  Paraffin embedded tissues from 75 patients with urothelial carcinomas were immunostained with specific antibodies raised against COX-1 and COX-2.  COX-1 expression was detected in smooth muscle cells in both benign and malignant bladders.  COX-2 immunoreactivity was absent in benign tissue and in specimens with low-grade urothelial carcinoma (0/23).  In contrast, expression of COX-2 was detected in malignant epithelial cells in 38% (17/47) of specimens with high-grade urothelial carcinomas.  Expression of COX-2 in high-grade bladder cancer was confirmed by radioactive in situ hybridization using a COX-2-selective riboprobe.  Both immunohistochem. and in situ hybridization showed COX-2 expression in a small subset of malignant cells.  COX-2 mRNA was also expressed in three out of seven malignant urothelial cell lines.  These data demonstrate elevated expression of COX-2 in a high percentage of high-grade bladder carcinomas, suggesting a possible role of COX-2 in the progression of bladder urothelial carcinoma and supporting its potential as a therapeutic target in human bladder carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT4KEYR4r_wLVg90H21EOLACvtfcHk0lg712u7Fht-CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlsVGmtr0%253D&md5=9b04d8d5610e89f3cf2cbee015addfeb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2964513-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252964513-0%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6mhoff%26aufirst%3DM.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DShappell%26aufirst%3DH.%2BW.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DJack%26aufirst%3DG.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DKoch%26aufirst%3DM.%2BO.%26aulast%3DShappell%26aufirst%3DS.%2BB.%26aulast%3DBreyer%26aufirst%3DM.%2BD.%26atitle%3DEnhanced%2520expression%2520of%2520cyclooxygenase-2%2520in%2520high%2520grade%2520human%2520transitional%2520cell%2520bladder%2520carcinomas%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2000%26volume%3D157%26spage%3D29%26epage%3D35%26doi%3D10.1016%2Fs0002-9440%2810%2964513-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagmohan-Changur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodde, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alman, B. A.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fsj.onc.1204107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11313976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsVKjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=451-460&author=R.+Poonauthor=R.+Smitsauthor=C.+Liauthor=S.+Jagmohan-Changurauthor=M.+Kongauthor=S.+Cheonauthor=C.+Yuauthor=R.+Foddeauthor=B.+A.+Alman&title=Cyclooxygenase-two+%28COX-2%29+modulates+proliferation+in+aggressive+fibromatosis+%28desmoid+tumor%29&doi=10.1038%2Fsj.onc.1204107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor)</span></div><div class="casAuthors">Poon, Raymond; Smits, Ron; Li, Catherine; Jagmohan-Changur, Shantie; Kong, Michael; Cheon, Sophia; Yu, Chunying; Fodde, Riccardo; Alman, Benjamin A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">451-460</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aggressive fibromatosis is a locally invasive soft tissue lesion.  Seventy-five per cent of cases harbor a somatic mutation in either the APC or β-catenin genes, resulting in β-catenin protein stabilization.  Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin synthesis that modulates the formation of colonic neoplasia, esp. in cases due to mutations resulting in β-catenin stabilization.  Human aggressive fibromatoses and lesions from the Apc+ / Apc1638N mouse (a murine model for Apc-driven fibromatosis) demonstrated elevated COX-2 levels.  COX-2 blockade either by the selective agent DFU or by non-selective COX blocking agents results in reduced proliferation in human tumor cell cultures.  Breeding mice with Cox-2-/- mice resulted in no difference in no. of aggressive fibromatoses formed, but in a smaller tumor size, while there was a decrease in no. of GI lesions by 50%.  Mice fed various COX blocking agents also showed a decline in tumor size.  COX-2 expression was regulated by tcf-dependent transcription in this lesion.  COX-2 partially regulates proliferation due to β-catenin stabilization in aggressive fibromatosis.  Although COX blockade alone does not cause tumor regression, this data suggests that it may have a role as an adjuvant therapy to slow tumor growth in this lesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVUl1nYn85kLVg90H21EOLACvtfcHk0lg712u7Fht-CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsVKjtLo%253D&md5=8c524ab0cb80b0e00913fafcae0b3f98</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204107%26sid%3Dliteratum%253Aachs%26aulast%3DPoon%26aufirst%3DR.%26aulast%3DSmits%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DJagmohan-Changur%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DM.%26aulast%3DCheon%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DFodde%26aufirst%3DR.%26aulast%3DAlman%26aufirst%3DB.%2BA.%26atitle%3DCyclooxygenase-two%2520%2528COX-2%2529%2520modulates%2520proliferation%2520in%2520aggressive%2520fibromatosis%2520%2528desmoid%2520tumor%2529%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D451%26epage%3D460%26doi%3D10.1038%2Fsj.onc.1204107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benamouzig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzzan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deyra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaussade, S.</span></span>; <span class="NLM_contrib-group">APACC Study Group</span> <span> </span><span class="NLM_article-title">Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1136/gut.2008.175406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1136%2Fgut.2008.175406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=20427397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvFKhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2010&pages=622-629&author=R.+Benamouzigauthor=B.+Uzzanauthor=A.+Martinauthor=J.+Deyraauthor=J.+Littleauthor=B.+Girardauthor=S.+Chaussadeauthor=APACC+Study+Group&title=Cyclooxygenase-2+expression+and+recurrence+of+colorectal+adenomas%3A+effect+of+aspirin+chemoprevention&doi=10.1136%2Fgut.2008.175406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention</span></div><div class="casAuthors">Benamouzig, Robert; Uzzan, Bernard; Martin, Antoine; Deyra, Jacques; Little, Julian; Girard, Bernard; Chaussade, Stanislas</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-629</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background: Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas.  Cyclooxygenase-2 (COX-2), one of its main target enzymes, is reportedly over-expressed in colorectal adenomas.  Aim: To assess COX-2 expression, in relation to adenoma recurrence and the protective effect of aspirin, in a large series of colorectal adenomas, recruited from a double-blind randomised controlled trial comparing recurrences after low-dose aspirin or placebo.  Methods: Follow-up colonoscopies were performed after 1 and 4 years to assess adenoma recurrence.  COX-2 expression was assessed by immunohistochem. for each adenoma obtained at baseline colonoscopy, sep. for epithelium, deep stroma and overall.  Architecture, grade of dysplasia, K-ras mutation, p53 and cyclin D1 expression were studied.  Results: COX-2 expression could be assessed in 219 adenomas from 136 patients: 128 adenomas (58%) from 59 patients strongly expressed COX-2.  Strong COX-2 expression predominated in adenomas larger than 10 mm (84/129 vs 44/90; p=0.02) and in adenomas showing high-grade dysplasia (22/29 vs 104/188; p=0.04).  Deep stromal but not epithelial initial expression of COX-2 predicted adenoma recurrence in the whole population (30/72 patients or 42% strongly expressed deep stromal COX-2 compared with 16/64 or 25% without recurrent adenoma; p=0.04).  The protective effect of aspirin was mainly obsd. in patients in whom COX-2 initial expression was low (RR for recurrence in patients taking aspirin with low COX-2 expression: 0.59; 95% CI 0.39 to 0.90; p=0.02).  There was no significant effect of aspirin at the end of the trial.  Conclusion: Over-expression of COX-2 was frequent and predominated in large and high-grade dysplasia adenomas.  Deep stromal but not epithelial initial expression of COX-2 predicted recurrence of adenomas.  Aspirin did not act preferentially on patients whose initial adenomas strongly expressed COX-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqexHP2P0a_xLVg90H21EOLACvtfcHk0ljxXmOgjW21kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvFKhsrw%253D&md5=e5b0d1409ea022eebbec145b1a461f2e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1136%2Fgut.2008.175406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.2008.175406%26sid%3Dliteratum%253Aachs%26aulast%3DBenamouzig%26aufirst%3DR.%26aulast%3DUzzan%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DDeyra%26aufirst%3DJ.%26aulast%3DLittle%26aufirst%3DJ.%26aulast%3DGirard%26aufirst%3DB.%26aulast%3DChaussade%26aufirst%3DS.%26aulast%3D%26atitle%3DCyclooxygenase-2%2520expression%2520and%2520recurrence%2520of%2520colorectal%2520adenomas%253A%2520effect%2520of%2520aspirin%2520chemoprevention%26jtitle%3DGut%26date%3D2010%26volume%3D59%26spage%3D622%26epage%3D629%26doi%3D10.1136%2Fgut.2008.175406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomozawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuno, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitayama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagawa, H.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1054/bjoc.2000.1270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1054%2Fbjoc.2000.1270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10917546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslens74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2000&pages=324-328&author=S.+Tomozawaauthor=N.+H.+Tsunoauthor=E.+Sunamiauthor=K.+Hatanoauthor=J.+Kitayamaauthor=T.+Osadaauthor=S.+Saitoauthor=T.+Tsuruoauthor=Y.+Shibataauthor=H.+Nagawa&title=Cyclooxygenase-2+overexpression+correlates+with+tumour+recurrence%2C+especially+haematogenous+metastasis%2C+of+colorectal+cancer&doi=10.1054%2Fbjoc.2000.1270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially hematogenous metastasis, of colorectal cancer</span></div><div class="casAuthors">Tomozawa, S.; Tsuno, N. H.; Sunami, E.; Hatano, K.; Kitayama, J.; Osada, T.; Saito, S.; Tsuruo, T.; Shibata, Y.; Nagawa, H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">324-328</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Epidemiol. studies have demonstrated that nonsteroidal anti-inflammatory drugs (NSAIDs), known to inhibit cyclooxygenase (COX), reduce the risk of colorectal cancer.  COX is a key enzyme in prostaglandin biosynthesis, and two isoforms of COX, COX-1 and COX-2, have been identified.  Recently COX-2 has been reported to frequently overexpress in colorectal neoplasms and to play a role in colorectal tumorigenesis and tumor progression.  In this study, using immunohistochem., we examd. COX-2 expression in advanced human colorectal cancer and its correlation with clinicopathol. features.  COX-2 expression was obsd. mainly in the cytoplasm of cancer cells in all the specimens examd., but some stromal cells and endothelial cells were also stained.  According to the grade of COX-2 expression of the cancer cells, patients were divided into high- and low-COX-2 expression groups.  High-COX-2 expression significantly correlated with tumor recurrence, esp. hematogenous metastasis.  These results suggest that a selective COX-2 inhibitor can be a novel class of therapeutic agents not only for tumorigenesis but also for hematogenous metastasis of cololectal cancer.  To our knowledge, this is the first report on the correlation between COX-2 overexpression and recurrence of colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE3FvAVoPF-rVg90H21EOLACvtfcHk0ljxXmOgjW21kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslens74%253D&md5=b430293923b4e27e76605915629a807f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2000.1270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2000.1270%26sid%3Dliteratum%253Aachs%26aulast%3DTomozawa%26aufirst%3DS.%26aulast%3DTsuno%26aufirst%3DN.%2BH.%26aulast%3DSunami%26aufirst%3DE.%26aulast%3DHatano%26aufirst%3DK.%26aulast%3DKitayama%26aufirst%3DJ.%26aulast%3DOsada%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DTsuruo%26aufirst%3DT.%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DNagawa%26aufirst%3DH.%26atitle%3DCyclooxygenase-2%2520overexpression%2520correlates%2520with%2520tumour%2520recurrence%252C%2520especially%2520haematogenous%2520metastasis%252C%2520of%2520colorectal%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2000%26volume%3D83%26spage%3D324%26epage%3D328%26doi%3D10.1054%2Fbjoc.2000.1270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cha, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, R. N.</span></span> <span> </span><span class="NLM_article-title">NSAIDs and cancer prevention: targets downstream of COX-2</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1146/annurev.med.57.121304.131253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1146%2Fannurev.med.57.121304.131253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=17100552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisV2jsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2007&pages=239-252&author=Y.+I.+Chaauthor=R.+N.+DuBois&title=NSAIDs+and+cancer+prevention%3A+targets+downstream+of+COX-2&doi=10.1146%2Fannurev.med.57.121304.131253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">NSAIDs and cancer prevention: targets downstream of COX-2</span></div><div class="casAuthors">Cha, Yong I.; DuBois, Raymond N.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">239-252, 2 plates</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Preclin. and clin. studies have clearly shown a benefit of non-steroidal anti-inflammatory drug (NSAID) use in reducing cancer risk.  However, the adverse gastrointestinal and cardiovascular side effects assocd. with NSAIDs and COX-2 selective inhibitors (coxibs) have provoked more scrutiny of the precise role of specific downstream mediators in the prostaglandin (PG) signaling cascade.  NSAIDs and coxibs inhibit PG biosynthesis.  One of the PGs produced at high levels in the tumor microenvironment is PGE2, which is thought to play a major role in cancer progression.  Thus, a better understanding of PGE2 signaling could enable identification of novel and safer therapeutic targets downstream of the cyclooxygenase enzymes.  We review the emerging mol. mechanisms by which COX-2-derived PGE2 is involved in cancer progression and delineate potential opportunities for development of novel pharmacol. approaches utilizing this pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ3LRrVwjZILVg90H21EOLACvtfcHk0ljxXmOgjW21kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisV2jsbc%253D&md5=169e6750f118f6b449b792b8563370d0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.57.121304.131253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.57.121304.131253%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DY.%2BI.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DNSAIDs%2520and%2520cancer%2520prevention%253A%2520targets%2520downstream%2520of%2520COX-2%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2007%26volume%3D58%26spage%3D239%26epage%3D252%26doi%3D10.1146%2Fannurev.med.57.121304.131253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, R. N.</span></span> <span> </span><span class="NLM_article-title">Eicosanoids and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/nrc2809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fnrc2809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=20168319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFemsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=181-193&author=D.+Wangauthor=R.+N.+DuBois&title=Eicosanoids+and+cancer&doi=10.1038%2Fnrc2809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Eicosanoids and cancer</span></div><div class="casAuthors">Wang, Dingzhi; DuBois, Raymond N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-193</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Eicosanoids, including prostaglandins and leukotrienes, are biol. active lipids that have been implicated in various pathol. processes, such as inflammation and cancer.  This Review highlights our understanding of the intricate roles of eicosanoids in epithelial-derived tumors and their microenvironment.  The knowledge of how these lipids orchestrate the complex interactions between transformed epithelial cells and the surrounding stromal cells is crucial for understanding tumor evolution, progression and metastasis.  Understanding the mol. mechanisms underlying the role of prostaglandins and other eicosanoids in cancer progression will help to develop more effective cancer chemopreventive and/or therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq_oPm3Qm5n7Vg90H21EOLACvtfcHk0ljVtUyJ4USS6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFemsbs%253D&md5=7a8cb25f2a7a8884439fdcfe7452d40a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrc2809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2809%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DEicosanoids%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D181%26epage%3D193%26doi%3D10.1038%2Fnrc2809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, R. N.</span></span> <span> </span><span class="NLM_article-title">Prostaglandins and cancer</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1136/gut.2004.047100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1136%2Fgut.2004.047100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16118353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1yquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2006&pages=115-122&author=D.+Wangauthor=R.+N.+Dubois&title=Prostaglandins+and+cancer&doi=10.1136%2Fgut.2004.047100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Prostaglandins and cancer</span></div><div class="casAuthors">Wang, D.; DuBois, R. N.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-122</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemoprevention has been considered as a possible approach for cancer prevention.  A significant effort has been made in the development of novel drugs for both cancer prevention and treatment over the past decade.  Recent epidemiol. studies and clin. trials indicate that long term use of aspirin and similar agents, also called non-steroidal anti-inflammatory drugs (NSAIDs), can decrease the incidence of certain malignancies, including colorectal, esophageal, breast, lung, and bladder cancers.  The best known targets of NSAIDs are cyclooxygenase (COX) enzymes, which convert arachidonic acid to prostaglandins (PGs) and thromboxane.  COX-2 derived prostaglandin E2 (PGE2) can promote tumor growth by binding its receptors and activating signaling pathways which control cell proliferation, migration, apoptosis, and/or angiogenesis.  However, the prolonged use of high dosages of COX-2 selective inhibitors (COXIBs) is assocd. with unacceptable cardiovascular side effects.  Thus it is crucial to develop more effective chemopreventive agents with minimal toxicity.  Recent efforts to identify the mol. mechanisms by which PGE2 promotes tumor growth and metastasis may provide opportunities for the development of safer strategies for cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozLiBOa60XjbVg90H21EOLACvtfcHk0ljVtUyJ4USS6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1yquw%253D%253D&md5=deb3293aa36c14a2ded00aa3a9fa7cf0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1136%2Fgut.2004.047100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.2004.047100%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DDubois%26aufirst%3DR.%2BN.%26atitle%3DProstaglandins%2520and%2520cancer%26jtitle%3DGut%26date%3D2006%26volume%3D55%26spage%3D115%26epage%3D122%26doi%3D10.1136%2Fgut.2004.047100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, R. N.</span></span> <span> </span><span class="NLM_article-title">Prostaglandin E2 promotes intestinal tumor growth via DNA methylation</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1038/nm.2608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fnm.2608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=22270723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFSmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=224-226&author=D.+Xiaauthor=D.+Wangauthor=S.-H.+Kimauthor=H.+Katohauthor=R.+N.+DuBois&title=Prostaglandin+E2+promotes+intestinal+tumor+growth+via+DNA+methylation&doi=10.1038%2Fnm.2608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Prostaglandin E2 promotes intestinal tumor growth via DNA methylation</span></div><div class="casAuthors">Xia, Dianren; Wang, Dingzhi; Kim, Sun-Hee; Katoh, Hiroshi; DuBois, Raymond N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-226</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although aberrant DNA methylation is considered to be one of the key ways by which tumor-suppressor and DNA-repair genes are silenced during tumor initiation and progression, the mechanisms underlying DNA methylation alterations in cancer remain unclear.  Here we show that prostaglandin E2 (PGE2) silences certain tumor-suppressor and DNA-repair genes through DNA methylation to promote tumor growth.  These findings uncover a previously unrecognized role for PGE2 in the promotion of tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTr1SGHi4NNbVg90H21EOLACvtfcHk0ljVtUyJ4USS6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFSmurk%253D&md5=fc7251a005fc2424129255e6d5638d71</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnm.2608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2608%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DKatoh%26aufirst%3DH.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DProstaglandin%2520E2%2520promotes%2520intestinal%2520tumor%2520growth%2520via%2520DNA%2520methylation%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D224%26epage%3D226%26doi%3D10.1038%2Fnm.2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohnai, N.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase isozymes and their gene structures and expression</span>. <i>Prostaglandins Other Lipid Mediators</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>68–69</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/s0090-6980(02)00024-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2FS0090-6980%2802%2900024-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=12432912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvV2nsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68%E2%80%9369&publication_year=2002&pages=95-114&author=T.+Tanabeauthor=N.+Tohnai&title=Cyclooxygenase+isozymes+and+their+gene+structures+and+expression&doi=10.1016%2Fs0090-6980%2802%2900024-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase isozymes and their gene structures and expression</span></div><div class="casAuthors">Tanabe, Tadashi; Tohnai, Norimitsu</div><div class="citationInfo"><span class="NLM_cas:title">Prostaglandins & Other Lipid Mediators</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">68-69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-114</span>CODEN:
                <span class="NLM_cas:coden">POLMFL</span>;
        ISSN:<span class="NLM_cas:issn">1098-8823</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The cyclooxygenase (COX, prostaglandin endoperoxide synthase) is a key enzyme in prostaglandin biosynthesis.  Two isoforms of COX, COX-1 and COX-2, have been identified by mol. biol. methods.  The amino acid sequence homol. between COX-1 and COX-2 is about 60% for the human enzymes.  COX-1 is constitutively expressed in most tissues and cells in animal species.  The COX-1 promoter region lacks a canonical TATA or CAAT box and is GC-rich.  These features are consistent with those of a housekeeping gene.  On the other hand, COX-2 is an inducible enzyme and is induced by various cytokines and mitogenic factors.  The induction of COX-2 is suppressed by dexamethasone and PGJ2.  There are many consensus cis-elements in the 5'-flanking region to regulate the expression of COX-2.  Among them, a CRE, an NF-κB site, a NF-IL6 motif and an E-box, regulate transcription independently or synergistically.  Most of the transcriptional signaling pathways require activation of the mitogen-activated protein kinase (MAPK) cascade.  Moreover, MAPK signaling pathways are involved in regulating COX-2 gene expression at the post-transcriptional level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqFxhemLq53rVg90H21EOLACvtfcHk0ljVtUyJ4USS6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvV2nsLs%253D&md5=98a5d784f864e819abd1c5b8a17d6004</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0090-6980%2802%2900024-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0090-6980%252802%252900024-2%26sid%3Dliteratum%253Aachs%26aulast%3DTanabe%26aufirst%3DT.%26aulast%3DTohnai%26aufirst%3DN.%26atitle%3DCyclooxygenase%2520isozymes%2520and%2520their%2520gene%2520structures%2520and%2520expression%26jtitle%3DProstaglandins%2520Other%2520Lipid%2520Mediators%26date%3D2002%26volume%3D68%25E2%2580%259369%26spage%3D95%26epage%3D114%26doi%3D10.1016%2Fs0090-6980%2802%2900024-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinchuk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzaskos, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketo, M. M.</span></span> <span> </span><span class="NLM_article-title">Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1016/s0092-8674(00)81988-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2FS0092-8674%2800%2981988-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=8945508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADyaK28XntlymsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1996&pages=803-809&author=M.+Oshimaauthor=J.+E.+Dinchukauthor=S.+L.+Kargmanauthor=H.+Oshimaauthor=B.+Hancockauthor=E.+Kwongauthor=J.+M.+Trzaskosauthor=J.+F.+Evansauthor=M.+M.+Taketo&title=Suppression+of+intestinal+polyposis+in+Apc+delta716+knockout+mice+by+inhibition+of+cyclooxygenase+2+%28COX-2%29&doi=10.1016%2Fs0092-8674%2800%2981988-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)</span></div><div class="casAuthors">Oshima, Masanobu; Dinchuk, Joseph E.; Kargman, Stacia L.; Oshima, Hiroko; Hancock, Bruno; Kwong, Elizabeth; Trzaskos, James M.; Evans, Jilly F.; Taketo, Makoto M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">803-809</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Two cyclooxygenase isoenzymes catalyze conversion of arachidonic acid to prostaglandin H2: constitutive COX-1 and inducible COX-2.  To assess the role of COX-2 in colorectal tumorigenesis, we detd. the effects of COX-2 gene (Ptgs2) knockouts and a novel COX-2 inhibitor on ApcΔ716 knockout mice, a model of human familial adenomatous polyposis.  A Ptgs2 null mutation reduced the no. and size of the intestinal polyps dramatically.  Furthermore, treating ApcΔ716 mice with a novel COX-2 inhibitor reduced the polyp no. more significantly than with sulindac, which inhibits both isoenzymes.  These results provide direct genetic evidence that COX-2 plays a key role in tumorigenesis and indicate that COX-2-selective inhibitors can be a novel class of therapeutic agents for colorectal polyposis and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3SIHZ--FNr7Vg90H21EOLACvtfcHk0lg37me1OPmWSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntlymsLc%253D&md5=f6fc36452bd2085932025aaa025936f5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981988-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981988-1%26sid%3Dliteratum%253Aachs%26aulast%3DOshima%26aufirst%3DM.%26aulast%3DDinchuk%26aufirst%3DJ.%2BE.%26aulast%3DKargman%26aufirst%3DS.%2BL.%26aulast%3DOshima%26aufirst%3DH.%26aulast%3DHancock%26aufirst%3DB.%26aulast%3DKwong%26aufirst%3DE.%26aulast%3DTrzaskos%26aufirst%3DJ.%2BM.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DTaketo%26aufirst%3DM.%2BM.%26atitle%3DSuppression%2520of%2520intestinal%2520polyposis%2520in%2520Apc%2520delta716%2520knockout%2520mice%2520by%2520inhibition%2520of%2520cyclooxygenase%25202%2520%2528COX-2%2529%26jtitle%3DCell%26date%3D1996%26volume%3D87%26spage%3D803%26epage%3D809%26doi%3D10.1016%2Fs0092-8674%2800%2981988-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukutake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatsugi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, K.</span></span> <span> </span><span class="NLM_article-title">Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1939</span>– <span class="NLM_lpage">1942</span>, <span class="refDoi"> DOI: 10.1093/carcin/19.11.1939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1093%2Fcarcin%2F19.11.1939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=9855006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADyaK1cXnvVCnu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1998&pages=1939-1942&author=M.+Fukutakeauthor=S.+Nakatsugiauthor=T.+Isoiauthor=M.+Takahashiauthor=T.+Ohtaauthor=S.+Mamiyaauthor=Y.+Taniguchiauthor=H.+Satoauthor=K.+Fukudaauthor=T.+Sugimuraauthor=K.+Wakabayashi&title=Suppressive+effects+of+nimesulide%2C+a+selective+inhibitor+of+cyclooxygenase-2%2C+on+azoxymethane-induced+colon+carcinogenesis+in+mice&doi=10.1093%2Fcarcin%2F19.11.1939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice</span></div><div class="casAuthors">Fukutake, Masato; Nakatsugi, Seiichi; Isoi, Takashi; Takahashi, Mami; Ohta, Toshihisa; Mamiya, Souichi; Taniguchi, Yasuaki; Sato, Hidetaka; Fukuda, Kazunori; Sugimura, Takashi; Wakabayashi, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1939-1942</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The effects of nimesulide, a selective inhibitor of cyclooxygenase-2 (COX-2) on azoxymethane (AOM)-induced colon carcinogenesis were investigated in mice.  AOM at a dose of 10 mg/kg body wt was administered to male ICR mice once a week for 6 wk.  The animals were fed on AIN-76A powder diet contg. nimesulide at doses of 200 or 400 p.p.m., starting the day before the first carcinogen treatment until the end of the expt., at week 30.  Administration of nimesulide reduced the incidence of colon carcinomas to 32 and 25% for the AOM + 200 and 400 p.p.m. nimesulide groups, resp., compared with the AOM + basal diet group (50%).  Multiplicities of colon carcinomas in the 200 and 400 p.p.m. nimesulide-treated groups were 0.70 ± 0.28 and 0.35 ± 0.11, resp., being significantly smaller than the AOM alone value (1.79 ± 0.47).  The sizes of the colon carcinomas in the nimesulide-treated groups were also decreased.  No significant influence on liver and lung tumor development was apparent.  Thus, nimesulide exerted a suppressive effect on AOM-induced colon carcinogenesis in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-A6HxAiQGsLVg90H21EOLACvtfcHk0lg37me1OPmWSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvVCnu74%253D&md5=483d5eb26bab6d5721c686372b937076</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2F19.11.1939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252F19.11.1939%26sid%3Dliteratum%253Aachs%26aulast%3DFukutake%26aufirst%3DM.%26aulast%3DNakatsugi%26aufirst%3DS.%26aulast%3DIsoi%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DT.%26aulast%3DMamiya%26aufirst%3DS.%26aulast%3DTaniguchi%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DSugimura%26aufirst%3DT.%26aulast%3DWakabayashi%26aufirst%3DK.%26atitle%3DSuppressive%2520effects%2520of%2520nimesulide%252C%2520a%2520selective%2520inhibitor%2520of%2520cyclooxygenase-2%252C%2520on%2520azoxymethane-induced%2520colon%2520carcinogenesis%2520in%2520mice%26jtitle%3DCarcinogenesis%26date%3D1998%26volume%3D19%26spage%3D1939%26epage%3D1942%26doi%3D10.1093%2Fcarcin%2F19.11.1939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arguello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketo, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1733</span>– <span class="NLM_lpage">1740</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11245490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvVeksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=1733-1740&author=M.+Oshimaauthor=N.+Muraiauthor=S.+Kargmanauthor=M.+Arguelloauthor=P.+Lukauthor=E.+Kwongauthor=M.+M.+Taketoauthor=J.+F.+Evans&title=Chemoprevention+of+intestinal+polyposis+in+the+Apcdelta716+mouse+by+rofecoxib%2C+a+specific+cyclooxygenase-2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoprevention of intestinal polyposis in the ApcΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor</span></div><div class="casAuthors">Oshima, Masanobu; Murai, Naomi; Kargman, Stacia; Arguello, Meztli; Luk, Pauline; Kwong, Elizabeth; Taketo, Makoto M.; Evans, Jilly F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1733-1740</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations in the human adenomatous polyposis (APC) gene are causative for familial adenomatous polyposis (FAP), a rare condition in which numerous colonic polyps arise during puberty and, if left untreated, lead to colon cancer.  The APC gene is a tumor suppressor that has been termed the "gatekeeper gene" for colon cancer.  In addn. to the 100% mutation rate in FAP patients, the APC gene is mutated in >80% of sporadic colon and intestinal cancers.  The Apc gene in mice has been mutated either by chem. carcinogenesis, resulting in the Min mouse ApcΔ850, or by heterologous recombination, resulting in the ApcΔ716 or ApcΔ1368 mice.  Although homozygote Apc-/- mice are embryonically lethal, the heterozygotes are viable but develop numerous intestinal polyps with loss of Apc heterozygosity within the polyps.  The proinflammatory, prooncogenic protein cyclooxygenase (COX)-2 has been shown to be markedly induced in the ApcΔ716 polyps at an early stage of polyp development.  We demonstrate here that treatment with the specific COX-2 inhibitor rofecoxib results in a dose-dependent redn. in the no. and size of intestinal and colonic polyps in the ApcΔ716 mouse.  The plasma concn. of rofecoxib that resulted in a 55% inhibition of polyp no. and an 80% inhibition of polyps > 1 mm in size is comparable with the human clin. steady-state concn. of 25 mg rofecoxib (Vioxx) taken once daily.  Polyps from both untreated and rofecoxib- or sulindac-treated ApcΔ716 mice expressed COX-1 and -2, whereas normal epithelium from all mice expressed COX-1 but minimal amts. of COX-2.  Polyps from either rofecoxib- or sulindac-treated mice had lower rates of DNA replication, expressed less proangiogenic vascular endothelial-derived growth factor and more membrane-bound β-catenin, but showed unchanged nuclear localization of this transcription factor.  This study showing the inhibition of polyposis in the ApcΔ716 mouse suggests that the specific COX-2 inhibitor rofecoxib (Vioxx) has potential as a chemopreventive agent in human intestinal and colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruBvlEU33JU7Vg90H21EOLACvtfcHk0lg37me1OPmWSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvVeksr4%253D&md5=9399fcfc94603a0b95564bae11d2e349</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOshima%26aufirst%3DM.%26aulast%3DMurai%26aufirst%3DN.%26aulast%3DKargman%26aufirst%3DS.%26aulast%3DArguello%26aufirst%3DM.%26aulast%3DLuk%26aufirst%3DP.%26aulast%3DKwong%26aufirst%3DE.%26aulast%3DTaketo%26aufirst%3DM.%2BM.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DChemoprevention%2520of%2520intestinal%2520polyposis%2520in%2520the%2520Apcdelta716%2520mouse%2520by%2520rofecoxib%252C%2520a%2520specific%2520cyclooxygenase-2%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D1733%26epage%3D1740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span> <span> </span><span class="NLM_article-title">Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">46</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-5-46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1186%2F1471-2407-5-46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=15892897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD2MzhsFWhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=46&author=H.+Kohnoauthor=R.+Suzukiauthor=S.+Sugieauthor=T.+Tanaka&title=Suppression+of+colitis-related+mouse+colon+carcinogenesis+by+a+COX-2+inhibitor+and+PPAR+ligands&doi=10.1186%2F1471-2407-5-46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands</span></div><div class="casAuthors">Kohno Hiroyuki; Suzuki Rikako; Sugie Shigeyuki; Tanaka Takuji</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  It is generally assumed that inflammatory bowel disease (IBD)-related carcinogenesis occurs as a result of chronic inflammation.  We previously developed a novel colitis-related mouse colon carcinogenesis model initiated with azoxymethane (AOM) and followed by dextran sodium sulfate (DSS).  In the present study we investigated whether a cyclooxygenase (COX)-2 inhibitor nimesulide and ligands for peroxisome proliferator-activated receptors (PPARs), troglitazone (a PPARgamma ligand) and bezafibrate (a PPARalpha ligand) inhibit colitis-related colon carcinogenesis using our model to evaluate the efficacy of these drugs in prevention of IBD-related colon carcinogenesis.  METHODS:  Female CD-1 (ICR) mice were given a single intraperitoneal administration of AOM (10 mg/kg body weight) and followed by one-week oral exposure of 2% (w/v) DSS in drinking water, and then maintained on the basal diets mixed with or without nimesulide (0.04%, w/w), troglitazone (0.05%, w/w), and bezafibrate (0.05%, w/w) for 14 weeks.  The inhibitory effects of dietary administration of these compounds were determined by histopathological and immunohistochemical analyses.  RESULTS:  Feeding with nimesulide and troglitazone significantly inhibited both the incidence and multiplicity of colonic adenocarcinoma induced by AOM/DSS in mice.  Bezafibrate feeding significantly reduced the incidence of colonic adenocarcinoma, but did not significantly lower the multiplicity.  Feeding with nimesulide and troglitazone decreased the proliferating cell nuclear antigen (PCNA)-labeling index and expression of beta-catenin, COX-2, inducible nitric oxide synthase (iNOS) and nitrotyrosine.  The treatments increased the apoptosis index in the colonic adenocarcinoma.  Feeding with bezafibrate also affected these parameters except for beta-catenin expression in the colonic malignancy.  CONCLUSION:  Dietary administration of nimesulide, troglitazone and bezafibrate effectively suppressed the development of colonic epithelial malignancy induced by AOM/DSS in female ICR mice.  The results suggest that COX-2 inhibitor and PPAR ligands could serve as an effective agent against colitis-related colon cancer development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyAfRYtKH1_UHdcurJClFcfW6udTcc2ebXsC4RE1QD0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzhsFWhug%253D%253D&md5=2a61a3291a0b0f39beea1b21832a61cd</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-5-46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-5-46%26sid%3Dliteratum%253Aachs%26aulast%3DKohno%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DSugie%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DT.%26atitle%3DSuppression%2520of%2520colitis-related%2520mouse%2520colon%2520carcinogenesis%2520by%2520a%2520COX-2%2520inhibitor%2520and%2520PPAR%2520ligands%26jtitle%3DBMC%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D46%26doi%3D10.1186%2F1471-2407-5-46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rácz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavoral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breazna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechuga, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstein, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eagle, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, B.</span></span> <span> </span><span class="NLM_article-title">Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1135</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1038/ajg.2011.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fajg.2011.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=21503000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BC3MrntVSjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2011&pages=1135-1146&author=N.+Arberauthor=J.+Spicakauthor=I.+R%C3%A1czauthor=M.+Zavoralauthor=A.+Breaznaauthor=P.+Gerlettiauthor=M.+J.+Lechugaauthor=N.+Collinsauthor=R.+B.+Rosensteinauthor=C.+J.+Eagleauthor=B.+Levin&title=Five-year+analysis+of+the+prevention+of+colorectal+sporadic+adenomatous+polyps+trial&doi=10.1038%2Fajg.2011.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial</span></div><div class="casAuthors">Arber Nadir; Spicak Julius; Racz Istvan; Zavoral Miroslav; Breazna Aurora; Gerletti Paola; Lechuga Maria J; Collins Neal; Rosenstein Rebecca B; Eagle Craig J; Levin Bernard</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of gastroenterology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1135-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Subjects in the Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trial (PRESAP/NCT00141193/www.clinicaltrials.gov) were studied to determine efficacy and safety at a year 5 assessment.  METHODS:  In this randomized, placebo-controlled, double-blind trial, 1,561 subjects with diagnosed colorectal adenomas removed within 3 months of the study's initiation were assessed after ~ 3 years on celecoxib followed by 2 years off.  Studied in 107 primary and secondary care settings, subjects were stratified by cardioprotective aspirin use and randomized to receive orally 400 ng celecoxib (933 subjects) or placebo (628 subjects) once daily.  Efficacy was measured by colonoscopy at years 1, 3, and 5, and safety was measured by investigators for the on-treatment period and collected by subject self-report over 2 years post-treatment.  RESULTS:  At year 5, the primary outcome measure was the rate of new adenomas measured cumulatively from baseline.  This rate was statistically significantly lower in the celecoxib group (51.4%) than in the placebo group (57.5%; P<0.001).  Similarly, the cumulative rate of new advanced adenomas was significantly lower in the celecoxib group (10.0%) than in the placebo group (13.8%; P=0.007).  However, the year 5 interval measure, which was not cumulative and did not take the rates of previous years into account, showed that after 2 years off treatment, the celecoxib group (27.0%) was 1.66 times more likely to have new adenomas than the placebo group (16.3%; P<0.0001).  Similarly, the percentage of patients with new advanced adenomas was significantly higher in the celecoxib group (5.0%) than in the placebo group (3.8%) (P=0.0072).  The evaluation of safety from baseline through year 5 indicated that the risks of serious cardiac disorders (relative risk (RR) 1.66; 95% confidence interval (CI) 1.01-2.73), selected renal/hypertension events (RR 1.35; 95% CI 1.09-1.68), and general vascular (RR 1.34; 95% CI 1.08-1.68) and cardiac disorders (RR 1.59; 95% CI 1.12-2.26) were higher in those taking celecoxib than in those on placebo.  CONCLUSIONS:  The year 5 cumulative measures of the incidence of new and advanced adenomas were significantly lower in the celecoxib group than in the placebo group, but the year 5 interval rates of these measures were significantly lower in the placebo group than the celecoxib group, perhaps suggesting a release of cyclooxygenase-2 inhibition.  Consistent with what has been previously reported, increased risk of renal/hypertension events and cardiac disorders associated with celecoxib therapy mandates caution in patient selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbWOm5UyaukMkU0YCbOU3EfW6udTcc2ebXsC4RE1QD0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrntVSjtw%253D%253D&md5=9c1087c8453feaad12169fb57afe6079</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fajg.2011.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajg.2011.116%26sid%3Dliteratum%253Aachs%26aulast%3DArber%26aufirst%3DN.%26aulast%3DSpicak%26aufirst%3DJ.%26aulast%3DR%25C3%25A1cz%26aufirst%3DI.%26aulast%3DZavoral%26aufirst%3DM.%26aulast%3DBreazna%26aufirst%3DA.%26aulast%3DGerletti%26aufirst%3DP.%26aulast%3DLechuga%26aufirst%3DM.%2BJ.%26aulast%3DCollins%26aufirst%3DN.%26aulast%3DRosenstein%26aufirst%3DR.%2BB.%26aulast%3DEagle%26aufirst%3DC.%2BJ.%26aulast%3DLevin%26aufirst%3DB.%26atitle%3DFive-year%2520analysis%2520of%2520the%2520prevention%2520of%2520colorectal%2520sporadic%2520adenomatous%2520polyps%2520trial%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2011%26volume%3D106%26spage%3D1135%26epage%3D1146%26doi%3D10.1038%2Fajg.2011.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zauber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawk, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertagnolli, M.</span></span> <span> </span><span class="NLM_article-title">Adenoma prevention with celecoxib (APC) study investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1071</span>– <span class="NLM_lpage">1080</span>, <span class="refDoi"> DOI: 10.1056/nejmoa050405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1056%2FNEJMoa050405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=15713944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Kqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1071-1080&author=S.+D.+Solomonauthor=J.+J.+V.+McMurrayauthor=M.+A.+Pfefferauthor=J.+Wittesauthor=R.+Fowlerauthor=P.+Finnauthor=W.+F.+Andersonauthor=A.+Zauberauthor=E.+Hawkauthor=M.+Bertagnolli&title=Adenoma+prevention+with+celecoxib+%28APC%29+study+investigators.+Cardiovascular+risk+associated+with+celecoxib+in+a+clinical+trial+for+colorectal+adenoma+prevention&doi=10.1056%2Fnejmoa050405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention</span></div><div class="casAuthors">Solomon, Scott D.; McMurray, John J. V.; Pfeffer, Marc A.; Wittes, Janet; Fowler, Robert; Finn, Peter; Anderson, William F.; Zauber, Ann; Hawk, Ernest; Bertagnolli, Monica</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1071-1080</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Selective cyclooxygenase-2(COX-2) inhibitors have come under scrutiny because of reports suggesting an increased cardiovascular risk assocd. with their use.  Exptl. research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern.  We reviewed all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who were enrolled in a trial comparing two doses of celecoxib (200 mg or 400 mg twice daily) with placebo for the prevention of colorectal adenomas.  All deaths were categorized as cardiovascular or noncardiovascular, and nonfatal cardiovascular events were categorized in a blinded fashion according to a prespecified scheme.  For all patients except those who died, 2.8 to 3.1 years of follow-up data were available.  A composite cardiovascular end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure was reached in 7 of 679 patients in the placebo group (1.0 %), as compared with 16 of 685 patients receiving 200 mg of celecoxib twice daily (2.3 %; hazard ratio, 2.3; 95 % confidence interval, 0.9 to 5.5) and with 23 of 671 patients receiving 400 mg of celecoxib twice daily (3.4 %; hazard ratio, 3.4; 95 % confidence interval, 1.4 to 7.8).  Similar trends were obsd. for other composite end points.  On the basis of these observations, the data and safety monitoring board recommended early discontinuation of the study drug.  Celecoxib use was assocd. with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure.  In light of recent reports of cardiovascular harm assocd. with treatment with other agents in this class, these data provide further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2PPDnO2tXU7Vg90H21EOLACvtfcHk0lh_wJv9MCkPzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Kqur4%253D&md5=5df251ddfc12b7d625c888ec7b09606b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050405%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DPfeffer%26aufirst%3DM.%2BA.%26aulast%3DWittes%26aufirst%3DJ.%26aulast%3DFowler%26aufirst%3DR.%26aulast%3DFinn%26aufirst%3DP.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DZauber%26aufirst%3DA.%26aulast%3DHawk%26aufirst%3DE.%26aulast%3DBertagnolli%26aufirst%3DM.%26atitle%3DAdenoma%2520prevention%2520with%2520celecoxib%2520%2528APC%2529%2520study%2520investigators.%2520Cardiovascular%2520risk%2520associated%2520with%2520celecoxib%2520in%2520a%2520clinical%2520trial%2520for%2520colorectal%2520adenoma%2520prevention%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1071%26epage%3D1080%26doi%3D10.1056%2Fnejmoa050405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y.</span></span> <span> </span><span class="NLM_article-title">N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">1831</span>– <span class="NLM_lpage">1842</span>, <span class="refDoi"> DOI: 10.1002/jps.23082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1002%2Fjps.23082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=22334096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1WhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2012&pages=1831-1842&author=Y.+Leeauthor=J.+Kimauthor=H.+Kimauthor=S.+Kangauthor=J.-H.+Yoonauthor=D.-D.+Kimauthor=Y.+M.+Kimauthor=Y.+Jung&title=N-succinylaspart-1-yl+celecoxib+is+a+potential+colon-specific+prodrug+of+celecoxib+with+improved+therapeutic+properties&doi=10.1002%2Fjps.23082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties</span></div><div class="casAuthors">Lee, Yonghyun; Kim, Jeongyun; Kim, Hyunjeong; Kang, Sookjin; Yoon, Jeong-Hyun; Kim, Dae-Duk; Kim, Young Mi; Jung, Yunjin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1831-1842</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To develop a colon-specific prodrug of celecoxib, a cyclooxygenase-2 selective inhibitor, which could improve cardiovascular toxicity and therapeutic effectiveness for chemoprevention of colorectal cancer, aspart-1-yl celecoxib (A1C) or aspart-4-yl celecoxib (A4C), succinyl celecoxib (SC), and N-succinylaspart-1-yl celecoxib (SA1C) or N-succinylaspart-4-yl celecoxib (SA4C) were prepd. and evaluated as a prodrug with such beneficial properties.  On incubation with the small intestinal contents while SC, SA1C, and SA4C were stable, A1C and A4C were degraded to liberate celecoxib.  In the cecal contents, the other conjugates except for SC and SA4C were cleaved to release celecoxib.  These results suggest the colon-specific delivery and activation of SA1C.  On oral administration of SA1C or celecoxib, no SA1C was detected in the blood and urine, indicating the limited absorption of SA1C.  SA1C delivered a much greater amt. of celecoxib to the large intestine while keeping the plasma concn. of celecoxib at much lower level, which is consistent with no change of the serum level of 6-ketoprostaglandin F1α whose decrease is assocd. with the cardiovascular toxicity of celecoxib.  Moreover, SA1C administered orally supplied a greater concn. of celecoxib for the whole colonic tissue.  Taken together, SA1C may be a colon-specific prodrug of celecoxib with improved therapeutic properties.  © 2012 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH8q8MLsDG3LVg90H21EOLACvtfcHk0ljwv3ydVrdMWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1WhsLY%253D&md5=2bed14ce990dcbe5f7b77d138d04d08c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fjps.23082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23082%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DYoon%26aufirst%3DJ.-H.%26aulast%3DKim%26aufirst%3DD.-D.%26aulast%3DKim%26aufirst%3DY.%2BM.%26aulast%3DJung%26aufirst%3DY.%26atitle%3DN-succinylaspart-1-yl%2520celecoxib%2520is%2520a%2520potential%2520colon-specific%2520prodrug%2520of%2520celecoxib%2520with%2520improved%2520therapeutic%2520properties%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D101%26spage%3D1831%26epage%3D1842%26doi%3D10.1002%2Fjps.23082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y.</span></span> <span> </span><span class="NLM_article-title">Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis</span>. <i>J. Drug Targeting</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.3109/1061186x.2012.693498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.3109%2F1061186X.2012.693498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=22632102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns1yqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=524-534&author=Y.+Leeauthor=H.+Kimauthor=W.+Kimauthor=J.-H.+Yoonauthor=S.+H.+Jeongauthor=Y.+Jung&title=Colon-specific+delivery+of+celecoxib+is+a+potential+strategy+to+improve+toxicological+and+pharmacological+properties+of+the+selective+Cox-2+inhibitor%3A+implication+in+treatment+of+familiar+adenomatous+polyposis&doi=10.3109%2F1061186x.2012.693498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis</span></div><div class="casAuthors">Lee, Yonghyun; Kim, Hyunjeong; Kim, Wooseong; Yoon, Jeong-Hyun; Jeong, Seong Hoon; Jung, Yunjin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">524-534</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1026-7158</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">In general, colon-specific delivery of a drug decreases systemic absorption and increases therapeutic concn. of the drug at the target site.  N-succinylglutam-1 or 5-yl celecoxib (SG1C and SG5C) were prepd. as a colon-specific prodrug of celecoxib, a selective Cox-2 inhibitor, and investigated whether the celecoxib derivs. could deliver celecoxib to the target site and improve cardiovascular toxicity and therapeutic effectiveness for the treatment of familiar adenomatous polyposis.  SG1C and SA5C were cleaved to release celecoxib in the cecal contents while stable in small intestinal contents.  The cecal release of celecoxib was much greater for SG1C than SG5C.  SG1C administered orally was barely detected in the blood and urine.  SG1C delivered much greater amt. of celecoxib to the large intestine while keeping the plasma concn. of celecoxib at much lower level compared with oral administration of free celecoxib.  Consistent with these pharmacokinetic results, SG1C supplied a greater concn. of celecoxib for the entire colonic tissue and did not change the serum level of 6-keto-PGF1α whose decrease is assocd. with the cardiovascular toxicity of celecoxib.  Taken together, colon-specific delivery of celecoxib using a prodrug approach may be a useful strategy to improve toxicol. and pharmacol. properties of celecoxib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR3Vyh3Q_nNbVg90H21EOLACvtfcHk0ljwv3ydVrdMWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns1yqu70%253D&md5=c38a57f47b7e9d7558ba471c7f6be296</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3109%2F1061186X.2012.693498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F1061186X.2012.693498%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DYoon%26aufirst%3DJ.-H.%26aulast%3DJeong%26aufirst%3DS.%2BH.%26aulast%3DJung%26aufirst%3DY.%26atitle%3DColon-specific%2520delivery%2520of%2520celecoxib%2520is%2520a%2520potential%2520strategy%2520to%2520improve%2520toxicological%2520and%2520pharmacological%2520properties%2520of%2520the%2520selective%2520Cox-2%2520inhibitor%253A%2520implication%2520in%2520treatment%2520of%2520familiar%2520adenomatous%2520polyposis%26jtitle%3DJ.%2520Drug%2520Targeting%26date%3D2012%26volume%3D20%26spage%3D524%26epage%3D534%26doi%3D10.3109%2F1061186x.2012.693498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filipski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span> <span> </span><span class="NLM_article-title">Intestinal targeting of drugs: rational design approaches and challenges</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.2174/1568026611313070002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.2174%2F1568026611313070002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=23578023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsVaqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=776-802&author=K.+J.+Filipskiauthor=M.+V.+Varmaauthor=A.+F.+El-Kattanauthor=C.+M.+Amblerauthor=R.+B.+Ruggeriauthor=T.+C.+Goosenauthor=K.+O.+Cameron&title=Intestinal+targeting+of+drugs%3A+rational+design+approaches+and+challenges&doi=10.2174%2F1568026611313070002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal targeting of drugs: rational design approaches and challenges</span></div><div class="casAuthors">Filipski, Kevin J.; Varma, Manthena V.; El-Kattan, Ayman F.; Ambler, Catherine M.; Ruggeri, Roger B.; Goosen, Theunis C.; Cameron, Kimberly O.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">776-802</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting drugs to the gastrointestinal tract has been and continues to be an active area of research.  Guttargeting is an effective means of increasing the local concn. of active substance at the desired site of action while minimizing concns. elsewhere in the body that could lead to unwanted side-effects.  Several approaches to intestinal targeting exist.  Physicochem. property manipulation can drive mols. to large, polar, low absorption space or alternatively to lipophilic, high clearance space in order to minimize systemic exposure.  Design of compds. that are substrates for transporters within the gastrointestinal tract, either uptake or efflux, or at the hepato-biliary interface, may help to increase intestinal concn.  Prodrug strategies have been shown to be effective particularly for colon targeting, and several different technol. formulation approaches are currently being researched.  This review provides examples of various approaches to intestinal targeting, and discusses challenges and areas in need of future scientific advances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn5CowmF-p-LVg90H21EOLACvtfcHk0ljwv3ydVrdMWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsVaqt7w%253D&md5=b950400c76b8d955ebd39e6cad4a20aa</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.2174%2F1568026611313070002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313070002%26sid%3Dliteratum%253Aachs%26aulast%3DFilipski%26aufirst%3DK.%2BJ.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26atitle%3DIntestinal%2520targeting%2520of%2520drugs%253A%2520rational%2520design%2520approaches%2520and%2520challenges%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D776%26epage%3D802%26doi%3D10.2174%2F1568026611313070002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span> <span> </span><span class="NLM_article-title">Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">524</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.00524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.3389%2Ffphar.2020.00524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=32425781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFKktbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=524&author=S.+Hua&title=Advances+in+oral+drug+delivery+for+regional+targeting+in+the+gastrointestinal+tract+-+influence+of+physiological%2C+pathophysiological+and+pharmaceutical+factors&doi=10.3389%2Ffphar.2020.00524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors</span></div><div class="casAuthors">Hua, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">00524</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The oral route is by far the most common route of drug administration in the gastrointestinal tract and can be used for both systemic drug delivery and for treating local gastrointestinal diseases.  It is the most preferred route by patients, due to its advantages, such as ease of use, non-invasiveness, and convenience for self administration.  Formulations can also be designed to enhance drug delivery to specific regions in the upper or lower gastrointestinal tract.  Despite the clear advantages offered by the oral route, drug delivery can be challenging as the human gastrointestinal tract is complex and displays a no. of physiol. barriers that affect drug delivery.  Among these challenges are poor drug stability, poor drug soly., and low drug permeability across the mucosal barriers.  Attempts to overcome these issues have focused on improved understanding of the physiol. of the gastrointestinal tract in both healthy and diseased states.  Innovative pharmaceutical approaches have also been explored to improve regional drug targeting in the gastrointestinal tract, including nanoparticulate formulations.  This review will discuss the physiol., pathophysiol., and pharmaceutical considerations influencing drug delivery for the oral route of administration, as well as the conventional and novel drug delivery approaches.  The translational challenges and development aspects of novel formulations will also be addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9AssynyIctbVg90H21EOLACvtfcHk0li-WVCrIwNpPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFKktbfP&md5=178306800c1f4256026282dffc97c354</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.00524%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26atitle%3DAdvances%2520in%2520oral%2520drug%2520delivery%2520for%2520regional%2520targeting%2520in%2520the%2520gastrointestinal%2520tract%2520-%2520influence%2520of%2520physiological%252C%2520pathophysiological%2520and%2520pharmaceutical%2520factors%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D524%26doi%3D10.3389%2Ffphar.2020.00524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madge, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawczuk, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreutter, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacani, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichenor, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaviya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seierstad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzolio, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a gut-restricted JAK inhibitor for the treatment of inflammatory bowel disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2915</span>– <span class="NLM_lpage">2929</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01439</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01439" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlOmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2915-2929&author=K.+A.+Leonardauthor=L.+A.+Madgeauthor=P.+J.+Krawczukauthor=A.+Wangauthor=K.+D.+Kreutterauthor=G.+M.+Bacaniauthor=W.+Chaiauthor=R.+C.+Smithauthor=M.+S.+Tichenorauthor=M.+C.+Harrisauthor=R.+Malaviyaauthor=M.+Seierstadauthor=M.+E.+Johnsonauthor=J.+D.+Venableauthor=S.+Kimauthor=G.+C.+Hirstauthor=A.+S.+Mathurauthor=T.+S.+Raoauthor=J.+P.+Edwardsauthor=M.+C.+Rizzolioauthor=T.+Koudriakova&title=Discovery+of+a+gut-restricted+JAK+inhibitor+for+the+treatment+of+inflammatory+bowel+disease&doi=10.1021%2Facs.jmedchem.9b01439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease</span></div><div class="casAuthors">Leonard, Kristi A.; Madge, Lisa A.; Krawczuk, Paul J.; Wang, Aihua; Kreutter, Kevin D.; Bacani, Genesis M.; Chai, Wenying; Smith, Russell C.; Tichenor, Mark S.; Harris, Michael C.; Malaviya, Ravi; Seierstad, Mark; Johnson, Marguerite E.; Venable, Jennifer D.; Kim, Suzie; Hirst, Gavin C.; Mathur, Ashok S.; Rao, Tadimeti S.; Edwards, James P.; Rizzolio, Michele C.; Koudriakova, Tatiana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2915-2929</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To identify Janus kinase (JAK) inhibitors that selectively target gastrointestinal tissues with limited systemic exposures, a class of imidazopyrrolopyridines with a range of phys. properties was prepd. and evaluated.  We identified compds. with low intrinsic permeability and detd. a correlation between permeability and physicochem. properties, clogP and tPSA, for a subset of compds.  This low intrinsic permeability translated into compds. displaying high colonic exposure and low systemic exposure after oral dosing at 25 mg/kg in mouse.  In a mouse PK/PD model, oral dosing of lead compd. 2 demonstrated dose-dependent inhibition of pSTAT phosphorylation in colonic explants post-oral dose but low systemic exposure and no measurable systemic pharmacodynamic activity.  We thus demonstrate the utility of JAK inhibitors with low intrinsic permeability as a feasible approach to develop gut-restricted, pharmacol. active mols. with a potential advantage over systemically available compds. that are limited by systemic on-target adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD40Yr_F26I7Vg90H21EOLACvtfcHk0li-WVCrIwNpPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlOmsLY%253D&md5=83d9007f45ba0c4d9c9dc00abfb49f9e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01439%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DK.%2BA.%26aulast%3DMadge%26aufirst%3DL.%2BA.%26aulast%3DKrawczuk%26aufirst%3DP.%2BJ.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DKreutter%26aufirst%3DK.%2BD.%26aulast%3DBacani%26aufirst%3DG.%2BM.%26aulast%3DChai%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DR.%2BC.%26aulast%3DTichenor%26aufirst%3DM.%2BS.%26aulast%3DHarris%26aufirst%3DM.%2BC.%26aulast%3DMalaviya%26aufirst%3DR.%26aulast%3DSeierstad%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26aulast%3DVenable%26aufirst%3DJ.%2BD.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26aulast%3DMathur%26aufirst%3DA.%2BS.%26aulast%3DRao%26aufirst%3DT.%2BS.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DRizzolio%26aufirst%3DM.%2BC.%26aulast%3DKoudriakova%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520gut-restricted%2520JAK%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520bowel%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2915%26epage%3D2929%26doi%3D10.1021%2Facs.jmedchem.9b01439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanwar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piplani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, S.</span></span> <span> </span><span class="NLM_article-title">Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis</span>. <i>Asian Pac. J. Cancer Prev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1329</span>– <span class="NLM_lpage">1333</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=21198287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FotlGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1329-1333&author=L.+Tanwarauthor=H.+Piplaniauthor=S.+Sanyal&title=Anti-proliferative+and+apoptotic+effects+of+etoricoxib%2C+a+selective+COX-2+inhibitor%2C+on+1%2C2-dimethylhydrazine+dihydrochloride-induced+colon+carcinogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis</span></div><div class="casAuthors">Tanwar Lalita; Piplani Honit; Sanyal Sn</div><div class="citationInfo"><span class="NLM_cas:title">Asian Pacific journal of cancer prevention : APJCP</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1329-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the present study, we assessed effects of etoricoxib, a non-steroidal anti-inflammatory drug, on proliferation and apoptosis in 1,2-dimethylhydrazine dihydrochloride (DMH) induced colon lesion development.  Male SD rats were divided into four groups: Group 1 controls receiving the vehicle treatment; Group 2 administered DMH weekly (30 mg/kg body weight, subcutaneously) alone; Group 3, DMH weekly plus etoricoxib (0.64 mg/kg body weight, orally) daily; and Group 4, etoricoxib alone.  After six weeks of treatment, animals were sacrificed and colons were analysed for morphological and histopathological features.  Well characterized pre-neoplastic aberrations such as multiple plaque lesions, hyperplasia and dysplasia were found in the DMH treated group whereas these features were reduced with co-administration of etoricoxib.  To study apoptosis, colonocytes were isolated by metal chelation from colonic sacs and studied by fluorescent staining and further confirmed by DNA fragmentation.  The DMH treated animals had fewer apoptotic nuclei as compared to the controls, but numbers were higher with DMH+etoricoxib as well as etoricoxib alone.  Expression of proliferative cell nuclear antigen (PCNA), assessed by Western blot analysis and immunohistochemistry, was found to be elevated by DMH treatment group and again reduced by etoricoxib.  Results for bromodeoxyuridine incorporation (BrdU) were in agreement.  It may be concluded that the drug, etoricoxib, has the potential to act as an anti-apoptotic and anti- proliferative agent in the colon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0e2HGwvlkQvtos8R3JUhXfW6udTcc2eb_cnQgybz-77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FotlGqsQ%253D%253D&md5=280c999372ebedfd43b8cdafaca558b7</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTanwar%26aufirst%3DL.%26aulast%3DPiplani%26aufirst%3DH.%26aulast%3DSanyal%26aufirst%3DS.%26atitle%3DAnti-proliferative%2520and%2520apoptotic%2520effects%2520of%2520etoricoxib%252C%2520a%2520selective%2520COX-2%2520inhibitor%252C%2520on%25201%252C2-dimethylhydrazine%2520dihydrochloride-induced%2520colon%2520carcinogenesis%26jtitle%3DAsian%2520Pac.%2520J.%2520Cancer%2520Prev.%26date%3D2010%26volume%3D11%26spage%3D1329%26epage%3D1333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Miedany, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youssef, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Gaafary, M.</span></span> <span> </span><span class="NLM_article-title">The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1111/j.1572-0241.2006.00384.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1111%2Fj.1572-0241.2006.00384.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16454836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28XitFSgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2006&pages=311-317&author=Y.+El%0AMiedanyauthor=S.+Youssefauthor=I.+Ahmedauthor=M.+El+Gaafary&title=The+gastrointestinal+safety+and+effect+on+disease+activity+of+etoricoxib%2C+a+selective+cox-2+inhibitor+in+inflammatory+bowel+diseases&doi=10.1111%2Fj.1572-0241.2006.00384.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases</span></div><div class="casAuthors">El Miedany, Yasser; Youssef, Sally; Ahmed, Ihab; El Gaafary, Maha</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">While traditional nonsteroidal antiinflammatory drugs (t-NSAIDs) are relatively contraindicated in patients with inflammatory bowel disease (IBD) for fear of disease aggravation, controlled clin. trials showed that cyclo-oxygenase-2 inhibitors have fewer gastrointestinal side effects than the t-NSAIDs.  Etoricoxib is a new antiinflammatory inhibitor that has high Cox-2 selectivity.  To assess the safety of etoricoxib and effect on disease activity in patients with IBD in a multicenter, double-blind, placebo-control study.  Study group included 76 patients suffering from IBD (ulcerative colitis (DC), and Crohn's disease (CD)).  The control group included 70 patients known to have UC and CD.  Patients of both groups were referred to the rheumatol. clinic for rheumatic manifestations that require antiinflammatory therapy and were intolerable to the t-NSAIDs.  The level of the IBD activity at the baseline visit, when drug/placebo therapy was initiated, was scored for all subjects included in the study.  In the study group the dose of etoricoxib ranged from 60 to 120 mg tablet once a day according to their rheumatic condition.  The control group received a placebo tablet once a day.  Adverse events related to the use of the study medication in 1 and 3 mo time were documented.  Etoricoxib/placebo therapy was stopped once the patient experience flare up of their IBD.  There was no significant difference between the patients and the control groups.  After 3 mo of etoricoxib therapy, 8 of 76 (10.53%) of the study group had aggravation of their underlying IBD and stopped the drug therapy, while 68 of 76 (89.5%) completed the study.  The mean disease activity index before etoricoxib therapy was 1.15 + 0.794, whereas it was 1.19 + 0.683 after therapy.  In the control group 8 of 70 (11.43%) experienced exacerbation of their symptoms while 62 of 70 (88.6%) completed the study.  In the control group the mean disease activity before treatment was 1.16 + 0.253, whereas after placebo therapy was 1.20 + 0.481.  Six-seven of 76 (88.2%) of the study group and 62 of 70 (88.6%) of the control group gave history of using t-NSAID therapy in addn. to PPI that caused flare up of their IBD.  For the patients who had to stop their drug therapy, all the adverse events occurred in the first month of drug/placebo challenge and all symptoms were reversible.  Etoricoxib therapy is safe and beneficial in most patients with IBD treatment with etoricoxib was not assocd. with exacerbation of the underlying IBD- and GI-related complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7mYyZQNQXWrVg90H21EOLACvtfcHk0ljpNwYCvz_I7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitFSgtrw%253D&md5=f848fd270519bbeef45c06488c4144bc</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fj.1572-0241.2006.00384.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1572-0241.2006.00384.x%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BMiedany%26aufirst%3DY.%26aulast%3DYoussef%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DI.%26aulast%3DEl%2BGaafary%26aufirst%3DM.%26atitle%3DThe%2520gastrointestinal%2520safety%2520and%2520effect%2520on%2520disease%2520activity%2520of%2520etoricoxib%252C%2520a%2520selective%2520cox-2%2520inhibitor%2520in%2520inflammatory%2520bowel%2520diseases%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2006%26volume%3D101%26spage%3D311%26epage%3D317%26doi%3D10.1111%2Fj.1572-0241.2006.00384.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G.</span>; <span class="NLM_string-name">Suarez, J.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Connolly, P.</span>; <span class="NLM_string-name">Ahn, K.</span></span> <span> </span><span class="NLM_article-title">Potent phenylpyridine and oxodihydrofuran inhibitors of cyclooxygenase-2: optimization towards long residence time with balanced internal energetics</span>.  <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, in press.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=32930576" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=G.+Tian&author=J.+Suarez&author=Z.+Zhang&author=P.+Connolly&author=K.+Ahn&title=Potent+phenylpyridine+and+oxodihydrofuran+inhibitors+of+cyclooxygenase-2%3A+optimization+towards+long+residence+time+with+balanced+internal+energetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DG.%26atitle%3DPotent%2520phenylpyridine%2520and%2520oxodihydrofuran%2520inhibitors%2520of%2520cyclooxygenase-2%253A%2520optimization%2520towards%2520long%2520residence%2520time%2520with%2520balanced%2520internal%2520energetics%26jtitle%3DBiochemistry%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00936.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1111%2Fj.1476-5381.2010.00936.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=20880390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=488-508&author=G.+Vauquelinauthor=S.+J.+Charlton&title=Long-lasting+target+binding+and+rebinding+as+mechanisms+to+prolong+in+vivo+drug+action&doi=10.1111%2Fj.1476-5381.2010.00936.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span></div><div class="casAuthors">Vauquelin, Georges; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-508</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  An increasing no. of examples in the literature suggest that the in vivo duration of drug action not only depends on macroscopic pharmacokinetic properties like plasma half-life and the time needed to equilibrate between the plasma and the effect compartments, but is also influenced by long-lasting target binding and rebinding.  The present review combines information from different research areas and simulations to explore the nature of these mechanisms and the conditions in which they are most prevalent.  Simulations reveal that these latter phenomena become esp. influential when there is no longer sufficient free drug around to maintain high levels of receptor occupancy.  There is not always a direct link between slow dissocn. and long-lasting in vivo target protection, as the rate of free drug elimination from the effect compartment is also a key influencing factor.  Local phenomena that hinder the diffusion of free drug mols. away from their target may allow them to consecutively bind to the same target and/or targets nearby (denoted as 'rebinding') even when their concn. in the bulk phase has already dropped to insignificant levels.  The micro-anat. properties of many effect compartments are likely to intensify this phenomenon.  By mimicking the complexity of tissues, intact cells offer the opportunity to investigate both mechanisms under the same, physiol. relevant conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzSGNmKeaTzrVg90H21EOLACvtfcHk0ljpNwYCvz_I7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE&md5=bd91e09a0fd79a2de6bf9ef0cfd3443e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00936.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00936.x%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DLong-lasting%2520target%2520binding%2520and%2520rebinding%2520as%2520mechanisms%2520to%2520prolong%2520in%2520vivo%2520drug%2520action%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D488%26epage%3D508%26doi%3D10.1111%2Fj.1476-5381.2010.00936.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krey, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Situ, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandvik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido-Rios, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighton, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganeshappa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abhyankar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinschek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panes, J.</span></span> <span> </span><span class="NLM_article-title">Development of gut-selective pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme</span>. <i>J. Crohns Colitis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1202</span>– <span class="NLM_lpage">1213</span>, <span class="refDoi"> DOI: 10.1093/ecco-jcc/jjaa049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1093%2Fecco-jcc%2Fjjaa049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=32161949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BB383isVartQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=1202-1213&author=W.+J.+Sandbornauthor=D.+D.+Nguyenauthor=D.+T.+Beattieauthor=P.+Brassilauthor=W.+Kreyauthor=J.+Wooauthor=E.+Situauthor=R.+Sanaauthor=E.+Sandvikauthor=M.+T.+Pulido-Riosauthor=R.+Bhandariauthor=J.+A.+Leightonauthor=R.+Ganeshappaauthor=D.+L.+Boyleauthor=B.+Abhyankarauthor=M.+A.+Kleinschekauthor=R.+A.+Grahamauthor=J.+Panes&title=Development+of+gut-selective+pan-Janus+kinase+inhibitor+TD-1473+for+ulcerative+colitis%3A+a+translational+medicine+programme&doi=10.1093%2Fecco-jcc%2Fjjaa049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme</span></div><div class="casAuthors">Sandborn William J; Nguyen Deanna D; Beattie David T; Brassil Patrick; Krey Whitney; Woo Jacky; Situ Eva; Sana Reuben; Sandvik Erik; Pulido-Rios M Teresa; Kleinschek Melanie A; Graham Richard A; Bhandari Raj; Leighton Jonathan A; Ganeshappa Ravi; Boyle David L; Abhyankar Brihad; Panes Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Crohn's & colitis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1202-1213</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND AIMS:  Oral systemic pan-Janus kinase [JAK] inhibition is effective for ulcerative colitis [UC] but is limited by toxicities.  We describe preclinical to clinical translation of TD-1473-an oral gut-selective pan-JAK inhibitor-from in vitro characterization through a Phase 1b study in patients with UC.  METHODS:  TD-1473 JAK inhibition potency was evaluated in vitro; plasma pharmacokinetics, safety and efficacy were assessed in mice.  In a first-time-in-human study, plasma pharmacokinetics and safety were assessed after single and multiple [14 days] ascending doses administered orally to healthy subjects.  The Phase 1b study randomized patients with moderately to severely active UC to receive once-daily oral TD-1473 20, 80 or 270 mg, or placebo for 28 days.  Plasma and colonic tissue concentrations were measured; safety was assessed; and efficacy was evaluated by UC clinical parameters, disease-surrogate biomarkers, endoscopy, histology and colonic tissue JAK signalling.  RESULTS:  TD-1473 exhibited potent pan-JAK inhibitory activity in vitro.  Oral TD-1473 administration to mice achieved high, biologically active colonic tissue concentrations with low plasma exposure and decreased oxazolone-induced colitis activity without reducing blood cell counts vs placebo.  TD-1473 administration in healthy human subjects and patients with UC yielded low plasma exposure and was generally well tolerated; treatment in patients with UC resulted in biologically active colonic tissue concentrations and descriptive trends toward reduced clinical, endoscopic and histological disease activity vs placebo.  CONCLUSION:  Gut-selective pan-JAK inhibition with TD-1473 administration resulted in high intestinal vs plasma drug exposure, local target engagement, and trends toward reduced UC disease activity. [Clinicaltrials.gov NCT02657122, NCT02818686].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfnFMNcI5A1mK_SFaaT9INfW6udTcc2eamdoQZFE5Hu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383isVartQ%253D%253D&md5=d954d19b2d5f046326ae7608a6e01180</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjaa049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjaa049%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DNguyen%26aufirst%3DD.%2BD.%26aulast%3DBeattie%26aufirst%3DD.%2BT.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DKrey%26aufirst%3DW.%26aulast%3DWoo%26aufirst%3DJ.%26aulast%3DSitu%26aufirst%3DE.%26aulast%3DSana%26aufirst%3DR.%26aulast%3DSandvik%26aufirst%3DE.%26aulast%3DPulido-Rios%26aufirst%3DM.%2BT.%26aulast%3DBhandari%26aufirst%3DR.%26aulast%3DLeighton%26aufirst%3DJ.%2BA.%26aulast%3DGaneshappa%26aufirst%3DR.%26aulast%3DBoyle%26aufirst%3DD.%2BL.%26aulast%3DAbhyankar%26aufirst%3DB.%26aulast%3DKleinschek%26aufirst%3DM.%2BA.%26aulast%3DGraham%26aufirst%3DR.%2BA.%26aulast%3DPanes%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520gut-selective%2520pan-Janus%2520kinase%2520inhibitor%2520TD-1473%2520for%2520ulcerative%2520colitis%253A%2520a%2520translational%2520medicine%2520programme%26jtitle%3DJ.%2520Crohns%2520Colitis.%26date%3D2020%26volume%3D14%26spage%3D1202%26epage%3D1213%26doi%3D10.1093%2Fecco-jcc%2Fjjaa049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plount
Price, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Analysis of binding affinities for celecoxib analogues with COX-1 and COX-2 from combined docking and monte carlo simulations and insight into the COX-2/COX-1 Selectivity</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">9455</span>– <span class="NLM_lpage">9466</span>, <span class="refDoi"> DOI: 10.1021/ja001018c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja001018c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=9455-9466&author=M.+L.+Plount%0APriceauthor=W.+L.+Jorgensen&title=Analysis+of+binding+affinities+for+celecoxib+analogues+with+COX-1+and+COX-2+from+combined+docking+and+monte+carlo+simulations+and+insight+into+the+COX-2%2FCOX-1+Selectivity&doi=10.1021%2Fja001018c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fja001018c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja001018c%26sid%3Dliteratum%253Aachs%26aulast%3DPlount%2BPrice%26aufirst%3DM.%2BL.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DAnalysis%2520of%2520binding%2520affinities%2520for%2520celecoxib%2520analogues%2520with%2520COX-1%2520and%2520COX-2%2520from%2520combined%2520docking%2520and%2520monte%2520carlo%2520simulations%2520and%2520insight%2520into%2520the%2520COX-2%252FCOX-1%2520Selectivity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D9455%26epage%3D9466%26doi%3D10.1021%2Fja001018c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graneto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamper, J. R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlitz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurumbail, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maziasz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talley, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, J.</span></span> <span> </span><span class="NLM_article-title">The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">7159</span>– <span class="NLM_lpage">7163</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2Fj.bmcl.2010.07.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=20709553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7159-7163&author=J.+L.+Wangauthor=D.+Limburgauthor=M.+J.+Granetoauthor=J.+Springerauthor=J.+R.+B.+Hamperauthor=S.+Liaoauthor=J.+L.+Pawlitzauthor=R.+G.+Kurumbailauthor=T.+Maziaszauthor=J.+J.+Talleyauthor=J.+R.+Kieferauthor=J.+Carter&title=The+novel+benzopyran+class+of+selective+cyclooxygenase-2+inhibitors.+Part+2%3A+the+second+clinical+candidate+having+a+shorter+and+favorable+human+half-life&doi=10.1016%2Fj.bmcl.2010.07.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life</span></div><div class="casAuthors">Wang, Jane L.; Limburg, David; Graneto, Matthew J.; Springer, John; Hamper, Joseph Rogier Bruce; Liao, Subo; Pawlitz, Jennifer L.; Kurumbail, Ravi G.; Maziasz, Timothy; Talley, John J.; Kiefer, James R.; Carter, Jeffery</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7159-7163</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this Letter, we provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data for a series of selective COX-2 inhibitors.  During the course of our structure-based drug design efforts, we discovered two distinct binding modes within the COX-2 active site for differently substituted members of this class.  The challenge of a undesirably long human half-life for the first clin. candidate 1 t 1/2 = 360 h was addressed by multiple strategies, leading to the discovery of 29b-(S) (SC-75416) with t 1/2 = 34 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3MuS8lF7TabVg90H21EOLACvtfcHk0lgg72ZoM6wwlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtb7O&md5=63eb8c45901f27b6d94669e834b26f95</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.054%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BL.%26aulast%3DLimburg%26aufirst%3DD.%26aulast%3DGraneto%26aufirst%3DM.%2BJ.%26aulast%3DSpringer%26aufirst%3DJ.%26aulast%3DHamper%26aufirst%3DJ.%2BR.%2BB.%26aulast%3DLiao%26aufirst%3DS.%26aulast%3DPawlitz%26aufirst%3DJ.%2BL.%26aulast%3DKurumbail%26aufirst%3DR.%2BG.%26aulast%3DMaziasz%26aufirst%3DT.%26aulast%3DTalley%26aufirst%3DJ.%2BJ.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DJ.%26atitle%3DThe%2520novel%2520benzopyran%2520class%2520of%2520selective%2520cyclooxygenase-2%2520inhibitors.%2520Part%25202%253A%2520the%2520second%2520clinical%2520candidate%2520having%2520a%2520shorter%2520and%2520favorable%2520human%2520half-life%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7159%26epage%3D7163%26doi%3D10.1016%2Fj.bmcl.2010.07.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malkowski, M. G.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of rofecoxib bound to human cyclooxygenase-2</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">772</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1107/s2053230x16014230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1107%2FS2053230X16014230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=27710942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1aktrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=772-776&author=B.+J.+Orlandoauthor=M.+G.+Malkowski&title=Crystal+structure+of+rofecoxib+bound+to+human+cyclooxygenase-2&doi=10.1107%2Fs2053230x16014230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of rofecoxib bound to human cyclooxygenase-2</span></div><div class="casAuthors">Orlando, Benjamin J.; Malkowski, Michael G.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">772-776</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Rofecoxib (Vioxx) was one of the first selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) to be approved for use in humans.  Within five years after its release to the public, Vioxx was withdrawn from the market owing to the adverse cardiovascular effects of the drug.  Despite the widespread knowledge of the development and withdrawal of Vioxx, relatively little is known at the mol. level about how the inhibitor binds to COX-2.  Vioxx is unique in that the inhibitor contains a Me sulfone moiety in place of the sulfonamide moiety found in other coxibs such as celecoxib and valdecoxib.  Here, new crystn. conditions were identified that allowed the structural detn. of human COX-2 in complex with Vioxx and the structure was subsequently detd. to 2.7 Å resoln.  The crystal structure provides the first at. level details of the binding of Vioxx to COX-2.  As anticipated, Vioxx binds with its Me sulfone moiety located in the side pocket of the cyclooxygenase channel, providing support for the isoform selectivity of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOl7fUeSagZrVg90H21EOLACvtfcHk0lgg72ZoM6wwlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1aktrrK&md5=43095603b1bd2dc112b6fb3990ee056e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1107%2FS2053230X16014230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X16014230%26sid%3Dliteratum%253Aachs%26aulast%3DOrlando%26aufirst%3DB.%2BJ.%26aulast%3DMalkowski%26aufirst%3DM.%2BG.%26atitle%3DCrystal%2520structure%2520of%2520rofecoxib%2520bound%2520to%2520human%2520cyclooxygenase-2%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2016%26volume%3D72%26spage%3D772%26epage%3D776%26doi%3D10.1107%2Fs2053230x16014230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. L.</span></span> <span> </span><span class="NLM_article-title">A cyclooxygenase-2-dependent prostaglandin E2 biosynthetic system in the Golgi apparatus</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">5606</span>– <span class="NLM_lpage">5620</span>, <span class="refDoi"> DOI: 10.1074/jbc.m114.632463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1074%2Fjbc.M114.632463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=25548276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsF2nurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=5606-5620&author=C.+Yuanauthor=W.+L.+Smith&title=A+cyclooxygenase-2-dependent+prostaglandin+E2+biosynthetic+system+in+the+Golgi+apparatus&doi=10.1074%2Fjbc.m114.632463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A Cyclooxygenase-2-dependent Prostaglandin E2 Biosynthetic System in the Golgi Apparatus</span></div><div class="casAuthors">Yuan, Chong; Smith, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5606-5620</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cyclooxygenases (COXs) catalyze the committed step in prostaglandin (PG) biosynthesis.  COX-1 is constitutively expressed and stable, whereas COX-2 is inducible and short lived.  COX-2 is degraded via endoplasmic reticulum (ER)-assocd. degrdn. (ERAD) following post-translational glycosylation of Asn-594.  COX-1 and COX-2 are found in abundance on the luminal surfaces of the ER and inner membrane of the nuclear envelope.  Using confocal immunocytofluorescence, we detected both COX-2 and microsomal PGE synthase-1 (mPGES-1) but not COX-1 in the Golgi app.  Inhibition of trafficking between the ER and Golgi retarded COX-2 ERAD.  COX-2 has a C-terminal STEL sequence, which is an inefficient ER retention signal.  Substituting this sequence with KDEL, a robust ER retention signal, concd. COX-2 in the ER where it was stable and slowly glycosylated on Asn-594.  Native COX-2 and a recombinant COX-2 having a Golgi targeting signal but not native COX-1 exhibited efficient catalytic coupling to mPGES-1.  We conclude that N-glycosylation of Asn-594 of COX-2 occurs in the ER, leading to anterograde movement of COX-2 to the Golgi where the Asn-594-linked glycan is trimmed prior to retrograde COX-2 transport to the ER for ERAD.  Having an inefficient ER retention signal leads to sluggish Golgi to ER transit of COX-2.  This permits significant Golgi residence time during which COX-2 can function catalytically.  Cytosolic phospholipase A2α, which mobilizes arachidonic acid for PG synthesis, preferentially translocates to the Golgi in response to physiol. Ca2+ mobilization.  We propose that cytosolic phospholipase A2α, COX-2, and mPGES-1 in the Golgi comprise a dedicated system for COX-2-dependent PGE2 biosynthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSs0vog1ec2LVg90H21EOLACvtfcHk0lgg72ZoM6wwlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsF2nurk%253D&md5=20c3616bdc0f950b6a5cd77f50f8a178</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.632463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.632463%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DW.%2BL.%26atitle%3DA%2520cyclooxygenase-2-dependent%2520prostaglandin%2520E2%2520biosynthetic%2520system%2520in%2520the%2520Golgi%2520apparatus%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D5606%26epage%3D5620%26doi%3D10.1074%2Fjbc.m114.632463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Troberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sneitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosorin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagström, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finel, M.</span></span> <span> </span><span class="NLM_article-title">Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.059303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1124%2Fdmd.114.059303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=25301937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=107-118&author=J.+Trobergauthor=E.+J%C3%A4rvinenauthor=M.+Munizauthor=N.+Sneitzauthor=J.+Mosorinauthor=M.+Hagstr%C3%B6mauthor=M.+Finel&title=Dog+UDP-glucuronosyltransferase+enzymes+of+subfamily+1A%3A+cloning%2C+expression%2C+and+activity&doi=10.1124%2Fdmd.114.059303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity</span></div><div class="casAuthors">Troberg, Johanna; Jarvinen, Erkka; Muniz, Maria; Sneitz, Nina; Mosorin, Johanna; Hagstrom, Marja; Finel, Moshe</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-118, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Understanding drug glucuronidation in the dog, a preclin. animal, is important but currently poorly characterized at the level of individual enzymes.  We have constructed cDNAs for the 10 dog UDP-glucuronosyltransferases of subfamily 1A (dUGT1As), expressed them in insect cells, and assayed their activity as well as the activity of the nine human UGT1As, toward 14 compds.  The goal was to find out whether individual dUGT1As and individual human UGT1As have similar substrate specificities.  The results revealed similarities but also many differences.  For example, similarly to the human UGT1A10, dUGT1A11 exhibited high glucuronidation activity toward the 3-OH of 17-β-estradiol, 17-α-estradiol, and ethinylestradiol, and also conjugated the drug entacapone.  Unlike the human UGT1A10, however, it failed to catalyze considerable rates of R-propranolol, diclofenac, and indomethacin glucuronidation.  The estrogen glucuronidation assays revealed that dUGT1A8 and dUGT1A10 have a capacity to catalyze the formation of (linked) diglucuronides, an activity no human UGT1A exhibited.  DUGT1A2-dUGT1A4 are homologs of the human UGT1A4, but none of them catalyzed N-glucuronidation of dexmedetomidine.  Contrary to the human UGT1A4, however, dUGT1A2-dUGT1A4 catalyzed indomethacin and diclofenac glucuronidation.  It may be concluded that, perhaps with the exception of UGT1A6, high similarities in substrate specificity between individual dog and human UGTs of subfamily 1A are rare or partial.  Activity assays with liver and intestine microsomes of both dog and human further revealed interspecies differences, particularly in glucuronidation rates.  In the dog, the microsomes assays also strongly suggested important roles for dUGTs of other subfamilies, mainly in the liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3TLXzGFFl5rVg90H21EOLACvtfcHk0li98gj-KRtQ1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7jO&md5=ff07227c57d689d3b8b75dc83f962b6e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.059303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.059303%26sid%3Dliteratum%253Aachs%26aulast%3DTroberg%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DE.%26aulast%3DMuniz%26aufirst%3DM.%26aulast%3DSneitz%26aufirst%3DN.%26aulast%3DMosorin%26aufirst%3DJ.%26aulast%3DHagstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DFinel%26aufirst%3DM.%26atitle%3DDog%2520UDP-glucuronosyltransferase%2520enzymes%2520of%2520subfamily%25201A%253A%2520cloning%252C%2520expression%252C%2520and%2520activity%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D107%26epage%3D118%26doi%3D10.1124%2Fdmd.114.059303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haston, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimble, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peppard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintavalla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toscano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, P. J.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1038%2Fsj.bjp.0706078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=15655513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVOmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2005&pages=538-550&author=R.+Esserauthor=C.+Berryauthor=Z.+Duauthor=J.+Dawsonauthor=A.+Foxauthor=R.+A.+Fujimotoauthor=W.+Hastonauthor=E.+F.+Kimbleauthor=J.+Koehlerauthor=J.+Peppardauthor=E.+Quadrosauthor=J.+Quintavallaauthor=K.+Toscanoauthor=L.+Urbanauthor=J.+van+Duzerauthor=X.+Zhangauthor=S.+Zhouauthor=P.+J.+Marshall&title=Preclinical+pharmacology+of+lumiracoxib%3A+a+novel+selective+inhibitor+of+cyclooxygenase-2&doi=10.1038%2Fsj.bjp.0706078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2</span></div><div class="casAuthors">Esser, Ronald; Berry, Carol; Du, Zhengming; Dawson, Janet; Fox, Alyson; Fujimoto, Roger A.; Haston, William; Kimble, Earl F.; Koehler, Julie; Peppard, Jane; Quadros, Elizabeth; Quintavalla, Joseph; Toscano, Karen; Urban, Laszlo; van Duzer, John; Zhang, Xiaoli; Zhou, Siyuan; Marshall, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">538-550</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This manuscript presents the preclin. profile of lumiracoxib, a novel cyclooxygenase-2 (COX-2) selective inhibitor.  Lumiracoxib inhibited purified COX-1 and COX-2 with Ki values of 3 and 0.06 μM, resp.  In cellular assays, lumiracoxib had an IC50 of 0.14 μM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concns. up to 30 μM (HEK 293 cells transfected with human COX-1).  In a human whole blood assay, IC50 values for lumiracoxib were 0.13 μM for COX-2 and 67 μM for COX-1 (COX-1/COX-2 selectivity ratio 515).  Lumiracoxib was rapidly absorbed following oral administration in rats with peak plasma levels being reached between 0.5 and 1 h.  Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B2 (TxB2) generation with an ID50 of 33 mg kg-1, whereas COX-2-derived prodn. of prostaglandin E2 (PGE2) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID50 value of 0.24 mg kg-1.  Efficacy of lumiracoxib in rat models of hyperalgesia, edema, pyresis and arthritis was dose-dependent and similar to diclofenac.  However, consistent with its low COX-1 inhibitory activity, lumiracoxib at a dose of 100 mg kg-1 orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).  Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the ref. NSAID, but with much improved gastrointestinal safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGFkSVhj6hjbVg90H21EOLACvtfcHk0li98gj-KRtQ1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVOmsbk%253D&md5=c56dbbee7e3bc394087d2cc450c24d47</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706078%26sid%3Dliteratum%253Aachs%26aulast%3DEsser%26aufirst%3DR.%26aulast%3DBerry%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DFox%26aufirst%3DA.%26aulast%3DFujimoto%26aufirst%3DR.%2BA.%26aulast%3DHaston%26aufirst%3DW.%26aulast%3DKimble%26aufirst%3DE.%2BF.%26aulast%3DKoehler%26aufirst%3DJ.%26aulast%3DPeppard%26aufirst%3DJ.%26aulast%3DQuadros%26aufirst%3DE.%26aulast%3DQuintavalla%26aufirst%3DJ.%26aulast%3DToscano%26aufirst%3DK.%26aulast%3DUrban%26aufirst%3DL.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DMarshall%26aufirst%3DP.%2BJ.%26atitle%3DPreclinical%2520pharmacology%2520of%2520lumiracoxib%253A%2520a%2520novel%2520selective%2520inhibitor%2520of%2520cyclooxygenase-2%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D144%26spage%3D538%26epage%3D550%26doi%3D10.1038%2Fsj.bjp.0706078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span> <span> </span><span class="NLM_article-title">LC-MS/MS assay for the simultaneous quantitation of thromboxane B2 and prostaglandin E2 to evaluate cyclooxygenase inhibition in human whole blood</span>. <i>J. Appl. Bioanal.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.17145/jab.20.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.17145%2Fjab.20.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1GmtLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=131-144&author=Y.+Shiauthor=H.+E.+Murreyauthor=K.+Ahnauthor=N.+Wengauthor=S.+Patel&title=LC-MS%2FMS+assay+for+the+simultaneous+quantitation+of+thromboxane+B2+and+prostaglandin+E2+to+evaluate+cyclooxygenase+inhibition+in+human+whole+blood&doi=10.17145%2Fjab.20.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">LC-MS/MS assay for the simultaneous quantitation of thromboxane B2 and prostaglandin E2 to evaluate cyclooxygenase inhibition in human whole blood</span></div><div class="casAuthors">Shi, Yifan; Murrey, Heather E.; Ahn, Kay; Weng, Naidong; Patel, Shefali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Bioanalysis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-144</span>CODEN:
                <span class="NLM_cas:coden">JABODF</span>;
        ISSN:<span class="NLM_cas:issn">2405-710X</span>.
    
            (<span class="NLM_cas:orgname">Betasciencepress Publishing</span>)
        </div><div class="casAbstract">Objectives: A high-throughput LC-MS method for TXB2 and PGE2 was developed for human whole blood assay for COX inhibition.  Methods: A surrogate analyte approach was used for the quantitation of TXB2 and PGE2 by LC-MS.  Fifty microliters plasma was processed using solidphase extn.  TXB2-d4 and PGE2-d4 were used as surrogate analytes.  The calibration curves were established for TXB2 from 0.1 to 500 ng/mL and for PGE2 from 0.05 to 500 ng/mL.  TXB1 was used as internal std.  Results: The response factor and parallelism between surrogate and authentic analyte were verified.  Heparinized whole blood assay for COX inhibition was optimized for sample pretreatment, stimulant concn. and incubation time.  Conclusion: The LC-MS assay was successfully used to analyze inhibitory activity of four com. available COX inhibitors.  The presented method offers a sensitive, high throughput and low-cost alternative to ELISA for human whole blood assay for COX inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoodLQBsztKc7Vg90H21EOLACvtfcHk0li98gj-KRtQ1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1GmtLrF&md5=ab3155d7669e1992e42a84a333077e19</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.17145%2Fjab.20.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17145%252Fjab.20.014%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DMurrey%26aufirst%3DH.%2BE.%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DWeng%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DS.%26atitle%3DLC-MS%252FMS%2520assay%2520for%2520the%2520simultaneous%2520quantitation%2520of%2520thromboxane%2520B2%2520and%2520prostaglandin%2520E2%2520to%2520evaluate%2520cyclooxygenase%2520inhibition%2520in%2520human%2520whole%2520blood%26jtitle%3DJ.%2520Appl.%2520Bioanal.%26date%3D2020%26volume%3D6%26spage%3D131%26epage%3D144%26doi%3D10.17145%2Fjab.20.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heijink, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleibeuker, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagengast, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosterhuis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koornstra, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G. E.</span></span> <span> </span><span class="NLM_article-title">Total abdominal 18F-FDG uptake reflects intestinal adenoma burden in Apc mutant mice</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.2967/jnumed.110.083956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.2967%2Fjnumed.110.083956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=21321272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BC3M3hsVGgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=431-436&author=D.+M.+Heijinkauthor=J.+H.+Kleibeukerauthor=W.+B.+Nagengastauthor=D.+Oosterhuisauthor=A.+H.+Brouwersauthor=J.+J.+Koornstraauthor=S.+de+Jongauthor=E.+G.+E.+de+Vries&title=Total+abdominal+18F-FDG+uptake+reflects+intestinal+adenoma+burden+in+Apc+mutant+mice&doi=10.2967%2Fjnumed.110.083956"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Total abdominal 18F-FDG uptake reflects intestinal adenoma burden in Apc mutant mice</span></div><div class="casAuthors">Heijink Dianne M; Kleibeuker Jan H; Nagengast Wouter B; Oosterhuis Dorenda; Brouwers Adrienne H; Koornstra Jan J; de Jong Steven; de Vries Elisabeth G E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">431-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Apc mutant (Apc(Min)) mice develop multiple adenomas in their intestines and are widely used to study colorectal carcinogenesis and chemopreventive approaches.  Molecular imaging of intestinal adenomas could potentially provide noninvasive longitudinal evaluation of these lesions in living mice.  Therefore, the aim of this study was to investigate the role of (18)F-FDG PET in the Apc(Min) mouse model.  METHODS:  Apc(Min) mice (n = 8) fed a purified diet were imaged serially after injection of (18)F-FDG at age 9 and 12 wk using a small-animal PET scanner.  Abdominal uptake of the tracer was quantified.  After dissection, intestines were imaged separately, and intestinal tracer uptake was quantified.  Tracer distribution was compared with results from microscopic examination regarding adenoma number and size.  Thereafter, findings were validated serially in 20 Apc(Min) mice aged 6, 8, 10, and 12 wk that received standard chow to increase adenoma numbers.  In vivo abdominal (18)F-FDG uptake was correlated with microscopy results.  RESULTS:  Microscopic examination showed that the mice developed 25-35 intestinal adenomas at age 12 wk.  Ex vivo (18)F-FDG PET of the dissected intestines visualized all large adenomas and most small adenomas.  Ex vivo total intestinal (18)F-FDG uptake correlated with in vivo total abdominal uptake and with the number of large adenomas at age 9 and 12 wk.  At 12 wk, there was a clear correlation between in vivo abdominal tracer uptake and the number of large adenomas but not the total number of lesions.  CONCLUSION:  Intestinal adenomas in Apc(Min) mice are metabolically active lesions that take up (18)F-FDG.  Abdominal (18)F-FDG uptake at age 12 wk serves as a readout modality for large intestinal adenomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhSdcYVQxSi6x48Rj5GnGofW6udTcc2ebiAXG_y8LJT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3hsVGgtw%253D%253D&md5=364983634028a7a108a7ca13fc8f89ef</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.110.083956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.110.083956%26sid%3Dliteratum%253Aachs%26aulast%3DHeijink%26aufirst%3DD.%2BM.%26aulast%3DKleibeuker%26aufirst%3DJ.%2BH.%26aulast%3DNagengast%26aufirst%3DW.%2BB.%26aulast%3DOosterhuis%26aufirst%3DD.%26aulast%3DBrouwers%26aufirst%3DA.%2BH.%26aulast%3DKoornstra%26aufirst%3DJ.%2BJ.%26aulast%3Dde%2BJong%26aufirst%3DS.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%2BE.%26atitle%3DTotal%2520abdominal%252018F-FDG%2520uptake%2520reflects%2520intestinal%2520adenoma%2520burden%2520in%2520Apc%2520mutant%2520mice%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2011%26volume%3D52%26spage%3D431%26epage%3D436%26doi%3D10.2967%2Fjnumed.110.083956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka-Kogo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onouchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimomura, A.</span></span> <span> </span><span class="NLM_article-title">Adenomatous polyposis coli (APC) plays multiple roles in the intestinal and colorectal epithelia</span>. <i>Med. Mol. Morphol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1007/s00795-006-0352-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1007%2Fs00795-006-0352-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=17572842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD2szlvFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=68-81&author=T.+Sendaauthor=A.+Iizuka-Kogoauthor=T.+Onouchiauthor=A.+Shimomura&title=Adenomatous+polyposis+coli+%28APC%29+plays+multiple+roles+in+the+intestinal+and+colorectal+epithelia&doi=10.1007%2Fs00795-006-0352-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Adenomatous polyposis coli (APC) plays multiple roles in the intestinal and colorectal epithelia</span></div><div class="casAuthors">Senda Takao; Iizuka-Kogo Akiko; Onouchi Takanori; Shimomura Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Medical molecular morphology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">68-81</span>
        ISSN:<span class="NLM_cas:issn">1860-1480</span>.
    </div><div class="casAbstract">The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis and in most sporadic colorectal tumors.  During both embryonic and postnatal periods, APC is widely expressed in a variety of tissues, including the brain and gastrointestinal tract.  The APC gene product (APC) is a large multidomain protein consisting of 2843 amino acids.  APC downregulates the Wnt signaling pathway through its binding to beta-catenin and Axin.  Most mutated APC proteins in colorectal tumors lack the beta-catenin-binding regions and fail to inhibit Wnt signaling, leading to the overproliferation of tumor cells.  Several mouse models (APC580D, APCDelta716, APC1309, APCMin, APC1638T) have been established to investigate carcinogenesis caused by APC mutations.  APC also binds to APC-stimulated guanine nucleotide exchange factor, the kinesin superfamily-associated protein 3, IQGAP1, microtubules, EB1, and discs large (DLG).  APC has both nuclear localization signals and nuclear export signals in its molecule, suggesting its occasional nuclear localization and export of beta-catenin from the nucleus.  APC is highly expressed in the intestinal and colorectal epithelia and may be involved in homeostasis of the enterocyte renewal phenomena, in which proliferation, migration, differentiation, and apoptosis are highly regulated both temporally and spatially.  Through the many binding proteins mentioned, APC can exert multiple functions involved in epithelial homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-4MRnRLUCxEPI-fCgwosgfW6udTcc2ebiAXG_y8LJT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szlvFCjtQ%253D%253D&md5=a4470cce4b39a3eb09296bbfafa1459c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs00795-006-0352-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00795-006-0352-5%26sid%3Dliteratum%253Aachs%26aulast%3DSenda%26aufirst%3DT.%26aulast%3DIizuka-Kogo%26aufirst%3DA.%26aulast%3DOnouchi%26aufirst%3DT.%26aulast%3DShimomura%26aufirst%3DA.%26atitle%3DAdenomatous%2520polyposis%2520coli%2520%2528APC%2529%2520plays%2520multiple%2520roles%2520in%2520the%2520intestinal%2520and%2520colorectal%2520epithelia%26jtitle%3DMed.%2520Mol.%2520Morphol.%26date%3D2007%26volume%3D40%26spage%3D68%26epage%3D81%26doi%3D10.1007%2Fs00795-006-0352-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickaryous, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, A.</span></span> <span> </span><span class="NLM_article-title">Apc mice: models, modifiers and mutants</span>. <i>Pathol., Res. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1016/j.prp.2008.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2Fj.prp.2008.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=18538487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A280%3ADC%252BD1cvks1ajtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2008&pages=479-490&author=A.+E.+McCartauthor=N.+K.+Vickaryousauthor=A.+Silver&title=Apc+mice%3A+models%2C+modifiers+and+mutants&doi=10.1016%2Fj.prp.2008.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Apc mice: models, modifiers and mutants</span></div><div class="casAuthors">McCart Amy E; Vickaryous Nicola K; Silver Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Pathology, research and practice</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">479-90</span>
        ISSN:<span class="NLM_cas:issn">0344-0338</span>.
    </div><div class="casAbstract">The mouse provides an excellent in vivo system with which to model human diseases and to test therapies.  Mutations in the Adenomatous polyposis coli (APC) gene are required to initiate familial adenomatous polyposis (FAP) and are also important in sporadic colorectal cancer tumorigenesis.  The (multiple intestinal neoplasia Min) mouse contains a point mutation in the Apc gene, develops numerous adenomas and was the first model used to study the involvement of the Apc gene in intestinal tumorigenesis.  The model has provided examples of modifying loci (called Modifiers of Min: Mom) in mice, demonstrating the principle of genetic modulation of disease severity.  A spectrum of Apc mutant mice has since been developed, each with defining characteristics, some more able to accurately model human polyposis and colon cancer.  We will focus our review on Apc mutant mouse models, the advent of models with concurrent or compound mutations and the importance of genetic background when modeling polyposis and cancer.  Brief consideration will be given to the use of these models in drug testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuLqm-nKM-kNbHMBt0mMIXfW6udTcc2ebiAXG_y8LJT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvks1ajtQ%253D%253D&md5=cf1f5603d54884e41710a3392b549e99</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.prp.2008.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prp.2008.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DMcCart%26aufirst%3DA.%2BE.%26aulast%3DVickaryous%26aufirst%3DN.%2BK.%26aulast%3DSilver%26aufirst%3DA.%26atitle%3DApc%2520mice%253A%2520models%252C%2520modifiers%2520and%2520mutants%26jtitle%3DPathol.%252C%2520Res.%2520Pract.%26date%3D2008%26volume%3D204%26spage%3D479%26epage%3D490%26doi%3D10.1016%2Fj.prp.2008.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corpet, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span> <span> </span><span class="NLM_article-title">How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2005.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2Fj.ejca.2005.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16084718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslyitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=1911-1922&author=D.+E.+Corpetauthor=F.+Pierre&title=How+good+are+rodent+models+of+carcinogenesis+in+predicting+efficacy+in+humans%3F+A+systematic+review+and+meta-analysis+of+colon+chemoprevention+in+rats%2C+mice+and+men&doi=10.1016%2Fj.ejca.2005.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men</span></div><div class="casAuthors">Corpet, Denis E.; Pierre, Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1911-1922</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumors in rodent and human colon share many histol. and genetic features.  To know if rodent models of colon carcinogenesis are good predictors of chemopreventive efficacy in humans, we conducted a meta-anal. of aspirin, β-carotene, calcium, and wheat bran studies.  Controlled intervention studies of adenoma recurrence in human volunteers were compared with chemoprevention studies of carcinogen-induced tumors in rats, and of polyps in Min (Apc(+/-)) mice: 6714 volunteers, 3911 rats and 458 mice were included in the meta-analyses.  Difference between models was small since most global relative risks were between 0.76 and 1.00.  A closer look showed that carcinogen-induced rat studies matched human trials for aspirin, calcium, carotene, and were compatible for wheat bran.  Min mice results were compatible with human results for aspirin, but discordant for calcium and wheat bran (no carotene study).  These few results suggest that rodent models roughly predict effect in humans, but the prediction is not accurate for all agents.  Based on three cases only, the carcinogen-induced rat model seems better than the Min mouse model.  However, rodent studies are useful to screen potential chemopreventive agents, and to study mechanisms of carcinogenesis and chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH3KBhHmna9LVg90H21EOLACvtfcHk0lgXEYHoa6TLhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslyitrk%253D&md5=dea93026b2eff3a750356b347210f3bb</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2005.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2005.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DCorpet%26aufirst%3DD.%2BE.%26aulast%3DPierre%26aufirst%3DF.%26atitle%3DHow%2520good%2520are%2520rodent%2520models%2520of%2520carcinogenesis%2520in%2520predicting%2520efficacy%2520in%2520humans%253F%2520A%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520colon%2520chemoprevention%2520in%2520rats%252C%2520mice%2520and%2520men%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D1911%26epage%3D1922%26doi%3D10.1016%2Fj.ejca.2005.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacoby, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelloff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubet, R. A.</span></span> <span> </span><span class="NLM_article-title">The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5040</span>– <span class="NLM_lpage">5044</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=11016626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntVamtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=5040-5044&author=R.+F.+Jacobyauthor=K.+Seibertauthor=C.+E.+Coleauthor=G.+Kelloffauthor=R.+A.+Lubet&title=The+cyclooxygenase-2+inhibitor+celecoxib+is+a+potent+preventive+and+therapeutic+agent+in+the+min+mouse+model+of+adenomatous+polyposis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis</span></div><div class="casAuthors">Jacoby, Russell F.; Seibert, Karen; Cole, Carolyn E.; Kelloff, Gary; Lubet, Ronald A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5040-5044</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidemiol. and animal studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce colon cancer risk.  NSAIDs nonselectively inhibit both the constitutive cyclooxygenase (COX) 1 assocd. with side effects and the desired therapeutic target COX-2, which is induced in inflammation and neoplasia.  We used the adenomatous polyposis coli (Apc) mutant Min mouse model to det. whether the selective COX-2 inhibitor celecoxib is effective for adenoma prevention and/or regression, and whether it might be safer than the nonselective NSAID previously shown to be most effective in this model, piroxicam.  Min mice (n = 120) were randomized to treatment with celecoxib (0, 150, 500, or 1500 ppm celecoxib mixed in the diet) or piroxicam.  To distinguish prevention from regression effects, groups were treated either "early" (before adenomas develop) or "late" (after most adenomas are established).  Celecoxib caused dramatic redns. in both the multiplicity and size of tumors in a dose-dependent manner (P < 0.01).  Early treatment with 1500 ppm of celecoxib was effective for prevention, decreasing tumor multiplicity to 29% and tumor size to only 17% of controls (P < 0.01).  Late treatment demonstrated regression effects, reducing tumor multiplicity and size by about half.  In contrast to the significant toxicity of piroxicam, which caused ulcers complicated by perforation and bleeding, celecoxib caused no gastrointestinal side effects and did not inhibit platelet thromboxane B2 at plasma drug levels similar to those obtained in early clin. trials in humans.  These results provide the first evidence that selective inhibitors of COX-2 are safe and effective for the prevention and regression of adenomas in a mouse model of adenomatous polyposis and strongly support ongoing clin. trials in humans with the same syndrome.  The broader population of patients with common sporadic adenomas that have somatic mutations of the same gene (APC) may also benefit from this treatment approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCWIaZxzkH37Vg90H21EOLACvtfcHk0lgXEYHoa6TLhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntVamtLs%253D&md5=8b63c8502278215654f1215c981beb65</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJacoby%26aufirst%3DR.%2BF.%26aulast%3DSeibert%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DC.%2BE.%26aulast%3DKelloff%26aufirst%3DG.%26aulast%3DLubet%26aufirst%3DR.%2BA.%26atitle%3DThe%2520cyclooxygenase-2%2520inhibitor%2520celecoxib%2520is%2520a%2520potent%2520preventive%2520and%2520therapeutic%2520agent%2520in%2520the%2520min%2520mouse%2520model%2520of%2520adenomatous%2520polyposis%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D5040%26epage%3D5044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wieder, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lordick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummeny, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siewer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, W. A.</span></span> <span> </span><span class="NLM_article-title">Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2029</span>– <span class="NLM_lpage">2034</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=16330567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=2029-2034&author=H.+A.+Wiederauthor=A.+J.+Beerauthor=F.+Lordickauthor=K.+Ottauthor=M.+Fischerauthor=E.+J.+Rummenyauthor=S.+Zieglerauthor=J.+R.+Siewerauthor=M.+Schwaigerauthor=W.+A.+Weber&title=Comparison+of+changes+in+tumor+metabolic+activity+and+tumor+size+during+chemotherapy+of+adenocarcinomas+of+the+esophagogastric+junction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction</span></div><div class="casAuthors">Wieder, Hinrich A.; Beer, Ambros J.; Lordick, Florian; Ott, Katja; Fischer, Michael; Rummeny, Ernst J.; Ziegler, Sibylle; Siewer, Joerg R.; Schwaiger, Markus; Weber, Wolfgang A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2029-2034</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">We evaluated the temporal relationship between chemotherapy-induced changes in tumor glucose use and tumor size.  Methods: Twenty patients with adenocarcinoma of the esophagogastric junction (AEG) were studied by 18F-FDG PET and CT scans before neoadjuvant chemotherapy, 14 d after the initiation of therapy, and 4 wk after the completion of therapy.  Results: The relative change in 18F-FDG uptake was more than 2 times larger than the decrease in tumor size at all time points (P < 0.01).  At 14 d after the initiation of chemotherapy, there was no correlation between the redn. in 18F-FDG uptake and tumor wall thickness.  The change in 18F-FDG uptake after 14 d of therapy was significantly correlated with the redn. in tumor size after the completion of therapy.  Conclusion: In AEG, changes in tumor metab. are a more sensitive parameter for assessing the effects of chemotherapy than are changes in tumor size.  Early changes in metabolic activity predict the subsequent redn. in tumor size.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroiwJywC8BirVg90H21EOLACvtfcHk0lhRBMMGZoNMQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVSrsQ%253D%253D&md5=45a50c535b2b5825c653c88f6665339c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWieder%26aufirst%3DH.%2BA.%26aulast%3DBeer%26aufirst%3DA.%2BJ.%26aulast%3DLordick%26aufirst%3DF.%26aulast%3DOtt%26aufirst%3DK.%26aulast%3DFischer%26aufirst%3DM.%26aulast%3DRummeny%26aufirst%3DE.%2BJ.%26aulast%3DZiegler%26aufirst%3DS.%26aulast%3DSiewer%26aufirst%3DJ.%2BR.%26aulast%3DSchwaiger%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DW.%2BA.%26atitle%3DComparison%2520of%2520changes%2520in%2520tumor%2520metabolic%2520activity%2520and%2520tumor%2520size%2520during%2520chemotherapy%2520of%2520adenocarcinomas%2520of%2520the%2520esophagogastric%2520junction%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2005%26volume%3D46%26spage%3D2029%26epage%3D2034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egashira, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi-Yanaga, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arioka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomooka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabeppu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaguri, T.</span></span> <span> </span><span class="NLM_article-title">Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">108</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1111/cas.13106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1111%2Fcas.13106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=27761963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKnu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=108-115&author=I.+Egashiraauthor=F.+Takahashi-Yanagaauthor=R.+Nishidaauthor=M.+Ariokaauthor=K.+Igawaauthor=K.+Tomookaauthor=Y.+Nakatsuauthor=T.+Tsuzukiauthor=Y.+Nakabeppuauthor=T.+Kitazonoauthor=T.+Sasaguri&title=Celecoxib+and+2%2C5-dimethylcelecoxib+inhibit+intestinal+cancer+growth+by+suppressing+the+Wnt%2F%CE%B2-catenin+signaling+pathway&doi=10.1111%2Fcas.13106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway</span></div><div class="casAuthors">Egashira, Issei; Takahashi-Yanaga, Fumi; Nishida, Risa; Arioka, Masaki; Igawa, Kazunobu; Tomooka, Katsuhiko; Nakatsu, Yoshimichi; Tsuzuki, Teruhisa; Nakabeppu, Yusaku; Kitazono, Takanari; Sasaguri, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">108-115</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We previously reported that celecoxib, a selective COX-2 inhibitor, strongly inhibited human colon cancer cell proliferation by suppressing the Wnt/β-catenin signaling pathway. 2,5-Dimethylcelecoxib (DM-celecoxib), a celecoxib analog that does not inhibit COX-2, has also been reported to have an antitumor effect.  In the present study, we elucidated whether DM-celecoxib inhibits intestinal cancer growth, and its underlying mechanism of action.  First, we compared the effect of DM-celecoxib with that of celecoxib on the human colon cancer cell lines HCT-116 and DLD-1. 2,5-Dimethylcelecoxib suppressed cell proliferation and inhibited T-cell factor 7-like 2 expression with almost the same strength as celecoxib. 2,5-Dimethylcelecoxib also inhibited the T-cell factor-dependent transcription activity and suppressed the expression of Wnt/β-catenin target gene products cyclin D1 and survivin.  Subsequently, we compared the in vivo effects of celecoxib and DM-celecoxib using the Mutyh-/- mouse model, in which oxidative stress induces multiple intestinal carcinomas.  Serum concns. of orally administered celecoxib and DM-celecoxib elevated to the levels enough to suppress cancer cell proliferation.  Repeated treatment with celecoxib and DM-celecoxib markedly reduced the no. and size of the carcinomas without showing toxicity.  These results suggest that the central mechanism for the anticancer effect of celecoxib derivs. is the suppression of the Wnt/β-catenin signaling pathway but not the inhibition of COX-2, and that DM-celecoxib might be a better lead compd. candidate than celecoxib for the development of novel anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbu-BBe6MiirVg90H21EOLACvtfcHk0lhRBMMGZoNMQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKnu7zJ&md5=8852e33d3a40bed0706e1dfa4a6b5c73</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fcas.13106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13106%26sid%3Dliteratum%253Aachs%26aulast%3DEgashira%26aufirst%3DI.%26aulast%3DTakahashi-Yanaga%26aufirst%3DF.%26aulast%3DNishida%26aufirst%3DR.%26aulast%3DArioka%26aufirst%3DM.%26aulast%3DIgawa%26aufirst%3DK.%26aulast%3DTomooka%26aufirst%3DK.%26aulast%3DNakatsu%26aufirst%3DY.%26aulast%3DTsuzuki%26aufirst%3DT.%26aulast%3DNakabeppu%26aufirst%3DY.%26aulast%3DKitazono%26aufirst%3DT.%26aulast%3DSasaguri%26aufirst%3DT.%26atitle%3DCelecoxib%2520and%25202%252C5-dimethylcelecoxib%2520inhibit%2520intestinal%2520cancer%2520growth%2520by%2520suppressing%2520the%2520Wnt%252F%25CE%25B2-catenin%2520signaling%2520pathway%26jtitle%3DCancer%2520Sci.%26date%3D2017%26volume%3D108%26spage%3D108%26epage%3D115%26doi%3D10.1111%2Fcas.13106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montrose, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sue, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yantiss, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leve, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoly, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suen, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benezra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamer, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannenberg, A. J.</span></span> <span> </span><span class="NLM_article-title">Celecoxib alters the intestinal microbiota and metabolome in association with reducing polyp burden</span>. <i>Cancer Prev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1158/1940-6207.capr-16-0095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1158%2F1940-6207.CAPR-16-0095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=27432344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyju73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=721-731&author=D.+C.+Montroseauthor=X.+K.+Zhouauthor=E.+M.+McNallyauthor=E.+Sueauthor=R.+K.+Yantissauthor=S.+S.+Grossauthor=N.+D.+Leveauthor=E.+D.+Karolyauthor=C.+S.+Suenauthor=L.+Lingauthor=R.+Benezraauthor=E.+G.+Pamerauthor=A.+J.+Dannenberg&title=Celecoxib+alters+the+intestinal+microbiota+and+metabolome+in+association+with+reducing+polyp+burden&doi=10.1158%2F1940-6207.capr-16-0095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden</span></div><div class="casAuthors">Montrose, David C.; Zhou, Xi Kathy; McNally, Erin M.; Sue, Erika; Yantiss, Rhonda K.; Gross, Steven S.; Leve, Nitai D.; Karoly, Edward D.; Suen, Chen S.; Ling, Lilan; Benezra, Robert; Pamer, Eric G.; Dannenberg, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Prevention Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">721-731</span>CODEN:
                <span class="NLM_cas:coden">CPRACC</span>;
        ISSN:<span class="NLM_cas:issn">1940-6207</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Treatment with celecoxib, a selective COX-2 inhibitor, reduces formation of premalignant adenomatous polyps in the gastrointestinal tracts of humans and mice.  In addn. to its chemopreventive activity, celecoxib can exhibit antimicrobial activity.  Differing bacterial profiles have been found in feces from colon cancer patients compared with those of normal subjects.  Moreover, preclin. studies suggest that bacteria can modulate intestinal tumorigenesis by secreting specific metabolites.  In the current study, we detd. whether celecoxib treatment altered the luminal microbiota and metabolome in assocn. with reducing intestinal polyp burden in mice.  Administration of celecoxib for 10 wk markedly reduced intestinal polyp burden in APCMin/+ mice.  Treatment with celecoxib also altered select luminal bacterial populations in both APCMin/+ and wild-type mice, including decreased Lactobacillaceae and Bifidobacteriaceae as well as increased Coriobacteriaceae.  Metabolomic anal. demonstrated that celecoxib caused a strong redn. in many fecal metabolites linked to carcinogenesis, including glucose, amino acids, nucleotides, and lipids.  Ingenuity Pathway Anal. suggested that these changes in metabolites may contribute to reduced cell proliferation.  To this end, we showed that celecoxib reduced cell proliferation in the base of normal appearing ileal and colonic crypts of APCMin/+ mice.  Consistent with this finding, lineage tracing indicated that celecoxib treatment reduced the rate at which Lgr5-pos. stem cells gave rise to differentiated cell types in the crypts.  Taken together, these results demonstrate that celecoxib alters the luminal microbiota and metabolome along with reducing epithelial cell proliferation in mice.  We hypothesize that these actions contribute to its chemopreventive activity.  Cancer Prev Res; 9(9); 721-31. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPJQWx8cqn7bVg90H21EOLACvtfcHk0lhRBMMGZoNMQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyju73K&md5=215d84e8c53026a9b74a862dc86cab0f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F1940-6207.CAPR-16-0095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1940-6207.CAPR-16-0095%26sid%3Dliteratum%253Aachs%26aulast%3DMontrose%26aufirst%3DD.%2BC.%26aulast%3DZhou%26aufirst%3DX.%2BK.%26aulast%3DMcNally%26aufirst%3DE.%2BM.%26aulast%3DSue%26aufirst%3DE.%26aulast%3DYantiss%26aufirst%3DR.%2BK.%26aulast%3DGross%26aufirst%3DS.%2BS.%26aulast%3DLeve%26aufirst%3DN.%2BD.%26aulast%3DKaroly%26aufirst%3DE.%2BD.%26aulast%3DSuen%26aufirst%3DC.%2BS.%26aulast%3DLing%26aufirst%3DL.%26aulast%3DBenezra%26aufirst%3DR.%26aulast%3DPamer%26aufirst%3DE.%2BG.%26aulast%3DDannenberg%26aufirst%3DA.%2BJ.%26atitle%3DCelecoxib%2520alters%2520the%2520intestinal%2520microbiota%2520and%2520metabolome%2520in%2520association%2520with%2520reducing%2520polyp%2520burden%26jtitle%3DCancer%2520Prev.%2520Res.%26date%3D2016%26volume%3D9%26spage%3D721%26epage%3D731%26doi%3D10.1158%2F1940-6207.capr-16-0095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brideau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschênes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesen, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riendeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.-C.</span></span> <span> </span><span class="NLM_article-title">2-Heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1720</span>, <span class="refDoi"> DOI: 10.1016/s0960-894x(99)00264-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1016%2FS0960-894X%2899%2900264-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10397507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADyaK1MXktVCis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=1715-1720&author=D.+Dub%C3%A9author=C.+Brideauauthor=D.+Desch%C3%AAnesauthor=R.+Fortinauthor=R.+W.+Friesenauthor=R.+Gordonauthor=Y.+Girardauthor=D.+Riendeauauthor=C.+Savoieauthor=C.-C.+Chan&title=2-Heterosubstituted-3-%284-methylsulfonyl%29phenyl-5-trifluoromethyl+pyridines+as+selective+and+orally+active+cyclooxygenase-2+inhibitors&doi=10.1016%2Fs0960-894x%2899%2900264-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">2-Heterosubstituted 3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)pyridines as selective and orally active cyclooxygenase-2 inhibitors</span></div><div class="casAuthors">Dube, Daniel; Brideau, Christine; Deschenes, Denis; Fortin, Rejean; Friesen, Richard W.; Gordon, Robert; Girard, Yves; Riendeau, Denis; Savoie, Chantal; Chan, Chi-Chung</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1715-1720</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">2-Alkoxy-, 2-(alkylthio)-, and 2-amino-3-[4-(methylsulfonyl)phenyl]pyridines were synthesized and shown to be highly potent and selective cyclooxygenase-2 (COX-2) inhibitors.  Structure-activity relationship studies demonstrated that the pyridine ring substituents play an important role in the COX-2 potency, selectivity vs. the COX-1 enzyme, and oral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_1P4ZDqcdBrVg90H21EOLACvtfcHk0lhArhShF_ZnJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVCis78%253D&md5=9c64d7a78971e5908a914aff6641a788</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900264-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900264-4%26sid%3Dliteratum%253Aachs%26aulast%3DDub%25C3%25A9%26aufirst%3DD.%26aulast%3DBrideau%26aufirst%3DC.%26aulast%3DDesch%25C3%25AAnes%26aufirst%3DD.%26aulast%3DFortin%26aufirst%3DR.%26aulast%3DFriesen%26aufirst%3DR.%2BW.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DGirard%26aufirst%3DY.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DSavoie%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DC.-C.%26atitle%3D2-Heterosubstituted-3-%25284-methylsulfonyl%2529phenyl-5-trifluoromethyl%2520pyridines%2520as%2520selective%2520and%2520orally%2520active%2520cyclooxygenase-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26spage%3D1715%26epage%3D1720%26doi%3D10.1016%2Fs0960-894x%2899%2900264-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drennen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheenstra, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanning, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilder, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">Structural re-engineering of the α-helix mimetic JY-1-106 into small molecules: disruption of the Mcl-1-Bak-BH3 protein-protein interaction with 2,6-di-substituted nicotinates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=10.1002%2Fcmdc.201500461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=26844930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=827-833&author=B.+Drennenauthor=J.+A.+Scheenstraauthor=J.+L.+Yapauthor=L.+Chenauthor=M.+E.+Lanningauthor=B.+M.+Rothauthor=P.+T.+Wilderauthor=S.+Fletcher&title=Structural+re-engineering+of+the+%CE%B1-helix+mimetic+JY-1-106+into+small+molecules%3A+disruption+of+the+Mcl-1-Bak-BH3+protein-protein+interaction+with+2%2C6-di-substituted+nicotinates&doi=10.1002%2Fcmdc.201500461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates</span></div><div class="casAuthors">Drennen, Brandon; Scheenstra, Jacob A.; Yap, Jeremy L.; Chen, Lijia; Lanning, Maryanna E.; Roth, Braden M.; Wilder, Paul T.; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">827-833</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The disruption of aberrant protein-protein interactions (PPIs) with synthetic agents remains a challenging goal in contemporary medicinal chem. but some progress has been made.  One such dysregulated PPI is that between the anti-apoptotic Bcl-2 proteins, including myeloid cell leukemia-1 (Mcl-1), and the α-helical Bcl-2 homol.-3 (BH3) domains of its pro-apoptotic counterparts, such as Bak.  Herein, we describe the discovery of small-mol. inhibitors of the Mcl-1 oncoprotein based on a novel chemotype.  Particularly, re-engineering of our α-helix mimetic JY-1-106 into 2,6-di-substituted nicotinates afforded inhibitors of comparable potencies but with significantly decreased mol. wts.  The most potent inhibitor 2-(benzyloxy)-6-(4-chloro-3,5-dimethylphenoxy)nicotinic acid (1 r: Ki=2.90 μm) likely binds in the p2 pocket of Mcl-1 and engages R263 in a salt bridge through its carboxylic acid, as supported by 2D 1H-15N HSQC NMR data.  Significantly, inhibitors were easily accessed in just four steps, which will facilitate future optimization efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop4jh0-PJZwrVg90H21EOLACvtfcHk0lhArhShF_ZnJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWjtbk%253D&md5=1a9f2e38a7653888b32ceb067a3dc270</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500461%26sid%3Dliteratum%253Aachs%26aulast%3DDrennen%26aufirst%3DB.%26aulast%3DScheenstra%26aufirst%3DJ.%2BA.%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLanning%26aufirst%3DM.%2BE.%26aulast%3DRoth%26aufirst%3DB.%2BM.%26aulast%3DWilder%26aufirst%3DP.%2BT.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DStructural%2520re-engineering%2520of%2520the%2520%25CE%25B1-helix%2520mimetic%2520JY-1-106%2520into%2520small%2520molecules%253A%2520disruption%2520of%2520the%2520Mcl-1-Bak-BH3%2520protein-protein%2520interaction%2520with%25202%252C6-di-substituted%2520nicotinates%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D827%26epage%3D833%26doi%3D10.1002%2Fcmdc.201500461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LN1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LN1','PDB','3LN1'); return false;">PDB: 3LN1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIR','PDB','5KIR'); return false;">PDB: 5KIR</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i89"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00890">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_58174"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00890?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00890</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular modeling; molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb">PDB</a>)</p></li><li><p class="inline">(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_002.csv">CSV</a>)</p></li><li><p class="inline">Assays and protocols: chemistry; metabolite identifications; PK; UGT phenotyping; glucuronidation <i>K</i><sub>m</sub> determination; survival extension; plots for derived free unbound fraction (fu %) in vivo potency; and HPLC traces of compounds <b>10</b>, <b>11</b>, <b>20</b>, <b>21</b>, <b>22</b>, and <b>23</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_001.pdb">jm1c00890_si_001.pdb (714.76 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_002.csv">jm1c00890_si_002.csv (3.83 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00890/suppl_file/jm1c00890_si_003.pdf">jm1c00890_si_003.pdf (1.87 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00890&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00890" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00890" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799197edb183d54","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
